

Appendix

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study

Rohan Khera MD, Arya Aminorroaya MD, Lovedeep Singh Dhingra MBBS, Phyllis M Thangaraj MD, Aline Pedroso Camargos MS, Fan Bu PhD, Xiyu Ding MS, Akihiko Nishimura PhD, Tara V Anand BS, Faaizah Arshad BS, Clair Blacketer MPH, Yi Chai PhD, Shounak Chattopadhyay PhD, Michael Cook BSc, David A Dorr MD, Talita Duarte-Salles PhD, Scott L DuVall PhD, Thomas Falconer MS, Tina E French RN, Elizabeth E Hanchrow MSN, Guneet Kaur, Wallis CY Lau PhD, Jing Li MS, Kelly Li BS, Yuntian Liu MPH, Yuan Lu ScD, Kenneth KC Man PhD, Michael E Matheny MD, Nestoras Mathioudakis MD, Jody-Ann McLeggon MPH, Michael F McLemore RN, Evan Minty MD, Daniel R Morales MD, Paul Nagy PhD, Anna Ostropolets PhD, Andrea Pistillo MSc, Thanh-Phuc Phan MBA, Nicole Pratt PhD, Carlen Reyes MD, Lauren Richter MD, Joseph Ross MD, Elise Ruan MD, Sarah L Seager BS, Katherine R Simon AA, Benjamin Viernes PhD, Jianxiao Yang MS, Can Yin MS, Seng Chan You MD, Jin J Zhou PhD, Patrick B Ryan PhD, Martijn J Schuemie PhD, Harlan M Krumholz MD, George Hripcsak MD, Marc A Suchard PhD

Correspondence to:

Marc A Suchard, MD, PhD

Departments of Biomathematics, Biostatistics and Human Genetics

6558 Gonda Building, 695 Charles E. Young Drive, South Los Angeles, CA 90095-1766

(310) 825-7442; msuchard@ucla.edu; @suchard_group

Cohort Definitions

OHDSI's ATLAS (<https://www.ohdsi.org/web/atlas>) is an open-source software tool for researchers to conduct scientific analyses on standardized observational data converted to the OMOP Common Data Model v5. Researchers can create cohorts by defining groups of people based on an exposure to a drug or diagnosis of a particular condition using healthcare claims data. ATLAS has vocabulary searching of medical concepts to identify people with specific conditions, drug exposures, etc. Patient profiles can be viewed within a specific cohort allowing visualization of a particular subject's health care records. Population effect level estimation analyses allow for comparing two different cohorts and leverage R packages. Here we have described the cohort definition for dipeptidyl peptidase-4 inhibitors (DPP4is) new users. The same method has been applied for defining cohorts of sodium-glucose co-transporter-2 inhibitors (SGLT2is), glucagon-like peptide-1 receptor agonists (GLP1-RAs), and sulfonylureas (SUs) new users.

I. **Class-vs-Class Exposure (DPP4is New-User) Cohort / OT1**

i. **Cohort Entry Events**

People with continuous observation of 365 days before the event may enter the cohort when observing any of the following:

1. drug exposure of 'DPP4 inhibitors' for the first time in the person's

history. Limit cohort entry events to the earliest event per person.

Restrict entry events to with all of the following criteria:

1. with the following event criteria: who are ≥ 18 years old.
2. having at least 1 condition occurrence of 'Type 2 diabetes mellitus,' starting anytime on or before cohort entry start date; allow events outside observation period.
3. having no condition occurrences of 'Type 1 diabetes mellitus,' starting anytime on or before cohort entry start date; allow events outside observation period.
4. having no condition occurrences of 'Secondary diabetes mellitus,' starting anytime on or before cohort entry start date; allow events outside observation period.

ii. **Additional Inclusion Criteria**

1. No prior GLP-1 receptor agonist exposure

Entry events having no drug exposures of 'GLP-1 receptor agonists,' starting anytime on or before cohort entry start date; allow events outside observation period.

2. No prior SGLT-2 inhibitor exposure

Entry events having no drug exposures of 'SGLT2 inhibitors,' starting anytime on or before cohort entry start date; allow events outside observation period.

3. No prior SU exposure

Entry events having no drug exposures of 'Sulfonylureas,' starting anytime on or before cohort entry start date; allow events outside observation period.

4. No prior other anti-diabetic exposure

Entry events having no drug exposures of 'Other anti-diabetics,' starting anytime on or before cohort entry start date; allow events outside observation period.

5. Prior metformin use

Entry events with any of the following criteria:

1. having at least 1 drug era of 'Metformin,' starting anytime up to 90 days before cohort entry start date; allow events outside observation period; with era length \geq 90 days.
 2. having at least 3 drug exposures of 'Metformin,' starting anytime on or before cohort entry start date; allow events outside observation period.
- No prior insulin use or combo initiation: Proxy for $<$ 30 days drug era anytime before index and no combination use on index

Entry events with all of the following criteria:

1. having no drug eras of 'Insulin,' starting anytime up to 30 days before cohort entry start date; allow events outside observation period; with era length $>$ 30 days.
2. having no drug eras of 'Insulin,' starting between 30 days before and 0 days after cohort entry start date; allow events outside observation period.

6. Higher cardiovascular risk

Entry events with any of the following criteria:

1. having at least 1 condition occurrence of 'Conditions indicating established cardio-vascular disease,' starting anytime on or before cohort entry start date; allow events outside observation period.
2. having at least 1 procedure occurrence of 'Procedures indicating established cardio-vascular disease,' starting anytime on or before cohort entry start date; allow events outside observation period.

Concept: Conditions indicating established cardiovascular disease

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
319844	Acute ischemic heart disease	413439005	SNOMED	NO	YES	NO
321318	Angina pectoris	194828000	SNOMED	NO	YES	NO

4124841	Aortic bifurcation syndrome	233972005	SNOMED	YES	YES	NO
312337	Arterial embolus and thrombosis	266262004	SNOMED	NO	YES	NO
4278217	Arterial thrombosis	65198009	SNOMED	NO	YES	NO
40484167	Arteriosclerosis of artery of extremity	443971004	SNOMED	NO	YES	NO
318443	Arteriosclerotic vascular disease	72092001	SNOMED	NO	YES	NO
314659	Arteritis	52089001	SNOMED	NO	NO	NO
40479625	Atherosclerosis of artery	441574008	SNOMED	NO	YES	NO
40484541	Atherosclerosis of autologous vein bypass graft of limb	442693003	SNOMED	YES	YES	NO
312902	Benign intracranial hypertension	68267002	SNOMED	YES	YES	NO
4288310	Carotid artery obstruction	69798007	SNOMED	YES	YES	NO
372924	Cerebral artery occlusion	20059004	SNOMED	NO	YES	NO
376713	Cerebral hemorrhage	274100004	SNOMED	NO	YES	NO
381591	Cerebrovascular disease	62914000	SNOMED	NO	YES	NO
316494	Cerebrovascular disorder in the puerperium	6594005	SNOMED	YES	YES	NO
315286	Chronic ischemic heart disease	413838009	SNOMED	NO	YES	NO
44782819	Chronic occlusion of artery of extremity	698816006	SNOMED	NO	YES	NO
4313767	Chronic peripheral venous hypertension	423674003	SNOMED	YES	YES	NO
372721	Congenital anomaly of cerebrovascular system	65587001	SNOMED	YES	YES	NO
316995	Coronary occlusion	63739005	SNOMED	NO	YES	NO
134057	Disorder of cardiovascular system	49601007	SNOMED	NO	NO	NO
40480453	Disorder of vein of lower extremity	441739009	SNOMED	YES	YES	NO
46272492	Dissection of artery	710864009	SNOMED	YES	YES	NO
4324690	Fracture of skull	71642004	SNOMED	YES	YES	NO
441246	Hemangioma of intracranial structure	93468003	SNOMED	YES	YES	NO
380113	Hemorrhage in optic nerve sheaths	14460007	SNOMED	YES	YES	NO
192763	Injury of blood vessel	57662003	SNOMED	YES	YES	NO
4275428	Injury of vein	64583005	SNOMED	YES	YES	NO
442774	Intermittent claudication	63491006	SNOMED	NO	YES	NO
439847	Intracranial hemorrhage	1386000	SNOMED	NO	YES	NO

434056	Late effects of cerebrovascular disease	195239002	SNOMED	NO	YES	NO
4146311	Leriche's syndrome	307816004	SNOMED	NO	YES	NO
4329847	Myocardial infarction	22298006	SNOMED	NO	YES	NO
4296029	Periarthritis	76805007	SNOMED	NO	YES	NO
260841	Perinatal subarachnoid hemorrhage	21202004	SNOMED	YES	YES	NO
317309	Peripheral arterial occlusive disease	399957001	SNOMED	NO	YES	NO
321822	Peripheral vascular disorder due to diabetes mellitus	421895002	SNOMED	NO	YES	NO
313928	Peripheral vascular complication	10596002	SNOMED	NO	YES	NO
321052	Peripheral vascular disease	400047006	SNOMED	NO	NO	NO
44782775	Peripheral vascular disease associated with another disorder	34881000119105	SNOMED	NO	YES	NO
318137	Phlebitis and thrombophlebitis of intracranial sinuses	192753009	SNOMED	YES	YES	NO
441039	Phlebitis of lower limb vein	312588002	SNOMED	NO	YES	NO
4067424	Polyarteritis	20258000	SNOMED	NO	YES	NO
320749	Polyarteritis nodosa	155441006	SNOMED	YES	YES	NO
443239	Precerebral arterial occlusion	266253001	SNOMED	NO	YES	NO
440417	Pulmonary embolism	59282003	SNOMED	YES	YES	NO
4318842	Renal vasculitis	95578000	SNOMED	NO	YES	NO
380943	Rupture of syphilitic cerebral aneurysm	186893003	SNOMED	YES	YES	NO
432923	Subarachnoid hemorrhage	21454007	SNOMED	NO	YES	NO
439040	Subdural hemorrhage	35486000	SNOMED	NO	YES	NO
320741	Thrombophlebitis	64156001	SNOMED	YES	YES	NO
4141106	Thrombosis of arteries of the extremities	33591000	SNOMED	NO	YES	NO
4132546	Traumatic brain injury	127295002	SNOMED	YES	YES	NO
4194610	Trunk arterial embolus	312593004	SNOMED	NO	YES	NO
318169	Varicose veins of lower extremity	72866009	SNOMED	YES	YES	NO
4189293	Vascular disorder of lower extremity	373408007	SNOMED	NO	YES	NO
443752	Ventricular hemorrhage	23276006	SNOMED	YES	YES	NO
432346	Dissection of vertebral artery	230730001	SNOMED	YES	YES	NO

Concept: Procedures indicating established cardiovascular disease

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
4150819	Operative procedure on coronary artery	31413008	SNOMED	NO	YES	NO
4331725	Operative procedure on artery of extremity	22701007	SNOMED	NO	YES	NO

iii. Cohort Exit

The cohort end date will be based on a continuous exposure to 'DPP4 inhibitors': allowing 30 days between exposures, adding 0 days after exposure ends, and using days supply and exposure end date for exposure duration.

iv. Cohort Eras

Entry events will be combined into cohort eras if they are within 0 days of each other.

v. Concept: DPP4 inhibitors

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
43013884	alogliptin	1368001	RxNorm	NO	YES	NO
40239216	linagliptin	1100699	RxNorm	NO	YES	NO
40166035	saxagliptin	857974	RxNorm	NO	YES	NO
1580747	sitagliptin	593411	RxNorm	NO	YES	NO
19122137	vildagliptin	596554	RxNorm	NO	YES	NO

vi. Concept: GLP-1 receptor agonists

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
44816332	albiglutide	1534763	RxNorm	NO	YES	NO
45774435	dulaglutide	1551291	RxNorm	NO	YES	NO
1583722	exenatide	60548	RxNorm	NO	YES	NO
40170911	liraglutide	475968	RxNorm	NO	YES	NO
44506754	lixisenatide	1440051	RxNorm	NO	YES	NO
793143	semaglutide	1991302	RxNorm	NO	YES	NO

vii. Concept: SGLT2 inhibitors

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
43526465	canagliflozin	1373458	RxNorm	NO	YES	NO
44785829	dapagliflozin	1488564	RxNorm	NO	YES	NO
45774751	empagliflozin	1545653	RxNorm	NO	YES	NO
793293	ertugliflozin	1992672	RxNorm	NO	YES	NO

viii. Concept: Sulfonylureas

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
1594973	chlorpropamide	2404	RxNorm	NO	YES	NO
1597756	glimepiride	25789	RxNorm	NO	YES	NO
1560171	glipizide	4821	RxNorm	NO	YES	NO
19097821	gliquidone	25793	RxNorm	NO	YES	NO
1559684	glyburide	4815	RxNorm	NO	YES	NO
1502809	tolazamide	10633	RxNorm	NO	YES	NO
1502855	tolbutamide	10635	RxNorm	NO	YES	NO

ix. Concept: Other anti-diabetics

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
1529331	acarbose	16681	RxNorm	NO	YES	NO
1530014	acetoexamide	173	RxNorm	NO	YES	NO
730548	bromocriptine	1760	RxNorm	NO	YES	NO
19033498	carbutamide	2068	RxNorm	NO	YES	NO
19001409	glibornuride	102846	RxNorm	NO	YES	NO
19059796	gliclazide	4816	RxNorm	NO	YES	NO
19001441	glymidine	102848	RxNorm	NO	YES	NO
1510202	migliitol	30009	RxNorm	NO	YES	NO
1502826	nateglinide	274332	RxNorm	NO	YES	NO
1525215	pioglitazone	33738	RxNorm	NO	YES	NO
1516766	repaglinide	73044	RxNorm	NO	YES	NO
1547504	rosiglitazone	84108	RxNorm	NO	YES	NO
1515249	trogliitazone	72610	RxNorm	NO	YES	NO

x. Concept: Insulin

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
1596977	insulin, regular, human	253182	RxNorm	NO	YES	NO
1550023	insulin lispro	86009	RxNorm	NO	YES	NO
1567198	insulin aspart, human	51428	RxNorm	NO	YES	NO
1502905	insulin glargine	274783	RxNorm	NO	YES	NO
1513876	insulin lispro protamine, human	314684	RxNorm	NO	YES	NO
1531601	insulin aspart protamine, human	352385	RxNorm	NO	YES	NO
1586346	insulin, regular, pork	221109	RxNorm	NO	YES	NO
1544838	insulin glulisine, human	400008	RxNorm	NO	YES	NO
1516976	insulin detemir	139825	RxNorm	NO	YES	NO
1590165	insulin, regular, beef-pork	235275	RxNorm	NO	YES	NO
1513849	lente insulin, human	314683	RxNorm	NO	YES	NO
1562586	lente insulin, pork	93108	RxNorm	NO	YES	NO
1588986	insulin human, rDNA origin	631657	RxNorm	NO	YES	NO

1513843	lente insulin, beef-pork	314682	RxNorm	NO	YES	NO
1586369	ultralente insulin, human	221110	RxNorm	NO	YES	NO
35605670	insulin argine	1740938	RxNorm	NO	YES	NO
35602717	insulin degludec	1670007	RxNorm	NO	YES	NO
21600713	INSULINS AND ANALOGUES	A10A	ATC	NO	YES	NO
19078608	insulin, protamine zinc, beef-pork 100 UNT/ML Injectable Suspension	311053	RxNorm	NO	YES	NO

xi. Concept: Metformin

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
1503297	metformin	6809	RxNorm	NO	YES	NO

xii. Concept: Secondary diabetes mellitus

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
195771	Secondary diabetes mellitus	8801005	SNOMED	NO	YES	NO

xiii. Concept: Type 1 diabetes mellitus

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
201254	Type 1 diabetes mellitus	46635009	SNOMED	NO	YES	NO
435216	Disorder due to type 1 diabetes mellitus	420868002	SNOMED	NO	YES	NO
200687	Renal disorder due to type 1 diabetes mellitus	421893009	SNOMED	NO	YES	NO
377821	Disorder of nervous system due to type 1 diabetes mellitus	421468001	SNOMED	NO	YES	NO
318712	Peripheral circulatory disorder due to type 1 diabetes mellitus	421365002	SNOMED	NO	YES	NO

xiv. Concept: Type 2 diabetes mellitus

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
201826	Type 2 diabetes mellitus	44054006	SNOMED	NO	YES	NO
443734	Ketoacidosis due to type 2 diabetes mellitus	421750000	SNOMED	NO	YES	NO
443767	Disorder of eye due to diabetes mellitus	25093002	SNOMED	NO	YES	NO
192279	Disorder of kidney due to diabetes mellitus	127013003	SNOMED	NO	YES	NO
443735	Coma due to diabetes mellitus	420662003	SNOMED	NO	YES	NO
376065	Disorder of nervous system due to type 2 diabetes mellitus	421326000	SNOMED	NO	YES	NO
443729	Peripheral circulatory disorder due to type 2 diabetes mellitus	422166005	SNOMED	NO	YES	NO
443732	Disorder due to type 2 diabetes mellitus	422014003	SNOMED	NO	YES	NO

II. Metformin Use Modifier

i. No prior metformin use

Entry events having no drug eras of 'Metformin,' starting anytime on or before cohort entry start date; allow events outside observation period.

III. Heterogeneity Study Inclusion Criteria

i. Lower age group

Entry events with the following event criteria: who are < 45 years old.

ii. Middle age group

Entry events with all of the following criteria:

1. with the following event criteria: who are \geq 45 years old.
2. with the following event criteria: who are < 65 years old.

iii. Older age group

Entry events with the following event criteria: who are \geq 65 years old.

iv. Female stratum

Entry events with the following event criteria: who are female.

v. Male stratum

Entry events with the following event criteria: who are male.

vi. Race stratum

Entry events with the following event criteria: race is: "black or african american," "black," "african american," "african," "bahamian," "barbadian," "dominican," "dominica islander," "haitian," "jamaican," "tobagoan," "trinidadian" or "west indian."

V. Escalation Exit Criteria

The cohort end date will be based on a continuous exposure to 'DPP4 inhibitors': allowing 30 days between exposures, adding 0 days after exposure ends, and using days supply and exposure end date for exposure duration.

The person also exits the cohort when encountering any of the following events:

1. drug exposures of 'All alternative target exposures.'
2. drug exposures of 'Other anti-diabetics.'
3. drug eras of 'Insulin,' with era length > 30 days.

i. Concept: All alternative target exposures

Concept ID	Concept Name	Code	Vocabulary	Excluded	Descendants	Mapped
44816332	albiglutide	1534763	RxNorm	NO	YES	NO
43526465	canagliflozin	1373458	RxNorm	NO	YES	NO
1594973	chlorpropamide	2404	RxNorm	NO	YES	NO
44785829	dapagliflozin	1488564	RxNorm	NO	YES	NO
45774435	dulaglutide	1551291	RxNorm	NO	YES	NO
45774751	empagliflozin	1545653	RxNorm	NO	YES	NO
793293	ertugliflozin	1992672	RxNorm	NO	YES	NO
1583722	exenatide	60548	RxNorm	NO	YES	NO
1597756	glimepiride	25789	RxNorm	NO	YES	NO
1560171	glipizide	4821	RxNorm	NO	YES	NO
19097821	gliquidone	25793	RxNorm	NO	YES	NO
1559684	glyburide	4815	RxNorm	NO	YES	NO
40170911	liraglutide	475968	RxNorm	NO	YES	NO
44506754	lixisenatide	1440051	RxNorm	NO	YES	NO
793143	semaglutide	1991302	RxNorm	NO	YES	NO
1502809	tolazamide	10633	RxNorm	NO	YES	NO
1502855	tolbutamide	10635	RxNorm	NO	YES	NO

Study Outcomes

We have assessed 3-point major adverse cardiovascular events (MACE) and 4-point MACE as the primary study outcomes, where 3-point (MACE) includes acute myocardial infarction, stroke, and sudden cardiac death; and 4-point MACE additionally includes hospitalization for heart failure. Secondary outcomes of interest include the four individual MACE components as defined below.

Acute Myocardial Infarction

Cohort Entry Events

People may enter the cohort when observing any of the following:

1. condition occurrences of '[LEGEND-T2DM] Acute myocardial Infarction'.

Restrict entry events to having at least 1 visit occurrence of 'Inpatient or ER visit', starting anytime on or before cohort entry start date and ending between 0 days before and all days after cohort entry start date.

Cohort Exit

The cohort end date will be offset from index event's start date plus 7 days.

Cohort Eras

Entry events will be combined into cohort eras if they are within 180 days of each other.

Concept Set Definitions

1. Inpatient or ER visit

Concept ID	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
262	Emergency Room and Inpatient Visit	Visit	Visit	NO	YES	NO
9203	Emergency Room Visit	Visit	Visit	NO	YES	NO
9201	Inpatient Visit	Visit	Visit	NO	YES	NO

2. Acute myocardial infarction

Concept ID	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
4329847	Myocardial infarction	Condition	SNOMED	NO	YES	NO
314666	Old myocardial infarction	Condition	SNOMED	YES	YES	NO

Stroke

Cohort Entry Events

People may enter the cohort when observing any of the following:

1. condition occurrences of '[LEGEND-T2DM] Stroke (ischemic or hemorrhagic)'.

Restrict entry events to having at least 1 visit occurrence of 'Inpatient or ER visit', starting between all days before and 1 days after cohort entry start date and ending between 0 days before and all days after cohort entry start date.

Cohort Exit

The cohort end date will be offset from index event's start date plus 7 days.

Cohort Eras

Entry events will be combined into cohort eras if they are within 180 days of each other.

Concept Set Definitions

1. Inpatient or ER visit

Concept ID	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
262	Emergency Room and Inpatient Visit	Visit	Visit	NO	YES	NO
9203	Emergency Room Visit	Visit	Visit	NO	YES	NO
9201	Inpatient Visit	Visit	Visit	NO	YES	NO

2. Stroke (ischemic or hemorrhagic)

Concept ID	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
372924	Cerebral artery occlusion	Condition	SNOMED	NO	NO	NO
375557	Cerebral embolism	Condition	SNOMED	NO	NO	NO
376713	Cerebral hemorrhage	Condition	SNOMED	NO	NO	NO
443454	Cerebral infarction	Condition	SNOMED	NO	YES	NO
441874	Cerebral thrombosis	Condition	SNOMED	NO	NO	NO
439847	Intracranial hemorrhage	Condition	SNOMED	NO	NO	NO
432923	Subarachnoid hemorrhage	Condition	SNOMED	NO	NO	NO
43530727	Spontaneous cerebral hemorrhage	Condition	SNOMED	NO	NO	NO
4148906	Spontaneous subarachnoid hemorrhage	Condition	SNOMED	NO	NO	NO

Sudden Cardiac Death

Cohort Entry Events

People may enter the cohort when observing any of the following:

1. condition occurrences of '[LEGEND HTN] Sudden cardiac death'.

Restrict entry events to having at least 1 visit occurrence of 'Inpatient or ER visit', starting anytime on or before cohort entry start date and ending between 0 days before and all days after cohort entry start date.

Cohort Exit

The cohort end date will be offset from index event's start date plus 7 days.

Cohort Eras

Entry events will be combined into cohort eras if they are within 180 days of each other.

Concept Set Definitions

1. Inpatient or ER visit

Concept ID	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
262	Emergency Room and Inpatient Visit	Visit	Visit	NO	YES	NO
9203	Emergency Room Visit	Visit	Visit	NO	YES	NO
9201	Inpatient Visit	Visit	Visit	NO	YES	NO

2. Sudden cardiac death

Concept ID	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
4048809	Brainstem death	Condition	SNOMED	NO	YES	NO
321042	Cardiac arrest	Condition	SNOMED	NO	YES	NO
442289	Death in less than 24 hours from onset of symptoms	Condition	SNOMED	NO	YES	NO
4317150	Sudden cardiac death	Condition	SNOMED	NO	YES	NO
4132309	Sudden death	Condition	SNOMED	NO	YES	NO
437894	Ventricular fibrillation	Condition	SNOMED	YES	YES	NO

Heart Failure Hospitalization

Cohort Entry Events

People may enter the cohort when observing any of the following:

1. visit occurrences of 'Inpatient or ER visit'; having at least 1 condition occurrence of '[LEGEND-T2DM] Heart Failure', starting between 0 days before and all days after 'Inpatient or ER visit' start date and starting anytime on or before 'Inpatient or ER visit' end date.

Cohort Exit

The cohort end date will be offset from index event's end date plus 0 days.

Cohort Eras

Entry events will be combined into cohort eras if they are within 7 days of each other.

Concept Set Definitions

1. Inpatient or ER visit

Concept ID	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
262	Emergency Room and Inpatient Visit	Visit	Visit	NO	YES	NO
9203	Emergency Room Visit	Visit	Visit	NO	YES	NO
9201	Inpatient Visit	Visit	Visit	NO	YES	NO

2. Heart Failure

Concept ID	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
315295	Congestive rheumatic heart failure	Condition	SNOMED	YES	YES	NO
316139	Heart failure	Condition	SNOMED	NO	YES	NO

Negative Control Outcomes

We selected negative controls using a process similar to that outlined in Voss et al. [1]. We first constructed a list of all conditions that satisfy the following criteria with respect to all drug exposures in the LEGEND-HTN study [2]:

- No Medline abstract where the MeSH terms suggests a drug-condition association [3],
- No mention of the drug-condition pair on a US product label in the “Adverse Drug Reactions” or “Postmarketing” section [4],
- No US spontaneous reports suggesting that the pair is in an adverse event relationship [5, 6],
- OMOP vocabulary does not suggest that the drug is indicated for the condition,
- Vocabulary conditional concepts are usable (i.e., not too broad, not suggestive of an adverse event relationship, no pregnancy related), and
- Exact condition concept itself is used in patient level data.

We then optimized the remaining condition concepts, such that parent concepts remove children as defined by the OMOP vocabulary and performed manual review to exclude any pairs that may still be in a causal relationship or too similar to the study outcome. This process led to a candidate list of 100 negative controls (**Supplementary Table 4**).

Supplemental References

1. Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. *J Biomed Inform.* 2017;66:72-81.
2. Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. *The Lancet.* 2019;394(10211):1816-26.
3. Winnenburg R, Sorbello A, Ripple A, Harpaz R, Tønning J, Szarfman A, et al. Leveraging MEDLINE indexing for pharmacovigilance—Inherent limitations and mitigation strategies. *Journal of Biomedical Informatics.* 2015;57:425-35.
4. Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. *Pharmacoepidemiology and Drug Safety.* 2013;22(3):294-301.
5. Evans S, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiology and Drug Safety.* 2001;10(6):483-6.
6. Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. *Scientific data.* 2016;3:160026.

Supplementary Table 1: Description of databases from the observational health data sciences and informatics network included in the study.

Name of Database	Abbreviation	Type of Data	Country of Origin	Years of Exposure Included
IBM MarketScan® Commercial Claims and Encounters Data (CCAЕ)	CCAЕ	Claims Data	USA	2011-2021
Germany Disease Analyser	GDA	EHR Data	Germany	1992-2021
UK-IQVIA Medical Research Data	IMRD	EHR Data	United Kingdom	2011-2019
IBM Health MarketScan® Multi-State Medicaid Database	MDCD	Claims Data	USA	2011-2020
IBM Health MarketScan® Medicare Supplemental and Coordination of Benefits Database	MDCR	Claims Data	USA	2011-2021
Optum© Clinformatics Extended Data Mart - Date of Death (DOD)	OCEDM	Claims Data	USA	2011-2021
Optum© de-identified Electronic Health Record Dataset	OEHR	Claims Data	USA	2011-2021
Information System for Research in Primary Care	SIDIAP	EHR Data	Spain	2011-2021
US Open Claims	USOC	Claims Data	USA	2000-2021
Department of Veterans Affairs Healthcare System	VA	EHR Data	USA	2011-2021

Supplementary Table 2: Brief descriptions of databases from the observational health data sciences and informatics network included in the study.

Name of Database	Abbreviation	Brief Description
US National Databases		
IBM MarketScan® Commercial Claims and Encounters Data	CCAЕ	IBM Health MarketScan® Commercial Claims and Encounters Database (CCAЕ) represent data from individuals enrolled in United States employer-sponsored insurance health plans. The data includes adjudicated health insurance claims (e.g. inpatient, outpatient, and outpatient pharmacy) as well as enrollment data from large employers and health plans who provide private healthcare coverage to employees, their spouses, and dependents. Additionally, it captures laboratory tests for a subset of the covered lives. This administrative claims database includes a variety of fee-for-service, preferred provider organizations, and capitated health plans.
IBM Health MarketScan® Multi-State Medicaid Database	MDCD	IBM MarketScan® Multi-State Medicaid Database (MDCD) adjudicated US health insurance claims for Medicaid enrollees from multiple states and includes hospital discharge diagnoses, outpatient diagnoses and procedures, and outpatient pharmacy claims as well as ethnicity and Medicare eligibility. Members maintain their same identifier even if they leave the system for a brief period however the dataset lacks lab data.
IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database	MDCR	IBM Health MarketScan® Medicare Supplemental and Coordination of Benefits Database (MDCR) represents health services of retirees in the United States with primary or Medicare supplemental coverage through privately insured fee-for-service, point-of-service, or capitated health plans. These data include adjudicated health insurance claims (e.g. inpatient, outpatient, and outpatient pharmacy). Additionally, it captures laboratory tests for a subset of the covered lives.
Optum Clinformatics Extended Data Mart - Date of Death (DOD)	OCEDM	Optum Clinformatics Extended DataMart is an adjudicated US administrative health claims database for members of private health insurance, who are fully insured in commercial plans or in administrative services only (ASOs), Legacy Medicare Choice Lives (prior to January 2006), and Medicare Advantage (Medicare Advantage Prescription Drug coverage starting January 2006). The population is primarily representative of commercial claims patients (0-65 years old) with some Medicare (65+ years old) however ages are capped at 90 years. It includes data captured from administrative claims processed from inpatient and outpatient medical services and prescriptions as dispensed, as well as results for outpatient lab tests processed by large national lab vendors who participate in data exchange with Optum. This dataset also provides date of death (month and year only) for members with both medical and pharmacy coverage from the Social Security Death Master File (however after 2011 reporting frequency changed due to changes in reporting requirements) and location information for patients is at the US state level.
Optum© de-identified Electronic Health Record Dataset	OEHR	Optum© de-identified Electronic Health Record Dataset represents Humedica’s Electronic Health Record data a medical records database. The medical record data includes clinical information, inclusive of prescriptions as prescribed and administered, lab results, vital signs, body measurements, diagnoses, procedures, and information derived from clinical Notes using Natural Language Processing (NLP).

Name of Database	Abbreviation	Brief Description
US Open Claims	USOC	US Open Claims is a United States database of open, pre-adjudicated claims from 2000 to present. Data are reported at anonymized patient level collected from office-based physicians and specialists via office management software and clearinghouse switch sources for the purpose of reimbursement. A subset of medical claims data has adjudicated claims.
US Health System Databases		
Department of Veterans Affairs health care system	VA	VA OMOP data reflects the national Department of Veterans Affairs health care system, which is the largest integrated provider of medical and mental health services in the United States. Care is provided at 170 VA Medical Centers and 1,063 outpatient sites serving more than 9 million enrolled Veterans each year.
Non-US Databases		
Germany Disease Analyser	GDA	Germany Disease Analyser is collected from extracts of patient management software used by general practitioners and specialists practicing in ambulatory care settings. Data coverage includes 40.2 million distinct person records, about 48.2% population in the country and collected from 2,800 providers. Patient visiting more than one provider are not cross identified for data protection reasons and therefore recorded as separate in the system. Dates of service include from 1992 through present. Observation time is defined by the first and last consultation dates. Germany has no mandatory general practitioner system and patient have free choice of specialist. Drugs are recorded as prescriptions of marketed products. No registration or approval is required for drug utilization studies.
Information System for Research in Primary Care	SIDIAP	The Information System for Research in Primary Care (SIDIAP; www.sidiap.org) is a primary care records database that covers approximately 80% of the population of Catalonia, North-East Spain. Healthcare is universal and tax-payer funded in the region, and primary care physicians are gatekeepers for all care and responsible for repeat prescriptions. For this study, SIDIAP was linked to the Minimum Basic Dataset (CMBD), a national population-based registry that includes hospital discharge information of mandatory registration.
UK-IQVIA Medical Research Data	IMRD	The UK-IQVIA Medical Research Data (IMRD), previously known as The Health Improvement Network (THIN), contains anonymized electronic health records from over 744 general practices in the UK, covering approximately 6% of the UK population. It contains data on prescriptions, diagnoses, referrals, and patient demographics broadly representative of the UK.

Supplementary Table 3: Pharmacological agents included in the drug classes.

GLP1-RA	SGLT2i	DPP4i	SU
Albiglutide	Canagliflozin	Alogliptin	Chlorpropamide
Dulaglutide	Dapagliflozin	Linagliptin	Glimepiride
Exenatide	Empagliflozin	Saxagliptin	Glipizide
Liraglutide	Ertugliflozin	Sitagliptin	Gliquidone
Lixisenatide		Vildagliptin	Glyburide
Semaglutide			Tolazamide
			Tolbutamide

Supplementary Table 4: Negative control outcomes.

Condition Concept
Abnormal posture
Abrasion and/or friction burn of multiple sites
Absent kidney
Anomaly of jaw size
Benign paroxysmal positional vertigo
Bizarre personal appearance
Cachexia
Colostomy present
Complication of gastrostomy
Developmental delay
Deviated nasal septum
Epidermoid cyst
Exhaustion due to excessive exertion
Feces contents abnormal
Foreign body in ear
Foreskin deficient
Galactosemia
Ganglion cyst
Genetic disorder carrier
Impacted cerumen
Inadequate sleep hygiene
Jellyfish poisoning
Lagophthalmos
Lipid storage disease
Lymphangioma
Malingering
Marfan's syndrome
Mechanical complication of internal orthopedic device, implant AND/OR graft
Minimal cognitive impairment
Nicotine dependence
Nonspecific tuberculin test reaction
Opioid abuse
Opioid intoxication
Physiological development failure
Poisoning by tranquilizer
Social exclusion
Symbolic dysfunction
Tooth loss
Toxic effect of lead compound
Toxic effect of tobacco and nicotine
Tracheostomy present
Unsatisfactory tooth restoration
Abnormal pupil
Abrasion and/or friction burn of trunk without infection
Absence of breast
Acquired hallux valgus
Acquired keratoderma
Anal and rectal polyp
Burn of forearm

Calcaneal spur
Cannabis abuse
Changes in skin texture
Chondromalacia of patella
Cocaine abuse
Complication due to Crohn's disease
Contact dermatitis
Contusion of knee
Crohn's disease
Derangement of knee
Difficulty sleeping
Disproportion of reconstructed breast
Effects of hunger
Endometriosis
Feces contents abnormal
Foreign body in orifice
Ganglion cyst
Hammer toe
Hereditary thrombophilia
High risk sexual behavior
Homocystinuria
Impacted cerumen
Impingement syndrome of shoulder region
Ingrowing nail
Injury of knee
Kwashiorkor
Late effect of contusion
Late effect of motor vehicle accident
Macular drusen
Melena
Nicotine dependence
Noise effects on inner ear
Non-toxic multinodular goiter
Nonspecific tuberculin test reaction
Opioid abuse
Passing flatus
Postviral fatigue syndrome
Presbyopia
Psychalgia
Ptotic breast
Regular astigmatism
Senile hyperkeratosis
Somatic dysfunction of lumbar region
Splinter of face without major open wound
Sprain of ankle
Strain of rotator cuff capsule
Tear film insufficiency
Tobacco dependence syndrome
Verruca vulgaris
Wrist joint pain
Wristdrop

Supplementary Table 5: Baseline patient characteristics for SGLT2is (T) and GLP1-RAs (C) new-users in the CCAE data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.1	0.2	0.03	0.2	0.2	0.01	0.1	0.1	-0.01
25 - 29	0.1	0.2	0.04	0.1	0.2	0.02	0.1	0.2	0.04
30 - 34	0.3	0.9	0.08	0.4	0.8	0.05	0.4	0.8	0.05
35 - 39	1.7	2.6	0.06	2.0	2.3	0.02	1.8	2.0	0.01
40 - 44	4.5	6.3	0.08	5.2	5.8	0.03	4.9	5.3	0.02
45 - 49	10.1	11.5	0.05	10.8	11.4	0.02	10.4	10.8	0.01
50 - 54	18.3	20.2	0.05	19.3	19.9	0.02	19.0	19.5	0.01
55 - 59	29.2	27.0	-0.05	28.1	27.4	-0.02	28.6	28.4	0.00
60 - 64	33.0	28.6	-0.10	31.5	29.6	-0.04	32.1	30.2	-0.04
65 - 69	2.8	2.4	-0.02	2.5	2.4	-0.01	2.7	2.7	0.00
Gender: female	38.1	53.8	0.32	48.2	46.1	-0.04	43.0	41.4	-0.03
Medical history: General									
Acute respiratory disease	29.6	33.5	0.09	33.6	32.5	-0.02	31.5	30.2	-0.03
Attention deficit hyperactivity disorder	1.1	1.5	0.03	1.6	1.5	-0.01	1.3	1.2	-0.01
Chronic liver disease	2.5	2.6	0.01	2.1	2.0	0.00	2.4	2.3	0.00
Chronic obstructive lung disease	5.2	5.5	0.01	5.8	5.1	-0.03	5.5	4.8	-0.03
Crohn's disease	0.3	0.4	0.02	0.4	0.5	0.01	0.3	0.5	0.02
Dementia	0.3	0.2	0.00	0.3	0.3	0.00	0.3	0.3	0.00
Depressive disorder	11.8	15.7	0.11	15.5	14.7	-0.02	13.7	13.4	-0.01
Gastroesophageal reflux disease	17.2	18.2	0.03	19.7	18.3	-0.04	18.5	17.8	-0.02
Gastrointestinal hemorrhage	2.0	2.8	0.05	2.4	2.5	0.00	2.2	2.4	0.01
Human immunodeficiency virus infection	0.4	0.3	-0.02	0.4	0.2	-0.02	0.3	0.3	-0.01
Hyperlipidemia	82.2	74.9	-0.18	80.3	79.9	-0.01	81.3	81.1	0.00
Hypertensive disorder	81.8	76.8	-0.12	81.1	81.0	0.00	81.5	81.9	0.01
Lesion of liver	0.8	0.9	0.01	1.0	0.9	-0.01	0.9	0.8	-0.01
Obesity	31.5	38.0	0.14	43.7	40.7	-0.06	37.6	36.0	-0.03
Osteoarthritis	24.5	29.5	0.11	28.9	28.3	-0.01	26.8	26.4	-0.01
Pneumonia	3.2	3.3	0.01	3.7	3.3	-0.02	3.5	2.8	-0.04
Psoriasis	2.2	2.7	0.03	2.7	2.7	0.00	2.4	2.6	0.01
Renal impairment	5.3	5.6	0.01	6.1	6.6	0.02	5.7	6.2	0.02
Rheumatoid arthritis	1.6	2.0	0.03	2.0	1.7	-0.03	1.7	1.5	-0.02
Schizophrenia	0.1	<0.1	-0.03	0.2	<0.1	-0.04	0.2	<0.1	-0.04
Ulcerative colitis	0.4	0.5	0.01	0.4	0.4	0.00	0.4	0.4	0.00
Urinary tract infectious disease	6.8	9.2	0.09	8.6	7.8	-0.03	7.7	7.5	-0.01
Viral hepatitis C	0.4	0.3	-0.01	0.3	0.2	-0.03	0.3	0.2	-0.02
Visual system disorder	28.1	30.2	0.05	30.2	30.2	0.00	29.2	29.4	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	5.0	4.8	-0.01	5.0	5.3	0.01	5.0	5.3	0.01
Cerebrovascular disease	9.1	8.6	-0.02	8.5	8.1	-0.01	8.9	8.3	-0.02
Coronary arteriosclerosis	34.8	28.0	-0.15	27.6	28.7	0.02	31.5	33.0	0.03
Heart disease	50.8	47.0	-0.08	45.5	46.8	0.03	48.5	50.4	0.04
Heart failure	6.7	5.7	-0.04	6.1	5.7	-0.01	6.5	5.9	-0.03
Ischemic heart disease	18.2	16.1	-0.06	17.1	17.4	0.01	17.1	17.4	0.01
Peripheral vascular disease	15.6	16.1	0.02	16.9	17.6	0.02	16.2	16.4	0.00
Pulmonary embolism	0.9	1.4	0.05	1.1	1.4	0.03	0.9	1.3	0.04
Venous thrombosis	1.5	2.0	0.04	1.7	1.8	0.01	1.6	1.7	0.00
Medical history: Neoplasms									
Hematologic neoplasm	1.0	1.0	0.00	1.2	1.1	-0.01	1.1	1.0	-0.01
Malignant lymphoma	0.4	0.5	0.02	0.4	0.7	0.03	0.4	0.6	0.03
Malignant neoplasm of anorectum	0.1	0.1	-0.02	0.2	<0.1	-0.02	0.2	0.1	-0.02
Malignant neoplastic disease	7.2	7.7	0.02	8.0	7.3	-0.03	7.6	7.1	-0.02
Malignant tumor of breast	1.2	1.5	0.02	1.6	1.2	-0.04	1.5	0.9	-0.05
Malignant tumor of colon	0.3	0.2	-0.02	0.3	0.3	-0.01	0.3	0.3	-0.01
Malignant tumor of lung	0.3	0.1	-0.04	0.3	<0.1	-0.06	0.3	0.1	-0.04
Malignant tumor of urinary bladder	0.2	0.2	0.00	0.2	0.2	0.01	0.2	0.3	0.01
Primary malignant neoplasm of prostate	1.1	0.8	-0.03	1.0	0.9	-0.01	1.0	0.9	-0.01
Medication use									
Agents acting on the renin-angiotensin system	74.5	70.6	-0.09	72.0	71.9	0.00	73.2	73.8	0.01
Antibacterials for systemic use	61.5	67.5	0.13	66.0	64.6	-0.03	63.8	62.8	-0.02
Antidepressants	30.2	41.0	0.23	37.8	36.2	-0.03	34.0	33.0	-0.02
Antiepileptics	17.2	21.9	0.12	20.9	20.4	-0.01	19.1	18.7	-0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antiinflammatory and antirheumatic products	39.0	42.3	0.07	42.4	41.7	-0.01	40.8	40.0	-0.02
Antineoplastic agents	4.5	6.8	0.10	5.9	5.5	-0.02	5.3	5.1	-0.01
Antipsoriatics	0.8	1.0	0.02	0.9	0.9	0.00	0.9	0.9	0.00
Antithrombotic agents	28.4	23.8	-0.10	24.5	24.6	0.00	26.7	27.1	0.01
Beta blocking agents	47.3	43.4	-0.08	43.7	43.6	0.00	45.7	46.2	0.01
Calcium channel blockers	27.3	26.5	-0.02	27.3	27.0	-0.01	27.2	27.1	0.00
Diuretics	42.5	49.4	0.14	46.3	45.2	-0.02	44.3	43.4	-0.02
Drugs for acid related disorders	31.2	35.8	0.10	33.9	33.0	-0.02	32.6	32.4	0.00
Drugs for obstructive airway diseases	42.0	48.1	0.12	47.9	46.3	-0.03	44.9	44.3	-0.01
Immunosuppressants	3.2	4.5	0.07	4.3	4.1	-0.01	3.8	3.8	0.00
Lipid modifying agents	80.0	75.1	-0.12	76.3	76.6	0.01	78.1	78.7	0.01
Opioids	31.3	35.2	0.08	33.6	33.2	-0.01	32.5	32.6	0.00
Psycholeptics	28.4	34.3	0.13	32.6	31.3	-0.03	30.5	29.9	-0.01
Psychostimulants	3.6	5.9	0.11	4.8	5.2	0.02	4.3	4.6	0.02

Supplementary Table 6: Baseline patient characteristics for SGLT2is (T) and GLP1-RAs (C) new-users in the OptumDOD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	0.02	0.1	<0.1	-0.01	0.1	0.1	0.00
30 - 34	0.2	0.5	0.05	0.3	0.4	0.02	0.2	0.4	0.02
35 - 39	0.7	1.6	0.08	0.9	1.3	0.04	0.8	1.1	0.03
40 - 44	2.1	3.4	0.08	2.7	2.8	0.01	2.5	2.7	0.01
45 - 49	4.6	6.4	0.08	5.5	5.4	0.00	5.0	5.3	0.01
50 - 54	7.7	11.4	0.13	9.5	9.8	0.01	8.7	8.8	0.00
55 - 59	12.7	14.9	0.06	13.8	14.1	0.01	13.2	13.5	0.01
60 - 64	15.2	16.7	0.04	16.2	16.5	0.01	15.6	16.2	0.01
65 - 69	19.0	17.8	-0.03	19.3	18.9	-0.01	19.1	18.3	-0.02
70 - 74	19.5	15.1	-0.12	17.1	16.8	-0.01	18.3	18.6	0.01
75 - 79	11.5	8.3	-0.11	9.6	9.6	0.00	10.6	10.5	0.00
80 - 84	4.6	2.7	-0.10	3.5	3.1	-0.02	4.1	3.5	-0.03
85 - 89	1.8	0.8	-0.09	1.5	0.9	-0.05	1.7	1.0	-0.06
90 - 94	0.2	<0.1	-0.05	0.2	<0.1	-0.03	0.2	<0.1	-0.05
Gender: female	38.7	52.9	0.29	50.5	47.6	-0.06	43.7	41.8	-0.04
Medical history: General									
Acute respiratory disease	27.8	30.1	0.05	29.2	28.0	-0.03	28.7	27.8	-0.02
Attention deficit hyperactivity disorder	0.7	1.3	0.05	1.0	0.8	-0.02	0.9	0.8	0.00
Chronic liver disease	2.2	2.7	0.04	2.1	2.3	0.01	2.2	2.1	-0.01
Chronic obstructive lung disease	14.6	14.5	0.00	15.2	14.8	-0.01	15.0	14.8	-0.01
Crohn's disease	0.4	0.3	-0.02	0.4	0.2	-0.04	0.4	0.2	-0.03
Dementia	1.7	1.8	0.00	1.7	1.9	0.01	1.7	1.8	0.01
Depressive disorder	17.9	24.4	0.16	24.0	21.7	-0.05	20.9	19.8	-0.03
Gastroesophageal reflux disease	25.1	26.6	0.04	27.4	25.5	-0.04	26.2	25.5	-0.02
Gastrointestinal hemorrhage	2.9	2.8	0.00	2.9	2.4	-0.03	2.9	2.6	-0.02
Human immunodeficiency virus infection	0.3	0.6	0.04	0.4	0.6	0.02	0.4	0.6	0.03
Hyperlipidemia	87.8	85.2	-0.07	85.2	85.5	0.01	86.7	87.1	0.01
Hypertensive disorder	88.4	86.0	-0.07	87.1	86.8	-0.01	88.0	88.1	0.00
Lesion of liver	1.6	1.5	-0.01	1.7	1.5	-0.01	1.7	1.4	-0.03
Obesity	33.7	47.9	0.29	46.8	43.4	-0.07	39.9	37.7	-0.04
Osteoarthritis	33.9	40.2	0.13	39.5	37.7	-0.04	36.7	36.2	-0.01
Pneumonia	5.0	5.4	0.02	5.1	5.0	0.00	5.2	5.3	0.00
Psoriasis	2.2	2.7	0.04	2.4	2.8	0.03	2.3	2.3	0.01
Renal impairment	17.4	16.0	-0.04	16.7	16.8	0.00	17.3	17.8	0.01
Rheumatoid arthritis	2.2	2.8	0.04	2.8	2.5	-0.02	2.5	2.3	-0.01
Schizophrenia	0.4	0.6	0.04	0.5	0.6	0.00	0.4	0.5	0.01
Ulcerative colitis	0.4	0.4	0.00	0.5	0.3	-0.03	0.5	0.5	0.00
Urinary tract infectious disease	9.1	11.7	0.09	10.8	10.0	-0.03	10.0	9.7	-0.01
Viral hepatitis C	0.6	0.7	0.01	0.6	0.7	0.02	0.6	0.7	0.01
Visual system disorder	45.2	42.8	-0.05	43.9	43.6	-0.01	44.8	44.4	-0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	12.4	9.5	-0.09	9.8	10.3	0.01	11.5	11.7	0.01
Cerebrovascular disease	13.3	11.3	-0.06	11.6	11.4	-0.01	12.7	12.4	-0.01
Coronary arteriosclerosis	44.7	33.8	-0.22	34.8	36.2	0.03	40.9	42.4	0.03
Heart disease	62.3	54.4	-0.16	54.7	56.0	0.03	59.5	61.3	0.04
Heart failure	16.4	12.0	-0.12	12.3	12.7	0.01	15.1	15.3	0.01
Ischemic heart disease	24.3	18.5	-0.14	18.9	19.4	0.01	22.2	22.6	0.01
Peripheral vascular disease	27.0	26.7	-0.01	27.2	27.5	0.01	27.2	26.9	-0.01
Pulmonary embolism	1.3	1.7	0.03	1.3	1.5	0.02	1.3	1.4	0.00
Venous thrombosis	2.3	2.3	0.00	2.3	2.2	-0.01	2.3	2.2	-0.01
Medical history: Neoplasms									
Hematologic neoplasm	1.3	1.2	-0.01	1.3	1.1	-0.01	1.3	1.1	-0.02
Malignant lymphoma	0.7	0.7	0.00	0.6	0.7	0.02	0.6	0.7	0.01
Malignant neoplasm of anorectum	0.2	0.2	-0.01	0.2	0.2	-0.01	0.2	0.2	-0.01
Malignant neoplastic disease	12.3	10.9	-0.04	11.6	11.2	-0.01	11.9	11.8	0.00
Malignant tumor of breast	1.5	1.8	0.03	1.9	1.7	-0.02	1.6	1.6	0.00
Malignant tumor of colon	0.6	0.7	0.01	0.5	0.6	0.02	0.6	0.6	0.00
Malignant tumor of lung	0.5	0.3	-0.03	0.5	0.4	-0.02	0.5	0.5	0.00
Malignant tumor of urinary bladder	0.5	0.5	0.00	0.3	0.4	0.02	0.4	0.4	0.01
Primary malignant neoplasm of prostate	2.8	1.8	-0.07	2.1	2.1	0.01	2.5	2.6	0.01
Medication use									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Agents acting on the renin-angiotensin system	76.9	72.7	-0.10	74.6	74.6	0.00	75.9	76.5	0.01
Antibacterials for systemic use	60.2	64.7	0.09	63.6	62.0	-0.03	62.0	60.9	-0.02
Antidepressants	31.8	43.0	0.23	41.6	39.2	-0.05	36.2	34.8	-0.03
Antiepileptics	22.5	29.3	0.16	28.3	27.2	-0.03	25.2	24.7	-0.01
Antiinflammatory and antirheumatic products	33.6	39.8	0.13	39.3	37.8	-0.03	36.3	34.9	-0.03
Antineoplastic agents	6.4	7.4	0.04	7.2	6.8	-0.01	6.7	6.6	-0.01
Antipsoriatics	0.5	0.9	0.04	0.6	0.8	0.02	0.6	0.8	0.03
Antithrombotic agents	35.2	27.4	-0.17	28.5	29.1	0.01	32.6	33.3	0.01
Beta blocking agents	55.3	47.4	-0.16	48.5	49.2	0.01	52.9	53.8	0.02
Calcium channel blockers	32.0	30.1	-0.04	31.5	31.0	-0.01	31.7	31.8	0.00
Diuretics	48.3	51.4	0.06	50.4	50.2	0.00	49.6	49.4	0.00
Drugs for acid related disorders	34.7	37.0	0.05	37.4	35.8	-0.03	36.0	35.4	-0.01
Drugs for obstructive airway diseases	43.5	50.7	0.14	49.5	48.6	-0.02	46.5	46.1	-0.01
Immunosuppressants	3.3	4.1	0.04	3.9	3.8	-0.01	3.7	3.3	-0.02
Lipid modifying agents	85.7	79.9	-0.15	81.6	82.4	0.02	84.0	84.1	0.00
Opioids	32.8	36.3	0.07	35.2	34.0	-0.03	34.2	32.9	-0.03
Psycholeptics	29.8	34.1	0.09	33.1	31.2	-0.04	31.6	30.0	-0.03
Psychostimulants	2.1	3.8	0.10	2.8	2.9	0.01	2.5	2.7	0.01

Supplementary Table 7: Baseline patient characteristics for SGLT2is (T) and GLP1-RAs (C) new-users in the MDCR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
50 - 54	<0.2	<0.4	0.03	<0.2	<0.7	-0.01	<0.3	<0.5	0.02
55 - 59	1.0	1.1	0.01	1.2	1.1	-0.01	1.1	0.7	-0.04
60 - 64	2.1	2.5	0.02	2.4	1.7	-0.04	2.2	2.3	0.01
65 - 69	27.8	34.6	0.15	29.1	32.3	0.07	28.2	31.3	0.07
70 - 74	36.9	36.8	0.00	36.7	36.3	-0.01	36.8	35.5	-0.03
75 - 79	21.3	16.2	-0.13	20.4	16.4	-0.10	21.0	17.7	-0.08
80 - 84	7.5	6.1	-0.06	7.1	8.5	0.05	7.3	8.1	0.03
85 - 89	2.6	2.0	-0.04	2.3	2.7	0.03	2.5	3.3	0.04
90 - 94	0.5	0.6	0.01	0.5	0.9	0.06	0.5	1.0	0.05
Gender: female	36.1	49.2	0.27	48.9	45.7	-0.06	39.8	38.0	-0.04
Medical history: General									
Acute respiratory disease	26.0	25.8	0.00	28.5	26.2	-0.05	26.9	25.0	-0.04
Attention deficit hyperactivity disorder	<0.2	<0.4	0.01	<0.2	<0.7	0.01	<0.3	<0.5	-0.01
Chronic liver disease	2.3	2.1	-0.02	2.9	1.5	-0.10	2.4	1.2	-0.09
Chronic obstructive lung disease	14.2	15.7	0.04	16.3	15.3	-0.03	16.3	15.3	-0.03
Crohn's disease	0.5	0.5	0.00	0.4	<0.7	0.00	0.5	<0.5	0.01
Dementia	1.9	2.1	0.02	2.5	3.0	0.03	2.1	2.6	0.03
Depressive disorder	9.9	13.8	0.12	15.4	15.9	0.01	11.7	12.1	0.01
Gastroesophageal reflux disease	19.0	17.2	-0.05	22.5	20.2	-0.06	20.3	18.8	-0.04
Gastrointestinal hemorrhage	3.8	2.9	-0.05	3.8	2.2	-0.10	3.8	2.2	-0.09
Human immunodeficiency virus infection	<0.2	<0.4	0.00	<0.2	<0.7	0.01	<0.3	<0.5	0.02
Hyperlipidemia	84.8	69.0	-0.38	84.6	83.2	-0.04	84.8	83.1	-0.05
Hypertensive disorder	87.7	81.4	-0.17	88.1	88.6	0.01	87.8	88.9	0.03
Lesion of liver	1.7	0.9	-0.07	1.6	0.9	-0.06	1.7	0.8	-0.08
Obesity	25.9	29.5	0.08	39.9	36.4	-0.07	30.3	27.3	-0.07
Osteoarthritis	36.1	39.4	0.07	41.1	41.9	0.02	37.5	37.9	0.01
Pneumonia	5.0	4.8	-0.01	5.5	5.0	-0.02	5.2	4.7	-0.02
Psoriasis	2.5	2.9	0.03	2.4	3.5	0.07	2.5	3.8	0.08
Renal impairment	14.5	14.5	0.00	16.0	17.9	0.05	15.0	16.9	0.05
Rheumatoid arthritis	1.7	1.9	0.01	2.1	2.3	0.01	1.8	1.7	0.00
Ulcerative colitis	0.5	<0.4	-0.02	0.6	<0.7	-0.01	0.5	0.7	0.02
Urinary tract infectious disease	8.1	11.5	0.12	9.8	11.8	0.06	8.6	10.3	0.06
Viral hepatitis C	0.6	<0.4	-0.09	0.5	<0.7	-0.07	0.6	<0.5	-0.07
Visual system disorder	57.8	51.6	-0.12	56.8	55.1	-0.04	57.5	55.2	-0.04
Medical history: Cardiovascular disease									
Atrial fibrillation	16.7	12.1	-0.13	15.1	12.9	-0.06	16.2	14.3	-0.05
Cerebrovascular disease	18.9	17.9	-0.03	18.6	17.9	-0.02	18.7	17.6	-0.03
Coronary arteriosclerosis	51.9	43.1	-0.18	43.1	45.6	0.05	49.4	51.0	0.03
Heart disease	71.2	62.3	-0.19	64.2	63.8	-0.01	69.2	68.7	-0.01
Heart failure	15.3	11.3	-0.12	15.7	12.1	-0.10	15.5	12.5	-0.09
Ischemic heart disease	21.9	17.9	-0.10	19.7	17.7	-0.05	21.3	18.7	-0.06
Peripheral vascular disease	24.9	22.5	-0.06	26.6	23.4	-0.07	25.5	22.6	-0.07
Pulmonary embolism	1.0	1.3	0.02	1.2	1.3	0.01	1.1	1.2	0.01
Venous thrombosis	2.2	2.1	-0.01	2.4	1.9	-0.04	2.3	1.6	-0.05
Medical history: Neoplasms									
Hematologic neoplasm	1.7	2.1	0.03	1.4	2.7	0.09	1.6	2.4	0.06
Malignant lymphoma	1.2	1.2	0.00	1.0	1.3	0.03	1.2	1.2	0.00
Malignant neoplastic disease	19.2	20.5	0.03	18.7	21.6	0.07	19.0	22.4	0.09
Malignant tumor of breast	2.2	3.8	0.09	3.3	3.6	0.02	2.5	3.1	0.04
Malignant tumor of colon	0.7	0.5	-0.02	0.8	<0.7	-0.03	0.7	0.6	-0.01
Malignant tumor of lung	0.4	0.8	0.04	0.4	1.1	0.09	0.4	1.1	0.08
Malignant tumor of urinary bladder	1.2	1.8	0.04	0.9	2.2	0.10	1.2	2.3	0.09
Primary malignant neoplasm of prostate	5.4	4.6	-0.04	4.6	4.8	0.01	5.2	5.7	0.02
Medication use									
Agents acting on the renin-angiotensin system	77.6	78.2	0.01	76.6	76.9	0.01	77.2	77.7	0.01
Antibacterials for systemic use	64.8	66.7	0.04	67.5	66.0	-0.03	65.6	64.4	-0.03
Antidepressants	27.0	36.6	0.21	38.3	34.5	-0.08	30.6	27.3	-0.07
Antiepileptics	19.7	21.2	0.04	24.4	21.2	-0.07	21.3	19.0	-0.06
Antiinflammatory and antirheumatic products	29.9	34.6	0.10	34.1	34.0	0.00	31.2	30.4	-0.02
Antineoplastic agents	8.4	10.1	0.06	9.3	9.9	0.02	8.7	10.3	0.06
Antipsoriatics	0.9	1.2	0.02	0.7	1.1	0.04	0.9	1.1	0.02

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antithrombotic agents	38.5	35.1	-0.07	35.6	33.9	-0.04	37.7	36.9	-0.02
Beta blocking agents	61.7	55.9	-0.12	55.5	57.7	0.04	59.8	62.1	0.05
Calcium channel blockers	35.9	33.7	-0.05	35.8	32.1	-0.08	36.0	32.7	-0.07
Diuretics	53.1	56.4	0.07	55.3	52.6	-0.06	53.7	50.8	-0.06
Drugs for acid related disorders	39.1	39.9	0.02	43.2	39.0	-0.09	40.5	37.8	-0.05
Drugs for obstructive airway diseases	48.5	53.1	0.09	53.1	53.2	0.00	53.1	53.2	0.00
Immunosuppressants	3.9	4.1	0.01	4.4	5.0	0.03	4.0	4.5	0.02
Lipid modifying agents	89.2	86.7	-0.08	86.4	87.5	0.03	88.3	87.7	-0.02
Opioids	28.9	32.1	0.07	32.9	31.7	-0.03	30.1	30.4	0.01
Psycholeptics	26.0	31.2	0.11	30.4	28.2	-0.05	27.5	25.8	-0.04
Psychostimulants	1.6	2.1	0.04	2.4	1.7	-0.04	1.9	1.6	-0.02

Supplementary Table 8: Baseline patient characteristics for SGLT2is (T) and GLP1-RAs (C) new-users in the Open Claims data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.1	0.2	0.02	0.2	0.2	0.00	0.1	0.2	0.00
25 - 29	0.2	0.3	0.03	0.2	0.3	0.01	0.2	0.3	0.01
30 - 34	0.4	0.8	0.05	0.6	0.6	0.00	0.5	0.6	0.01
35 - 39	1.0	1.7	0.06	1.4	1.5	0.00	1.2	1.3	0.01
40 - 44	2.4	3.8	0.08	2.9	3.0	0.00	2.9	3.0	0.00
45 - 49	5.2	7.1	0.08	6.6	6.4	-0.01	5.9	5.9	0.00
50 - 54	9.4	11.9	0.08	11.1	11.0	0.00	11.1	11.0	0.00
55 - 59	14.5	16.5	0.06	16.3	16.0	-0.01	15.3	15.1	0.00
60 - 64	18.0	18.3	0.01	18.7	18.5	-0.01	18.2	17.9	-0.01
65 - 69	17.5	16.7	-0.02	17.1	17.4	0.01	17.2	17.4	0.01
70 - 74	14.4	12.2	-0.06	12.9	13.1	0.01	13.6	13.7	0.00
75 - 79	10.0	6.8	-0.12	7.5	7.6	0.00	8.9	8.9	0.00
80 - 84	6.1	3.3	-0.13	3.8	3.8	0.00	5.2	5.1	0.00
85 - 89	0.5	0.3	-0.04	0.3	0.3	0.00	0.4	0.4	-0.01
Gender: female	39.9	54.4	0.29	50.7	50.0	-0.01	44.9	44.6	-0.01
Medical history: General									
Acute respiratory disease	15.6	17.1	0.04	16.3	16.1	0.00	16.3	16.1	0.00
Attention deficit hyperactivity disorder	0.5	0.9	0.05	0.7	0.7	0.00	0.6	0.6	0.00
Chronic liver disease	1.3	1.1	-0.01	1.2	1.1	-0.01	1.3	1.2	0.00
Crohn's disease	0.2	0.2	0.00	0.2	0.2	-0.01	0.2	0.2	-0.01
Dementia	0.9	0.7	-0.02	0.8	0.8	0.00	0.9	0.9	0.00
Depressive disorder	8.0	12.0	0.13	10.6	10.2	-0.01	9.5	9.4	0.00
Gastroesophageal reflux disease	10.6	12.7	0.06	11.8	11.5	-0.01	11.4	11.3	0.00
Gastrointestinal hemorrhage	1.8	1.8	0.00	1.7	1.7	0.00	1.7	1.7	0.00
Human immunodeficiency virus infection	0.3	0.4	0.01	0.3	0.3	0.00	0.3	0.3	0.00
Hyperlipidemia	53.2	50.1	-0.06	50.4	50.2	0.00	52.3	52.3	0.00
Hypertensive disorder	60.7	59.4	-0.03	59.1	58.9	-0.01	60.4	60.6	0.00
Lesion of liver	0.8	0.9	0.00	0.9	0.8	-0.01	0.9	0.8	-0.01
Obesity	13.9	23.1	0.24	19.5	18.7	-0.02	17.2	17.2	0.00
Osteoarthritis	19.0	23.6	0.11	21.9	21.6	-0.01	20.6	20.8	0.00
Pneumonia	3.4	3.4	0.00	3.3	3.2	0.00	3.4	3.3	0.00
Psoriasis	1.2	1.5	0.03	1.3	1.3	0.00	1.3	1.3	0.00
Renal impairment	9.5	8.2	-0.04	8.6	8.3	-0.01	9.3	9.0	-0.01
Rheumatoid arthritis	1.3	1.8	0.04	1.6	1.5	0.00	1.5	1.5	0.00
Schizophrenia	0.3	0.3	0.00	0.4	0.3	-0.01	0.3	0.3	-0.01
Ulcerative colitis	0.3	0.2	0.00	0.3	0.2	-0.01	0.3	0.2	-0.01
Urinary tract infectious disease	5.2	6.5	0.06	6.0	5.9	0.00	5.7	5.7	0.00
Viral hepatitis C	0.4	0.3	-0.01	0.4	0.3	-0.01	0.4	0.3	0.00
Visual system disorder	21.8	21.3	-0.01	21.1	21.1	0.00	21.7	21.6	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	8.4	6.1	-0.09	7.7	7.5	-0.01	7.7	7.5	-0.01
Cerebrovascular disease	7.5	6.4	-0.04	6.6	6.5	0.00	7.1	7.1	0.00
Coronary arteriosclerosis	28.2	20.2	-0.19	21.4	21.5	0.00	21.4	21.5	0.00
Heart disease	44.2	35.4	-0.18	36.6	36.5	0.00	41.3	41.2	0.00
Heart failure	11.3	6.8	-0.16	7.4	7.1	-0.01	10.0	9.1	-0.03
Ischemic heart disease	13.9	9.7	-0.13	10.3	10.2	0.00	12.5	12.2	-0.01
Pulmonary embolism	0.8	1.1	0.03	0.9	0.9	0.00	0.9	0.9	0.00
Venous thrombosis	1.3	1.2	0.00	1.2	1.2	0.00	1.3	1.2	0.00
Medical history: Neoplasms									
Hematologic neoplasm	0.8	0.8	0.00	0.8	0.8	0.00	0.8	0.8	0.00
Malignant lymphoma	0.5	0.4	-0.01	0.5	0.4	-0.01	0.5	0.5	0.00
Malignant neoplasm of anorectum	0.1	0.1	-0.02	0.1	0.1	-0.02	0.1	0.1	-0.01
Malignant neoplastic disease	7.5	6.9	-0.02	7.0	6.9	0.00	7.3	7.2	0.00
Malignant tumor of breast	1.1	1.3	0.02	1.3	1.3	0.00	1.2	1.2	0.00
Malignant tumor of colon	0.3	0.3	0.00	0.3	0.3	0.00	0.3	0.3	0.00
Malignant tumor of lung	0.3	0.3	-0.01	0.3	0.3	0.00	0.3	0.3	0.00
Malignant tumor of urinary bladder	0.3	0.3	0.00	0.3	0.3	0.00	0.3	0.4	0.01
Primary malignant neoplasm of prostate	1.6	1.2	-0.04	1.3	1.3	0.00	1.5	1.5	0.00
Medication use									
Agents acting on the renin-angiotensin system	74.6	68.7	-0.13	70.7	70.6	0.00	72.9	72.7	0.00
Antibacterials for systemic use	58.9	63.4	0.09	62.4	61.5	-0.02	60.7	60.4	-0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antidepressants	32.1	42.9	0.22	40.3	39.2	-0.02	36.1	35.9	0.00
Antiepileptics	23.4	30.0	0.15	28.1	27.6	-0.01	25.9	25.9	0.00
Antiinflammatory and antirheumatic products	39.5	43.4	0.08	42.0	41.6	-0.01	40.9	40.6	0.00
Antineoplastic agents	5.9	7.2	0.05	6.7	6.5	-0.01	6.3	6.2	0.00
Antipsoriatics	0.8	1.1	0.03	1.0	1.0	0.00	0.9	0.9	0.00
Antithrombotic agents	38.2	29.8	-0.18	31.1	31.2	0.00	35.4	35.4	0.00
Beta blocking agents	55.8	47.1	-0.18	48.8	48.7	0.00	52.9	52.9	0.00
Calcium channel blockers	31.9	30.4	-0.03	31.1	31.2	0.00	31.4	31.7	0.00
Diuretics	47.8	49.1	0.02	48.8	48.2	-0.01	48.6	47.9	-0.01
Drugs for acid related disorders	40.6	43.3	0.06	42.4	42.0	-0.01	41.7	41.6	0.00
Drugs for obstructive airway diseases	42.7	48.7	0.12	47.2	46.5	-0.01	45.0	44.7	-0.01
Immunosuppressants	3.4	4.4	0.05	4.0	3.9	0.00	3.7	3.7	0.00
Lipid modifying agents	82.5	76.1	-0.16	78.2	78.3	0.00	80.5	80.4	0.00
Opioids	28.2	31.9	0.08	30.5	30.3	-0.01	29.6	29.8	0.00
Psycholeptics	26.2	31.8	0.12	30.1	29.5	-0.01	28.3	28.2	0.00
Psychostimulants	2.7	4.7	0.11	3.9	3.7	-0.01	3.4	3.4	0.00

Supplementary Table 9: Baseline patient characteristics for SGLT2is (T) and GLP1-RAs (C) new-users in the OptumEHR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
15 - 19	<0.1	<0.1	0.01	<0.1	<0.1	0.00	<0.1	<0.1	0.00
20 - 24	<0.1	0.1	0.02	0.1	<0.1	-0.02	0.1	<0.1	-0.02
25 - 29	0.1	0.4	0.06	0.1	0.4	0.05	0.1	0.2	0.03
30 - 34	0.4	0.6	0.03	0.6	0.5	-0.01	0.5	0.5	0.00
35 - 39	1.2	2.0	0.07	1.5	1.8	0.03	1.3	1.6	0.02
40 - 44	3.3	4.8	0.08	4.1	4.1	0.00	3.7	3.8	0.00
45 - 49	6.6	8.3	0.06	7.5	7.9	0.01	7.0	7.5	0.02
50 - 54	10.8	14.3	0.11	13.0	12.8	0.00	11.8	12.0	0.01
55 - 59	17.1	17.6	0.01	17.6	17.9	0.01	17.3	17.5	0.00
60 - 64	20.8	19.8	-0.02	20.3	20.3	0.00	20.5	20.3	0.00
65 - 69	16.2	15.2	-0.03	15.7	16.0	0.01	15.8	16.7	0.02
70 - 74	12.5	9.7	-0.09	10.8	10.5	-0.01	11.8	11.6	-0.01
75 - 79	6.8	5.0	-0.08	5.6	5.3	-0.01	6.3	5.7	-0.03
80 - 84	3.1	1.6	-0.10	2.3	1.8	-0.03	2.8	2.0	-0.05
85 - 89	1.0	0.4	-0.07	0.9	0.5	-0.05	1.0	0.6	-0.05
Gender: female	35.4	50.2	0.30	49.0	45.8	-0.06	40.9	38.1	-0.06
Race									
Asian	1.9	1.1	-0.06	1.4	1.3	-0.01	1.7	1.4	-0.03
Black or African American	8.1	10.1	0.07	9.4	9.8	0.01	8.6	8.7	0.00
White	83.7	83.6	0.00	83.1	83.8	0.02	83.4	84.7	0.03
Ethnicity									
Hispanic or Latino	4.5	4.0	-0.02	4.5	3.8	-0.04	4.6	4.0	-0.03
Not Hispanic or Latino	86.3	88.3	0.06	87.8	88.0	0.01	86.8	87.6	0.03
Medical history: General									
Acute respiratory disease	19.3	21.3	0.05	21.7	20.2	-0.04	20.3	19.0	-0.03
Attention deficit hyperactivity disorder	0.6	1.0	0.04	1.0	0.9	-0.01	0.8	0.8	0.00
Chronic liver disease	2.2	2.7	0.03	2.6	2.5	0.00	2.4	2.5	0.01
Chronic obstructive lung disease	9.9	10.2	0.01	10.7	9.9	-0.03	10.3	9.9	-0.01
Crohn's disease	0.3	0.4	0.02	0.3	0.4	0.01	0.3	0.4	0.01
Dementia	0.8	0.9	0.01	0.8	0.8	0.00	0.8	0.8	0.00
Depressive disorder	14.7	21.4	0.18	20.7	18.5	-0.05	17.4	16.3	-0.03
Gastroesophageal reflux disease	21.8	24.8	0.07	24.7	22.6	-0.05	23.0	21.9	-0.03
Gastrointestinal hemorrhage	1.6	2.0	0.03	1.7	1.9	0.01	1.6	1.9	0.02
Human immunodeficiency virus infection	0.2	0.2	0.01	0.2	0.3	0.02	0.2	0.2	0.00
Hyperlipidemia	78.1	74.6	-0.08	73.9	75.1	0.03	76.5	77.1	0.01
Hypertensive disorder	78.9	77.5	-0.03	77.1	77.0	0.00	78.4	78.5	0.00
Lesion of liver	0.9	1.1	0.02	1.0	1.1	0.00	0.9	1.0	0.01
Obesity	33.2	47.5	0.29	46.1	42.8	-0.06	39.0	36.6	-0.05
Osteoarthritis	20.9	25.3	0.10	24.6	23.9	-0.02	22.7	22.0	-0.02
Pneumonia	2.4	3.0	0.04	2.7	2.9	0.01	2.6	2.8	0.01
Psoriasis	1.7	2.3	0.04	1.9	2.0	0.00	1.8	2.2	0.03
Renal impairment	8.7	9.1	0.01	9.3	8.8	-0.02	9.0	8.8	0.00
Rheumatoid arthritis	1.6	1.8	0.01	2.1	1.6	-0.04	1.9	1.4	-0.04
Schizophrenia	0.2	0.3	0.03	0.2	0.2	0.00	0.2	0.3	0.01
Ulcerative colitis	0.3	0.4	0.00	0.3	0.4	0.02	0.3	0.3	0.00
Urinary tract infectious disease	3.9	5.2	0.06	5.1	4.5	-0.02	4.4	4.3	0.00
Viral hepatitis C	0.4	0.8	0.05	0.5	0.9	0.05	0.5	0.8	0.05
Visual system disorder	13.0	15.0	0.06	14.0	14.4	0.01	13.6	13.7	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	8.8	7.5	-0.05	7.5	7.9	0.01	8.4	8.6	0.01
Cerebrovascular disease	9.1	8.6	-0.02	8.9	8.4	-0.02	8.9	8.4	-0.02
Coronary arteriosclerosis	47.4	34.5	-0.26	34.8	37.3	0.05	42.4	44.9	0.05
Heart disease	61.8	52.6	-0.19	51.6	54.3	0.05	58.0	60.6	0.05
Heart failure	9.9	7.8	-0.07	9.3	9.3	0.00	9.3	9.3	0.00
Ischemic heart disease	22.0	17.8	-0.11	17.6	18.2	0.01	20.4	21.0	0.02
Peripheral vascular disease	20.3	20.9	0.01	21.7	20.7	-0.03	20.9	19.7	-0.03
Pulmonary embolism	0.9	1.1	0.03	1.1	1.1	0.00	1.1	1.1	0.00
Venous thrombosis	1.8	1.8	0.00	2.0	1.7	-0.03	1.8	1.7	-0.01
Medical history: Neoplasms									
Hematologic neoplasm	0.9	0.6	-0.03	1.0	0.6	-0.04	1.0	0.6	-0.04
Malignant lymphoma	0.5	0.5	0.01	0.5	0.6	0.01	0.5	0.5	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant neoplasm of anorectum	0.1	0.2	0.03	0.1	0.2	0.02	0.1	0.1	0.02
Malignant neoplastic disease	7.1	7.2	0.00	7.5	7.3	-0.01	7.3	6.9	-0.02
Malignant tumor of breast	1.0	1.4	0.03	1.4	1.3	-0.01	1.2	1.0	-0.02
Malignant tumor of colon	0.4	0.2	-0.03	0.4	0.2	-0.04	0.4	0.2	-0.04
Malignant tumor of lung	0.2	0.1	-0.02	0.2	0.2	-0.02	0.2	0.1	-0.03
Malignant tumor of urinary bladder	0.4	0.3	0.00	0.3	0.4	0.01	0.4	0.5	0.01
Primary malignant neoplasm of prostate	1.7	1.0	-0.06	1.3	1.2	-0.01	1.6	1.4	-0.01
Medication use									
Agents acting on the renin-angiotensin system	75.2	71.3	-0.09	72.3	72.1	0.00	72.3	72.1	0.00
Antibacterials for systemic use	45.0	50.3	0.11	49.8	47.9	-0.04	47.1	46.2	-0.02
Antidepressants	31.9	42.5	0.22	41.5	38.8	-0.05	36.0	34.4	-0.03
Antiepileptics	21.1	26.5	0.13	25.9	24.0	-0.04	23.3	22.1	-0.03
Antiinflammatory and antirheumatic products	71.6	70.5	-0.03	70.4	69.8	-0.01	71.4	71.2	0.00
Antineoplastic agents	4.9	6.1	0.05	5.9	5.7	-0.01	5.9	5.7	-0.01
Antipsoriatics	0.4	0.8	0.06	0.5	0.8	0.04	0.4	0.8	0.05
Antithrombotic agents	68.3	61.2	-0.15	61.7	62.7	0.02	65.7	66.8	0.02
Beta blocking agents	58.9	51.7	-0.14	52.4	53.2	0.01	56.3	57.0	0.01
Calcium channel blockers	30.2	29.3	-0.02	30.0	29.3	-0.02	30.0	29.0	-0.02
Diuretics	45.2	50.4	0.10	49.6	48.8	-0.02	47.0	46.5	-0.01
Drugs for acid related disorders	46.4	49.0	0.05	49.8	46.9	-0.06	47.7	46.5	-0.02
Drugs for obstructive airway diseases	46.3	54.1	0.16	53.2	51.5	-0.04	49.4	47.4	-0.04
Immunosuppressants	3.1	4.4	0.07	3.8	4.2	0.02	3.5	3.9	0.02
Lipid modifying agents	86.7	81.5	-0.14	82.4	83.2	0.02	84.8	85.9	0.03
Opioids	31.7	36.6	0.10	35.1	34.7	-0.01	33.3	32.9	-0.01
Psycholeptics	33.4	39.4	0.12	37.6	36.9	-0.02	35.5	34.7	-0.02
Psychostimulants	3.4	5.1	0.09	4.8	4.7	0.00	4.0	4.0	0.00

Supplementary Table 10: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the CCAE data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	0.02	0.1	0.1	0.02	0.1	0.1	0.02
30 - 34	0.3	0.5	0.03	0.3	0.3	0.00	0.3	0.4	0.01
35 - 39	1.7	1.5	-0.01	1.7	1.5	-0.02	1.6	1.4	-0.02
40 - 44	4.5	4.3	-0.01	4.7	4.1	-0.03	4.7	4.3	-0.02
45 - 49	10.1	9.3	-0.03	9.9	9.8	-0.01	10.0	9.5	-0.02
50 - 54	18.3	18.1	0.00	18.5	18.1	-0.01	18.7	18.1	-0.01
55 - 59	29.2	27.6	-0.04	28.6	28.9	0.01	27.9	27.9	0.00
60 - 64	33.0	35.0	0.04	33.2	34.0	0.02	33.3	35.0	0.04
65 - 69	2.8	3.6	0.04	2.9	3.2	0.02	3.2	3.3	0.01
Gender: female	38.1	42.2	0.08	40.6	40.1	-0.01	41.3	40.6	-0.01
Medical history: General									
Acute respiratory disease	29.6	30.6	0.02	30.5	30.4	0.00	30.5	30.4	0.00
Attention deficit hyperactivity disorder	1.1	0.7	-0.05	1.1	0.9	-0.02	1.1	0.9	-0.02
Chronic liver disease	2.5	4.1	0.09	2.9	2.6	-0.02	3.5	3.2	-0.02
Chronic obstructive lung disease	5.2	6.2	0.04	5.3	5.4	0.01	5.7	5.9	0.01
Crohn's disease	0.3	0.4	0.01	0.3	0.3	0.00	0.4	0.4	0.00
Dementia	0.3	0.3	0.01	0.3	0.4	0.02	0.3	0.4	0.02
Depressive disorder	11.8	10.6	-0.04	11.8	11.9	0.01	11.8	12.1	0.01
Gastroesophageal reflux disease	17.2	14.7	-0.07	17.6	17.6	0.00	17.5	17.6	0.00
Gastrointestinal hemorrhage	2.0	2.7	0.04	2.1	2.1	0.00	2.2	2.3	0.01
Human immunodeficiency virus infection	0.4	0.3	-0.01	0.3	0.4	0.01	0.3	0.4	0.02
Hyperlipidemia	82.2	75.0	-0.18	81.1	82.0	0.02	80.7	81.0	0.01
Hypertensive disorder	81.8	76.5	-0.13	81.2	81.4	0.00	81.2	81.4	0.00
Lesion of liver	0.8	0.9	0.01	0.8	0.8	0.00	0.8	1.0	0.02
Obesity	31.5	19.6	-0.28	29.5	29.9	0.01	28.6	28.7	0.00
Osteoarthritis	24.5	23.7	-0.02	24.9	25.2	0.01	25.5	25.4	0.00
Pneumonia	3.2	3.2	0.00	3.1	3.3	0.01	3.4	3.3	-0.01
Psoriasis	2.2	1.7	-0.03	2.2	1.9	-0.02	2.2	1.9	-0.02
Renal impairment	5.3	5.8	0.02	5.5	5.5	0.00	5.9	6.2	0.01
Rheumatoid arthritis	1.6	1.6	0.00	1.6	1.4	-0.02	1.7	1.5	-0.02
Schizophrenia	0.1	0.2	0.02	0.1	0.2	0.03	0.1	0.2	0.03
Ulcerative colitis	0.4	0.4	-0.01	0.4	0.3	-0.01	0.5	0.4	-0.01
Urinary tract infectious disease	6.8	8.9	0.07	7.4	7.2	-0.01	7.6	7.7	0.00
Viral hepatitis C	0.4	0.5	0.02	0.4	0.2	-0.03	0.4	0.4	-0.01
Visual system disorder	28.1	28.3	0.00	29.2	29.3	0.00	29.6	29.3	-0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	5.0	4.8	-0.01	4.7	4.9	0.01	4.9	5.1	0.01
Cerebrovascular disease	9.1	10.4	0.04	9.4	9.0	-0.01	9.9	9.3	-0.02
Coronary arteriosclerosis	34.8	32.1	-0.06	30.5	31.8	0.03	31.4	32.0	0.01
Heart disease	50.8	49.4	-0.03	47.2	48.0	0.02	48.6	48.6	0.00
Heart failure	6.7	5.8	-0.04	5.4	5.9	0.02	5.8	6.2	0.01
Ischemic heart disease	18.2	16.8	-0.04	15.9	16.5	0.02	15.9	16.5	0.02
Peripheral vascular disease	15.6	13.7	-0.05	14.8	15.2	0.01	14.8	15.2	0.01
Pulmonary embolism	0.9	0.8	0.00	0.8	1.0	0.02	0.9	0.9	0.00
Venous thrombosis	1.5	1.9	0.03	1.6	1.8	0.01	1.7	1.8	0.01
Medical history: Neoplasms									
Hematologic neoplasm	1.0	1.2	0.02	1.0	1.0	0.00	1.2	1.1	-0.01
Malignant lymphoma	0.4	0.6	0.03	0.4	0.4	0.01	0.4	0.5	0.02
Malignant neoplasm of anorectum	0.1	0.2	0.01	0.1	0.1	-0.01	0.1	0.1	0.00
Malignant neoplastic disease	7.2	8.4	0.04	7.5	7.6	0.00	7.5	7.6	0.00
Malignant tumor of breast	1.2	1.5	0.03	1.4	1.2	-0.02	1.4	1.2	-0.02
Malignant tumor of colon	0.3	0.4	0.02	0.3	0.3	0.00	0.4	0.4	0.00
Malignant tumor of lung	0.3	0.3	0.01	0.3	0.3	-0.01	0.4	0.3	-0.02
Malignant tumor of urinary bladder	0.2	0.4	0.03	0.2	0.3	0.02	0.2	0.3	0.03
Primary malignant neoplasm of prostate	1.1	1.2	0.01	1.1	1.1	0.00	1.1	1.2	0.01
Medication use									
Agents acting on the renin-angiotensin system	74.5	73.8	-0.01	73.7	73.5	0.00	73.6	73.9	0.01
Antibacterials for systemic use	61.5	64.3	0.06	62.4	61.7	-0.01	63.0	62.4	-0.01
Antidepressants	30.2	29.3	-0.02	30.1	29.5	-0.01	30.1	29.7	-0.01
Antiepileptics	17.2	16.1	-0.03	17.8	17.6	0.00	17.8	17.6	0.00
Antiinflammatory and antirheumatic products	39.0	35.2	-0.08	39.1	38.5	-0.01	39.0	38.3	-0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antineoplastic agents	4.5	5.6	0.05	4.6	4.9	0.02	4.7	5.0	0.01
Antipsoriatics	0.8	0.7	-0.01	0.8	0.5	-0.03	0.8	0.6	-0.02
Antithrombotic agents	28.4	26.1	-0.05	25.8	26.6	0.02	26.4	26.7	0.01
Beta blocking agents	47.3	46.6	-0.01	44.7	45.4	0.01	45.2	45.9	0.01
Calcium channel blockers	27.3	27.0	-0.01	27.1	27.5	0.01	27.1	27.2	0.00
Diuretics	42.5	43.7	0.02	42.3	41.8	-0.01	42.6	42.3	-0.01
Drugs for acid related disorders	31.2	32.2	0.02	31.6	30.8	-0.02	32.1	31.6	-0.01
Drugs for obstructive airway diseases	42.0	41.3	-0.01	42.6	41.8	-0.02	42.9	42.4	-0.01
Immunosuppressants	3.2	3.0	-0.01	3.3	2.9	-0.02	3.3	3.2	-0.01
Lipid modifying agents	80.0	78.3	-0.04	78.2	78.3	0.00	78.5	78.2	-0.01
Opioids	31.3	32.5	0.03	31.8	31.0	-0.02	33.3	31.7	-0.03
Psycholeptics	28.4	28.9	0.01	28.2	27.8	-0.01	29.1	28.5	-0.01
Psychostimulants	3.6	3.2	-0.02	3.7	3.3	-0.02	3.6	3.4	-0.01

Supplementary Table 11: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the GermanyDA data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
30 - 34	0.2	0.1	-0.02	0.2	<0.1	-0.03	0.4	0.1	-0.05
35 - 39	0.4	0.3	-0.02	0.5	0.4	-0.02	0.7	0.3	-0.05
40 - 44	1.0	0.9	0.00	1.0	1.0	0.00	0.9	1.0	0.00
45 - 49	3.1	2.6	-0.03	3.1	2.8	-0.02	2.9	2.5	-0.03
50 - 54	7.0	5.8	-0.05	6.8	6.0	-0.03	6.4	6.1	-0.01
55 - 59	12.2	10.4	-0.06	12.1	11.9	-0.01	11.7	10.8	-0.03
60 - 64	17.1	13.2	-0.11	15.7	16.1	0.01	14.6	14.3	-0.01
65 - 69	16.5	14.6	-0.05	16.8	16.8	0.00	16.9	15.5	-0.04
70 - 74	15.4	15.7	0.01	15.3	15.1	-0.01	15.1	14.7	-0.01
75 - 79	13.3	16.6	0.09	13.8	15.1	0.04	15.0	16.1	0.03
80 - 84	9.6	12.4	0.09	10.2	9.7	-0.02	10.7	11.8	0.03
85 - 89	3.5	5.7	0.10	3.8	4.0	0.01	3.9	5.3	0.07
90 - 94	0.6	1.5	0.09	0.6	1.0	0.04	0.7	1.4	0.07
Gender: female	30.7	40.5	0.21	34.3	32.3	-0.04	39.0	37.5	-0.03
Medical history: General									
Acute respiratory disease	16.2	18.2	0.05	16.5	16.0	-0.01	17.6	17.1	-0.01
Attention deficit hyperactivity disorder	<0.1	0.2	0.04	<0.1	<0.1	0.04	<0.1	0.2	0.06
Chronic liver disease	0.7	0.5	-0.02	0.6	0.5	-0.02	0.5	0.5	0.01
Chronic obstructive lung disease	8.0	8.7	0.03	7.8	8.3	0.02	9.2	8.4	-0.03
Crohn's disease	0.2	0.2	0.00	0.1	0.2	0.01	0.1	0.2	0.01
Dementia	1.4	3.2	0.12	1.6	1.5	-0.01	2.1	2.9	0.05
Depressive disorder	9.2	10.4	0.04	9.1	9.2	0.00	10.9	10.1	-0.03
Gastroesophageal reflux disease	2.5	3.0	0.03	2.4	2.6	0.01	2.7	2.8	0.00
Gastrointestinal hemorrhage	1.0	1.0	0.00	0.9	0.9	0.00	0.8	1.0	0.02
Hyperlipidemia	28.8	30.4	0.04	28.0	27.6	-0.01	27.7	28.5	0.02
Hypertensive disorder	47.8	54.7	0.14	47.8	46.8	-0.02	50.0	50.6	0.01
Lesion of liver	0.7	0.8	0.01	0.6	0.8	0.03	0.6	0.8	0.03
Obesity	10.2	8.2	-0.07	9.4	9.3	0.00	9.6	8.9	-0.03
Osteoarthritis	11.9	14.1	0.07	12.2	12.6	0.01	12.6	13.3	0.02
Pneumonia	2.1	3.1	0.07	2.0	2.3	0.02	2.4	2.8	0.03
Psoriasis	1.7	1.4	-0.02	1.8	1.5	-0.02	1.6	1.6	0.00
Renal impairment	7.1	9.5	0.09	7.1	6.7	-0.02	7.8	8.7	0.03
Rheumatoid arthritis	1.5	1.5	0.00	1.5	1.0	-0.04	1.6	1.4	-0.02
Schizophrenia	0.2	0.2	0.00	0.2	0.3	0.02	0.3	0.2	-0.02
Ulcerative colitis	0.2	0.3	0.02	0.1	0.2	0.01	0.1	0.3	0.03
Urinary tract infectious disease	4.5	6.1	0.07	4.9	5.3	0.02	5.1	5.7	0.02
Visual system disorder	8.1	10.9	0.10	8.5	8.4	-0.01	9.2	9.6	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	4.7	5.0	0.01	4.3	4.8	0.02	4.3	4.8	0.02
Cerebrovascular disease	8.0	9.6	0.06	8.2	8.2	0.00	8.0	8.9	0.03
Coronary arteriosclerosis	14.6	10.1	-0.14	12.2	11.8	-0.01	11.0	11.6	0.02
Heart disease	46.9	45.4	-0.03	42.6	42.6	0.00	41.8	44.3	0.05
Heart failure	13.4	11.4	-0.06	10.7	10.5	-0.01	10.9	11.2	0.01
Ischemic heart disease	26.5	25.4	-0.03	23.5	22.8	-0.02	22.6	24.0	0.03
Peripheral vascular disease	12.0	12.5	0.01	11.8	11.0	-0.03	10.9	12.3	0.04
Pulmonary embolism	0.7	0.9	0.03	0.5	0.7	0.03	0.5	0.9	0.05
Venous thrombosis	1.8	2.0	0.01	1.8	1.8	0.00	2.4	2.0	-0.03
Medical history: Neoplasms									
Hematologic neoplasm	0.3	0.5	0.03	0.3	0.4	0.01	0.6	0.4	-0.02
Malignant lymphoma	0.2	0.4	0.02	0.2	0.3	0.01	0.4	0.4	-0.01
Malignant neoplasm of anorectum	<0.1	0.2	0.04	<0.1	0.2	0.02	<0.1	0.2	0.04
Malignant neoplastic disease	4.7	6.8	0.09	5.0	5.3	0.01	5.8	6.3	0.02
Malignant tumor of breast	0.6	0.6	0.01	0.5	0.3	-0.03	0.9	0.5	-0.04
Malignant tumor of colon	0.4	0.5	0.02	0.4	0.4	0.00	0.3	0.5	0.02
Malignant tumor of lung	<0.1	0.2	0.03	<0.1	0.2	0.04	<0.1	0.2	0.03
Malignant tumor of urinary bladder	0.2	0.3	0.01	0.2	0.1	-0.02	0.4	0.2	-0.04
Primary malignant neoplasm of prostate	0.8	1.1	0.03	0.9	0.9	0.00	0.7	0.9	0.03
Medication use									
Agents acting on the renin-angiotensin system	79.3	77.3	-0.05	77.3	76.7	-0.01	76.7	77.3	0.01
Antibacterials for systemic use	22.8	28.9	0.14	24.1	22.6	-0.04	27.7	26.1	-0.04
Antidepressants	11.1	12.5	0.04	11.8	11.1	-0.02	13.1	12.2	-0.03

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antiepileptics	5.5	6.6	0.05	5.7	5.8	0.01	6.2	6.7	0.02
Antiinflammatory and antirheumatic products	53.5	54.9	0.03	52.0	52.6	0.01	53.5	53.9	0.01
Antineoplastic agents	1.4	1.3	0.00	1.3	1.0	-0.03	1.5	1.2	-0.02
Antipsoriatics	0.5	0.6	0.00	0.5	0.5	0.00	0.5	0.6	0.02
Antithrombotic agents	56.3	53.4	-0.06	52.5	53.6	0.02	52.4	54.0	0.03
Beta blocking agents	62.9	61.9	-0.02	60.6	60.5	0.00	61.0	61.7	0.02
Calcium channel blockers	39.6	38.6	-0.02	39.1	39.3	0.00	39.9	39.5	-0.01
Diuretics	58.3	59.1	0.02	56.0	55.9	0.00	58.1	57.6	-0.01
Drugs for acid related disorders	42.9	43.9	0.02	42.5	42.3	0.00	44.6	44.3	0.00
Drugs for obstructive airway diseases	19.8	20.5	0.02	19.9	20.1	0.00	21.0	20.3	-0.02
Immunosuppressants	1.0	0.8	-0.03	1.0	0.6	-0.05	0.8	0.7	-0.01
Lipid modifying agents	70.0	61.5	-0.18	65.5	66.5	0.02	62.1	64.2	0.04
Opioids	12.5	14.9	0.07	12.9	12.8	0.00	14.5	14.0	-0.02
Psycholeptics	9.3	11.8	0.08	9.7	9.7	0.00	11.7	11.2	-0.02
Psychostimulants	0.1	0.3	0.04	0.2	<0.1	-0.02	0.3	0.2	-0.03

Supplementary Table 12: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the Optum-DOD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	-0.01	0.1	<0.1	-0.02	0.1	<0.1	-0.02
30 - 34	0.2	0.3	0.01	0.3	0.3	0.01	0.3	0.3	0.01
35 - 39	0.7	0.6	-0.01	0.9	0.6	-0.03	0.9	0.5	-0.05
40 - 44	2.1	1.6	-0.04	1.8	1.6	-0.02	1.8	1.4	-0.03
45 - 49	4.6	3.6	-0.05	4.1	3.7	-0.02	3.7	3.4	-0.01
50 - 54	7.7	6.6	-0.04	7.3	6.9	-0.01	6.7	6.5	-0.01
55 - 59	12.7	10.1	-0.08	11.4	11.7	0.01	11.4	10.5	-0.03
60 - 64	15.2	12.7	-0.07	13.7	14.0	0.01	13.1	12.7	-0.01
65 - 69	19.0	16.6	-0.06	18.9	19.0	0.00	18.0	17.9	0.00
70 - 74	19.5	18.9	-0.01	20.1	21.0	0.02	19.1	20.5	0.04
75 - 79	11.5	14.2	0.08	13.0	12.7	-0.01	12.6	13.6	0.03
80 - 84	4.6	9.1	0.18	7.8	7.8	0.00	7.8	7.8	0.00
85 - 89	1.8	5.1	0.18	2.4	2.1	-0.02	4.2	4.3	0.01
90 - 94	0.2	0.4	0.03	0.2	0.5	0.04	0.2	0.5	0.06
Gender: female	38.7	47.3	0.17	42.8	42.2	-0.01	45.4	44.4	-0.02
Medical history: General									
Acute respiratory disease	27.8	29.2	0.03	28.2	28.0	0.00	29.7	28.5	-0.03
Attention deficit hyperactivity disorder	0.7	0.6	-0.02	0.7	0.8	0.02	0.6	0.7	0.01
Chronic liver disease	2.2	4.0	0.10	2.5	2.4	-0.01	3.5	2.9	-0.03
Chronic obstructive lung disease	14.6	15.5	0.03	14.8	14.6	0.00	16.0	15.8	0.00
Crohn's disease	0.4	0.4	0.01	0.4	0.4	0.00	0.5	0.3	-0.02
Dementia	1.7	4.7	0.17	2.2	2.2	0.00	4.2	4.1	0.00
Depressive disorder	17.9	17.4	-0.01	18.0	18.1	0.00	19.4	18.8	-0.02
Gastroesophageal reflux disease	25.1	23.6	-0.03	25.1	24.3	-0.02	26.2	25.3	-0.02
Gastrointestinal hemorrhage	2.9	3.8	0.05	2.9	3.0	0.00	3.5	3.4	0.00
Human immunodeficiency virus infection	0.3	0.3	0.00	0.3	0.5	0.04	0.3	0.4	0.02
Hyperlipidemia	87.8	87.1	-0.02	86.9	87.0	0.00	87.0	87.1	0.00
Hypertensive disorder	88.4	88.1	-0.01	87.7	87.7	0.00	88.5	88.2	-0.01
Lesion of liver	1.6	1.5	0.00	1.6	1.4	-0.02	2.0	1.5	-0.04
Obesity	33.7	23.3	-0.23	30.2	31.1	0.02	29.1	29.2	0.00
Osteoarthritis	33.9	35.9	0.04	35.1	35.2	0.00	36.9	36.3	-0.01
Pneumonia	5.0	6.3	0.06	4.9	5.1	0.01	6.1	6.1	0.00
Psoriasis	2.2	1.8	-0.03	2.2	1.9	-0.02	2.2	1.9	-0.02
Renal impairment	17.4	23.7	0.16	19.2	18.7	-0.01	22.5	22.7	0.00
Rheumatoid arthritis	2.2	2.5	0.02	2.4	2.5	0.01	2.8	2.6	-0.01
Schizophrenia	0.4	0.5	0.02	0.4	0.6	0.03	0.4	0.6	0.03
Ulcerative colitis	0.4	0.5	0.00	0.4	0.3	-0.02	0.6	0.4	-0.02
Urinary tract infectious disease	9.1	15.6	0.20	10.7	10.4	-0.01	13.6	13.3	-0.01
Viral hepatitis C	0.6	0.7	0.01	0.6	0.6	0.00	0.7	0.7	0.00
Visual system disorder	45.2	47.7	0.05	47.1	46.3	-0.02	48.3	47.7	-0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	12.4	13.0	0.02	11.8	12.0	0.01	12.6	13.3	0.02
Cerebrovascular disease	13.3	16.3	0.08	13.5	13.6	0.00	14.8	14.9	0.00
Coronary arteriosclerosis	44.7	38.4	-0.13	39.5	40.2	0.01	39.1	40.3	0.02
Heart disease	62.3	59.4	-0.06	58.1	58.3	0.01	59.2	60.0	0.02
Heart failure	16.4	14.7	-0.05	13.8	13.9	0.00	15.3	15.6	0.01
Ischemic heart disease	24.3	20.5	-0.09	21.1	21.3	0.00	21.4	21.5	0.00
Peripheral vascular disease	27.0	26.2	-0.02	27.0	27.4	0.01	27.7	28.1	0.01
Pulmonary embolism	1.3	1.3	0.00	1.4	1.3	-0.01	1.7	1.5	-0.02
Venous thrombosis	2.3	2.5	0.01	2.4	1.9	-0.03	2.8	2.3	-0.03
Medical history: Neoplasms									
Hematologic neoplasm	1.3	1.6	0.02	1.4	1.3	-0.01	1.4	1.5	0.01
Malignant lymphoma	0.7	0.8	0.01	0.7	0.7	0.00	0.7	0.8	0.01
Malignant neoplasm of anorectum	0.2	0.3	0.02	0.3	0.2	0.00	0.3	0.3	0.01
Malignant neoplastic disease	12.3	14.3	0.06	12.9	12.2	-0.02	13.0	13.7	0.02
Malignant tumor of breast	1.5	2.2	0.05	1.9	2.0	0.01	1.9	2.0	0.01
Malignant tumor of colon	0.6	0.8	0.03	0.6	0.5	-0.01	0.6	0.8	0.02
Malignant tumor of lung	0.5	0.7	0.03	0.5	0.6	0.02	0.5	0.7	0.02
Malignant tumor of urinary bladder	0.5	0.7	0.04	0.5	0.6	0.01	0.5	0.7	0.03
Primary malignant neoplasm of prostate	2.8	3.2	0.02	3.0	2.7	-0.02	2.9	3.1	0.01
Medication use									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Agents acting on the renin-angiotensin system	76.9	75.8	-0.03	75.8	75.9	0.00	76.0	76.0	0.00
Antibacterials for systemic use	60.2	63.9	0.08	61.6	61.2	-0.01	63.2	62.4	-0.02
Antidepressants	31.8	31.6	0.00	32.0	31.4	-0.01	33.6	32.3	-0.03
Antiepileptics	22.5	22.2	-0.01	23.2	23.0	-0.01	24.3	24.0	-0.01
Antiinflammatory and antirheumatic products	33.6	32.3	-0.03	33.6	33.8	0.00	34.4	33.3	-0.02
Antineoplastic agents	6.4	7.2	0.03	7.0	7.0	0.00	7.0	7.0	0.00
Antipsoriatics	0.5	0.7	0.02	0.6	0.6	0.00	0.5	0.7	0.03
Antithrombotic agents	35.2	31.5	-0.08	32.0	31.9	0.00	33.1	33.1	0.00
Beta blocking agents	55.3	52.3	-0.06	51.9	52.2	0.00	53.1	53.2	0.00
Calcium channel blockers	32.0	33.6	0.04	32.7	32.2	-0.01	33.7	33.5	0.00
Diuretics	48.3	49.6	0.03	47.4	47.3	0.00	49.2	48.6	-0.01
Drugs for acid related disorders	34.7	36.2	0.03	35.5	35.2	-0.01	37.1	36.8	-0.01
Drugs for obstructive airway diseases	43.5	43.9	0.01	44.2	43.7	-0.01	45.7	44.6	-0.02
Immunosuppressants	3.3	3.3	0.00	3.6	3.2	-0.02	3.6	3.3	-0.02
Lipid modifying agents	85.7	82.6	-0.08	84.2	84.5	0.01	83.6	84.2	0.01
Opioids	32.8	33.2	0.01	32.3	31.8	-0.01	33.9	33.1	-0.02
Psycholeptics	29.8	29.7	0.00	29.4	28.6	-0.02	31.5	29.9	-0.04
Psychostimulants	2.1	2.0	-0.01	2.0	2.3	0.02	2.2	2.1	0.00

Supplementary Table 13: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the MDCR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
50 - 54	<0.2	0.1	-0.01	<0.2	<0.3	0.01	<0.2	0.2	0.02
55 - 59	1.0	0.4	-0.07	1.1	0.6	-0.05	1.1	0.5	-0.07
60 - 64	2.1	1.5	-0.05	2.2	1.8	-0.03	2.6	1.6	-0.07
65 - 69	27.8	22.1	-0.13	27.2	27.8	0.01	22.1	23.3	0.03
70 - 74	36.9	28.8	-0.17	35.9	32.7	-0.07	34.9	30.3	-0.10
75 - 79	21.3	22.1	0.02	21.0	22.5	0.04	21.0	22.1	0.03
80 - 84	7.5	15.0	0.24	8.4	9.2	0.03	10.5	12.7	0.07
85 - 89	2.6	7.3	0.22	3.2	3.3	0.01	5.3	6.4	0.04
90 - 94	0.5	2.3	0.15	0.6	1.5	0.09	2.1	2.4	0.02
95 - 99	<0.2	0.4	0.06	<0.2	0.4	0.05	<0.2	0.5	0.08
Gender: female	36.1	44.1	0.16	38.2	38.5	0.01	43.7	42.8	-0.02
Medical history: General									
Acute respiratory disease	26.0	25.4	-0.01	27.1	25.2	-0.04	29.0	26.2	-0.06
Attention deficit hyperactivity disorder	<0.2	0.1	0.00	0.2	0.2	0.01	0.2	0.2	0.01
Chronic liver disease	2.3	2.7	0.02	2.5	1.9	-0.04	3.1	2.6	-0.03
Chronic obstructive lung disease	14.2	14.2	0.00	14.3	13.3	-0.03	14.9	15.0	0.00
Crohn's disease	0.5	0.3	-0.03	0.6	<0.3	-0.06	0.3	0.3	0.00
Dementia	1.9	4.1	0.13	2.1	3.0	0.06	2.5	4.4	0.10
Depressive disorder	9.9	8.6	-0.04	10.0	10.0	0.00	11.9	10.7	-0.04
Gastroesophageal reflux disease	19.0	14.6	-0.12	19.1	19.7	0.01	17.8	19.0	0.03
Gastrointestinal hemorrhage	3.8	4.2	0.02	4.1	2.5	-0.09	3.5	3.8	0.02
Hyperlipidemia	84.8	65.7	-0.46	84.0	84.6	0.02	82.3	81.2	-0.03
Hypertensive disorder	87.7	78.4	-0.25	86.8	87.6	0.02	87.0	86.9	0.00
Lesion of liver	1.7	0.9	-0.07	1.5	1.1	-0.04	1.5	1.3	-0.02
Obesity	25.9	11.0	-0.39	22.9	24.1	0.03	17.8	18.9	0.03
Osteoarthritis	36.1	34.6	-0.03	36.5	35.7	-0.02	36.0	37.4	0.03
Pneumonia	5.0	6.6	0.07	4.9	4.3	-0.03	5.5	6.0	0.02
Psoriasis	2.5	1.6	-0.06	2.4	1.6	-0.06	2.1	1.8	-0.02
Renal impairment	14.5	17.8	0.09	15.1	13.8	-0.04	18.0	19.8	0.04
Rheumatoid arthritis	1.7	2.0	0.02	1.6	1.9	0.02	1.5	2.0	0.04
Ulcerative colitis	0.5	0.6	0.02	0.5	0.7	0.02	0.4	0.6	0.03
Urinary tract infectious disease	8.1	12.3	0.14	8.6	7.9	-0.02	12.3	11.9	-0.01
Viral hepatitis C	0.6	0.3	-0.06	0.6	0.5	-0.01	0.3	0.3	0.00
Visual system disorder	57.8	54.7	-0.06	56.9	58.4	0.03	57.1	57.5	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	16.7	16.7	0.00	16.3	16.1	-0.01	17.1	18.0	0.02
Cerebrovascular disease	18.9	21.7	0.07	18.4	17.0	-0.04	20.6	20.2	-0.01
Coronary arteriosclerosis	51.9	43.7	-0.16	47.7	50.1	0.05	41.8	45.9	0.08
Heart disease	71.2	66.6	-0.10	68.1	68.2	0.00	66.9	67.5	0.01
Heart failure	15.3	14.5	-0.02	13.9	12.5	-0.04	15.5	14.9	-0.02
Ischemic heart disease	21.9	19.4	-0.06	21.4	20.8	-0.01	21.4	19.9	-0.04
Peripheral vascular disease	24.9	22.2	-0.06	23.8	25.4	0.04	22.7	25.0	0.05
Pulmonary embolism	1.0	1.2	0.02	1.0	0.8	-0.02	1.5	1.5	0.00
Venous thrombosis	2.2	2.7	0.03	2.4	1.6	-0.06	2.1	2.7	0.04
Medical history: Neoplasms									
Hematologic neoplasm	1.7	2.1	0.03	1.7	1.7	0.00	1.2	2.3	0.09
Malignant lymphoma	1.2	1.1	-0.01	1.1	1.1	0.00	0.8	1.1	0.03
Malignant neoplasm of anorectum	0.3	0.3	0.00	0.4	<0.3	-0.02	0.4	0.3	-0.02
Malignant neoplastic disease	19.2	21.1	0.05	18.9	19.5	0.02	19.4	21.0	0.04
Malignant tumor of breast	2.2	2.8	0.04	2.3	2.2	0.00	2.5	2.9	0.02
Malignant tumor of colon	0.7	1.0	0.04	0.7	0.8	0.02	0.7	1.0	0.04
Malignant tumor of lung	0.4	0.8	0.05	0.5	1.0	0.06	0.4	1.0	0.07
Malignant tumor of urinary bladder	1.2	1.5	0.02	1.3	1.4	0.01	1.6	1.8	0.01
Primary malignant neoplasm of prostate	5.4	5.0	-0.02	5.3	5.3	0.00	5.8	5.1	-0.03
Medication use									
Agents acting on the renin-angiotensin system	77.6	77.1	-0.01	77.1	76.5	-0.01	75.6	76.7	0.03
Antibacterials for systemic use	64.8	66.1	0.03	65.3	62.8	-0.05	66.0	65.3	-0.01
Antidepressants	27.0	26.6	-0.01	27.5	25.8	-0.04	27.3	26.5	-0.02
Antiepileptics	19.7	17.7	-0.05	19.8	18.6	-0.03	18.8	19.0	0.00
Antiinflammatory and antirheumatic products	29.9	29.5	-0.01	30.1	31.9	0.04	27.2	30.1	0.06
Antineoplastic agents	8.4	9.3	0.03	8.7	8.1	-0.02	9.9	8.3	-0.06

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antipsoriaties	0.9	0.9	0.00	0.9	0.4	-0.06	0.6	0.7	0.01
Antithrombotic agents	38.5	37.2	-0.03	37.2	36.0	-0.03	37.0	37.3	0.00
Beta blocking agents	61.7	60.9	-0.02	59.7	60.1	0.01	58.5	60.9	0.05
Calcium channel blockers	35.9	38.4	0.05	35.7	36.2	0.01	35.3	38.2	0.06
Diuretics	53.1	54.1	0.02	52.2	50.4	-0.04	51.7	51.9	0.00
Drugs for acid related disorders	39.1	37.7	-0.03	39.1	38.0	-0.02	39.6	37.9	-0.04
Drugs for obstructive airway diseases	48.5	44.4	-0.08	48.3	47.1	-0.02	46.9	46.4	-0.01
Immunosuppressants	3.9	3.5	-0.02	3.8	3.9	0.01	3.3	3.8	0.02
Lipid modifying agents	89.2	84.6	-0.14	87.9	87.3	-0.02	86.3	85.5	-0.02
Opioids	28.9	32.1	0.07	29.4	28.4	-0.02	30.4	30.7	0.01
Psycholeptics	26.0	29.3	0.07	27.1	25.8	-0.03	28.6	27.5	-0.03
Psychostimulants	1.6	1.5	-0.01	1.7	1.6	-0.01	1.2	1.3	0.01

Supplementary Table 14: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the MDCD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	<0.4	0.2	0.02	<0.4	<0.4	0.05	<0.3	0.2	0.05
25 - 29	1.4	0.5	-0.09	1.5	0.7	-0.08	1.7	0.5	-0.11
30 - 34	2.4	1.6	-0.06	2.5	1.7	-0.05	2.6	1.6	-0.07
35 - 39	5.9	4.2	-0.08	6.0	5.2	-0.03	5.5	4.6	-0.04
40 - 44	8.4	7.0	-0.05	8.4	7.7	-0.03	7.5	7.5	0.00
45 - 49	14.5	12.1	-0.07	14.4	13.6	-0.02	15.2	12.5	-0.08
50 - 54	17.9	16.3	-0.04	17.4	16.4	-0.03	17.9	16.0	-0.05
55 - 59	22.9	21.2	-0.04	23.1	22.9	0.00	23.7	22.1	-0.04
60 - 64	18.0	19.4	0.04	18.1	18.8	0.02	17.5	19.7	0.06
65 - 69	4.3	6.8	0.11	4.3	5.8	0.07	4.0	6.2	0.10
70 - 74	2.7	4.2	0.09	2.7	2.5	-0.01	2.4	3.6	0.07
75 - 79	0.5	3.2	0.20	0.6	1.9	0.12	0.4	2.7	0.19
80 - 84	0.7	2.2	0.13	0.7	1.2	0.05	0.8	1.7	0.07
85 - 89	<0.4	1.1	0.11	<0.4	1.1	0.10	0.7	1.0	0.04
Gender: female	56.4	61.2	0.10	56.8	58.7	0.04	61.4	60.1	-0.03
Race									
Black or African American	22.7	21.9	-0.02	22.9	20.9	-0.05	23.8	22.9	-0.02
White	63.6	62.5	-0.02	63.2	62.8	-0.01	63.1	61.2	-0.04
Ethnicity									
Hispanic or Latino	1.9	2.0	0.00	1.8	2.5	0.05	1.3	2.2	0.07
Medical history: General									
Acute respiratory disease	38.7	39.8	0.02	38.2	39.4	0.02	42.1	39.0	-0.06
Attention deficit hyperactivity disorder	1.9	1.2	-0.06	1.9	2.1	0.02	1.8	1.4	-0.03
Chronic liver disease	3.8	5.8	0.09	4.0	4.0	0.00	5.5	5.0	-0.03
Chronic obstructive lung disease	29.8	32.3	0.05	29.6	29.5	0.00	31.7	30.7	-0.02
Crohn's disease	0.5	0.3	-0.02	0.5	<0.4	-0.04	0.4	0.3	-0.01
Dementia	1.6	3.9	0.14	1.7	2.9	0.09	1.4	3.8	0.15
Depressive disorder	37.3	36.9	-0.01	36.5	37.8	0.03	35.8	37.2	0.03
Gastroesophageal reflux disease	31.7	32.2	0.01	31.9	32.4	0.01	31.9	32.4	0.01
Gastrointestinal hemorrhage	4.1	4.9	0.04	3.8	4.4	0.03	4.0	4.7	0.04
Human immunodeficiency virus infection	0.6	0.7	0.00	0.7	0.7	0.01	1.1	0.8	-0.03
Hyperlipidemia	74.7	75.6	0.02	74.2	75.8	0.04	72.8	76.3	0.08
Hypertensive disorder	84.9	87.1	0.06	84.9	86.5	0.05	85.9	87.3	0.04
Lesion of liver	1.7	1.8	0.01	1.7	1.8	0.01	1.4	2.1	0.05
Obesity	43.6	36.3	-0.15	42.9	44.2	0.03	44.4	40.9	-0.07
Osteoarthritis	45.7	44.9	-0.01	46.4	45.3	-0.02	46.4	45.3	-0.02
Pneumonia	7.6	10.0	0.08	7.5	7.7	0.01	9.8	9.6	-0.01
Psoriasis	1.8	1.6	-0.01	1.7	1.4	-0.03	1.6	1.6	0.00
Renal impairment	12.3	15.2	0.08	12.5	12.1	-0.01	13.7	15.4	0.05
Rheumatoid arthritis	2.8	2.7	-0.01	2.8	2.8	0.00	4.1	2.7	-0.08
Schizophrenia	3.7	5.0	0.07	3.7	3.8	0.01	4.9	4.6	-0.01
Ulcerative colitis	<0.4	0.2	-0.01	<0.4	<0.4	-0.01	0.9	0.3	-0.08
Urinary tract infectious disease	10.6	14.5	0.12	10.5	12.0	0.05	11.9	13.3	0.04
Viral hepatitis C	2.4	2.6	0.02	2.3	2.5	0.01	2.7	2.7	0.00
Visual system disorder	48.6	46.6	-0.04	48.5	48.6	0.00	48.9	47.1	-0.04
Medical history: Cardiovascular disease									
Atrial fibrillation	6.5	7.5	0.04	6.2	6.5	0.01	6.4	7.4	0.04
Cerebrovascular disease	11.4	13.5	0.06	11.5	10.0	-0.05	12.2	12.3	0.00
Coronary arteriosclerosis	33.6	34.0	0.01	32.7	33.7	0.02	32.1	33.8	0.04
Heart disease	55.0	56.9	0.04	54.0	55.2	0.03	54.3	55.5	0.02
Heart failure	18.1	17.7	-0.01	17.0	16.8	-0.01	16.4	17.2	0.02
Ischemic heart disease	22.5	23.2	0.02	22.2	23.1	0.02	20.6	22.8	0.05
Peripheral vascular disease	22.4	22.7	0.01	22.2	20.8	-0.03	21.2	22.5	0.03
Pulmonary embolism	1.8	1.9	0.01	1.7	2.5	0.05	1.9	2.1	0.02
Venous thrombosis	2.4	3.0	0.03	2.4	2.0	-0.03	2.6	2.7	0.01
Medical history: Neoplasms									
Hematologic neoplasm	0.8	1.3	0.05	0.8	1.1	0.03	0.8	1.1	0.03
Malignant lymphoma	<0.4	0.7	0.05	0.5	0.6	0.01	0.5	0.6	0.01
Malignant neoplasm of anorectum	<0.4	0.2	0.04	<0.4	<0.4	0.07	<0.3	0.3	0.05
Malignant neoplastic disease	6.1	8.4	0.09	6.2	7.4	0.05	5.9	8.0	0.08
Malignant tumor of breast	1.6	2.0	0.03	1.7	1.7	0.00	1.7	1.7	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant tumor of colon	<0.4	0.6	0.06	<0.4	0.7	0.07	<0.3	0.6	0.08
Malignant tumor of lung	<0.4	0.7	0.08	<0.4	0.6	0.07	<0.3	0.6	0.08
Malignant tumor of urinary bladder	<0.4	0.2	0.02	<0.4	<0.4	-0.02	<0.3	0.2	0.03
Primary malignant neoplasm of prostate	<0.4	0.8	0.06	<0.4	0.6	0.04	0.3	0.8	0.06
Medication use									
Agents acting on the renin-angiotensin system	68.7	71.2	0.05	68.6	70.0	0.03	69.8	69.9	0.00
Antibacterials for systemic use	69.6	71.2	0.04	69.2	69.2	0.00	71.4	69.9	-0.03
Antidepressants	55.8	58.0	0.04	55.9	56.7	0.01	56.7	57.9	0.02
Antiepileptics	50.9	48.8	-0.04	50.8	51.4	0.01	51.1	50.7	-0.01
Antiinflammatory and antirheumatic products	66.3	59.9	-0.13	66.0	65.8	0.00	64.7	63.0	-0.04
Antineoplastic agents	5.4	5.5	0.01	5.3	6.0	0.03	5.5	5.2	-0.01
Antipsoriatics	0.4	0.7	0.04	0.4	0.5	0.02	<0.3	0.6	0.07
Antithrombotic agents	45.1	44.8	0.00	43.9	43.2	-0.01	42.8	45.0	0.04
Beta blocking agents	52.8	51.4	-0.03	52.3	49.7	-0.05	51.3	51.1	0.00
Calcium channel blockers	28.2	32.5	0.09	28.9	26.8	-0.05	32.1	31.5	-0.01
Diuretics	53.4	54.6	0.02	53.0	51.1	-0.04	55.5	53.0	-0.05
Drugs for acid related disorders	55.8	58.2	0.05	55.8	56.3	0.01	57.5	57.3	0.00
Drugs for obstructive airway diseases	64.8	63.5	-0.03	64.3	64.0	-0.01	65.3	63.7	-0.03
Immunosuppressants	3.0	3.2	0.01	2.8	4.3	0.08	3.2	3.5	0.01
Lipid modifying agents	77.6	78.5	0.02	77.3	78.6	0.03	75.5	78.2	0.06
Opioids	51.0	53.5	0.05	50.4	50.6	0.00	52.7	52.1	-0.01
Psycholeptics	53.8	54.1	0.00	53.2	51.1	-0.04	54.5	52.7	-0.03
Psychostimulants	5.6	5.1	-0.02	5.5	5.3	-0.01	5.8	4.9	-0.04

Supplementary Table 15: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the Open Claims data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.1	0.1	0.00	0.1	0.1	0.00	0.1	0.1	0.00
25 - 29	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	0.00
30 - 34	0.4	0.4	-0.01	0.4	0.4	-0.01	0.4	0.4	-0.01
35 - 39	1.0	0.9	-0.01	1.1	1.0	-0.01	1.1	0.9	-0.01
40 - 44	2.4	2.0	-0.03	2.4	2.4	0.00	2.3	2.2	-0.01
45 - 49	5.2	4.2	-0.05	5.2	5.2	0.00	4.9	4.7	-0.01
50 - 54	9.4	7.7	-0.06	9.2	9.3	0.01	8.7	8.5	0.00
55 - 59	14.5	11.8	-0.08	14.1	14.3	0.00	13.4	13.2	-0.01
60 - 64	18.0	14.9	-0.09	17.5	17.3	0.00	16.9	16.2	-0.02
65 - 69	17.5	16.6	-0.02	17.0	17.5	0.01	16.7	17.0	0.01
70 - 74	14.4	15.5	0.03	14.5	14.6	0.00	14.7	14.9	0.01
75 - 79	10.0	17.5	0.22	10.9	10.2	-0.02	13.2	14.0	0.02
80 - 84	6.1	8.0	0.07	7.0	7.2	0.01	7.0	7.2	0.01
85 - 89	0.5	0.2	-0.05	0.3	0.4	0.02	0.3	0.4	0.01
Gender: female	39.9	48.5	0.17	43.7	43.7	0.00	46.0	45.7	-0.01
Medical history: General									
Acute respiratory disease	15.6	17.7	0.06	16.2	16.5	0.01	17.0	17.0	0.00
Attention deficit hyperactivity disorder	0.5	0.3	-0.02	0.4	0.4	-0.01	0.4	0.4	-0.01
Chronic liver disease	1.3	1.9	0.05	1.4	1.4	-0.01	1.8	1.7	-0.01
Chronic obstructive lung disease	8.8	10.2	0.05	8.6	8.7	0.00	9.5	9.6	0.00
Crohn's disease	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	-0.01
Dementia	0.9	2.3	0.11	1.7	1.7	0.00	1.7	1.7	0.00
Depressive disorder	8.0	8.8	0.03	8.3	8.4	0.00	8.8	8.6	-0.01
Gastroesophageal reflux disease	10.6	11.4	0.03	10.9	10.9	0.00	11.5	11.2	-0.01
Gastrointestinal hemorrhage	1.8	2.4	0.04	1.9	1.8	0.00	2.2	2.1	0.00
Human immunodeficiency virus infection	0.3	0.3	0.01	0.3	0.3	0.01	0.3	0.3	0.01
Hyperlipidemia	53.2	54.5	0.03	54.2	53.9	-0.01	54.2	53.9	-0.01
Hypertensive disorder	60.7	63.8	0.06	60.9	61.2	0.01	62.5	62.7	0.00
Lesion of liver	0.8	1.0	0.01	0.9	0.9	0.00	0.9	0.9	0.00
Obesity	13.9	11.3	-0.08	13.2	13.2	0.00	12.9	12.6	-0.01
Osteoarthritis	19.0	21.9	0.07	19.8	20.1	0.01	21.1	21.0	0.00
Pneumonia	3.4	4.2	0.04	3.3	3.2	-0.01	3.9	3.8	0.00
Psoriasis	1.2	1.0	-0.01	1.1	1.1	0.00	1.1	1.1	0.00
Renal impairment	9.5	12.9	0.11	9.3	8.8	-0.02	10.9	11.2	0.01
Rheumatoid arthritis	1.3	1.6	0.03	1.6	1.5	-0.01	1.6	1.5	-0.01
Schizophrenia	0.3	0.5	0.03	0.4	0.4	0.01	0.4	0.5	0.01
Ulcerative colitis	0.3	0.3	0.00	0.3	0.2	0.00	0.3	0.2	0.00
Urinary tract infectious disease	5.2	8.6	0.13	6.0	6.1	0.00	7.4	7.3	0.00
Viral hepatitis C	0.4	0.5	0.02	0.4	0.4	0.00	0.4	0.5	0.00
Visual system disorder	21.8	25.0	0.07	22.7	22.7	0.00	23.8	23.7	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	8.4	8.8	0.01	7.5	7.5	0.00	8.2	8.3	0.00
Cerebrovascular disease	7.5	10.2	0.10	7.9	8.0	0.00	7.9	8.0	0.00
Coronary arteriosclerosis	28.2	25.3	-0.06	25.1	24.9	0.00	25.1	24.9	0.00
Heart disease	44.2	42.6	-0.03	40.7	40.4	-0.01	42.3	42.1	0.00
Heart failure	11.3	9.6	-0.06	8.5	8.2	-0.01	9.7	9.3	-0.01
Ischemic heart disease	13.9	12.2	-0.05	11.9	12.0	0.00	11.9	12.0	0.00
Peripheral vascular disease	13.3	14.0	0.02	13.0	13.2	0.00	13.8	13.7	0.00
Pulmonary embolism	0.8	0.9	0.01	0.8	0.8	0.01	0.9	0.9	0.01
Venous thrombosis	1.3	1.6	0.03	1.3	1.3	0.00	1.4	1.5	0.01
Medical history: Neoplasms									
Hematologic neoplasm	0.8	1.1	0.03	0.9	0.9	0.00	1.0	1.0	0.01
Malignant lymphoma	0.5	0.6	0.01	0.5	0.5	0.00	0.6	0.6	0.00
Malignant neoplasm of anorectum	0.1	0.2	0.01	0.2	0.2	0.00	0.2	0.2	0.00
Malignant neoplastic disease	7.5	9.4	0.07	7.8	7.9	0.01	8.4	8.7	0.01
Malignant tumor of breast	1.1	1.6	0.04	1.3	1.3	0.00	1.4	1.4	0.00
Malignant tumor of colon	0.3	0.5	0.03	0.4	0.4	0.00	0.4	0.4	0.00
Malignant tumor of lung	0.3	0.5	0.03	0.3	0.4	0.00	0.4	0.4	0.01
Malignant tumor of urinary bladder	0.3	0.5	0.03	0.4	0.4	0.01	0.4	0.5	0.00
Primary malignant neoplasm of prostate	1.6	1.9	0.02	1.6	1.6	0.00	1.7	1.8	0.01
Medication use									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Agents acting on the renin-angiotensin system	74.6	73.8	-0.02	73.1	73.2	0.00	73.4	73.6	0.00
Antibacterials for systemic use	58.9	62.5	0.07	60.4	60.8	0.01	61.7	61.4	0.00
Antidepressants	32.1	32.9	0.02	32.5	32.3	0.00	33.4	32.7	-0.01
Antiepileptics	23.4	25.3	0.04	24.0	24.3	0.01	24.8	24.8	0.00
Antiinflammatory and antirheumatic products	39.5	40.2	0.01	40.0	40.5	0.01	40.8	40.3	-0.01
Antineoplastic agents	5.9	6.3	0.02	5.9	6.0	0.00	6.2	6.2	0.00
Antithrombotic agents	38.2	37.2	-0.02	35.6	35.4	0.00	36.8	36.7	0.00
Beta blocking agents	55.8	53.3	-0.05	52.6	52.2	-0.01	53.1	53.1	0.00
Calcium channel blockers	31.9	34.1	0.05	32.1	32.2	0.00	32.4	33.1	0.01
Diuretics	47.8	47.9	0.00	46.2	45.7	-0.01	47.5	47.1	-0.01
Drugs for acid related disorders	40.6	43.8	0.06	41.1	41.3	0.00	42.8	42.7	0.00
Drugs for obstructive airway diseases	42.7	43.8	0.02	43.1	43.3	0.00	43.9	43.7	0.00
Immunosuppressants	3.4	3.7	0.02	3.5	3.6	0.01	3.5	3.6	0.01
Lipid modifying agents	82.5	80.0	-0.06	80.9	80.5	-0.01	80.5	80.4	0.00
Opioids	28.2	31.6	0.07	29.3	29.4	0.00	30.7	30.4	-0.01
Psycholeptics	26.2	28.6	0.06	28.2	27.8	-0.01	28.2	27.8	-0.01
Psychostimulants	2.7	2.5	-0.01	2.7	2.6	-0.01	2.7	2.6	-0.01

Supplementary Table 16: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the OptumEHR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	0.00	0.1	0.1	-0.02	0.2	0.1	-0.03
30 - 34	0.4	0.3	-0.02	0.4	0.3	-0.01	0.3	0.3	-0.01
35 - 39	1.2	1.0	-0.02	1.1	1.1	0.00	1.1	1.0	-0.01
40 - 44	3.3	2.2	-0.07	3.1	2.7	-0.02	2.8	2.5	-0.02
45 - 49	6.6	5.1	-0.06	6.3	6.0	-0.01	5.6	5.4	-0.01
50 - 54	10.8	8.9	-0.06	10.5	10.3	-0.01	9.9	9.5	-0.01
55 - 59	17.1	13.5	-0.10	16.3	16.7	0.01	15.1	15.0	0.00
60 - 64	20.8	16.4	-0.11	19.9	20.4	0.01	18.2	18.4	0.00
65 - 69	16.2	16.7	0.01	16.3	16.7	0.01	16.4	16.5	0.00
70 - 74	12.5	14.3	0.05	13.1	13.3	0.01	12.9	13.6	0.02
75 - 79	6.8	11.6	0.17	7.8	7.6	-0.01	9.0	9.3	0.01
80 - 84	3.1	7.6	0.20	3.8	3.5	-0.01	6.4	6.2	-0.01
85 - 89	1.0	2.3	0.10	1.2	1.3	0.01	1.9	2.1	0.02
Gender: female	35.4	43.2	0.16	38.2	37.6	-0.01	42.0	40.6	-0.03
Race									
Asian	1.9	1.9	0.00	1.9	2.1	0.01	2.0	2.0	0.00
Black or African American	8.1	9.5	0.05	8.5	9.0	0.02	9.2	9.3	0.00
White	83.7	82.3	-0.04	83.2	82.4	-0.02	82.4	82.3	0.00
Ethnicity									
Hispanic or Latino	4.5	4.8	0.01	4.5	4.7	0.01	4.4	4.7	0.02
Not Hispanic or Latino	86.3	87.8	0.05	86.7	86.3	-0.01	87.3	87.0	-0.01
Medical history: General									
Acute respiratory disease	19.3	20.0	0.02	19.6	19.4	0.00	19.8	19.8	0.00
Attention deficit hyperactivity disorder	0.6	0.4	-0.03	0.6	0.5	-0.02	0.5	0.5	-0.01
Chronic liver disease	2.2	3.1	0.06	2.4	2.2	-0.02	2.8	2.6	-0.02
Chronic obstructive lung disease	9.9	11.5	0.05	10.2	9.9	-0.01	10.6	11.1	0.02
Crohn's disease	0.3	0.3	0.00	0.3	0.3	-0.01	0.3	0.3	-0.01
Dementia	0.8	2.1	0.11	0.9	1.0	0.01	1.3	1.7	0.04
Depressive disorder	14.7	15.0	0.01	15.0	14.6	-0.01	15.8	15.1	-0.02
Gastrointestinal hemorrhage	1.6	2.2	0.05	1.6	2.1	0.04	1.7	2.1	0.03
Human immunodeficiency virus infection	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	-0.01
Hyperlipidemia	78.1	77.3	-0.02	77.2	77.3	0.00	77.2	77.3	0.00
Hypertensive disorder	78.9	79.2	0.01	78.4	79.0	0.01	79.7	79.4	-0.01
Lesion of liver	0.9	1.0	0.01	0.9	0.8	-0.01	1.1	1.0	-0.01
Obesity	33.2	25.8	-0.16	30.8	31.4	0.01	29.9	29.3	-0.01
Osteoarthritis	20.9	22.6	0.04	21.1	21.2	0.00	22.4	22.2	0.00
Pneumonia	2.4	3.1	0.04	2.4	2.5	0.00	2.6	2.9	0.02
Psoriasis	1.7	1.5	-0.02	1.7	1.7	0.00	1.7	1.6	-0.01
Renal impairment	8.7	12.6	0.13	9.4	9.1	-0.01	11.2	11.4	0.01
Rheumatoid arthritis	1.6	1.5	-0.01	1.8	1.4	-0.03	2.2	1.5	-0.05
Schizophrenia	0.2	0.3	0.03	0.2	0.2	0.01	0.1	0.3	0.03
Ulcerative colitis	0.3	0.3	-0.01	0.4	0.4	0.00	0.3	0.3	0.00
Urinary tract infectious disease	3.9	6.9	0.13	4.4	4.6	0.01	6.2	5.8	-0.01
Viral hepatitis C	0.4	0.6	0.03	0.4	0.5	0.02	0.4	0.6	0.03
Visual system disorder	13.0	15.2	0.06	13.4	13.5	0.00	15.1	14.5	-0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	8.8	10.7	0.06	8.9	8.9	0.00	9.6	10.0	0.01
Cerebrovascular disease	9.1	11.4	0.07	9.6	9.1	-0.01	10.6	10.2	-0.01
Coronary arteriosclerosis	47.4	42.6	-0.10	44.1	44.5	0.01	42.0	43.3	0.03
Heart disease	61.8	59.5	-0.05	59.3	59.3	0.00	59.1	59.3	0.00
Heart failure	9.9	9.2	-0.03	8.8	8.1	-0.03	9.5	9.0	-0.02
Ischemic heart disease	22.0	19.2	-0.07	20.3	20.6	0.01	20.3	20.0	-0.01
Peripheral vascular disease	20.3	17.7	-0.06	18.9	19.6	0.02	19.1	18.9	-0.01
Pulmonary embolism	0.9	0.9	0.00	1.1	0.9	-0.03	1.1	0.9	-0.03
Venous thrombosis	1.8	1.9	0.01	1.8	1.8	0.00	2.3	1.7	-0.04
Medical history: Neoplasms									
Hematologic neoplasm	0.9	1.2	0.02	1.0	1.1	0.01	1.1	1.1	0.00
Malignant lymphoma	0.5	0.7	0.03	0.5	0.5	0.00	0.6	0.7	0.00
Malignant neoplasm of anorectum	0.1	0.1	0.03	0.1	0.1	0.01	<0.1	0.1	0.03
Malignant neoplastic disease	7.1	9.5	0.09	7.5	7.8	0.01	8.6	8.7	0.00
Malignant tumor of breast	1.0	1.5	0.04	1.1	1.1	0.00	1.4	1.3	-0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant tumor of colon	0.4	0.4	0.01	0.3	0.4	0.01	0.4	0.4	0.00
Malignant tumor of lung	0.2	0.5	0.04	0.3	0.3	0.02	0.2	0.4	0.03
Malignant tumor of urinary bladder	0.4	0.5	0.03	0.4	0.4	0.00	0.4	0.5	0.01
Primary malignant neoplasm of prostate	1.7	2.0	0.02	1.7	1.8	0.01	1.6	1.8	0.01
Medication use									
Agents acting on the renin-angiotensin system	75.2	73.7	-0.03	74.3	73.9	-0.01	74.3	73.9	-0.01
Antibacterials for systemic use	45.0	47.0	0.04	45.6	45.7	0.00	47.6	46.3	-0.03
Antidepressants	31.9	32.8	0.02	32.6	32.5	0.00	33.6	32.8	-0.02
Antiepileptics	21.1	22.1	0.03	21.8	22.2	0.01	23.1	22.4	-0.02
Antiinflammatory and antirheumatic products	71.6	69.1	-0.06	70.7	70.6	0.00	70.0	70.3	0.01
Antineoplastic agents	4.9	5.2	0.01	5.1	5.0	-0.01	6.0	5.0	-0.04
Antipsoriatics	0.4	0.8	0.05	0.4	0.6	0.03	0.5	0.7	0.04
Antithrombotic agents	68.3	67.1	-0.03	67.3	67.0	0.00	67.1	67.3	0.00
Beta blocking agents	58.9	57.5	-0.03	57.3	57.5	0.00	57.1	57.9	0.02
Calcium channel blockers	30.2	31.7	0.03	30.1	30.3	0.00	30.9	31.3	0.01
Diuretics	45.2	47.8	0.05	45.1	44.7	-0.01	46.9	46.2	-0.01
Drugs for acid related disorders	46.4	48.1	0.03	47.1	46.0	-0.02	48.6	47.4	-0.02
Drugs for obstructive airway diseases	46.3	47.3	0.02	46.8	46.8	0.00	47.8	47.5	0.00
Immunosuppressants	3.1	2.9	-0.01	3.2	3.0	-0.01	3.4	2.9	-0.03
Lipid modifying agents	86.7	83.6	-0.09	85.6	85.4	-0.01	84.0	84.7	0.02
Opioids	31.7	34.8	0.06	32.2	32.7	0.01	34.2	33.8	-0.01
Psycholeptics	33.4	35.6	0.05	33.8	33.6	0.00	35.3	35.1	0.00
Psychostimulants	3.4	2.5	-0.05	3.4	3.1	-0.02	3.1	2.8	-0.02

Supplementary Table 17: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
30 - 34	<0.2	<0.1	0.00	<0.2	<0.1	-0.03	<0.2	<0.1	-0.03
35 - 39	<0.2	0.1	0.03	<0.2	<0.3	0.06	<0.2	0.1	0.04
40 - 44	1.0	0.4	-0.06	1.1	0.4	-0.08	1.2	0.3	-0.10
45 - 49	2.8	1.9	-0.06	2.9	2.6	-0.02	2.6	1.7	-0.07
50 - 54	6.3	4.0	-0.10	5.7	5.9	0.01	4.2	4.2	0.00
55 - 59	11.9	7.8	-0.14	10.8	10.2	-0.02	9.7	8.7	-0.03
60 - 64	16.6	12.9	-0.10	16.0	14.5	-0.04	13.6	13.1	-0.01
65 - 69	18.9	14.9	-0.11	18.2	18.4	0.00	15.4	15.6	0.00
70 - 74	17.7	16.4	-0.03	18.3	20.2	0.05	19.7	17.7	-0.05
75 - 79	13.6	15.7	0.06	14.2	13.6	-0.02	14.2	15.0	0.02
80 - 84	7.3	13.2	0.19	8.0	8.9	0.03	8.3	11.9	0.12
85 - 89	3.0	9.0	0.25	3.6	3.3	-0.02	8.2	8.3	0.00
90 - 94	0.7	3.1	0.18	0.9	1.4	0.05	1.6	2.8	0.08
95 - 99	<0.2	0.5	0.06	0.2	<0.3	0.03	1.3	0.5	-0.09
Gender: female	21.0	28.4	0.17	23.9	24.6	0.02	31.8	27.3	-0.10
Medical history: General									
Acute respiratory disease	13.2	13.9	0.02	13.2	13.6	0.01	16.5	14.5	-0.06
Chronic liver disease	0.3	0.3	0.01	0.3	<0.3	-0.04	0.3	0.2	-0.01
Chronic obstructive lung disease	2.3	2.4	0.01	2.0	1.5	-0.04	1.6	2.2	0.04
Dementia	0.3	1.0	0.08	0.4	0.6	0.04	0.3	0.7	0.05
Depressive disorder	1.0	2.6	0.11	1.0	1.1	0.01	1.4	2.0	0.05
Gastroesophageal reflux disease	1.4	1.3	0.00	1.4	1.8	0.03	1.0	1.8	0.07
Gastrointestinal hemorrhage	1.3	2.1	0.07	1.2	1.8	0.05	1.2	2.1	0.07
Hyperlipidemia	1.9	2.7	0.05	2.0	1.2	-0.06	2.9	1.9	-0.06
Hypertensive disorder	3.2	3.7	0.03	3.1	2.5	-0.03	3.6	2.8	-0.04
Lesion of liver	<0.2	0.4	0.04	<0.2	<0.3	0.03	<0.2	0.3	0.06
Obesity	5.9	6.7	0.03	5.9	5.6	-0.01	7.1	6.0	-0.04
Osteoarthritis	3.4	5.3	0.09	3.6	3.0	-0.03	4.6	4.5	-0.01
Pneumonia	2.2	2.3	0.01	2.1	1.9	-0.02	2.8	2.1	-0.04
Psoriasis	0.2	0.3	0.02	0.2	<0.3	0.01	<0.2	0.3	0.03
Renal impairment	2.0	6.8	0.23	2.5	2.1	-0.03	3.0	5.9	0.14
Rheumatoid arthritis	<0.2	0.1	-0.01	0.2	<0.3	-0.04	0.4	<0.1	-0.07
Urinary tract infectious disease	4.8	7.5	0.11	5.5	5.9	0.02	8.0	7.8	-0.01
Viral hepatitis C	<0.2	0.1	0.02	<0.2	<0.3	-0.02	0.2	0.1	-0.02
Visual system disorder	13.3	17.8	0.12	14.8	15.2	0.01	15.1	17.3	0.06
Medical history: Cardiovascular disease									
Atrial fibrillation	3.3	2.9	-0.02	2.6	2.6	0.00	3.5	2.9	-0.04
Cerebrovascular disease	2.4	6.4	0.20	2.9	3.1	0.01	4.2	5.0	0.04
Heart disease	31.4	24.0	-0.17	21.6	23.9	0.06	21.2	23.2	0.05
Heart failure	5.0	4.3	-0.03	3.4	3.3	-0.01	3.7	4.1	0.02
Ischemic heart disease	22.4	14.7	-0.20	13.7	15.6	0.06	14.3	14.6	0.01
Peripheral vascular disease	3.5	5.2	0.08	4.1	2.9	-0.06	3.8	4.3	0.03
Pulmonary embolism	<0.2	0.2	0.02	<0.2	<0.3	0.01	0.2	0.2	0.00
Venous thrombosis	0.5	1.1	0.07	0.4	0.5	0.01	0.4	0.9	0.06
Medical history: Neoplasms									
Hematologic neoplasm	<0.2	0.2	0.04	<0.2	<0.3	0.04	<0.2	0.2	0.04
Malignant neoplasm of anorectum	<0.2	0.1	0.01	<0.2	<0.3	0.02	0.2	0.1	-0.01
Malignant neoplastic disease	2.1	3.9	0.11	2.4	2.9	0.03	3.3	3.5	0.01
Malignant tumor of breast	<0.2	0.1	0.03	<0.2	<0.3	0.03	<0.2	0.1	0.04
Malignant tumor of colon	<0.2	0.5	0.06	<0.2	0.4	0.04	0.2	0.4	0.05
Malignant tumor of lung	<0.2	0.1	0.01	<0.2	<0.1	0.03	<0.2	<0.1	0.03
Malignant tumor of urinary bladder	<0.2	0.5	0.07	<0.2	<0.3	0.00	<0.2	0.4	0.04
Primary malignant neoplasm of prostate	<0.2	0.4	0.04	0.3	<0.3	-0.03	0.2	0.3	0.01
Medication use									
Agents acting on the renin-angiotensin system	82.4	75.2	-0.18	77.5	78.1	0.01	73.5	77.2	0.09
Antibacterials for systemic use	39.5	43.5	0.08	41.0	40.1	-0.02	44.4	43.3	-0.02
Antidepressants	19.1	23.1	0.10	21.0	21.9	0.02	25.1	23.1	-0.05
Antiepileptics	11.0	11.8	0.03	12.0	12.9	0.03	13.3	12.0	-0.04
Antiinflammatory and antirheumatic products	82.2	74.9	-0.18	79.6	81.4	0.04	80.1	76.7	-0.08
Antineoplastic agents	1.4	2.2	0.05	1.7	2.5	0.06	1.3	2.2	0.07
Antipsoriatics	1.7	2.0	0.02	1.8	1.6	-0.02	2.1	2.0	-0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antithrombotic agents	91.9	85.5	-0.20	88.6	89.8	0.04	83.6	88.1	0.13
Beta blocking agents	72.6	57.3	-0.33	65.6	67.9	0.05	61.0	61.7	0.01
Calcium channel blockers	33.1	36.6	0.07	34.7	35.1	0.01	34.5	36.3	0.04
Diuretics	55.7	56.9	0.03	52.4	52.8	0.01	54.3	57.2	0.06
Drugs for acid related disorders	76.4	75.2	-0.03	73.4	74.0	0.01	76.2	75.9	-0.01
Drugs for obstructive airway diseases	32.1	32.3	0.00	32.4	31.6	-0.02	32.7	32.8	0.00
Immunosuppressants	1.6	1.6	0.00	1.8	1.7	-0.01	1.4	1.8	0.04
Lipid modifying agents	92.0	84.5	-0.23	89.6	91.3	0.06	87.0	86.5	-0.01
Opioids	20.0	20.5	0.01	20.5	21.2	0.02	21.8	21.0	-0.02
Psycholeptics	30.2	35.9	0.12	30.9	31.4	0.01	36.6	34.2	-0.05
Psychostimulants	24.0	13.7	-0.26	18.8	19.3	0.01	16.3	16.6	0.01

Supplementary Table 18: Baseline patient characteristics for SGLT2is (T) and DPP4is (C) new-users in the VA data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
30 - 34	<0.1	0.1	0.03	<0.1	<0.3	0.01	<0.1	<0.1	0.03
35 - 39	0.2	0.3	0.02	0.3	0.3	0.00	0.3	0.4	0.01
40 - 44	0.6	0.8	0.02	0.7	0.9	0.03	0.7	0.8	0.02
45 - 49	2.1	2.0	-0.01	2.1	2.1	0.00	2.0	1.9	0.00
50 - 54	4.7	4.8	0.00	4.7	5.4	0.03	4.3	5.1	0.04
55 - 59	8.0	8.1	0.00	8.2	8.1	0.00	8.8	7.9	-0.03
60 - 64	13.4	12.2	-0.04	12.6	12.2	-0.01	12.9	12.3	-0.02
65 - 69	17.7	20.9	0.08	17.9	17.8	0.00	20.4	19.1	-0.03
70 - 74	31.9	27.2	-0.10	32.1	31.0	-0.03	30.2	29.5	-0.01
75 - 79	14.5	11.7	-0.08	13.5	13.4	0.00	12.1	12.7	0.02
80 - 84	4.3	6.5	0.10	4.9	5.1	0.01	5.0	5.6	0.03
85 - 89	1.8	3.8	0.12	2.3	2.4	0.01	2.9	3.0	0.01
90 - 94	0.4	1.3	0.10	0.5	0.9	0.05	0.4	1.1	0.07
95 - 99	<0.1	0.3	0.06	0.1	0.3	0.05	<0.1	0.4	0.07
100 - 104	<0.1	<0.1	-0.01	<0.1	<0.3	-0.01	<0.1	<0.1	-0.01
Gender: female	3.4	5.2	0.09	4.1	4.2	0.00	4.8	4.4	-0.02
Race									
Asian	1.0	1.1	0.01	0.8	0.8	0.00	0.7	0.9	0.02
Black or African American	13.6	13.6	0.00	12.7	12.9	0.00	14.8	12.4	-0.07
White	78.1	78.1	0.00	78.9	79.0	0.00	77.8	79.4	0.04
Unknown	5.5	5.6	0.00	5.8	5.4	-0.02	5.2	5.3	0.01
Native Hawaiian or Other Pacific Islander	0.8	1.0	0.02	0.8	1.1	0.02	0.8	1.1	0.03
American Indian or Alaska Native	0.9	0.7	-0.02	0.9	0.8	-0.02	0.8	0.8	0.01
Ethnicity									
Hispanic or Latino	5.7	4.4	-0.06	5.3	5.1	-0.01	4.7	5.0	0.02
Not Hispanic or Latino	91.9	93.4	0.06	92.2	92.6	0.02	92.8	93.0	0.00
Medical history: General									
Acute respiratory disease	9.8	9.9	0.00	9.6	9.1	-0.02	10.6	9.4	-0.04
Attention deficit hyperactivity disorder	0.5	0.5	0.00	0.4	0.4	-0.01	0.4	0.5	0.01
Chronic liver disease	2.4	2.2	-0.01	2.3	1.8	-0.03	2.6	2.1	-0.03
Chronic obstructive lung disease	18.5	17.2	-0.03	17.2	18.1	0.02	17.5	17.6	0.00
Crohn's disease	0.2	0.2	0.00	0.3	<0.3	-0.03	0.2	0.1	-0.02
Dementia	1.6	2.8	0.09	1.7	1.8	0.01	2.2	2.5	0.02
Gastroesophageal reflux disease	23.2	22.6	-0.01	22.2	22.7	0.01	22.3	22.5	0.00
Gastrointestinal hemorrhage	1.6	1.3	-0.03	1.6	1.3	-0.03	1.7	1.4	-0.03
Human immunodeficiency virus infection	0.5	0.4	0.00	0.4	0.3	-0.03	0.4	0.4	0.00
Hyperlipidemia	77.1	75.6	-0.03	74.9	75.9	0.02	76.8	76.2	-0.01
Hypertensive disorder	82.0	79.5	-0.06	80.3	80.3	0.00	81.6	80.3	-0.03
Lesion of liver	2.0	1.5	-0.04	2.0	1.8	-0.02	2.4	1.7	-0.05
Obesity	31.7	26.6	-0.11	29.1	29.7	0.01	29.1	29.7	0.01
Osteoarthritis	22.7	23.0	0.01	22.6	23.1	0.01	22.6	23.1	0.01
Pneumonia	2.6	1.9	-0.05	2.3	1.8	-0.04	2.3	1.9	-0.03
Psoriasis	1.9	1.9	0.00	1.8	1.7	0.00	1.5	1.7	0.02
Renal impairment	12.6	11.6	-0.03	10.7	10.9	0.01	11.4	11.5	0.00
Rheumatoid arthritis	0.9	0.8	-0.01	0.9	0.9	0.01	1.3	0.8	-0.05
Schizophrenia	0.6	0.9	0.04	0.6	0.6	0.00	1.1	0.7	-0.05
Ulcerative colitis	0.4	0.4	0.01	0.4	0.4	0.00	0.4	0.4	0.00
Urinary tract infectious disease	1.8	3.0	0.08	1.8	2.1	0.02	2.2	2.7	0.03
Viral hepatitis C	1.3	1.1	-0.01	1.2	0.8	-0.04	1.0	1.1	0.01
Visual system disorder	47.4	48.9	0.03	47.8	47.3	-0.01	48.3	47.4	-0.02
Medical history: Cardiovascular disease									
Atrial fibrillation	17.1	12.2	-0.14	13.4	14.5	0.03	13.9	14.6	0.02
Cerebrovascular disease	7.9	7.5	-0.01	7.9	7.3	-0.02	7.5	7.5	0.00
Coronary arteriosclerosis	57.1	36.6	-0.42	45.0	48.2	0.06	42.4	46.4	0.08
Heart disease	73.9	55.1	-0.40	62.1	65.3	0.07	57.9	63.0	0.10
Heart failure	20.3	8.2	-0.35	9.9	11.2	0.04	12.7	11.8	-0.03
Ischemic heart disease	25.2	16.1	-0.23	17.0	17.6	0.02	17.1	18.7	0.04
Peripheral vascular disease	11.4	10.9	-0.01	11.1	11.1	0.00	11.4	11.2	-0.01
Pulmonary embolism	1.0	0.9	-0.01	0.8	0.9	0.01	0.8	0.9	0.01
Venous thrombosis	1.3	1.7	0.04	1.6	1.7	0.01	2.3	1.9	-0.03
Medical history: Neoplasms									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Hematologic neoplasm	1.3	1.3	0.01	1.2	1.4	0.02	1.3	1.3	0.00
Malignant lymphoma	0.9	0.8	-0.01	0.8	0.7	-0.01	0.8	0.7	-0.01
Malignant neoplasm of anorectum	<0.1	0.1	0.00	0.1	<0.3	-0.01	<0.1	<0.1	-0.01
Malignant neoplastic disease	10.9	11.5	0.02	11.0	10.7	-0.01	11.2	11.2	0.00
Malignant tumor of breast	<0.1	0.1	0.02	<0.1	<0.3	0.03	0.6	0.1	-0.08
Malignant tumor of colon	0.4	0.6	0.02	0.4	0.7	0.03	0.4	0.5	0.01
Malignant tumor of lung	0.6	0.5	-0.01	0.7	0.6	-0.02	0.6	0.6	0.00
Malignant tumor of urinary bladder	0.8	0.8	0.00	0.7	0.8	0.01	1.2	0.7	-0.04
Primary malignant neoplasm of prostate	3.8	4.2	0.02	3.8	3.6	-0.01	3.9	4.1	0.01
Medication use									
Agents acting on the renin-angiotensin system	73.2	66.9	-0.14	68.0	68.4	0.01	67.2	68.3	0.02
Antibacterials for systemic use	29.4	31.0	0.03	28.4	28.6	0.00	31.1	29.5	-0.04
Antidepressants	35.6	37.0	0.03	36.3	35.7	-0.01	38.4	36.5	-0.04
Antiepileptics	28.6	30.2	0.04	29.5	28.5	-0.02	29.9	29.5	-0.01
Antiinflammatory and antirheumatic products	56.5	50.9	-0.11	52.7	52.9	0.00	53.0	53.1	0.00
Antineoplastic agents	5.0	4.9	0.00	5.1	4.8	-0.01	6.3	4.9	-0.06
Antipsoriatics	1.0	1.0	0.01	1.0	1.0	0.00	1.0	1.0	0.00
Antithrombotic agents	61.5	50.3	-0.23	54.2	55.1	0.02	54.8	55.0	0.00
Beta blocking agents	66.9	54.3	-0.26	57.6	59.6	0.04	57.7	58.7	0.02
Calcium channel blockers	31.6	31.4	0.00	31.0	31.5	0.01	31.4	30.7	-0.01
Diuretics	46.7	41.0	-0.12	40.5	41.3	0.02	43.7	42.3	-0.03
Drugs for obstructive airway diseases	45.4	44.7	-0.01	46.1	45.1	-0.02	46.1	45.1	-0.02
Immunosuppressants	3.1	2.6	-0.03	2.9	2.3	-0.04	2.6	2.3	-0.02
Lipid modifying agents	89.2	84.7	-0.14	86.4	86.7	0.01	86.8	86.1	-0.02
Opioids	17.3	19.2	0.05	16.3	16.1	-0.01	17.7	17.7	0.00
Psycholeptics	24.8	25.3	0.01	24.0	23.7	-0.01	24.6	24.4	0.00
Psychostimulants	1.2	1.6	0.03	1.3	1.4	0.00	1.6	1.3	-0.02

Supplementary Table 19: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the CCAE data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	-0.03	0.1	0.1	-0.01	0.1	0.1	-0.02
30 - 34	0.3	0.4	-0.02	0.3	0.4	-0.01	0.4	0.4	-0.01
35 - 39	1.7	1.6	0.01	1.8	1.4	0.03	1.8	1.5	0.02
40 - 44	4.5	4.2	0.01	4.5	4.3	0.01	4.8	4.2	0.03
45 - 49	10.1	9.2	0.03	10.1	10.0	0.00	10.3	9.6	0.03
50 - 54	18.3	17.7	0.01	18.4	18.1	0.01	18.4	17.8	0.01
55 - 59	29.2	27.3	0.04	28.5	28.8	-0.01	27.7	27.6	0.00
60 - 64	33.0	35.6	-0.06	33.1	33.7	-0.01	33.3	35.3	-0.04
65 - 69	2.8	3.8	-0.06	3.1	3.1	0.00	3.1	3.5	-0.02
Gender: female	38.1	39.2	-0.02	39.0	38.9	0.00	39.9	38.7	0.02
Medical history: General									
Acute respiratory disease	29.6	28.4	0.02	29.0	29.5	-0.01	30.0	29.7	0.01
Attention deficit hyperactivity disorder	1.1	0.5	0.07	1.1	0.9	0.01	1.0	0.8	0.02
Chronic liver disease	2.5	3.9	-0.08	2.8	2.3	0.03	3.3	2.9	0.02
Chronic obstructive lung disease	5.2	7.0	-0.07	5.3	5.5	0.00	6.3	6.4	-0.01
Crohn's disease	0.3	0.3	0.00	0.3	0.3	0.00	0.3	0.3	0.00
Dementia	0.3	0.4	-0.02	0.3	0.3	-0.01	0.3	0.4	-0.01
Depressive disorder	11.8	10.6	0.04	11.7	12.1	-0.01	12.0	12.5	-0.01
Gastroesophageal reflux disease	17.2	12.8	0.12	17.0	17.3	-0.01	17.0	16.9	0.00
Gastrointestinal hemorrhage	2.0	2.7	-0.05	2.1	2.3	-0.01	2.2	2.4	-0.02
Human immunodeficiency virus infection	0.4	0.3	0.02	0.3	0.5	-0.03	0.3	0.4	-0.03
Hyperlipidemia	82.2	68.9	0.31	80.5	81.4	-0.02	78.5	79.2	-0.02
Hypertensive disorder	81.8	73.1	0.21	81.4	81.8	-0.01	81.1	81.2	0.00
Lesion of liver	0.8	1.2	-0.04	0.8	1.0	-0.02	0.9	1.2	-0.04
Obesity	31.5	17.5	0.33	29.9	30.5	-0.01	28.5	28.4	0.00
Osteoarthritis	24.5	21.8	0.06	24.2	24.7	-0.01	25.3	24.6	0.02
Pneumonia	3.2	4.0	-0.04	3.1	3.0	0.01	3.6	3.6	0.00
Psoriasis	2.2	1.5	0.05	2.1	2.0	0.01	2.0	1.9	0.00
Renal impairment	5.3	6.3	-0.04	5.4	5.3	0.00	6.7	6.9	-0.01
Rheumatoid arthritis	1.6	1.4	0.01	1.5	1.5	0.00	1.5	1.5	0.00
Schizophrenia	0.1	0.1	-0.01	0.1	0.1	-0.02	0.1	0.1	-0.01
Ulcerative colitis	0.4	0.4	0.00	0.4	0.4	-0.01	0.4	0.5	-0.01
Urinary tract infectious disease	6.8	8.5	-0.06	6.9	6.8	0.00	7.3	7.6	-0.01
Viral hepatitis C	0.4	0.6	-0.04	0.4	0.4	0.00	0.4	0.5	-0.02
Visual system disorder	28.1	25.6	0.06	27.6	27.9	-0.01	27.3	27.7	-0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	5.0	5.0	0.00	4.8	4.9	-0.01	5.0	5.3	-0.01
Cerebrovascular disease	9.1	11.0	-0.06	8.9	9.1	-0.01	9.7	9.8	0.00
Coronary arteriosclerosis	34.8	33.8	0.02	31.9	32.7	-0.02	31.8	32.4	-0.01
Heart disease	50.8	51.1	-0.01	47.7	48.3	-0.01	48.5	48.6	0.00
Heart failure	6.7	7.0	-0.01	5.7	5.8	0.00	5.8	6.5	-0.03
Ischemic heart disease	18.2	19.6	-0.04	16.6	16.8	-0.01	16.9	17.3	-0.01
Peripheral vascular disease	15.6	12.5	0.09	15.4	15.3	0.00	14.7	14.6	0.00
Pulmonary embolism	0.9	0.9	0.00	0.9	0.9	-0.01	0.9	1.1	-0.02
Venous thrombosis	1.5	1.8	-0.02	1.6	1.4	0.01	1.9	1.8	0.01
Medical history: Neoplasms									
Hematologic neoplasm	1.0	1.3	-0.02	1.0	1.0	-0.01	1.1	1.2	-0.01
Malignant lymphoma	0.4	0.6	-0.03	0.3	0.5	-0.02	0.3	0.5	-0.03
Malignant neoplasm of anorectum	0.1	0.2	-0.03	0.1	0.1	0.01	0.1	0.2	-0.01
Malignant neoplastic disease	7.2	8.1	-0.03	7.1	7.1	0.00	7.1	7.1	0.00
Malignant tumor of breast	1.2	1.4	-0.02	1.2	1.4	-0.01	1.5	1.4	0.01
Malignant tumor of colon	0.3	0.5	-0.03	0.4	0.2	0.03	0.3	0.3	0.00
Malignant tumor of lung	0.3	0.4	-0.02	0.3	0.2	0.03	0.4	0.3	0.01
Malignant tumor of urinary bladder	0.2	0.4	-0.03	0.2	0.2	-0.01	0.2	0.3	-0.02
Primary malignant neoplasm of prostate	1.1	1.1	-0.01	1.1	1.0	0.00	1.2	1.1	0.00
Medication use									
Agents acting on the renin-angiotensin system	74.5	73.2	0.03	73.8	74.0	0.00	73.5	73.9	-0.01
Antibacterials for systemic use	61.5	62.8	-0.03	61.3	61.0	0.00	62.1	61.7	0.01
Antidepressants	30.2	30.2	0.00	29.8	30.2	-0.01	30.3	30.4	0.00
Antiepileptics	17.2	16.5	0.02	17.4	17.2	0.01	18.8	18.0	0.02
Antiinflammatory and antirheumatic products	39.0	34.5	0.09	38.9	38.6	0.00	38.5	38.2	0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antineoplastic agents	4.5	5.5	-0.05	4.5	4.7	-0.01	4.5	4.7	-0.01
Antipsoriatics	0.8	0.7	0.01	0.7	0.6	0.01	0.6	0.6	0.00
Antithrombotic agents	28.4	27.7	0.02	26.9	27.1	0.00	27.5	28.1	-0.01
Beta blocking agents	47.3	49.1	-0.04	45.5	45.8	0.00	46.2	47.0	-0.01
Calcium channel blockers	27.3	27.1	0.00	27.3	27.3	0.00	27.0	27.9	-0.02
Diuretics	42.5	44.9	-0.05	42.4	41.9	0.01	43.2	42.8	0.01
Drugs for acid related disorders	31.2	31.3	0.00	30.5	30.7	0.00	31.2	30.5	0.01
Drugs for obstructive airway diseases	42.0	38.3	0.07	41.3	41.1	0.00	41.7	41.0	0.01
Immunosuppressants	3.2	2.5	0.04	3.1	2.9	0.01	3.0	3.0	0.00
Lipid modifying agents	80.0	76.7	0.08	78.6	78.8	-0.01	77.5	78.1	-0.01
Opioids	31.3	33.9	-0.06	31.4	31.3	0.00	34.7	33.2	0.03
Psycholeptics	28.4	28.9	-0.01	27.8	28.1	0.00	30.2	29.0	0.03
Psychostimulants	3.6	2.8	0.04	3.4	3.2	0.01	3.5	3.0	0.03

Supplementary Table 20: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the GermanyDA data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	<0.1	<0.2	-0.01	<0.7	<0.2	0.05	<0.1	<0.2	0.02
30 - 34	0.2	<0.2	0.01	<0.7	<0.2	0.05	0.3	<0.2	0.06
35 - 39	0.4	0.4	0.00	0.7	0.7	0.00	0.6	0.4	0.02
40 - 44	1.0	1.1	-0.01	1.2	1.1	0.01	0.9	1.0	-0.01
45 - 49	3.1	2.2	0.05	2.8	2.3	0.03	3.1	2.7	0.03
50 - 54	7.0	4.5	0.11	5.5	5.6	0.00	7.0	4.9	0.09
55 - 59	12.2	8.1	0.14	9.8	9.0	0.03	11.7	14.6	-0.09
60 - 64	17.1	13.6	0.10	14.2	13.0	0.04	16.5	13.7	0.08
65 - 69	16.5	16.9	-0.01	16.6	16.5	0.00	16.6	19.0	-0.06
70 - 74	15.4	19.2	-0.10	13.4	15.0	-0.04	14.7	14.8	0.00
75 - 79	13.3	18.4	-0.14	16.6	16.7	0.00	14.3	15.2	-0.03
80 - 84	9.6	10.5	-0.03	11.9	12.0	0.00	9.9	9.1	0.03
85 - 89	3.5	3.9	-0.02	5.3	5.8	-0.03	3.7	3.3	0.02
90 - 94	0.6	0.9	-0.04	1.4	2.1	-0.05	0.6	1.1	-0.06
Gender: female	30.7	43.5	-0.27	41.1	39.6	0.03	33.4	30.5	0.06
Medical history: General									
Acute respiratory disease	16.2	17.7	-0.04	18.5	15.3	0.09	16.7	16.4	0.01
Attention deficit hyperactivity disorder	<0.1	0.7	-0.10	<0.1	0.7	-0.11	<0.1	0.7	-0.11
Chronic liver disease	0.7	0.3	0.05	1.1	<0.2	0.12	0.6	<0.2	0.09
Chronic obstructive lung disease	8.0	8.7	-0.03	9.5	8.6	0.03	8.7	7.7	0.04
Crohn's disease	0.2	0.2	0.00	0.1	0.3	-0.04	0.1	0.3	-0.04
Dementia	1.4	3.9	-0.16	2.6	3.1	-0.03	1.6	1.8	-0.02
Depressive disorder	9.2	11.6	-0.08	12.7	12.2	0.01	10.2	15.6	-0.16
Gastroesophageal reflux disease	2.5	2.5	0.00	3.6	2.5	0.07	2.8	2.5	0.02
Gastrointestinal hemorrhage	1.0	1.3	-0.03	1.0	0.7	0.03	0.9	0.4	0.06
Hyperlipidemia	28.8	34.4	-0.12	29.0	28.1	0.02	28.5	25.8	0.06
Hypertensive disorder	47.8	64.4	-0.34	52.6	51.8	0.01	49.3	48.2	0.02
Lesion of liver	0.7	0.8	-0.01	0.7	0.7	0.00	0.6	1.2	-0.06
Obesity	10.2	8.4	0.06	9.7	9.3	0.01	10.6	7.6	0.10
Osteoarthritis	11.9	16.9	-0.14	15.8	13.7	0.06	12.9	12.2	0.02
Pneumonia	2.1	2.6	-0.04	2.2	2.1	0.01	2.0	1.7	0.02
Psoriasis	1.7	1.6	0.00	1.9	1.3	0.05	1.5	0.6	0.09
Renal impairment	7.1	7.1	0.00	6.9	6.7	0.01	6.7	5.1	0.07
Rheumatoid arthritis	1.5	1.7	-0.02	1.5	1.4	0.01	1.5	0.8	0.06
Schizophrenia	0.2	0.2	-0.01	<0.7	0.2	0.04	0.2	0.2	-0.01
Ulcerative colitis	0.2	0.2	0.00	0.1	<0.2	0.02	0.1	<0.2	0.02
Urinary tract infectious disease	4.5	6.1	-0.07	5.1	5.4	-0.01	4.7	3.2	0.07
Visual system disorder	8.1	11.7	-0.12	10.2	10.7	-0.01	8.4	11.5	-0.10
Medical history: Cardiovascular disease									
Atrial fibrillation	4.7	3.4	0.06	4.7	4.0	0.03	4.3	2.4	0.11
Cerebrovascular disease	8.0	10.7	-0.09	10.2	9.3	0.03	8.4	9.5	-0.04
Coronary arteriosclerosis	14.6	7.7	0.22	8.9	9.2	-0.01	13.3	13.9	-0.02
Heart disease	46.9	49.3	-0.05	40.5	37.2	0.07	44.5	45.1	-0.01
Heart failure	13.4	13.2	0.00	10.7	9.1	0.05	12.8	9.3	0.11
Ischemic heart disease	26.5	32.4	-0.13	21.7	20.0	0.04	24.9	25.8	-0.02
Peripheral vascular disease	12.0	12.4	-0.01	11.1	12.8	-0.05	11.3	10.2	0.04
Pulmonary embolism	0.7	0.5	0.03	<0.7	0.5	-0.02	0.6	0.2	0.06
Venous thrombosis	1.8	1.6	0.02	1.8	1.7	0.01	1.9	2.3	-0.03
Medical history: Neoplasms									
Malignant lymphoma	0.2	0.3	-0.02	<0.7	<0.2	0.04	0.2	<0.2	0.06
Malignant neoplasm of anorectum	<0.1	0.2	-0.03	<0.1	<0.2	0.01	<0.1	<0.2	0.01
Malignant neoplastic disease	4.7	7.4	-0.11	4.4	5.4	-0.05	4.4	3.7	0.04
Malignant tumor of breast	0.6	1.3	-0.07	0.7	0.8	-0.01	0.7	0.8	-0.01
Malignant tumor of colon	0.4	0.4	-0.01	<0.7	0.3	0.00	0.4	0.2	0.03
Malignant tumor of lung	<0.1	0.2	-0.04	<0.7	0.4	-0.05	<0.1	<0.2	-0.01
Malignant tumor of urinary bladder	0.2	0.3	-0.02	<0.7	<0.2	0.05	0.2	<0.2	0.06
Primary malignant neoplasm of prostate	0.8	1.4	-0.06	<0.7	1.2	-0.09	0.7	1.0	-0.03
Medication use									
Agents acting on the renin-angiotensin system	79.3	73.7	0.13	74.1	73.9	0.00	77.7	78.2	-0.01
Antibacterials for systemic use	22.8	31.2	-0.19	27.7	25.7	0.04	24.0	23.3	0.02
Antidepressants	11.1	11.4	-0.01	12.9	10.5	0.07	11.6	12.3	-0.02

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antiepileptics	5.5	4.4	0.05	4.6	4.0	0.03	5.2	4.1	0.05
Antiinflammatory and antirheumatic products	53.5	59.0	-0.11	51.7	51.8	0.00	53.5	53.2	0.00
Antineoplastic agents	1.4	1.4	0.00	1.1	1.7	-0.05	1.3	1.2	0.01
Antipsoriatics	0.5	0.3	0.03	<0.7	<0.2	0.07	0.6	<0.2	0.09
Antithrombotic agents	56.3	50.9	0.11	47.6	48.8	-0.02	53.5	54.1	-0.01
Beta blocking agents	62.9	59.0	0.08	61.1	58.9	0.05	61.7	60.2	0.03
Calcium channel blockers	39.6	36.9	0.05	42.5	39.8	0.05	39.5	43.3	-0.08
Diuretics	58.3	60.7	-0.05	56.2	54.6	0.03	57.6	59.2	-0.03
Drugs for acid related disorders	42.9	38.8	0.08	42.3	43.2	-0.02	43.2	48.9	-0.11
Drugs for obstructive airway diseases	19.8	19.2	0.02	18.5	18.4	0.00	19.6	17.5	0.05
Immunosuppressants	1.0	0.8	0.02	0.9	0.4	0.06	0.9	0.4	0.06
Lipid modifying agents	70.0	52.1	0.37	56.8	57.5	-0.01	65.5	70.3	-0.10
Opioids	12.5	15.8	-0.09	15.1	14.1	0.03	13.4	16.9	-0.10
Psycholeptics	9.3	13.4	-0.13	10.7	11.0	-0.01	9.8	9.8	0.00
Psychostimulants	0.1	0.7	-0.09	<0.7	<0.2	0.05	0.3	<0.2	0.06

Supplementary Table 21: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the OptumDOD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
30 - 34	0.2	0.2	0.00	0.3	0.2	0.02	0.2	0.2	0.01
35 - 39	0.7	0.6	0.02	0.8	0.6	0.02	1.0	0.5	0.06
40 - 44	2.1	1.3	0.06	1.9	1.8	0.01	1.7	1.3	0.03
45 - 49	4.6	3.0	0.08	3.1	3.1	0.00	3.1	3.1	0.00
50 - 54	7.7	5.6	0.09	7.4	7.5	0.00	5.6	5.5	0.01
55 - 59	12.7	8.9	0.12	11.9	12.5	-0.02	10.3	9.3	0.03
60 - 64	15.2	11.7	0.10	14.5	14.9	-0.01	12.3	12.1	0.01
65 - 69	19.0	17.8	0.03	19.4	19.1	0.01	19.0	18.7	0.01
70 - 74	19.5	20.9	-0.04	20.1	20.7	-0.01	20.7	21.9	-0.03
75 - 79	11.5	15.6	-0.12	12.0	11.6	0.01	13.5	14.7	-0.03
80 - 84	4.6	9.5	-0.19	5.0	4.7	0.02	8.0	8.2	-0.01
85 - 89	1.8	4.6	-0.16	2.0	1.9	0.01	4.2	4.3	0.00
90 - 94	0.2	0.3	-0.01	0.2	0.3	-0.03	0.2	0.3	-0.03
Gender: female	38.7	44.2	-0.11	40.0	39.8	0.01	44.6	43.1	0.03
Medical history: General									
Acute respiratory disease	27.8	28.1	-0.01	27.4	27.4	0.00	29.6	27.7	0.04
Attention deficit hyperactivity disorder	0.7	0.4	0.04	0.7	0.7	0.00	0.7	0.5	0.03
Chronic liver disease	2.2	3.7	-0.09	2.3	2.3	0.00	3.8	2.9	0.05
Chronic obstructive lung disease	14.6	17.2	-0.07	14.5	14.5	0.00	17.5	17.0	0.01
Crohn's disease	0.4	0.3	0.01	0.4	0.3	0.02	0.3	0.3	0.01
Dementia	1.7	4.4	-0.16	1.9	1.9	0.00	4.4	4.0	0.02
Depressive disorder	17.9	17.1	0.02	17.9	17.9	0.00	21.1	18.6	0.06
Gastroesophageal reflux disease	25.1	22.2	0.07	24.4	24.3	0.00	25.7	24.1	0.04
Gastrointestinal hemorrhage	2.9	4.0	-0.06	2.8	2.8	0.00	3.7	3.5	0.01
Human immunodeficiency virus infection	0.3	0.2	0.02	0.3	0.4	0.00	0.2	0.3	-0.01
Hyperlipidemia	87.8	85.0	0.08	86.9	87.6	-0.02	84.9	86.0	-0.03
Hypertensive disorder	88.4	87.4	0.03	87.9	87.6	0.01	87.6	87.7	0.00
Lesion of liver	1.6	1.9	-0.03	2.5	1.9	0.04	2.5	1.9	0.04
Obesity	33.7	23.4	0.23	31.8	32.6	-0.02	29.3	28.3	0.02
Osteoarthritis	33.9	34.4	-0.01	33.9	33.7	0.00	37.7	35.3	0.05
Pneumonia	5.0	7.2	-0.09	5.0	4.9	0.00	6.8	6.6	0.01
Psoriasis	2.2	1.6	0.04	2.2	2.0	0.02	2.0	1.8	0.02
Renal impairment	17.4	24.9	-0.18	17.8	16.7	0.03	24.5	24.4	0.00
Rheumatoid arthritis	2.2	2.5	-0.02	2.5	2.5	0.00	2.5	2.5	0.00
Schizophrenia	0.4	0.5	-0.02	0.4	0.4	0.00	0.4	0.5	-0.01
Ulcerative colitis	0.4	0.4	0.01	0.5	0.4	0.01	0.6	0.4	0.03
Urinary tract infectious disease	9.1	14.7	-0.18	9.4	9.3	0.00	13.8	13.1	0.02
Viral hepatitis C	0.6	0.8	-0.02	0.6	0.7	-0.02	0.8	0.8	-0.01
Visual system disorder	45.2	47.2	-0.04	45.9	45.4	0.01	48.4	47.9	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	12.4	13.1	-0.02	11.6	11.3	0.01	12.6	13.0	-0.01
Cerebrovascular disease	13.3	16.3	-0.08	13.3	13.0	0.01	15.2	14.8	0.01
Coronary arteriosclerosis	44.7	40.0	0.10	41.8	42.3	-0.01	38.6	40.3	-0.04
Heart disease	62.3	60.6	0.04	59.0	59.9	-0.02	59.0	59.9	-0.02
Heart failure	16.4	16.0	0.01	14.4	14.3	0.00	15.5	15.8	-0.01
Ischemic heart disease	24.3	22.2	0.05	22.0	22.7	-0.02	21.3	21.9	-0.02
Peripheral vascular disease	27.0	26.1	0.02	27.1	27.3	0.00	28.2	27.9	0.01
Pulmonary embolism	1.3	1.4	-0.01	1.4	1.2	0.01	1.6	1.5	0.01
Venous thrombosis	2.3	2.8	-0.03	2.3	2.2	0.00	2.8	2.7	0.01
Medical history: Neoplasms									
Hematologic neoplasm	1.3	2.0	-0.05	1.4	1.5	-0.01	1.6	1.9	-0.02
Malignant lymphoma	0.7	0.9	-0.02	0.7	0.8	-0.01	0.8	0.9	-0.01
Malignant neoplasm of anorectum	0.2	0.4	-0.02	0.2	0.3	-0.01	0.4	0.3	0.01
Malignant neoplastic disease	12.3	15.1	-0.08	12.5	12.3	0.01	13.5	14.6	-0.03
Malignant tumor of breast	1.5	2.1	-0.05	1.6	1.7	-0.01	1.9	2.0	-0.01
Malignant tumor of colon	0.6	0.9	-0.04	0.6	0.6	0.00	1.0	0.9	0.01
Malignant tumor of lung	0.5	0.9	-0.05	0.5	0.5	-0.01	0.6	0.9	-0.03
Malignant tumor of urinary bladder	0.5	0.9	-0.06	0.5	0.7	-0.02	0.5	0.9	-0.04
Primary malignant neoplasm of prostate	2.8	3.1	-0.02	2.9	2.5	0.02	2.8	3.0	-0.01
Medication use									
Agents acting on the renin-angiotensin system	76.9	75.8	0.03	76.4	75.8	0.01	76.1	76.2	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antibacterials for systemic use	60.2	62.4	-0.04	60.2	59.8	0.01	63.2	61.4	0.04
Antidepressants	31.8	30.3	0.03	31.7	31.6	0.00	33.6	31.6	0.04
Antiepileptics	22.5	21.9	0.01	22.8	23.1	-0.01	25.5	24.1	0.03
Antiinflammatory and antirheumatic products	33.6	30.4	0.07	33.2	33.8	-0.01	34.4	31.9	0.05
Antineoplastic agents	6.4	6.6	-0.01	6.2	6.2	0.00	6.6	6.5	0.00
Antipsoriatics	0.5	0.7	-0.01	0.6	0.6	-0.01	0.4	0.7	-0.03
Antithrombotic agents	35.2	32.2	0.06	33.4	33.7	-0.01	33.2	33.0	0.00
Beta blocking agents	55.3	54.6	0.02	53.5	53.4	0.00	54.1	54.3	0.00
Calcium channel blockers	32.0	34.2	-0.05	32.3	32.0	0.01	32.3	32.0	0.01
Diuretics	48.3	50.8	-0.05	47.7	46.9	0.01	49.8	49.3	0.01
Drugs for acid related disorders	34.7	35.0	-0.01	34.4	34.2	0.00	37.4	35.9	0.03
Drugs for obstructive airway diseases	43.5	41.5	0.04	42.8	43.3	-0.01	45.1	42.7	0.05
Immunosuppressants	3.3	2.8	0.03	3.3	3.0	0.02	3.2	3.0	0.01
Lipid modifying agents	85.7	81.1	0.12	84.8	85.1	-0.01	82.1	83.1	-0.03
Opioids	32.8	33.5	-0.01	32.1	32.7	-0.01	35.6	33.6	0.04
Psycholeptics	29.8	28.8	0.02	28.8	29.1	0.00	31.9	29.5	0.05
Psychostimulants	2.1	1.4	0.05	2.0	2.0	0.00	2.1	1.6	0.04

Supplementary Table 22: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the MDCR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
50 - 54	<0.2	0.1	0.01	<0.3	0.2	0.00	<0.2	0.1	-0.01
55 - 59	1.0	0.5	0.06	1.0	0.6	0.05	0.9	0.5	0.05
60 - 64	2.1	1.3	0.06	2.1	1.6	0.04	2.1	1.6	0.04
65 - 69	27.8	19.8	0.19	26.9	27.2	-0.01	20.4	22.3	-0.05
70 - 74	36.9	28.4	0.18	36.4	35.4	0.02	31.3	29.9	0.03
75 - 79	21.3	23.3	-0.05	21.3	22.1	-0.02	21.3	22.1	-0.02
80 - 84	7.5	16.4	-0.28	8.3	8.0	0.01	13.3	13.8	-0.01
85 - 89	2.6	7.6	-0.23	3.1	3.4	-0.02	8.6	6.9	0.06
90 - 94	0.5	2.2	-0.14	0.6	1.3	-0.08	0.7	2.2	-0.13
95 - 99	<0.2	0.3	-0.05	<0.3	0.3	-0.03	<0.2	0.3	-0.05
Gender: female	36.1	42.6	-0.13	37.3	38.0	-0.01	41.8	40.9	0.02
Medical history: General									
Acute respiratory disease	26.0	24.4	0.04	25.7	26.0	-0.01	30.5	26.4	0.09
Attention deficit hyperactivity disorder	<0.2	0.1	0.01	<0.3	0.4	-0.05	0.2	0.3	-0.02
Chronic liver disease	2.3	2.3	0.00	2.6	1.7	0.06	2.3	2.3	0.00
Chronic obstructive lung disease	14.2	15.2	-0.03	14.4	14.7	-0.01	18.3	16.2	0.06
Crohn's disease	0.5	0.3	0.04	0.5	0.3	0.02	0.4	0.3	0.00
Dementia	1.9	4.5	-0.15	2.1	2.5	-0.03	1.9	5.3	-0.19
Depressive disorder	9.9	8.2	0.06	9.7	11.2	-0.05	17.4	12.2	0.15
Gastroesophageal reflux disease	19.0	11.8	0.20	18.2	19.1	-0.02	18.4	18.4	0.00
Gastrointestinal hemorrhage	3.8	4.6	-0.04	3.7	2.9	0.04	2.9	3.8	-0.05
Human immunodeficiency virus infection	<0.2	0.1	0.02	<0.3	0.1	-0.01	<0.2	0.1	-0.03
Hyperlipidemia	84.8	52.6	0.74	83.4	85.2	-0.05	82.0	79.3	0.07
Hypertensive disorder	87.7	71.3	0.42	87.0	87.8	-0.03	87.3	86.6	0.02
Lesion of liver	1.7	1.3	0.04	1.7	1.3	0.04	1.8	1.4	0.03
Obesity	25.9	8.2	0.48	24.0	24.6	-0.01	15.7	18.3	-0.07
Osteoarthritis	36.1	30.1	0.13	36.0	35.7	0.00	39.0	36.2	0.06
Pneumonia	5.0	8.3	-0.13	4.9	5.1	-0.01	7.5	7.3	0.01
Psoriasis	2.5	1.4	0.08	2.6	2.2	0.03	1.7	2.0	-0.02
Renal impairment	14.5	16.4	-0.05	15.3	14.7	0.02	17.1	21.6	-0.11
Rheumatoid arthritis	1.7	1.8	-0.01	1.6	1.8	-0.01	1.4	2.0	-0.04
Ulcerative colitis	0.5	0.4	0.01	0.5	0.4	0.01	0.4	0.4	-0.01
Urinary tract infectious disease	8.1	12.3	-0.14	8.5	9.0	-0.02	14.5	12.6	0.05
Viral hepatitis C	0.6	0.3	0.06	0.7	0.3	0.05	0.3	0.3	0.00
Visual system disorder	57.8	50.1	0.16	55.6	56.8	-0.02	54.7	54.7	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	16.7	16.4	0.01	16.4	16.2	0.00	17.3	18.0	-0.02
Cerebrovascular disease	18.9	22.0	-0.08	17.4	17.5	0.00	21.3	19.5	0.05
Coronary arteriosclerosis	51.9	44.3	0.15	48.5	50.7	-0.04	40.4	45.5	-0.10
Heart disease	71.2	66.9	0.09	65.2	66.6	-0.03	65.2	66.6	-0.03
Heart failure	15.3	16.6	-0.04	13.6	12.5	0.03	17.1	15.6	0.04
Peripheral vascular disease	24.9	20.0	0.12	23.5	23.7	-0.01	22.1	23.2	-0.03
Pulmonary embolism	1.0	1.3	-0.02	1.0	1.4	-0.04	1.7	1.6	0.01
Venous thrombosis	2.2	3.0	-0.05	2.4	2.5	-0.01	1.8	3.2	-0.09
Medical history: Neoplasms									
Hematologic neoplasm	1.7	2.1	-0.03	1.7	1.9	-0.01	1.0	2.4	-0.11
Malignant lymphoma	1.2	1.0	0.02	1.1	1.2	-0.01	0.6	1.3	-0.07
Malignant neoplasm of anorectum	0.3	0.5	-0.02	0.4	0.3	0.01	0.4	0.4	0.00
Malignant neoplastic disease	19.2	20.4	-0.03	18.9	19.7	-0.02	17.4	21.2	-0.10
Malignant tumor of breast	2.2	2.6	-0.03	2.3	2.3	0.00	2.2	2.5	-0.02
Malignant tumor of colon	0.7	1.1	-0.04	0.7	0.6	0.02	0.8	0.9	-0.02
Malignant tumor of lung	0.4	1.1	-0.07	0.5	0.8	-0.04	0.3	1.2	-0.10
Malignant tumor of urinary bladder	1.2	1.4	-0.02	1.3	1.1	0.02	1.8	1.4	0.03
Primary malignant neoplasm of prostate	5.4	5.3	0.01	5.4	5.0	0.02	5.2	5.3	-0.01
Medication use									
Agents acting on the renin-angiotensin system	77.6	74.3	0.08	77.5	75.7	0.04	77.0	75.6	0.03
Antibacterials for systemic use	64.8	65.0	0.00	64.4	63.9	0.01	65.9	65.0	0.02
Antidepressants	27.0	27.3	-0.01	27.5	26.9	0.01	28.0	27.8	0.00
Antiepileptics	19.7	17.3	0.06	18.8	19.4	-0.01	19.1	20.0	-0.02
Antiinflammatory and antirheumatic products	29.9	27.6	0.05	30.0	29.2	0.02	27.7	28.2	-0.01
Antineoplastic agents	8.4	9.6	-0.04	8.4	8.3	0.00	8.8	8.4	0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antipsoriaties	0.9	0.8	0.02	1.0	0.8	0.02	0.4	0.9	-0.06
Beta blocking agents	61.7	61.0	0.02	60.7	61.1	-0.01	59.6	61.1	-0.03
Calcium channel blockers	35.9	37.1	-0.02	35.8	35.4	0.01	34.4	37.2	-0.06
Diuretics	53.1	56.7	-0.07	52.2	51.0	0.02	54.9	52.8	0.04
Drugs for acid related disorders	39.1	36.7	0.05	37.0	37.4	-0.01	37.4	36.6	0.02
Drugs for obstructive airway diseases	48.5	41.9	0.13	47.3	48.3	-0.02	47.0	45.9	0.02
Immunosuppressants	3.9	2.9	0.05	3.7	3.9	-0.01	3.0	3.7	-0.04
Lipid modifying agents	89.2	80.2	0.25	88.0	88.4	-0.01	87.4	84.2	0.09
Opioids	28.9	32.4	-0.08	28.7	29.5	-0.02	32.5	32.3	0.00
Psycholeptics	26.0	29.0	-0.07	26.3	26.0	0.01	31.4	28.4	0.07
Psychostimulants	1.6	1.3	0.03	1.8	1.4	0.03	1.0	1.3	-0.02

Supplementary Table 23: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the MDCD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
15 - 19	<0.4	<0.1	0.01	<0.4	0.1	0.01	<0.3	<0.1	0.01
20 - 24	<0.4	0.3	-0.05	<0.4	0.3	-0.05	<0.3	0.3	-0.06
25 - 29	1.4	0.7	0.07	1.5	0.8	0.07	2.9	0.7	0.16
30 - 34	2.4	1.9	0.04	2.5	1.9	0.04	3.0	1.8	0.08
35 - 39	5.9	4.1	0.08	6.1	4.6	0.06	5.6	4.5	0.05
40 - 44	8.4	6.8	0.06	8.3	8.3	0.00	7.3	7.1	0.01
45 - 49	14.5	11.9	0.08	14.0	13.0	0.03	12.6	12.0	0.02
50 - 54	17.9	17.0	0.02	18.0	17.3	0.02	19.2	17.1	0.05
55 - 59	22.9	21.4	0.04	22.8	22.8	0.00	22.7	22.6	0.00
60 - 64	18.0	20.2	-0.06	18.2	19.2	-0.03	19.0	20.8	-0.04
65 - 69	4.3	6.8	-0.11	4.4	5.8	-0.06	4.2	6.1	-0.09
70 - 74	2.7	3.9	-0.07	2.6	3.2	-0.04	1.9	3.3	-0.09
75 - 79	0.5	2.4	-0.15	0.5	1.3	-0.08	0.3	1.8	-0.15
80 - 84	0.7	1.6	-0.09	0.7	1.0	-0.03	0.6	1.1	-0.06
85 - 89	<0.4	0.9	-0.09	<0.4	0.5	-0.05	0.7	0.7	0.00
Gender: female	56.4	58.4	-0.04	56.4	55.0	0.03	57.4	56.2	0.03
Race									
Black or African American	22.7	25.5	-0.07	22.8	20.6	0.05	25.6	25.4	0.01
White	63.6	58.0	0.11	63.4	64.3	-0.02	62.3	57.9	0.09
Ethnicity									
Hispanic or Latino	1.9	2.1	-0.01	1.8	2.4	-0.04	1.3	2.3	-0.07
Medical history: General									
Acute respiratory disease	38.7	40.7	-0.04	38.5	39.8	-0.03	45.6	40.2	0.11
Attention deficit hyperactivity disorder	1.9	1.2	0.06	1.8	1.8	0.00	1.9	1.5	0.03
Chronic liver disease	3.8	7.0	-0.14	3.9	4.2	-0.02	8.5	6.0	0.10
Chronic obstructive lung disease	29.8	31.2	-0.03	29.9	29.9	0.00	33.6	31.2	0.05
Crohn's disease	0.5	0.4	0.01	0.5	0.5	0.00	0.3	0.5	-0.03
Dementia	1.6	3.2	-0.11	1.6	2.1	-0.04	1.5	3.1	-0.11
Depressive disorder	37.3	36.0	0.03	36.7	39.0	-0.05	37.6	38.4	-0.02
Gastroesophageal reflux disease	31.7	30.7	0.02	31.5	33.8	-0.05	35.5	32.8	0.06
Gastrointestinal hemorrhage	4.1	5.2	-0.05	4.1	4.0	0.00	4.0	4.7	-0.04
Human immunodeficiency virus infection	0.6	0.6	0.00	0.6	0.6	0.01	2.4	0.6	0.15
Hyperlipidemia	74.7	72.4	0.05	74.6	75.6	-0.02	71.1	73.8	-0.06
Hypertensive disorder	84.9	86.4	-0.04	87.6	87.1	0.01	87.6	87.1	0.01
Lesion of liver	1.7	2.5	-0.06	1.7	2.4	-0.05	1.6	2.5	-0.06
Obesity	43.6	35.4	0.17	43.3	43.0	0.01	44.8	40.1	0.10
Osteoarthritis	45.7	42.7	0.06	45.2	46.1	-0.02	45.6	43.8	0.04
Pneumonia	7.6	10.4	-0.10	7.6	8.2	-0.02	10.1	9.6	0.02
Psoriasis	1.8	1.3	0.04	1.7	1.9	-0.02	1.3	1.6	-0.03
Renal impairment	12.3	15.7	-0.10	12.4	11.7	0.02	14.2	16.2	-0.06
Rheumatoid arthritis	2.8	2.5	0.02	2.7	2.1	0.04	4.1	2.3	0.10
Schizophrenia	3.7	5.3	-0.08	3.5	4.4	-0.05	6.0	5.2	0.03
Ulcerative colitis	<0.4	0.3	0.00	<0.4	0.3	0.00	0.8	0.3	0.07
Urinary tract infectious disease	10.6	15.4	-0.14	10.6	10.8	-0.01	13.2	13.9	-0.02
Viral hepatitis C	2.4	3.5	-0.07	2.4	2.6	-0.01	2.4	2.6	-0.01
Visual system disorder	48.6	43.6	0.10	48.3	47.8	0.01	43.4	44.8	-0.03
Medical history: Cardiovascular disease									
Atrial fibrillation	6.5	7.6	-0.04	6.5	6.6	0.00	6.7	7.1	-0.01
Cerebrovascular disease	11.4	14.6	-0.10	11.2	11.0	0.01	12.0	12.8	-0.03
Coronary arteriosclerosis	33.6	33.1	0.01	33.3	32.9	0.01	33.6	32.1	0.03
Heart disease	55.0	57.8	-0.06	54.6	54.3	0.00	55.5	55.8	-0.01
Heart failure	18.1	19.3	-0.03	17.8	17.2	0.02	19.3	18.5	0.02
Ischemic heart disease	22.5	23.8	-0.03	22.3	23.1	-0.02	22.3	23.1	-0.02
Peripheral vascular disease	22.4	21.4	0.02	22.4	21.9	0.01	19.9	21.9	-0.05
Pulmonary embolism	1.8	2.0	-0.01	1.7	1.9	-0.01	3.0	2.1	0.06
Venous thrombosis	2.4	3.2	-0.05	2.5	2.9	-0.02	2.2	3.1	-0.06
Medical history: Neoplasms									
Hematologic neoplasm	0.8	1.4	-0.06	0.8	1.2	-0.04	0.7	1.3	-0.06
Malignant lymphoma	<0.4	0.5	-0.03	<0.4	0.4	-0.01	0.4	0.5	-0.01
Malignant neoplasm of anorectum	<0.4	0.4	-0.06	<0.4	0.3	-0.05	<0.3	0.3	-0.06
Malignant neoplastic disease	6.1	8.4	-0.09	6.0	7.1	-0.05	5.6	8.1	-0.10

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant tumor of breast	1.6	1.7	-0.01	1.6	1.3	0.03	1.5	1.5	-0.01
Malignant tumor of colon	<0.4	0.6	-0.06	<0.4	0.4	-0.03	<0.3	0.5	-0.07
Malignant tumor of lung	<0.4	0.7	-0.08	<0.4	0.6	-0.07	<0.3	0.7	-0.10
Malignant tumor of urinary bladder	<0.4	0.3	-0.04	<0.4	0.4	-0.04	<0.3	0.4	-0.05
Primary malignant neoplasm of prostate	<0.4	0.7	-0.06	<0.4	0.5	-0.04	<0.3	0.7	-0.07
Medication use									
Agents acting on the renin-angiotensin system	68.7	71.0	-0.05	68.8	67.5	0.03	67.8	69.8	-0.04
Antibacterials for systemic use	69.6	70.6	-0.02	72.0	69.7	0.05	72.0	69.7	0.05
Antidepressants	55.8	55.0	0.02	55.7	57.0	-0.03	58.3	55.4	0.06
Antiepileptics	50.9	45.8	0.10	50.4	49.2	0.02	48.0	48.4	-0.01
Antiinflammatory and antirheumatic products	66.3	58.8	0.15	66.1	65.9	0.00	65.3	62.6	0.06
Antineoplastic agents	5.4	4.9	0.02	5.3	4.2	0.05	4.2	4.5	-0.01
Antipsoriatics	0.4	0.6	-0.03	<0.4	0.6	-0.04	<0.3	0.6	-0.07
Antithrombotic agents	45.1	43.2	0.04	44.7	44.8	0.00	44.5	44.9	-0.01
Beta blocking agents	52.8	52.6	0.00	52.5	51.4	0.02	52.1	52.5	-0.01
Calcium channel blockers	28.2	33.7	-0.12	28.6	27.4	0.03	36.3	32.7	0.08
Diuretics	53.4	56.8	-0.07	53.2	51.8	0.03	56.0	55.0	0.02
Drugs for acid related disorders	55.8	54.8	0.02	55.4	55.8	-0.01	59.4	55.2	0.09
Drugs for obstructive airway diseases	64.8	60.9	0.08	64.5	63.3	0.03	65.0	62.2	0.06
Immunosuppressants	3.0	2.6	0.02	3.0	2.7	0.01	3.8	2.7	0.06
Lipid modifying agents	77.6	74.9	0.06	77.3	77.5	0.00	71.8	76.0	-0.10
Opioids	51.0	54.6	-0.07	50.7	48.8	0.04	54.2	52.7	0.03
Psycholeptics	53.8	53.0	0.02	56.8	53.0	0.08	56.8	53.0	0.08
Psychostimulants	5.6	4.0	0.07	5.5	4.5	0.05	5.4	4.2	0.06

Supplementary Table 24: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the Open Claims data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.1	0.1	0.00	0.1	0.1	0.00	0.2	0.1	0.01
25 - 29	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	0.00
30 - 34	0.4	0.4	0.00	0.4	0.4	0.00	0.4	0.4	0.00
35 - 39	1.0	0.9	0.02	1.1	1.1	0.00	1.0	0.9	0.01
40 - 44	2.4	1.9	0.04	2.4	2.6	-0.01	2.4	2.6	-0.01
45 - 49	5.2	4.0	0.06	5.2	5.3	0.00	4.6	4.4	0.01
50 - 54	9.4	7.4	0.07	9.3	9.4	0.00	8.2	7.9	0.01
55 - 59	14.5	11.4	0.09	14.1	14.5	-0.01	12.5	12.1	0.01
60 - 64	18.0	14.2	0.10	17.6	17.8	0.00	15.9	15.3	0.02
65 - 69	17.5	17.3	0.00	17.5	18.1	-0.01	17.3	17.6	-0.01
70 - 74	14.4	16.5	-0.06	14.7	14.4	0.01	14.7	14.4	0.01
75 - 79	10.0	18.0	-0.23	10.5	9.5	0.03	14.5	15.6	-0.03
80 - 84	6.1	7.4	-0.05	6.4	6.3	0.01	7.0	7.1	0.00
85 - 89	0.5	0.2	0.06	0.4	0.5	0.00	0.3	0.3	0.00
Gender: female	39.9	44.7	-0.10	40.9	41.9	-0.02	43.7	44.0	-0.01
Medical history: General									
Acute respiratory disease	15.6	16.9	-0.04	15.3	16.1	-0.02	16.9	16.7	0.01
Attention deficit hyperactivity disorder	0.5	0.3	0.03	0.4	0.4	0.00	0.4	0.3	0.01
Chronic liver disease	1.3	1.8	-0.05	1.3	1.3	0.00	1.9	1.7	0.01
Chronic obstructive lung disease	8.8	11.1	-0.08	8.7	8.8	0.00	10.9	10.5	0.01
Crohn's disease	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	0.00
Dementia	0.9	1.9	-0.09	1.0	0.9	0.00	1.7	1.7	0.00
Depressive disorder	8.0	8.8	-0.03	8.0	8.4	-0.01	9.0	8.7	0.01
Gastroesophageal reflux disease	10.6	10.4	0.01	10.4	10.6	-0.01	11.1	10.6	0.02
Gastrointestinal hemorrhage	1.8	2.3	-0.04	1.8	1.8	0.00	1.8	1.8	0.00
Human immunodeficiency virus infection	0.3	0.2	0.01	0.3	0.3	0.00	0.3	0.3	0.00
Hyperlipidemia	53.2	50.0	0.06	51.4	50.9	0.01	51.4	50.9	0.01
Hypertensive disorder	60.7	61.3	-0.01	59.9	59.9	0.00	61.6	61.2	0.01
Lesion of liver	0.8	1.1	-0.02	0.9	0.9	-0.01	1.1	1.0	0.01
Obesity	13.9	11.2	0.08	13.4	13.6	-0.01	12.6	12.0	0.02
Osteoarthritis	19.0	20.4	-0.04	18.9	19.3	-0.01	20.7	20.3	0.01
Pneumonia	3.4	4.6	-0.06	3.2	3.4	-0.01	3.2	3.4	-0.01
Psoriasis	1.2	0.9	0.03	1.1	1.1	0.00	1.1	1.1	0.00
Renal impairment	9.5	13.2	-0.12	9.2	8.8	0.01	11.6	12.2	-0.02
Rheumatoid arthritis	1.3	1.4	-0.01	1.3	1.3	0.00	1.5	1.4	0.01
Schizophrenia	0.3	0.5	-0.02	0.3	0.4	0.00	0.4	0.4	0.00
Ulcerative colitis	0.3	0.2	0.00	0.2	0.2	0.00	0.3	0.2	0.00
Urinary tract infectious disease	5.2	7.7	-0.10	5.4	5.4	0.00	7.7	7.2	0.02
Viral hepatitis C	0.4	0.5	-0.03	0.4	0.4	0.00	0.5	0.5	0.00
Visual system disorder	21.8	23.4	-0.04	21.8	21.5	0.01	23.1	23.0	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	8.4	8.9	-0.02	7.8	7.5	0.01	8.5	8.6	-0.01
Cerebrovascular disease	7.5	9.6	-0.08	7.4	7.3	0.00	9.1	9.0	0.00
Coronary arteriosclerosis	28.2	25.4	0.06	26.2	25.1	0.03	25.9	25.6	0.01
Heart disease	44.2	42.3	0.04	41.7	40.4	0.03	42.5	42.1	0.01
Heart failure	11.3	10.2	0.04	9.4	8.7	0.03	10.1	9.9	0.01
Ischemic heart disease	13.9	12.6	0.04	12.8	12.2	0.02	12.8	12.6	0.00
Peripheral vascular disease	13.3	13.9	-0.02	13.2	13.3	0.00	13.9	13.8	0.00
Pulmonary embolism	0.8	0.9	-0.01	0.8	0.8	0.00	1.0	0.9	0.01
Venous thrombosis	1.3	1.6	-0.03	1.2	1.3	-0.01	1.2	1.3	-0.01
Medical history: Neoplasms									
Hematologic neoplasm	0.8	1.2	-0.04	0.8	0.9	0.00	1.1	1.1	0.00
Malignant lymphoma	0.5	0.6	-0.02	0.5	0.5	0.00	0.7	0.6	0.01
Malignant neoplasm of anorectum	0.1	0.2	-0.01	0.2	0.1	0.01	0.2	0.2	0.01
Malignant neoplastic disease	7.5	9.4	-0.07	7.6	7.4	0.00	9.1	8.9	0.01
Malignant tumor of breast	1.1	1.4	-0.02	1.2	1.2	0.00	1.3	1.3	0.00
Malignant tumor of colon	0.3	0.5	-0.03	0.3	0.3	0.00	0.5	0.5	0.00
Malignant tumor of lung	0.3	0.6	-0.04	0.3	0.4	-0.01	0.5	0.5	-0.01
Malignant tumor of urinary bladder	0.3	0.5	-0.03	0.4	0.3	0.00	0.4	0.3	0.00
Primary malignant neoplasm of prostate	1.6	2.0	-0.03	1.6	1.5	0.01	1.8	1.8	0.00
Medication use									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Agents acting on the renin-angiotensin system	74.6	73.2	0.03	73.5	73.0	0.01	73.3	73.2	0.00
Antibacterials for systemic use	58.9	60.5	-0.03	58.8	59.6	-0.02	61.4	60.8	0.01
Antidepressants	32.1	32.4	-0.01	31.9	32.6	-0.01	33.3	32.6	0.01
Antiepileptics	23.4	25.2	-0.04	23.6	24.0	-0.01	26.0	25.2	0.02
Antiinflammatory and antirheumatic products	39.5	37.6	0.04	39.2	39.4	0.00	39.4	38.5	0.02
Antineoplastic agents	5.9	5.4	0.02	5.6	5.9	-0.01	5.7	5.6	0.00
Antipsoriatics	0.8	0.8	0.01	0.8	0.8	0.00	0.9	0.8	0.00
Antithrombotic agents	38.2	36.6	0.03	36.4	35.5	0.02	36.8	36.5	0.01
Beta blocking agents	55.8	54.5	0.03	53.9	52.8	0.02	53.8	54.3	-0.01
Calcium channel blockers	31.9	33.6	-0.04	31.9	31.8	0.00	32.4	33.3	-0.02
Diuretics	47.8	48.6	-0.02	46.6	46.0	0.01	48.4	47.9	0.01
Drugs for acid related disorders	40.6	41.1	-0.01	39.9	40.0	0.00	42.0	41.0	0.02
Drugs for obstructive airway diseases	42.7	41.0	0.03	41.9	42.5	-0.01	42.4	41.6	0.02
Immunosuppressants	3.4	2.9	0.03	3.2	3.2	0.00	3.2	3.0	0.01
Lipid modifying agents	82.5	77.9	0.12	81.3	80.7	0.01	78.8	78.8	0.00
Opioids	28.2	31.3	-0.07	28.2	28.7	-0.01	31.6	30.9	0.01
Psycholeptics	26.2	27.8	-0.04	25.9	26.4	-0.01	28.5	27.7	0.02
Psychostimulants	2.7	2.2	0.03	2.6	2.6	0.00	2.5	2.3	0.01

Supplementary Table 25: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the OptumEHR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	<0.1	0.1	-0.01	<0.1	0.1	-0.02	<0.1	0.1	-0.02
30 - 34	0.4	0.3	0.01	0.4	0.4	0.01	0.4	0.3	0.01
35 - 39	1.2	0.9	0.03	1.2	1.0	0.01	1.4	0.9	0.04
40 - 44	3.3	2.0	0.08	3.1	3.1	0.00	2.8	2.3	0.03
45 - 49	6.6	4.6	0.08	6.3	6.4	0.00	5.0	5.1	0.00
50 - 54	10.8	8.2	0.09	10.6	10.8	-0.01	8.5	8.8	-0.01
55 - 59	17.1	12.6	0.13	16.6	16.8	-0.01	13.6	13.7	0.00
60 - 64	20.8	15.6	0.14	20.2	20.7	-0.01	17.1	16.9	0.00
65 - 69	16.2	16.3	0.00	16.4	16.7	-0.01	17.0	16.3	0.02
70 - 74	12.5	15.4	-0.08	13.0	12.6	0.01	13.9	14.7	-0.02
75 - 79	6.8	13.2	-0.22	7.4	6.9	0.02	9.6	10.6	-0.03
80 - 84	3.1	8.7	-0.24	3.4	3.1	0.02	8.6	8.0	0.02
85 - 89	1.0	2.0	-0.08	1.2	1.2	0.00	1.8	2.2	-0.03
Gender: female	35.4	39.3	-0.08	36.4	36.2	0.00	39.9	38.8	0.02
Race									
Asian	1.9	1.7	0.01	1.8	1.9	-0.01	1.7	1.8	-0.01
Black or African American	8.1	8.0	0.00	8.2	8.3	0.00	7.8	8.3	-0.02
White	83.7	84.5	-0.02	83.8	83.5	0.01	84.6	83.9	0.02
Ethnicity									
Hispanic or Latino	4.5	4.9	-0.02	4.4	4.6	-0.01	4.3	4.7	-0.02
Not Hispanic or Latino	86.3	88.4	-0.06	87.6	87.3	0.01	89.2	88.2	0.03
Medical history: General									
Acute respiratory disease	19.3	18.1	0.03	19.1	19.2	0.00	17.7	18.7	-0.03
Attention deficit hyperactivity disorder	0.6	0.4	0.03	0.6	0.6	0.00	0.5	0.5	0.00
Chronic liver disease	2.2	3.1	-0.06	2.3	2.3	0.00	3.1	2.9	0.01
Chronic obstructive lung disease	9.9	12.1	-0.07	10.2	10.1	0.01	12.3	11.9	0.01
Crohn's disease	0.3	0.2	0.00	0.2	0.3	0.00	0.3	0.3	0.01
Dementia	0.8	2.2	-0.12	0.8	1.0	-0.01	1.4	1.9	-0.04
Depressive disorder	14.7	15.1	-0.01	14.9	14.7	0.00	17.0	15.3	0.05
Gastroesophageal reflux disease	21.8	19.8	0.05	21.5	21.4	0.00	22.0	20.9	0.03
Gastrointestinal hemorrhage	1.6	2.2	-0.05	1.6	1.5	0.01	1.8	2.0	-0.02
Human immunodeficiency virus infection	0.2	0.2	0.00	0.2	0.2	0.00	0.1	0.2	-0.02
Hyperlipidemia	78.1	73.9	0.10	76.5	77.0	-0.01	74.9	74.4	0.01
Hypertensive disorder	78.9	76.8	0.05	77.9	78.7	-0.02	78.2	77.3	0.02
Lesion of liver	0.9	1.2	-0.03	1.0	1.1	-0.01	2.0	1.2	0.06
Obesity	33.2	23.7	0.21	31.6	32.8	-0.03	29.4	27.3	0.05
Osteoarthritis	20.9	22.2	-0.03	20.9	20.8	0.00	23.6	22.5	0.03
Pneumonia	2.4	3.8	-0.08	2.4	2.6	-0.01	3.3	3.6	-0.01
Psoriasis	1.7	1.5	0.02	1.7	1.6	0.01	1.7	1.5	0.01
Renal impairment	8.7	13.9	-0.16	9.0	8.5	0.02	14.8	13.4	0.04
Rheumatoid arthritis	1.6	1.5	0.01	1.6	1.5	0.01	1.9	1.5	0.03
Schizophrenia	0.2	0.3	-0.03	0.2	0.3	-0.02	0.2	0.3	-0.03
Ulcerative colitis	0.3	0.3	0.01	0.4	0.3	0.01	0.3	0.3	0.00
Urinary tract infectious disease	3.9	6.7	-0.13	4.1	4.2	0.00	7.7	6.0	0.07
Viral hepatitis C	0.4	0.7	-0.04	0.5	0.6	-0.01	0.4	0.7	-0.04
Visual system disorder	13.0	18.0	-0.14	13.2	13.1	0.01	18.9	16.8	0.05
Medical history: Cardiovascular disease									
Atrial fibrillation	8.8	10.7	-0.06	8.7	8.5	0.01	10.6	10.3	0.01
Cerebrovascular disease	9.1	11.5	-0.08	9.4	9.0	0.01	11.1	10.6	0.02
Coronary arteriosclerosis	47.4	42.8	0.09	44.9	45.4	-0.01	41.4	42.2	-0.02
Heart disease	61.8	59.1	0.06	59.6	59.8	0.00	59.2	58.4	0.02
Heart failure	9.9	10.3	-0.01	9.1	9.2	0.00	10.8	10.1	0.02
Ischemic heart disease	22.0	19.6	0.06	20.8	21.0	-0.01	19.6	20.0	-0.01
Peripheral vascular disease	20.3	17.9	0.06	19.7	19.4	0.01	19.6	18.7	0.02
Pulmonary embolism	0.9	1.1	-0.02	0.9	1.0	-0.01	1.2	1.1	0.00
Venous thrombosis	1.8	1.9	-0.01	1.7	1.5	0.02	2.3	1.8	0.03
Medical history: Neoplasms									
Hematologic neoplasm	0.9	1.2	-0.02	1.0	0.9	0.01	1.2	1.1	0.00
Malignant lymphoma	0.5	0.7	-0.03	0.5	0.5	0.01	0.6	0.6	0.00
Malignant neoplasm of anorectum	0.1	0.2	-0.04	<0.1	0.1	-0.02	<0.1	0.1	-0.02
Malignant neoplastic disease	7.1	9.9	-0.10	7.3	7.3	0.00	9.3	9.2	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant tumor of breast	1.0	1.3	-0.03	1.1	1.0	0.00	1.0	1.2	-0.02
Malignant tumor of colon	0.4	0.6	-0.03	0.3	0.3	0.00	0.2	0.5	-0.05
Malignant tumor of lung	0.2	0.5	-0.04	0.2	0.4	-0.03	0.2	0.5	-0.04
Malignant tumor of urinary bladder	0.4	0.6	-0.03	0.4	0.5	-0.01	0.4	0.5	-0.01
Primary malignant neoplasm of prostate	1.7	2.2	-0.04	1.7	1.6	0.01	1.9	2.0	-0.01
Medication use									
Agents acting on the renin-angiotensin system	75.2	73.0	0.05	74.5	74.3	0.00	73.0	73.3	-0.01
Antibacterials for systemic use	45.0	46.2	-0.02	44.7	44.9	0.00	48.8	46.0	0.06
Antidepressants	31.9	32.0	0.00	32.2	32.4	0.00	36.5	32.4	0.09
Antiepileptics	21.1	22.2	-0.03	21.3	21.4	0.00	25.0	22.9	0.05
Antiinflammatory and antirheumatic products	71.6	69.5	0.05	70.8	70.7	0.00	70.1	70.3	0.00
Antineoplastic agents	4.9	4.8	0.01	4.8	4.7	0.00	5.7	4.9	0.04
Antipsoriatics	0.4	0.6	-0.03	0.4	0.5	-0.02	0.7	0.6	0.01
Antithrombotic agents	68.3	68.9	-0.01	67.4	66.9	0.01	67.0	68.3	-0.03
Beta blocking agents	58.9	59.5	-0.01	57.7	57.8	0.00	58.3	58.5	0.00
Calcium channel blockers	30.2	30.4	0.00	29.9	30.0	0.00	30.9	30.6	0.01
Diuretics	45.2	48.4	-0.06	45.0	44.5	0.01	47.7	47.1	0.01
Drugs for acid related disorders	46.4	47.8	-0.03	46.2	45.7	0.01	49.9	47.8	0.04
Drugs for obstructive airway diseases	46.3	46.1	0.00	48.9	46.8	0.04	48.9	46.8	0.04
Immunosuppressants	3.1	2.8	0.02	3.0	3.0	0.00	3.8	3.0	0.04
Lipid modifying agents	86.7	82.4	0.12	85.7	85.5	0.00	83.1	83.1	0.00
Opioids	31.7	36.2	-0.10	32.1	32.0	0.00	38.4	35.5	0.06
Psycholeptics	33.4	34.4	-0.02	33.1	33.4	-0.01	36.3	34.3	0.04
Psychostimulants	3.4	2.3	0.07	3.2	3.1	0.00	2.9	2.6	0.02

Supplementary Table 26: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
35 - 39	<0.2	0.2	-0.05	<0.2	<0.4	-0.01	<0.2	<0.4	-0.01
40 - 44	1.0	1.1	-0.01	<1.6	1.6	-0.03	1.2	0.8	0.04
45 - 49	2.8	2.5	0.02	5.6	3.4	0.11	4.0	2.7	0.07
50 - 54	6.3	6.2	0.00	7.8	5.7	0.09	6.7	3.6	0.14
55 - 59	11.9	10.9	0.03	12.5	9.8	0.09	12.3	19.0	-0.19
60 - 64	16.6	15.2	0.04	16.9	16.7	0.01	16.3	16.3	0.00
65 - 69	18.9	16.3	0.07	20.4	20.4	0.00	18.9	17.3	0.04
70 - 74	17.7	16.2	0.04	16.9	17.3	-0.01	17.9	10.8	0.20
75 - 79	13.6	13.9	-0.01	10.0	11.3	-0.04	12.6	8.5	0.14
80 - 84	7.3	10.5	-0.11	5.3	8.5	-0.12	6.5	4.9	0.07
85 - 89	3.0	5.6	-0.13	2.2	4.3	-0.12	2.8	15.2	-0.44
90 - 94	0.7	1.0	-0.04	<1.6	0.9	-0.08	0.6	0.8	-0.03
95 - 99	<0.2	0.2	-0.02	<1.6	<0.5	0.06	<0.2	<0.4	0.04
Gender: female	21.0	28.8	-0.18	30.7	28.8	0.04	25.4	21.1	0.10
Medical history: General									
Acute respiratory disease	13.2	11.5	0.05	14.7	16.9	-0.06	14.0	12.7	0.04
Chronic liver disease	0.3	0.6	-0.05	<1.6	<0.5	0.04	0.5	<0.4	0.08
Chronic obstructive lung disease	2.3	2.9	-0.04	1.9	1.8	0.01	2.1	1.0	0.09
Dementia	0.3	1.3	-0.11	0.3	0.5	-0.04	0.3	0.5	-0.04
Depressive disorder	1.0	3.7	-0.18	<1.6	2.7	-0.11	1.3	1.9	-0.05
Gastroesophageal reflux disease	1.4	0.8	0.06	1.9	2.8	-0.06	1.3	3.6	-0.15
Gastrointestinal hemorrhage	1.3	1.4	-0.01	1.9	1.5	0.03	1.5	0.7	0.08
Hyperlipidemia	1.9	4.0	-0.13	1.9	1.3	0.04	1.7	0.9	0.07
Hypertensive disorder	3.2	6.0	-0.13	4.1	3.3	0.04	3.0	15.7	-0.44
Lesion of liver	<0.2	0.6	-0.07	<0.2	<0.4	-0.02	<0.2	<0.4	-0.02
Obesity	5.9	7.9	-0.08	8.2	8.9	-0.03	7.1	7.0	0.00
Osteoarthritis	3.4	5.4	-0.10	4.4	4.4	0.00	4.1	2.6	0.08
Pneumonia	2.2	2.2	0.00	<1.6	1.8	-0.04	1.8	1.0	0.07
Psoriasis	0.2	0.7	-0.07	<1.6	0.8	-0.07	<0.2	<0.4	-0.01
Renal impairment	2.0	3.2	-0.07	2.2	2.2	0.00	1.9	2.4	-0.03
Rheumatoid arthritis	<0.2	<0.2	0.00	<1.6	<0.5	0.13	0.7	<0.4	0.11
Urinary tract infectious disease	4.8	3.9	0.05	6.0	5.5	0.02	5.3	3.8	0.07
Viral hepatitis C	<0.2	<0.2	-0.02	<1.6	<0.5	0.05	0.4	<0.4	0.07
Visual system disorder	13.3	17.0	-0.10	20.4	20.6	0.00	14.6	14.2	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	3.3	3.1	0.01	<1.6	2.4	-0.06	2.9	1.6	0.09
Cerebrovascular disease	2.4	8.3	-0.26	5.3	6.3	-0.04	3.4	3.2	0.01
Heart disease	31.4	27.7	0.08	22.3	23.0	-0.02	28.4	18.6	0.23
Heart failure	5.0	3.9	0.05	2.8	2.6	0.02	4.2	1.2	0.19
Ischemic heart disease	22.4	19.3	0.08	14.7	13.8	0.03	20.3	10.9	0.26
Peripheral vascular disease	3.5	6.5	-0.14	6.0	5.1	0.04	3.7	2.5	0.07
Pulmonary embolism	<0.2	0.2	-0.03	<0.2	<0.4	0.02	<0.2	<0.4	0.02
Venous thrombosis	0.5	1.1	-0.06	<1.6	1.6	-0.13	0.5	0.8	-0.05
Medical history: Neoplasms									
Malignant neoplastic disease	2.1	2.8	-0.05	2.8	4.0	-0.06	1.9	2.4	-0.03
Malignant tumor of breast	<0.2	0.2	-0.04	<0.2	<0.4	-0.01	<0.2	<0.4	-0.01
Malignant tumor of colon	<0.2	0.4	-0.04	<1.6	<0.5	0.02	<0.2	<0.4	0.00
Malignant tumor of urinary bladder	<0.2	0.5	-0.06	<0.2	<0.4	-0.03	<0.2	<0.4	-0.03
Primary malignant neoplasm of prostate	<0.2	0.3	-0.03	<1.6	1.0	-0.08	<0.2	0.9	-0.10
Medication use									
Agents acting on the renin-angiotensin system	82.4	69.1	0.31	73.7	75.6	-0.04	79.9	65.4	0.33
Antibacterials for systemic use	39.5	35.3	0.09	44.5	44.3	0.00	41.1	46.0	-0.10
Antidepressants	19.1	20.9	-0.04	23.8	24.5	-0.02	21.4	16.7	0.12
Antiepileptics	11.0	9.2	0.06	13.5	14.1	-0.02	13.6	9.1	0.14
Antiinflammatory and antirheumatic products	82.2	72.3	0.24	82.1	79.6	0.06	81.0	74.0	0.17
Antineoplastic agents	1.4	1.6	-0.01	2.2	0.9	0.10	1.8	<0.4	0.14
Antipsoriatics	1.7	1.4	0.03	1.9	1.1	0.06	2.0	0.6	0.12
Antithrombotic agents	91.9	78.3	0.39	82.8	83.2	-0.01	87.3	86.4	0.03
Beta blocking agents	72.6	50.6	0.46	58.9	59.5	-0.01	68.7	69.7	-0.02
Calcium channel blockers	33.1	32.1	0.02	32.6	31.0	0.04	32.6	22.9	0.22
Diuretics	55.7	50.0	0.11	47.6	50.8	-0.06	54.3	48.0	0.12

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Drugs for acid related disorders	76.4	68.5	0.18	70.5	70.8	-0.01	74.2	67.9	0.14
Drugs for obstructive airway diseases	32.1	27.3	0.10	29.8	29.4	0.01	31.9	24.7	0.16
Immunosuppressants	1.6	1.2	0.04	2.2	1.1	0.09	1.5	0.5	0.09
Lipid modifying agents	92.0	79.0	0.38	83.7	84.6	-0.02	89.0	88.6	0.01
Opioids	20.0	16.5	0.09	21.3	23.4	-0.05	21.5	15.5	0.15
Psycholeptics	30.2	33.4	-0.07	35.4	37.0	-0.03	32.1	26.5	0.12
Psychostimulants	24.0	13.7	0.26	11.6	13.6	-0.06	21.0	11.7	0.25

Supplementary Table 27: Baseline patient characteristics for SGLT2is (T) and SUs (C) new-users in the VA data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
30 - 34	<0.1	0.1	-0.03	<0.2	0.1	-0.03	<0.1	0.1	-0.03
35 - 39	0.2	0.3	-0.01	0.3	0.3	0.00	0.2	0.4	-0.03
40 - 44	0.6	0.9	-0.02	0.7	0.8	-0.01	0.7	0.8	-0.02
45 - 49	2.1	2.5	-0.02	2.1	2.2	0.00	2.4	2.4	0.00
50 - 54	4.7	5.9	-0.05	4.7	5.4	-0.03	4.1	5.2	-0.05
55 - 59	8.0	11.7	-0.12	8.1	7.9	0.01	14.1	8.6	0.18
60 - 64	13.4	19.2	-0.16	13.5	13.7	-0.01	13.0	13.8	-0.02
65 - 69	17.7	21.4	-0.09	17.8	17.7	0.00	22.0	23.2	-0.03
70 - 74	31.9	17.1	0.35	31.8	30.3	0.03	27.7	26.1	0.04
75 - 79	14.5	10.9	0.11	13.8	13.6	0.01	9.3	10.7	-0.04
80 - 84	4.3	6.9	-0.11	4.4	4.9	-0.02	4.1	5.1	-0.04
85 - 89	1.8	2.7	-0.06	2.1	2.2	-0.01	2.0	2.7	-0.04
90 - 94	0.4	0.6	-0.03	0.4	0.8	-0.04	0.2	0.8	-0.08
95 - 99	<0.1	0.1	-0.01	<0.2	0.1	-0.02	<0.1	0.1	-0.04
Gender: female	3.4	2.9	0.02	3.6	3.8	-0.01	3.5	3.9	-0.02
Race									
Asian	1.0	0.5	0.06	0.9	0.8	0.02	0.4	0.7	-0.03
Black or African American	13.6	10.8	0.09	12.3	12.4	0.00	13.9	12.8	0.03
White	78.1	78.0	0.00	79.3	79.3	0.00	79.7	79.3	0.01
Unknown	5.5	9.3	-0.14	5.7	5.7	0.00	5.0	5.6	-0.03
Native Hawaiian or Other Pacific Islander	0.8	0.8	0.01	0.9	1.0	0.00	0.5	0.9	-0.04
American Indian or Alaska Native	0.9	0.6	0.03	0.8	0.8	0.00	0.5	0.8	-0.05
Ethnicity									
Hispanic or Latino	5.7	4.6	0.05	5.7	5.5	0.01	4.2	5.6	-0.06
Not Hispanic or Latino	91.9	89.8	0.07	92.0	92.2	-0.01	92.8	92.1	0.03
Medical history: General									
Acute respiratory disease	9.8	10.3	-0.02	9.9	9.3	0.02	13.2	11.2	0.06
Attention deficit hyperactivity disorder	0.5	0.3	0.04	0.4	0.5	-0.01	0.6	0.4	0.03
Chronic liver disease	2.4	2.4	0.00	2.3	2.6	-0.02	1.8	3.0	-0.07
Chronic obstructive lung disease	18.5	16.3	0.06	17.3	17.7	-0.01	15.1	18.0	-0.08
Crohn's disease	0.2	0.2	0.00	0.3	0.2	0.02	0.1	0.2	-0.02
Dementia	1.6	1.6	0.00	1.6	1.8	-0.02	1.8	2.2	-0.03
Depressive disorder	22.3	21.5	0.02	21.9	22.4	-0.01	24.7	23.0	0.04
Gastroesophageal reflux disease	23.2	22.4	0.02	22.7	23.4	-0.02	22.7	23.7	-0.02
Gastrointestinal hemorrhage	1.6	1.7	-0.01	1.8	1.5	0.02	1.3	1.6	-0.02
Human immunodeficiency virus infection	0.5	0.3	0.03	0.4	0.5	-0.01	0.2	0.5	-0.04
Hyperlipidemia	77.1	78.1	-0.02	75.5	76.2	-0.02	77.2	75.3	0.04
Hypertensive disorder	82.0	82.6	-0.02	81.0	81.0	0.00	80.7	80.5	0.00
Lesion of liver	2.0	1.2	0.07	2.0	2.3	-0.02	1.9	2.0	-0.01
Obesity	31.7	28.0	0.08	29.9	30.2	-0.01	28.6	28.0	0.01
Osteoarthritis	22.7	24.2	-0.04	22.6	22.1	0.01	22.1	23.3	-0.03
Pneumonia	2.6	2.0	0.04	2.3	2.3	0.00	1.9	2.5	-0.04
Psoriasis	1.9	1.6	0.02	2.1	1.7	0.03	1.2	1.7	-0.04
Renal impairment	12.6	7.8	0.16	8.5	11.5	-0.10	8.5	11.5	-0.10
Rheumatoid arthritis	0.9	1.0	-0.01	1.0	0.7	0.03	0.7	0.9	-0.03
Schizophrenia	0.6	1.0	-0.05	0.6	0.7	-0.01	1.2	0.8	0.04
Ulcerative colitis	0.4	0.3	0.01	0.3	0.4	-0.01	0.3	0.4	-0.01
Urinary tract infectious disease	1.8	2.9	-0.07	2.0	2.1	-0.01	2.2	2.9	-0.05
Viral hepatitis C	1.3	1.8	-0.04	1.3	1.4	-0.01	0.9	1.8	-0.08
Visual system disorder	47.4	47.5	0.00	47.3	46.1	0.02	49.8	49.5	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	17.1	9.2	0.24	14.4	15.3	-0.03	12.1	12.2	0.00
Cerebrovascular disease	7.9	10.5	-0.09	7.8	7.3	0.02	8.1	7.9	0.01
Coronary atherosclerosis	57.1	37.4	0.40	50.7	52.6	-0.04	43.7	41.1	0.05
Heart disease	73.9	62.2	0.25	67.5	68.9	-0.03	55.8	59.0	-0.06
Heart failure	20.3	9.3	0.31	13.2	14.4	-0.04	11.1	10.6	0.01
Ischemic heart disease	25.2	29.6	-0.10	20.5	20.6	0.00	17.9	19.2	-0.03
Peripheral vascular disease	11.4	11.9	-0.02	11.2	11.4	0.00	13.5	11.4	0.07
Pulmonary embolism	1.0	0.7	0.03	1.0	1.2	-0.01	0.8	1.1	-0.03
Venous thrombosis	1.3	1.4	-0.01	1.4	1.8	-0.03	1.3	1.9	-0.05
Medical history: Neoplasms									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Hematologic neoplasm	1.3	1.0	0.03	1.2	1.4	-0.02	0.9	1.3	-0.04
Malignant lymphoma	0.9	0.5	0.05	0.5	0.8	-0.04	0.5	0.8	-0.04
Malignant neoplasm of anorectum	<0.1	0.2	-0.02	<0.2	0.1	-0.01	<0.1	0.1	-0.03
Malignant neoplastic disease	10.9	11.4	-0.02	10.8	10.6	0.01	9.3	11.3	-0.06
Malignant tumor of breast	<0.1	0.1	-0.02	<0.2	0.1	0.00	0.8	0.1	0.10
Malignant tumor of colon	0.4	0.8	-0.04	0.4	0.5	-0.01	0.3	0.5	-0.04
Malignant tumor of lung	0.6	0.3	0.05	0.4	0.6	-0.03	0.4	0.6	-0.03
Malignant tumor of urinary bladder	0.8	0.9	-0.01	0.8	0.7	0.01	1.1	0.9	0.02
Primary malignant neoplasm of prostate	3.8	4.6	-0.04	3.7	3.8	0.00	2.7	4.0	-0.07
Medication use									
Agents acting on the renin-angiotensin system	73.2	75.9	-0.06	70.7	71.1	-0.01	67.2	70.6	-0.07
Antibacterials for systemic use	29.4	33.8	-0.09	28.9	28.9	0.00	29.6	33.2	-0.08
Antidepressants	35.6	36.4	-0.02	36.8	36.6	0.00	42.2	38.3	0.08
Antiepileptics	28.6	23.3	0.12	29.3	29.2	0.00	34.1	30.9	0.07
Antiinflammatory and antirheumatic products	56.5	50.5	0.12	54.0	53.9	0.00	54.4	53.3	0.02
Antineoplastic agents	5.0	3.3	0.08	5.3	5.0	0.01	4.5	4.4	0.00
Antipsoriatics	1.0	0.8	0.02	1.0	1.0	0.01	1.1	0.9	0.02
Antithrombotic agents	61.5	49.9	0.24	56.8	57.4	-0.01	57.8	52.2	0.11
Beta blocking agents	66.9	61.9	0.11	61.7	63.0	-0.03	60.2	59.0	0.03
Calcium channel blockers	31.6	31.2	0.01	31.4	31.1	0.01	32.4	30.9	0.03
Diuretics	46.7	49.2	-0.05	42.8	43.8	-0.02	45.4	44.4	0.02
Drugs for acid related disorders	49.1	50.1	-0.02	48.3	48.2	0.00	51.7	50.1	0.03
Drugs for obstructive airway diseases	45.4	39.1	0.13	44.6	44.7	0.00	48.7	44.6	0.08
Immunosuppressants	3.1	1.7	0.09	3.3	2.7	0.03	1.9	2.6	-0.04
Lipid modifying agents	89.2	86.0	0.10	88.1	87.6	0.02	88.3	85.7	0.08
Opioids	17.3	23.8	-0.16	16.7	16.6	0.00	20.5	21.3	-0.02
Psycholeptics	24.8	24.1	0.02	24.2	23.6	0.01	27.0	25.2	0.04
Psychostimulants	1.2	1.4	-0.01	1.2	1.4	-0.01	1.9	1.5	0.03

Supplementary Table 28: Baseline patient characteristics for GLP1-RAs (T) and DPP4is (C) new-users in the CCAE data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.2	0.1	-0.03	0.2	0.1	-0.03	0.2	0.1	-0.01
30 - 34	0.9	0.5	-0.05	0.9	0.4	-0.06	0.7	0.5	-0.02
35 - 39	2.6	1.5	-0.08	2.3	1.8	-0.03	2.1	1.6	-0.04
40 - 44	6.3	4.3	-0.09	5.8	5.8	0.00	5.0	4.6	-0.02
45 - 49	11.5	9.3	-0.07	11.2	10.5	-0.02	10.3	9.8	-0.01
50 - 54	20.2	18.1	-0.05	20.0	19.5	-0.01	19.2	18.5	-0.02
55 - 59	27.0	27.6	0.01	27.1	26.6	-0.01	27.9	27.3	-0.01
60 - 64	28.6	35.0	0.14	29.8	32.3	0.05	31.1	34.0	0.06
65 - 69	2.4	3.6	0.07	2.7	2.9	0.02	3.3	3.4	0.01
Gender: female	53.8	42.2	-0.23	50.9	52.0	0.02	44.1	44.9	0.02
Medical history: General									
Acute respiratory disease	33.5	30.6	-0.06	32.7	33.2	0.01	30.5	31.4	0.02
Attention deficit hyperactivity disorder	1.5	0.7	-0.08	1.3	1.1	-0.02	0.9	0.8	-0.01
Chronic liver disease	2.6	4.1	0.08	4.1	3.8	-0.02	4.1	3.8	-0.02
Chronic obstructive lung disease	5.5	6.2	0.03	5.5	6.0	0.02	5.7	6.1	0.02
Crohn's disease	0.4	0.4	-0.01	0.4	0.3	-0.01	0.6	0.4	-0.03
Dementia	0.2	0.3	0.02	0.3	0.4	0.02	0.3	0.4	0.00
Depressive disorder	15.7	10.6	-0.15	14.1	14.7	0.02	11.7	11.8	0.00
Gastroesophageal reflux disease	18.2	14.7	-0.10	17.0	17.7	0.02	14.9	15.7	0.02
Gastrointestinal hemorrhage	2.8	2.7	-0.01	2.7	2.8	0.01	2.9	2.7	-0.01
Human immunodeficiency virus infection	0.3	0.3	0.01	0.2	0.4	0.03	0.2	0.3	0.02
Hyperlipidemia	74.9	75.0	0.00	75.7	76.1	0.01	76.1	75.2	-0.02
Hypertensive disorder	76.8	76.5	-0.01	77.2	77.3	0.00	78.3	76.9	-0.03
Lesion of liver	0.9	0.9	0.00	0.8	0.9	0.02	0.7	0.9	0.03
Obesity	38.0	19.6	-0.42	32.5	34.8	0.05	24.6	24.4	0.00
Osteoarthritis	29.5	23.7	-0.13	28.3	28.9	0.01	24.8	25.2	0.01
Pneumonia	3.3	3.2	-0.01	3.3	3.6	0.02	3.2	3.3	0.01
Psoriasis	2.7	1.7	-0.06	2.4	2.1	-0.02	1.8	1.9	0.00
Renal impairment	5.6	5.8	0.01	5.6	6.0	0.02	5.6	5.8	0.01
Rheumatoid arthritis	2.0	1.6	-0.03	1.8	1.7	-0.01	1.6	1.7	0.00
Schizophrenia	<0.1	0.2	0.04	<0.1	0.2	0.06	<0.1	0.2	0.06
Ulcerative colitis	0.5	0.4	-0.02	0.5	0.3	-0.04	0.5	0.3	-0.03
Urinary tract infectious disease	9.2	8.9	-0.01	9.0	9.0	0.00	8.8	8.9	0.00
Viral hepatitis C	0.3	0.5	0.03	0.3	0.3	0.00	0.3	0.4	0.02
Visual system disorder	30.2	28.3	-0.04	29.9	30.5	0.01	28.0	28.8	0.02
Medical history: Cardiovascular disease									
Atrial fibrillation	4.8	4.8	0.00	5.0	4.7	-0.01	5.2	4.8	-0.02
Cerebrovascular disease	8.6	10.4	0.06	8.8	8.3	-0.02	8.9	9.9	0.03
Coronary arteriosclerosis	28.0	32.1	0.09	28.6	27.3	-0.03	31.7	31.0	-0.02
Heart disease	47.0	49.4	0.05	46.9	45.6	-0.03	49.4	48.4	-0.02
Heart failure	5.7	5.8	0.00	5.5	6.0	0.02	5.1	5.9	0.03
Ischemic heart disease	16.1	16.8	0.02	15.9	15.5	-0.01	17.4	16.5	-0.02
Peripheral vascular disease	16.1	13.7	-0.07	15.5	15.2	-0.01	14.2	14.2	0.00
Pulmonary embolism	1.4	0.8	-0.05	1.3	1.1	-0.02	1.0	0.9	-0.01
Venous thrombosis	2.0	1.9	-0.01	2.0	2.0	0.00	1.9	1.9	0.00
Medical history: Neoplasms									
Hematologic neoplasm	1.0	1.2	0.03	1.0	1.2	0.02	0.9	1.2	0.03
Malignant lymphoma	0.5	0.6	0.00	0.5	0.5	0.00	0.4	0.5	0.01
Malignant neoplasm of anorectum	0.1	0.2	0.03	0.1	<0.1	-0.01	0.1	0.2	0.02
Malignant neoplastic disease	7.7	8.4	0.02	7.8	8.9	0.04	8.6	8.4	-0.01
Malignant tumor of breast	1.5	1.5	0.01	1.5	2.2	0.06	1.3	1.6	0.03
Malignant tumor of colon	0.2	0.4	0.03	0.3	0.3	0.01	0.3	0.4	0.02
Malignant tumor of lung	0.1	0.3	0.05	0.1	0.3	0.04	0.1	0.3	0.04
Malignant tumor of urinary bladder	0.2	0.4	0.03	0.2	0.1	-0.02	0.4	0.3	-0.02
Primary malignant neoplasm of prostate	0.8	1.2	0.04	0.8	0.9	0.01	1.3	1.1	-0.02
Medication use									
Agents acting on the renin-angiotensin system	70.6	73.8	0.07	71.8	71.4	-0.01	74.7	73.1	-0.04
Antibacterials for systemic use	67.5	64.3	-0.07	66.7	66.8	0.00	65.1	65.0	0.00
Antidepressants	41.0	29.3	-0.25	38.2	38.9	0.02	32.2	32.1	0.00
Antiepileptics	21.9	16.1	-0.15	20.8	21.1	0.01	17.2	17.7	0.01
Antiinflammatory and antirheumatic products	42.3	35.2	-0.15	40.8	41.0	0.00	36.8	37.1	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antineoplastic agents	6.8	5.6	-0.05	6.3	6.7	0.02	5.5	5.8	0.01
Antipsoriatics	1.0	0.7	-0.03	0.9	0.8	-0.01	0.7	0.7	0.01
Antithrombotic agents	23.8	26.1	0.05	24.3	24.1	0.00	24.8	25.5	0.02
Beta blocking agents	43.4	46.6	0.06	43.9	44.3	0.01	45.9	46.0	0.00
Calcium channel blockers	26.5	27.0	0.01	26.6	26.5	0.00	27.3	26.9	-0.01
Diuretics	49.4	43.7	-0.12	47.7	47.1	-0.01	45.2	44.9	-0.01
Drugs for acid related disorders	35.8	32.2	-0.08	32.7	33.0	0.01	32.7	33.0	0.01
Drugs for obstructive airway diseases	48.1	41.3	-0.14	46.5	46.8	0.01	43.6	43.1	-0.01
Immunosuppressants	4.5	3.0	-0.07	4.0	3.8	-0.01	3.3	3.3	0.00
Lipid modifying agents	75.1	78.3	0.07	76.2	76.0	0.00	78.6	77.5	-0.03
Opioids	35.2	32.5	-0.06	35.1	34.3	-0.02	32.8	33.1	0.01
Psycholeptics	34.3	28.9	-0.11	33.2	33.1	0.00	29.9	30.2	0.01
Psychostimulants	5.9	3.2	-0.13	5.1	4.9	-0.01	4.0	3.8	-0.01

Supplementary Table 29: Baseline patient characteristics for GLP1-RAs (T) and DPP4is (C) new-users in the OptumDOD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	-0.02	0.1	<0.1	-0.01	0.4	0.1	-0.08
30 - 34	0.5	0.3	-0.04	0.6	0.3	-0.04	0.9	0.3	-0.08
35 - 39	1.6	0.6	-0.09	1.5	0.9	-0.05	1.0	0.8	-0.02
40 - 44	3.4	1.6	-0.11	2.8	2.5	-0.02	2.2	1.8	-0.02
45 - 49	6.4	3.6	-0.13	5.5	5.1	-0.02	4.3	4.1	-0.01
50 - 54	11.4	6.6	-0.17	9.6	9.5	0.00	9.6	9.5	0.00
55 - 59	14.9	10.1	-0.14	13.6	13.5	0.00	10.4	11.1	0.02
60 - 64	16.7	12.7	-0.11	14.3	13.6	-0.02	14.3	13.6	-0.02
65 - 69	17.8	16.6	-0.03	19.0	18.8	-0.01	16.7	16.9	0.00
70 - 74	15.1	18.9	0.10	16.8	18.8	0.05	17.3	18.6	0.03
75 - 79	8.3	14.2	0.19	10.1	9.9	0.00	13.9	13.0	-0.03
80 - 84	2.7	9.1	0.28	3.4	3.2	-0.01	7.2	7.7	0.02
85 - 89	0.8	5.1	0.26	1.0	1.2	0.02	3.8	4.2	0.02
90 - 94	<0.1	0.4	0.08	0.1	0.4	0.07	0.1	0.4	0.07
Gender: female	52.9	47.3	-0.11	51.0	51.9	0.02	48.5	48.4	0.00
Medical history: General									
Acute respiratory disease	30.1	29.2	-0.02	29.2	30.7	0.03	30.6	29.6	-0.02
Attention deficit hyperactivity disorder	1.3	0.6	-0.07	0.8	1.1	0.03	0.6	0.7	0.01
Chronic liver disease	2.7	4.0	0.07	3.1	3.0	-0.01	3.5	3.7	0.01
Chronic obstructive lung disease	14.5	15.5	0.03	14.4	15.8	0.04	16.0	15.6	-0.01
Crohn's disease	0.3	0.4	0.02	0.2	0.4	0.03	0.3	0.4	0.01
Dementia	1.8	4.7	0.17	2.0	2.3	0.02	3.3	4.1	0.04
Depressive disorder	24.4	17.4	-0.17	21.6	22.4	0.02	19.0	19.1	0.00
Gastroesophageal reflux disease	26.6	23.6	-0.07	25.2	26.2	0.02	25.8	24.6	-0.03
Gastrointestinal hemorrhage	2.8	3.8	0.06	2.9	3.1	0.01	3.9	3.6	-0.01
Human immunodeficiency virus infection	0.6	0.3	-0.04	0.5	0.7	0.02	0.5	0.4	-0.01
Hyperlipidemia	85.2	87.1	0.06	85.4	85.6	0.01	87.2	86.8	-0.01
Hypertensive disorder	86.0	88.1	0.06	86.1	87.2	0.03	89.2	87.8	-0.04
Lesion of liver	1.5	1.5	0.00	1.5	1.4	-0.01	1.2	1.5	0.03
Obesity	47.9	23.3	-0.53	38.8	42.2	0.07	28.4	29.0	0.01
Osteoarthritis	40.2	35.9	-0.09	38.6	39.3	0.02	38.4	37.2	-0.03
Pneumonia	5.4	6.3	0.04	4.9	5.1	0.00	7.4	6.1	-0.05
Psoriasis	2.7	1.8	-0.07	2.5	2.1	-0.03	1.8	1.9	0.00
Renal impairment	16.0	23.7	0.19	17.5	17.8	0.01	23.6	22.2	-0.03
Rheumatoid arthritis	2.8	2.5	-0.02	2.6	3.1	0.03	3.1	2.6	-0.03
Schizophrenia	0.6	0.5	-0.01	0.5	0.6	0.01	0.4	0.5	0.02
Ulcerative colitis	0.4	0.5	0.01	0.4	0.3	-0.01	0.6	0.4	-0.03
Urinary tract infectious disease	11.7	15.6	0.12	12.0	12.4	0.01	16.3	14.7	-0.04
Viral hepatitis C	0.7	0.7	0.00	0.7	0.5	-0.03	0.7	0.7	0.00
Visual system disorder	42.8	47.7	0.10	44.4	44.9	0.01	44.4	44.9	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	9.5	13.0	0.11	9.7	9.9	0.01	11.9	12.3	0.01
Cerebrovascular disease	11.3	16.3	0.14	12.0	11.8	0.00	14.8	15.2	0.01
Coronary arteriosclerosis	33.8	38.4	0.10	35.1	35.3	0.00	37.6	37.6	0.00
Heart disease	54.4	59.4	0.10	55.1	55.5	0.01	60.2	58.5	-0.03
Heart failure	12.0	14.7	0.08	12.0	12.2	0.01	14.7	14.3	-0.01
Ischemic heart disease	18.5	20.5	0.05	18.3	19.0	0.02	20.4	20.1	-0.01
Peripheral vascular disease	26.7	26.2	-0.01	26.9	27.0	0.00	25.9	26.6	0.02
Pulmonary embolism	1.7	1.3	-0.03	1.5	1.7	0.01	1.5	1.4	-0.01
Venous thrombosis	2.3	2.5	0.01	2.3	1.9	-0.03	3.0	2.5	-0.03
Medical history: Neoplasms									
Hematologic neoplasm	1.2	1.6	0.04	1.2	1.3	0.01	1.3	1.5	0.02
Malignant lymphoma	0.7	0.8	0.01	0.6	0.7	0.01	0.6	0.8	0.02
Malignant neoplasm of anorectum	0.2	0.3	0.03	0.2	0.3	0.01	0.3	0.3	0.01
Malignant neoplastic disease	10.9	14.3	0.10	11.5	11.0	-0.01	11.5	11.0	-0.01
Malignant tumor of breast	1.8	2.2	0.03	1.9	1.8	-0.01	2.3	2.1	-0.02
Malignant tumor of colon	0.7	0.8	0.01	0.8	0.5	-0.04	0.8	0.8	-0.01
Malignant tumor of lung	0.3	0.7	0.05	0.4	0.5	0.03	0.9	0.7	-0.03
Malignant tumor of urinary bladder	0.5	0.7	0.04	0.5	0.5	-0.01	1.1	0.7	-0.04
Primary malignant neoplasm of prostate	1.8	3.2	0.09	2.1	2.0	-0.01	3.5	2.9	-0.04
Medication use									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Agents acting on the renin-angiotensin system	72.7	75.8	0.07	73.6	72.5	-0.03	76.1	75.0	-0.03
Antibacterials for systemic use	64.7	63.9	-0.02	63.4	65.1	0.04	64.2	64.1	0.00
Antidepressants	43.0	31.6	-0.24	39.2	41.3	0.04	33.8	34.3	0.01
Antiepileptics	29.3	22.2	-0.16	27.0	28.2	0.03	23.9	23.9	0.00
Antiinflammatory and antirheumatic products	39.8	32.3	-0.16	36.9	38.1	0.03	31.9	33.9	0.04
Antineoplastic agents	7.4	7.2	-0.01	7.2	6.9	-0.01	6.8	7.2	0.01
Antipsoriatics	0.9	0.7	-0.02	0.8	0.7	0.00	0.8	0.7	0.00
Antithrombotic agents	27.4	31.5	0.09	27.9	28.7	0.02	30.0	30.9	0.02
Beta blocking agents	47.4	52.3	0.10	48.0	48.2	0.00	52.5	51.4	-0.02
Calcium channel blockers	30.1	33.6	0.08	30.8	31.1	0.00	30.8	31.1	0.00
Diuretics	51.4	49.6	-0.04	50.3	50.7	0.01	52.5	50.1	-0.05
Drugs for acid related disorders	37.0	36.2	-0.02	36.2	37.2	0.02	38.6	36.6	-0.04
Drugs for obstructive airway diseases	50.7	43.9	-0.14	48.6	50.0	0.03	47.6	45.6	-0.04
Immunosuppressants	4.1	3.3	-0.05	3.7	3.9	0.01	3.4	3.4	0.00
Lipid modifying agents	79.9	82.6	0.07	81.1	80.7	-0.01	80.7	82.2	0.04
Opioids	36.3	33.2	-0.06	34.6	36.0	0.03	32.9	33.9	0.02
Psycholeptics	34.1	29.7	-0.09	32.1	33.6	0.03	29.0	30.8	0.04
Psychostimulants	3.8	2.0	-0.11	3.1	3.6	0.03	2.6	2.4	-0.01

Supplementary Table 30: Baseline patient characteristics for GLP1-RAs (T) and DPP4is (C) new-users in the MDCR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
50 - 54	<0.4	0.1	-0.03	<0.4	<0.5	0.03	<0.2	0.1	0.00
55 - 59	1.1	0.4	-0.07	1.1	0.7	-0.04	0.6	0.5	-0.01
60 - 64	2.5	1.5	-0.07	2.5	1.8	-0.05	2.3	1.5	-0.06
65 - 69	34.6	22.1	-0.28	33.8	35.2	0.03	23.1	23.2	0.00
70 - 74	36.8	28.8	-0.17	36.5	32.0	-0.10	33.5	29.1	-0.09
75 - 79	16.2	22.1	0.15	16.2	17.0	0.02	21.7	21.6	0.00
80 - 84	6.1	15.0	0.29	6.8	6.5	-0.01	10.7	14.2	0.11
85 - 89	2.0	7.3	0.26	2.2	3.7	0.09	7.8	6.9	-0.03
90 - 94	0.6	2.3	0.14	0.7	2.2	0.12	<0.2	2.3	0.19
Gender: female	49.2	44.1	-0.10	48.4	47.1	-0.03	44.6	44.4	0.00
Medical history: General									
Acute respiratory disease	25.8	25.4	-0.01	26.2	24.9	-0.03	28.9	25.5	-0.07
Attention deficit hyperactivity disorder	<0.4	0.1	-0.01	<0.4	<0.5	0.06	<0.2	0.2	0.04
Chronic liver disease	2.1	2.7	0.04	2.2	1.9	-0.02	2.0	2.7	0.05
Chronic obstructive lung disease	15.7	14.2	-0.04	15.5	14.9	-0.02	16.7	14.4	-0.06
Crohn's disease	0.5	0.3	-0.03	<0.4	<0.5	-0.06	0.3	0.3	0.01
Dementia	2.1	4.1	0.11	2.2	3.4	0.07	2.5	4.1	0.09
Depressive disorder	13.8	8.6	-0.16	13.0	12.4	-0.02	10.0	9.0	-0.03
Gastroesophageal reflux disease	17.2	14.6	-0.07	17.1	18.5	0.04	12.2	15.0	0.08
Gastrointestinal hemorrhage	2.9	4.2	0.07	2.7	3.7	0.06	2.8	4.1	0.07
Hyperlipidemia	69.0	65.7	-0.07	71.1	77.0	0.14	63.7	66.4	0.06
Hypertensive disorder	81.4	78.4	-0.08	82.2	82.6	0.01	82.3	78.7	-0.09
Lesion of liver	0.9	0.9	0.00	1.0	0.9	0.00	0.4	1.0	0.07
Obesity	29.5	11.0	-0.47	27.2	30.5	0.07	11.2	12.7	0.05
Osteoarthritis	39.4	34.6	-0.10	38.5	41.3	0.06	33.5	35.1	0.03
Pneumonia	4.8	6.6	0.08	5.0	5.1	0.00	3.5	6.4	0.13
Psoriasis	2.9	1.6	-0.09	3.2	2.3	-0.06	2.2	1.7	-0.04
Renal impairment	14.5	17.8	0.09	15.0	18.3	0.09	17.6	17.7	0.00
Rheumatoid arthritis	1.9	2.0	0.01	1.8	2.2	0.03	1.0	2.0	0.08
Schizophrenia	<0.4	0.2	-0.03	<0.4	<0.5	-0.02	<0.2	0.2	0.00
Ulcerative colitis	<0.4	0.6	0.04	<0.4	0.8	0.05	<0.2	0.6	0.07
Urinary tract infectious disease	11.5	12.3	0.02	11.3	10.0	-0.04	11.6	12.1	0.02
Viral hepatitis C	<0.4	0.3	0.04	<0.4	<0.5	0.06	<0.2	0.3	0.06
Visual system disorder	51.6	54.7	0.06	51.8	55.0	0.06	59.5	54.6	-0.10
Medical history: Cardiovascular disease									
Atrial fibrillation	12.1	16.7	0.13	11.8	12.6	0.03	16.6	16.3	-0.01
Cerebrovascular disease	17.9	21.7	0.10	18.0	18.0	0.00	18.7	21.4	0.07
Coronary arteriosclerosis	43.1	43.7	0.01	42.1	42.2	0.00	44.3	43.6	-0.01
Heart disease	62.3	66.6	0.09	61.5	62.2	0.01	69.5	66.2	-0.07
Heart failure	11.3	14.5	0.09	11.1	13.5	0.07	14.8	14.3	-0.01
Ischemic heart disease	17.9	19.4	0.04	17.5	16.9	-0.02	18.2	19.3	0.03
Peripheral vascular disease	22.5	22.2	-0.01	23.1	24.6	0.04	20.9	22.5	0.04
Pulmonary embolism	1.3	1.2	0.00	1.2	1.9	0.06	3.2	1.3	-0.13
Venous thrombosis	2.1	2.7	0.04	2.0	2.3	0.02	2.5	2.7	0.01
Medical history: Neoplasms									
Hematologic neoplasm	2.1	2.1	0.01	2.0	1.8	-0.02	1.4	2.2	0.06
Malignant lymphoma	1.2	1.1	0.00	1.1	0.9	-0.01	0.5	1.1	0.07
Malignant neoplastic disease	20.5	21.1	0.01	21.1	18.7	-0.06	24.2	21.1	-0.07
Malignant tumor of breast	3.8	2.8	-0.05	3.8	3.5	-0.02	3.9	2.9	-0.06
Malignant tumor of colon	0.5	1.0	0.06	0.6	0.9	0.04	0.2	1.0	0.10
Malignant tumor of lung	0.8	0.8	0.00	0.9	1.0	0.01	0.9	0.9	0.00
Malignant tumor of urinary bladder	1.8	1.5	-0.02	1.9	1.4	-0.04	3.7	1.5	-0.14
Primary malignant neoplasm of prostate	4.6	5.0	0.02	4.5	4.8	0.01	7.5	5.0	-0.10
Medication use									
Agents acting on the renin-angiotensin system	78.2	77.1	-0.03	78.9	77.1	-0.04	75.5	77.1	0.04
Antibacterials for systemic use	66.7	66.1	-0.01	66.9	65.7	-0.03	62.0	66.1	0.09
Antidepressants	36.6	26.6	-0.22	34.6	35.1	0.01	32.2	27.4	-0.10
Antiepileptics	21.2	17.7	-0.09	20.2	23.6	0.08	16.3	18.1	0.05
Antiinflammatory and antirheumatic products	34.6	29.5	-0.11	33.6	34.8	0.03	29.6	30.0	0.01
Antineoplastic agents	10.1	9.3	-0.03	9.9	9.0	-0.03	8.5	9.4	0.03
Antipsoriatics	1.2	0.9	-0.03	1.1	0.7	-0.04	0.9	0.9	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antithrombotic agents	35.1	37.2	0.04	34.9	35.3	0.01	40.3	37.0	-0.07
Beta blocking agents	55.9	60.9	0.10	56.7	57.3	0.01	65.8	60.5	-0.11
Calcium channel blockers	33.7	38.4	0.10	33.7	35.1	0.03	32.3	38.0	0.12
Diuretics	56.4	54.1	-0.05	55.2	56.0	0.01	53.3	54.1	0.01
Drugs for acid related disorders	39.9	37.7	-0.04	38.9	41.3	0.05	31.4	38.0	0.14
Drugs for obstructive airway diseases	53.1	44.4	-0.18	52.2	52.7	0.01	46.6	45.1	-0.03
Immunosuppressants	4.1	3.5	-0.03	3.8	4.8	0.05	2.8	3.6	0.05
Lipid modifying agents	86.7	84.6	-0.06	86.9	85.2	-0.05	85.5	84.7	-0.02
Opioids	32.1	32.1	0.00	32.1	33.5	0.03	31.3	32.1	0.02
Psycholeptics	31.2	29.3	-0.04	30.8	30.4	-0.01	33.2	29.4	-0.08
Psychostimulants	2.1	1.5	-0.05	2.1	1.9	-0.01	1.2	1.5	0.03

Supplementary Table 31: Baseline patient characteristics for GLP1-RAs (T) and DPP4is (C) new-users in the Open Claims data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.2	0.1	-0.02	0.2	0.2	-0.01	0.2	0.2	0.00
25 - 29	0.3	0.2	-0.03	0.3	0.2	-0.02	0.3	0.2	-0.01
30 - 34	0.8	0.4	-0.05	0.6	0.6	0.00	0.5	0.5	-0.01
35 - 39	1.7	0.9	-0.07	1.4	1.4	0.00	1.2	1.1	-0.01
40 - 44	3.8	2.0	-0.11	3.1	3.1	0.00	2.6	2.4	-0.01
45 - 49	7.1	4.2	-0.12	6.2	6.0	-0.01	5.0	4.9	-0.01
50 - 54	11.9	7.7	-0.14	10.5	10.5	0.00	8.7	8.7	0.00
55 - 59	16.5	11.7	-0.14	15.3	15.5	0.00	13.1	13.0	0.00
60 - 64	18.3	14.9	-0.09	17.7	17.9	0.00	16.0	15.9	0.00
65 - 69	16.7	16.6	0.00	17.3	17.6	0.01	16.5	16.7	0.00
70 - 74	12.2	15.5	0.10	13.8	13.7	0.00	14.8	14.7	0.00
75 - 79	6.8	17.5	0.33	8.5	8.3	-0.01	13.8	14.7	0.03
80 - 84	3.3	8.0	0.20	4.5	4.6	0.00	7.0	6.8	-0.01
85 - 89	0.3	0.2	-0.01	0.3	0.4	0.02	0.2	0.2	0.01
Gender: female	54.4	48.6	-0.12	51.5	51.9	0.01	50.1	49.9	0.00
Medical history: General									
Acute respiratory disease	17.1	17.7	0.01	16.6	17.0	0.01	17.8	17.7	0.00
Attention deficit hyperactivity disorder	0.9	0.3	-0.07	0.6	0.6	0.00	0.5	0.4	-0.01
Chronic liver disease	1.1	1.9	0.06	1.3	1.3	0.00	1.8	1.7	-0.01
Chronic obstructive lung disease	8.8	10.2	0.05	9.0	9.2	0.01	9.9	10.0	0.00
Crohn's disease	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	0.00
Dementia	0.7	2.3	0.12	0.9	1.0	0.01	1.9	1.9	0.00
Depressive disorder	12.0	8.9	-0.10	10.4	10.9	0.02	10.0	9.8	-0.01
Gastroesophageal reflux disease	12.7	11.4	-0.04	11.7	12.0	0.01	11.9	11.7	0.00
Gastrointestinal hemorrhage	1.8	2.4	0.04	1.8	1.8	0.00	2.2	2.2	0.00
Human immunodeficiency virus infection	0.4	0.3	-0.01	0.4	0.4	0.01	0.3	0.3	0.00
Hyperlipidemia	50.1	54.4	0.09	50.2	50.5	0.01	53.3	53.5	0.00
Hypertensive disorder	59.4	63.9	0.09	59.3	59.4	0.00	63.0	62.8	0.00
Lesion of liver	0.9	1.0	0.01	0.8	1.0	0.01	0.8	1.0	0.01
Obesity	23.1	11.3	-0.32	17.5	18.1	0.01	15.0	14.1	-0.03
Osteoarthritis	23.6	21.9	-0.04	22.2	22.4	0.01	22.8	22.4	-0.01
Pneumonia	3.4	4.2	0.04	3.3	3.4	0.00	4.0	4.1	0.01
Psoriasis	1.5	1.0	-0.04	1.3	1.3	0.00	1.3	1.1	-0.01
Renal impairment	8.2	12.9	0.15	9.0	9.2	0.01	11.5	11.9	0.01
Rheumatoid arthritis	1.8	1.6	-0.01	1.6	1.6	0.00	1.6	1.6	0.00
Schizophrenia	0.3	0.5	0.02	0.4	0.5	0.02	0.4	0.5	0.01
Ulcerative colitis	0.2	0.3	0.01	0.2	0.3	0.01	0.2	0.3	0.01
Urinary tract infectious disease	6.5	8.7	0.08	6.6	6.7	0.00	8.1	8.2	0.00
Viral hepatitis C	0.3	0.5	0.03	0.4	0.4	0.00	0.5	0.5	0.00
Visual system disorder	21.3	24.9	0.09	21.7	21.9	0.00	23.5	24.0	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	6.1	8.8	0.10	6.4	6.3	-0.01	8.0	8.1	0.00
Cerebrovascular disease	6.4	10.2	0.14	6.9	6.8	0.00	8.8	9.2	0.01
Coronary arteriosclerosis	20.2	25.2	0.12	23.7	24.1	0.01	23.7	24.1	0.01
Heart disease	35.4	42.5	0.15	36.1	36.0	0.00	40.4	40.8	0.01
Heart failure	6.8	9.6	0.10	7.0	7.3	0.01	8.4	9.0	0.02
Ischemic heart disease	9.7	12.1	0.08	10.0	9.9	0.00	11.0	11.6	0.02
Peripheral vascular disease	13.3	13.9	0.02	13.0	13.3	0.01	13.6	13.8	0.01
Pulmonary embolism	1.1	0.9	-0.01	1.0	1.0	0.00	1.0	0.9	0.00
Venous thrombosis	1.2	1.6	0.03	1.4	1.5	0.01	1.4	1.5	0.01
Medical history: Neoplasms									
Hematologic neoplasm	0.8	1.1	0.03	0.9	0.8	-0.01	1.0	1.0	0.00
Malignant lymphoma	0.4	0.6	0.02	0.5	0.5	0.00	0.6	0.6	0.00
Malignant neoplasm of anorectum	0.1	0.2	0.03	0.1	0.1	0.02	0.2	0.2	0.00
Malignant neoplastic disease	6.9	9.4	0.09	7.3	7.4	0.00	8.7	8.8	0.00
Malignant tumor of breast	1.3	1.5	0.02	1.3	1.4	0.01	1.4	1.6	0.01
Malignant tumor of colon	0.3	0.5	0.03	0.3	0.3	-0.01	0.4	0.5	0.01
Malignant tumor of lung	0.3	0.5	0.04	0.3	0.3	0.00	0.4	0.4	0.00
Malignant tumor of urinary bladder	0.3	0.5	0.04	0.4	0.4	0.00	0.6	0.5	-0.01
Primary malignant neoplasm of prostate	1.2	1.9	0.06	1.4	1.3	0.00	1.9	1.7	-0.01
Medication use									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Agents acting on the renin-angiotensin system	68.7	73.7	0.11	70.3	70.5	0.00	72.1	72.6	0.01
Antibacterials for systemic use	63.4	62.5	-0.02	62.3	62.4	0.00	62.8	62.6	0.00
Antidepressants	42.9	32.9	-0.21	38.8	39.6	0.02	36.5	35.5	-0.02
Antiepileptics	30.0	25.3	-0.11	27.9	28.6	0.02	26.9	26.6	-0.01
Antiinflammatory and antirheumatic products	43.4	40.2	-0.06	41.9	42.2	0.01	41.4	41.0	-0.01
Antineoplastic agents	7.2	6.3	-0.03	6.5	6.6	0.01	6.6	6.5	0.00
Antipsoriatics	1.1	0.9	-0.02	1.0	1.0	0.00	0.9	1.0	0.00
Antithrombotic agents	29.8	37.2	0.16	31.4	31.2	0.00	34.8	35.4	0.01
Beta blocking agents	47.1	53.3	0.12	48.4	48.4	0.00	51.2	51.8	0.01
Calcium channel blockers	30.4	34.0	0.08	31.3	31.2	0.00	32.1	33.1	0.02
Diuretics	49.1	47.8	-0.03	47.8	47.9	0.00	47.8	48.1	0.01
Drugs for acid related disorders	43.3	43.7	0.01	42.5	42.6	0.00	44.0	43.7	-0.01
Drugs for obstructive airway diseases	48.7	43.8	-0.10	46.6	47.0	0.01	45.1	45.2	0.00
Immunosuppressants	4.4	3.7	-0.03	4.0	4.1	0.00	3.9	3.9	0.00
Lipid modifying agents	76.1	79.9	0.09	77.6	77.8	0.00	78.6	79.2	0.02
Opioids	31.9	31.5	-0.01	31.0	31.4	0.01	31.9	31.8	0.00
Psycholeptics	31.8	28.6	-0.07	29.7	30.4	0.01	30.0	29.6	-0.01
Psychostimulants	4.7	2.5	-0.12	3.6	3.8	0.01	3.1	3.0	0.00

Supplementary Table 32: Baseline patient characteristics for GLP1-RAs (T) and DPP4is (C) new-users in the OptumEHR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.4	0.1	-0.06	0.4	<0.1	-0.05	0.3	0.1	-0.04
30 - 34	0.6	0.3	-0.05	0.6	0.4	-0.02	0.5	0.3	-0.03
35 - 39	2.0	1.0	-0.08	2.0	1.5	-0.04	1.4	1.1	-0.02
40 - 44	4.8	2.2	-0.15	3.9	3.8	0.00	2.6	2.5	0.00
45 - 49	8.3	5.1	-0.13	7.3	7.2	0.00	5.7	5.5	-0.01
50 - 54	14.3	8.9	-0.17	13.2	13.6	0.01	10.1	10.1	0.00
55 - 59	17.6	13.5	-0.11	17.3	16.8	-0.01	14.5	14.4	0.00
60 - 64	19.8	16.4	-0.09	19.7	20.6	0.02	17.4	17.4	0.00
65 - 69	15.2	16.7	0.04	16.1	16.4	0.01	16.9	16.5	-0.01
70 - 74	9.7	14.3	0.14	10.9	10.8	0.00	13.6	13.4	0.00
75 - 79	5.0	11.6	0.24	6.0	5.4	-0.02	9.7	10.2	0.02
80 - 84	1.6	7.6	0.29	1.9	2.0	0.01	5.7	6.4	0.03
85 - 89	0.4	2.3	0.16	0.5	1.1	0.06	1.6	2.0	0.03
Gender: female	50.2	43.2	-0.14	47.6	47.5	0.00	44.5	44.5	0.00
Race									
Asian	1.1	1.9	0.07	1.3	1.5	0.02	1.2	1.9	0.06
Black or African American	10.1	9.5	-0.02	10.1	9.4	-0.02	10.0	9.6	-0.01
White	83.6	82.3	-0.03	83.4	82.5	-0.02	83.5	82.5	-0.03
Ethnicity									
Hispanic or Latino	4.0	4.8	0.04	4.0	5.0	0.05	3.9	4.7	0.04
Not Hispanic or Latino	88.3	87.8	-0.01	88.0	86.9	-0.03	87.7	87.9	0.01
Medical history: General									
Acute respiratory disease	21.3	20.0	-0.03	20.1	21.1	0.02	18.6	20.3	0.04
Attention deficit hyperactivity disorder	1.0	0.4	-0.08	0.9	0.7	-0.02	0.6	0.5	-0.01
Chronic liver disease	2.7	3.1	0.02	2.8	2.3	-0.03	3.3	2.9	-0.02
Chronic obstructive lung disease	10.2	11.5	0.04	10.6	10.3	-0.01	12.0	11.4	-0.02
Crohn's disease	0.4	0.3	-0.02	0.4	0.3	-0.01	0.3	0.3	0.00
Dementia	0.9	2.1	0.10	0.9	0.9	0.00	0.9	1.8	0.08
Depressive disorder	21.4	15.0	-0.17	19.1	19.8	0.02	16.3	16.2	0.00
Gastroesophageal reflux disease	24.8	21.8	-0.07	22.7	24.3	0.04	22.9	22.3	-0.01
Gastrointestinal hemorrhage	2.0	2.2	0.01	2.1	1.9	-0.02	3.0	2.2	-0.06
Human immunodeficiency virus infection	0.2	0.2	-0.01	0.2	0.3	0.02	0.1	0.2	0.03
Hyperlipidemia	74.6	77.3	0.06	74.4	74.5	0.00	78.2	76.7	-0.04
Hypertensive disorder	77.5	79.2	0.04	76.7	78.0	0.03	80.2	78.9	-0.03
Lesion of liver	1.1	1.0	0.00	1.0	1.0	0.00	0.8	1.0	0.03
Obesity	47.5	25.8	-0.46	39.6	42.7	0.06	30.0	30.2	0.00
Osteoarthritis	25.3	22.6	-0.06	23.4	23.1	-0.01	22.5	23.1	0.01
Pneumonia	3.0	3.1	0.01	2.9	2.9	0.00	3.0	3.1	0.00
Psoriasis	2.3	1.5	-0.06	2.0	1.9	0.00	1.8	1.6	-0.02
Renal impairment	9.1	12.6	0.12	9.2	9.9	0.02	11.2	12.0	0.02
Rheumatoid arthritis	1.8	1.5	-0.02	1.7	1.8	0.00	1.6	1.6	0.00
Schizophrenia	0.3	0.3	0.00	0.3	0.2	-0.01	0.3	0.3	0.00
Ulcerative colitis	0.4	0.3	-0.01	0.4	0.4	-0.01	0.2	0.3	0.02
Urinary tract infectious disease	5.2	6.9	0.07	5.2	5.5	0.02	5.8	6.5	0.03
Viral hepatitis C	0.8	0.6	-0.02	0.9	0.5	-0.05	0.6	0.6	0.00
Visual system disorder	15.0	15.2	0.01	14.0	14.6	0.02	13.0	15.3	0.07
Medical history: Cardiovascular disease									
Atrial fibrillation	7.5	10.7	0.11	7.8	7.8	0.00	9.9	10.1	0.01
Cerebrovascular disease	8.6	11.4	0.09	8.8	9.1	0.01	10.4	10.9	0.02
Coronary arteriosclerosis	34.5	42.6	0.17	36.0	34.1	-0.04	40.9	40.8	0.00
Heart disease	52.6	59.5	0.14	53.8	51.3	-0.05	58.8	57.7	-0.02
Heart failure	7.8	9.2	0.05	7.9	7.8	-0.01	9.5	8.9	-0.02
Ischemic heart disease	17.8	19.2	0.04	18.0	17.2	-0.02	19.1	18.7	-0.01
Peripheral vascular disease	20.9	17.7	-0.08	18.9	21.2	0.06	16.7	18.4	0.04
Pulmonary embolism	1.1	0.9	-0.02	1.0	0.9	-0.01	1.0	0.9	-0.01
Venous thrombosis	1.8	1.9	0.00	1.7	1.8	0.01	1.9	1.9	0.00
Medical history: Neoplasms									
Hematologic neoplasm	0.6	1.2	0.06	0.7	1.0	0.04	1.0	1.1	0.01
Malignant lymphoma	0.5	0.7	0.02	0.6	0.4	-0.03	0.4	0.7	0.03
Malignant neoplasm of anorectum	0.2	0.1	0.00	0.1	<0.1	-0.01	0.3	0.1	-0.04
Malignant neoplastic disease	7.2	9.5	0.08	7.3	7.4	0.00	9.1	9.0	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant tumor of breast	1.4	1.5	0.01	1.3	1.2	-0.01	1.2	1.5	0.02
Malignant tumor of colon	0.2	0.4	0.04	0.2	0.3	0.02	0.1	0.4	0.05
Malignant tumor of lung	0.1	0.5	0.06	0.2	0.4	0.05	0.1	0.4	0.06
Malignant tumor of urinary bladder	0.3	0.5	0.03	0.4	0.5	0.01	0.4	0.5	0.01
Primary malignant neoplasm of prostate	1.0	2.0	0.08	1.1	1.1	0.00	2.2	1.8	-0.03
Medication use									
Agents acting on the renin-angiotensin system	71.3	73.7	0.06	72.1	72.5	0.01	73.7	73.4	-0.01
Antibacterials for systemic use	50.3	47.0	-0.07	48.0	47.8	0.00	47.0	47.5	0.01
Antidepressants	42.5	32.8	-0.20	39.3	40.5	0.03	34.6	34.8	0.00
Antiepileptics	26.5	22.1	-0.10	24.7	25.7	0.02	22.3	23.0	0.02
Antiinflammatory and antirheumatic products	70.5	69.1	-0.03	70.0	70.2	0.00	69.6	69.4	0.00
Antineoplastic agents	6.1	5.2	-0.04	5.6	5.8	0.01	5.6	5.8	0.01
Antipsoriatics	0.8	0.8	-0.01	0.7	0.9	0.02	0.7	0.8	0.01
Antithrombotic agents	61.2	67.1	0.12	62.9	62.4	-0.01	66.3	65.9	-0.01
Beta blocking agents	51.7	57.5	0.12	52.8	52.0	-0.02	57.8	56.3	-0.03
Calcium channel blockers	29.3	31.7	0.05	29.3	30.1	0.02	31.7	31.2	-0.01
Diuretics	50.4	47.8	-0.05	48.7	48.9	0.00	50.2	48.2	-0.04
Drugs for acid related disorders	49.0	48.1	-0.02	47.6	48.6	0.02	48.6	48.3	-0.01
Drugs for obstructive airway diseases	54.1	47.3	-0.14	51.3	51.9	0.01	46.7	48.8	0.04
Immunosuppressants	4.4	2.9	-0.08	4.0	3.5	-0.02	3.7	3.0	-0.04
Lipid modifying agents	81.5	83.6	0.06	82.7	81.7	-0.03	84.2	83.4	-0.02
Opioids	36.6	34.8	-0.04	35.4	34.0	-0.03	36.0	35.0	-0.02
Psycholeptics	39.4	35.6	-0.08	37.4	37.0	-0.01	35.4	36.4	0.02
Psychostimulants	5.1	2.5	-0.14	3.1	2.9	-0.01	3.1	2.9	-0.01

Supplementary Table 33: Baseline patient characteristics for GLP1-RAs (T) and SUs (C) new-users in the CCAE data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.2	0.1	0.02	0.2	0.2	0.01	0.3	0.1	0.03
30 - 34	0.9	0.4	0.06	0.9	0.6	0.03	0.8	0.5	0.04
35 - 39	2.6	1.6	0.07	2.2	2.2	0.00	2.3	1.7	0.04
40 - 44	6.3	4.2	0.09	5.8	5.7	0.00	5.1	4.5	0.03
45 - 49	11.5	9.2	0.08	11.1	11.1	0.00	9.5	9.7	-0.01
50 - 54	20.2	17.7	0.06	19.7	19.5	0.01	19.2	18.1	0.03
55 - 59	27.0	27.3	-0.01	27.2	27.1	0.00	27.3	27.1	0.00
60 - 64	28.6	35.6	-0.15	30.0	30.8	-0.02	32.1	34.7	-0.05
65 - 69	2.4	3.8	-0.08	2.7	2.8	0.00	3.3	3.6	-0.02
Gender: female	53.8	39.2	0.30	50.3	51.4	-0.02	40.6	41.6	-0.02
Medical history: General									
Acute respiratory disease	33.5	28.4	0.11	32.3	32.5	0.00	28.8	29.5	-0.02
Attention deficit hyperactivity disorder	1.5	0.5	0.10	1.2	1.1	0.01	0.7	0.7	0.00
Chronic liver disease	2.6	3.9	-0.07	3.0	2.9	0.01	4.6	3.8	0.04
Chronic obstructive lung disease	5.5	7.0	-0.06	5.5	5.8	-0.01	6.8	6.8	0.00
Crohn's disease	0.4	0.3	0.02	0.4	0.3	0.02	0.7	0.3	0.05
Dementia	0.2	0.4	-0.02	0.2	0.3	-0.01	0.3	0.4	-0.01
Depressive disorder	15.7	10.6	0.15	14.0	15.0	-0.03	12.3	11.8	0.01
Gastroesophageal reflux disease	18.2	12.8	0.15	16.3	17.1	-0.02	13.6	14.1	-0.01
Gastrointestinal hemorrhage	2.8	2.7	0.00	2.9	2.7	0.01	3.2	2.7	0.03
Human immunodeficiency virus infection	0.3	0.3	0.00	0.3	0.4	-0.03	0.2	0.3	-0.01
Hyperlipidemia	74.9	68.9	0.13	74.0	74.6	-0.01	71.4	71.3	0.00
Hypertensive disorder	76.8	73.1	0.09	76.9	77.4	-0.01	76.9	75.1	0.04
Lesion of liver	0.9	1.2	-0.03	0.7	1.1	-0.04	1.0	1.2	-0.02
Obesity	38.0	17.5	0.47	31.8	34.2	-0.05	22.0	21.9	0.00
Osteoarthritis	29.5	21.8	0.18	27.9	28.4	-0.01	22.9	23.6	-0.02
Pneumonia	3.3	4.0	-0.03	3.2	3.3	-0.01	3.8	3.9	0.00
Psoriasis	2.7	1.5	0.08	2.2	2.2	0.00	1.6	1.7	-0.01
Renal impairment	5.6	6.3	-0.03	5.7	5.4	0.01	5.6	6.4	-0.03
Rheumatoid arthritis	2.0	1.4	0.04	1.8	1.9	-0.01	1.7	1.5	0.01
Schizophrenia	<0.1	0.1	-0.04	<0.1	0.2	-0.05	<0.1	0.2	-0.05
Ulcerative colitis	0.5	0.4	0.01	0.5	0.4	0.01	0.6	0.4	0.03
Urinary tract infectious disease	9.2	8.5	0.03	9.0	9.0	0.00	8.4	8.6	-0.01
Viral hepatitis C	0.3	0.6	-0.05	0.3	0.4	-0.01	0.3	0.6	-0.04
Visual system disorder	30.2	25.6	0.10	29.3	29.2	0.00	25.5	26.5	-0.02
Medical history: Cardiovascular disease									
Atrial fibrillation	4.8	5.0	-0.01	4.9	4.9	0.00	5.3	5.1	0.01
Cerebrovascular disease	8.6	11.0	-0.08	8.7	8.5	0.00	9.4	10.3	-0.03
Coronary arteriosclerosis	28.0	33.8	-0.13	29.0	28.9	0.00	32.8	32.3	0.01
Heart disease	47.0	51.1	-0.08	47.0	46.8	0.01	50.4	49.4	0.02
Heart failure	5.7	7.0	-0.05	5.5	5.9	-0.01	6.4	6.7	-0.01
Ischemic heart disease	16.1	19.6	-0.09	16.1	16.1	0.00	19.5	18.2	0.04
Peripheral vascular disease	16.1	12.5	0.10	15.6	15.3	0.01	13.0	13.2	-0.01
Pulmonary embolism	1.4	0.9	0.04	1.3	1.1	0.01	1.0	1.0	0.00
Venous thrombosis	2.0	1.8	0.01	2.0	1.7	0.02	1.6	1.8	-0.02
Medical history: Neoplasms									
Hematologic neoplasm	1.0	1.3	-0.03	0.9	1.0	-0.02	0.7	1.2	-0.05
Malignant lymphoma	0.5	0.6	-0.01	0.5	0.5	0.00	0.3	0.6	-0.03
Malignant neoplasm of anorectum	0.1	0.2	-0.04	<0.1	0.1	-0.02	0.2	0.2	-0.01
Malignant neoplastic disease	7.7	8.1	-0.01	7.4	7.9	-0.02	7.9	8.0	0.00
Malignant tumor of breast	1.5	1.4	0.01	1.4	1.5	-0.01	1.1	1.4	-0.02
Malignant tumor of colon	0.2	0.5	-0.04	0.3	0.3	-0.01	0.4	0.5	-0.02
Malignant tumor of lung	0.1	0.4	-0.06	0.1	0.2	-0.02	0.2	0.4	-0.03
Malignant tumor of urinary bladder	0.2	0.4	-0.03	0.2	0.2	0.00	0.4	0.3	0.01
Primary malignant neoplasm of prostate	0.8	1.1	-0.04	0.9	0.9	0.00	1.6	1.1	0.04
Medication use									
Agents acting on the renin-angiotensin system	70.6	73.2	-0.06	72.7	71.3	0.03	74.2	73.3	0.02
Antibacterials for systemic use	67.5	62.8	0.10	66.6	66.4	0.00	64.7	63.6	0.02
Antidepressants	41.0	30.2	0.23	38.3	39.1	-0.01	33.7	32.0	0.04
Antiepileptics	21.9	16.5	0.14	20.8	21.0	0.00	18.1	17.7	0.01
Antiinflammatory and antirheumatic products	42.3	34.5	0.16	40.6	41.2	-0.01	36.3	36.2	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antineoplastic agents	6.8	5.5	0.05	6.3	6.5	-0.01	5.3	5.4	-0.01
Antipsoriatics	1.0	0.7	0.03	0.8	0.9	-0.01	0.5	0.7	-0.02
Antithrombotic agents	23.8	27.7	-0.09	24.5	24.2	0.01	27.0	27.2	0.00
Beta blocking agents	43.4	49.1	-0.12	44.7	44.4	0.01	48.4	48.2	0.00
Calcium channel blockers	26.5	27.1	-0.01	26.3	26.8	-0.01	27.8	27.2	0.01
Diuretics	49.4	44.9	0.09	48.9	48.7	0.00	45.8	45.6	0.00
Drugs for acid related disorders	35.8	31.3	0.09	34.5	34.6	0.00	31.0	31.8	-0.02
Drugs for obstructive airway diseases	48.1	38.3	0.20	45.4	46.1	-0.01	42.3	40.5	0.04
Immunosuppressants	4.5	2.5	0.11	3.7	3.6	0.00	2.7	2.8	-0.01
Lipid modifying agents	75.1	76.7	-0.04	76.3	75.8	0.01	77.9	77.0	0.02
Opioids	35.2	33.9	0.03	34.9	35.1	0.00	34.5	34.5	0.00
Psycholeptics	34.3	28.9	0.11	33.0	32.9	0.00	28.8	30.1	-0.03
Psychostimulants	5.9	2.8	0.15	3.3	3.3	0.00	3.3	3.3	0.00

Supplementary Table 34: Baseline patient characteristics for GLP1-RAs (T) and SUs (C) new-users in the Optum-DOD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	0.02	0.1	0.1	0.00	0.4	0.1	0.07
30 - 34	0.5	0.2	0.06	0.5	0.3	0.04	0.8	0.2	0.08
35 - 39	1.6	0.6	0.10	1.5	1.3	0.02	0.8	0.7	0.02
40 - 44	3.4	1.3	0.13	3.0	2.8	0.02	1.5	1.5	0.00
45 - 49	6.4	3.0	0.16	5.8	5.8	0.00	3.3	3.3	0.00
50 - 54	11.4	5.6	0.21	9.8	10.1	-0.01	5.4	6.1	-0.03
55 - 59	14.9	8.9	0.19	14.0	14.3	-0.01	8.3	9.5	-0.04
60 - 64	16.7	11.7	0.14	16.4	16.5	0.00	12.0	12.3	-0.01
65 - 69	17.8	17.8	0.00	18.7	18.8	0.00	18.6	17.9	0.02
70 - 74	15.1	20.9	-0.15	16.4	17.1	-0.02	18.9	20.4	-0.04
75 - 79	8.3	15.6	-0.23	9.4	8.9	0.02	17.3	14.8	0.07
80 - 84	2.7	9.5	-0.29	3.1	2.8	0.02	7.5	8.8	-0.04
85 - 89	0.8	4.6	-0.24	0.9	0.9	0.00	5.0	4.2	0.04
90 - 94	<0.1	0.3	-0.06	<0.1	0.3	-0.05	0.1	0.3	-0.06
Gender: female	52.9	44.2	0.17	50.5	51.3	-0.01	43.4	45.0	-0.03
Medical history: General									
Acute respiratory disease	30.1	28.1	0.04	29.2	29.8	-0.01	31.4	28.3	0.07
Attention deficit hyperactivity disorder	1.3	0.4	0.09	0.9	1.2	-0.03	0.5	0.5	0.00
Chronic liver disease	2.7	3.7	-0.05	2.9	2.7	0.01	3.1	3.6	-0.03
Chronic obstructive lung disease	14.5	17.2	-0.07	14.6	15.1	-0.02	19.0	17.0	0.05
Crohn's disease	0.3	0.3	0.00	0.2	0.3	-0.02	0.5	0.3	0.03
Dementia	1.8	4.4	-0.15	1.9	2.0	-0.01	4.0	4.1	-0.01
Depressive disorder	24.4	17.1	0.18	22.2	23.9	-0.04	17.9	18.0	0.00
Gastroesophageal reflux disease	26.6	22.2	0.10	25.2	26.5	-0.03	24.3	22.8	0.04
Gastrointestinal hemorrhage	2.8	4.0	-0.06	2.8	3.0	-0.01	4.2	3.9	0.02
Human immunodeficiency virus infection	0.6	0.2	0.06	0.5	0.3	0.02	0.3	0.2	0.01
Hyperlipidemia	85.2	85.0	0.01	84.9	85.3	-0.01	87.4	85.0	0.07
Hypertensive disorder	86.0	87.4	-0.04	86.6	86.4	0.00	89.4	87.3	0.06
Lesion of liver	1.5	1.9	-0.03	1.5	1.8	-0.02	1.3	1.9	-0.05
Obesity	47.9	23.4	0.53	42.7	45.6	-0.06	25.9	26.0	0.00
Osteoarthritis	40.2	34.4	0.12	39.0	39.6	-0.01	37.2	35.0	0.05
Pneumonia	5.4	7.2	-0.07	5.0	5.3	-0.02	10.0	7.0	0.11
Psoriasis	2.7	1.6	0.08	2.6	2.3	0.02	1.4	1.7	-0.02
Renal impairment	16.0	24.9	-0.22	17.0	16.7	0.01	29.6	24.0	0.13
Rheumatoid arthritis	2.8	2.5	0.02	2.4	2.8	-0.02	2.6	2.5	0.01
Schizophrenia	0.6	0.5	0.02	0.6	0.5	0.01	0.4	0.5	-0.01
Ulcerative colitis	0.4	0.4	0.00	0.4	0.3	0.01	0.7	0.4	0.04
Urinary tract infectious disease	11.7	14.7	-0.09	11.5	11.2	0.01	19.8	14.3	0.14
Viral hepatitis C	0.7	0.8	-0.01	0.7	0.7	0.00	0.7	0.8	0.00
Visual system disorder	42.8	47.2	-0.09	43.7	43.8	0.00	47.6	46.8	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	9.5	13.1	-0.11	9.6	9.5	0.01	14.1	12.7	0.04
Cerebrovascular disease	11.3	16.3	-0.15	11.7	11.4	0.01	16.6	15.8	0.02
Coronary arteriosclerosis	33.8	40.0	-0.13	35.1	34.8	0.01	41.3	39.4	0.04
Heart disease	54.4	60.6	-0.12	54.9	54.2	0.01	62.6	59.9	0.06
Heart failure	12.0	16.0	-0.11	12.1	12.1	0.00	18.6	15.6	0.08
Ischemic heart disease	18.5	22.2	-0.09	18.5	18.8	-0.01	24.3	21.8	0.06
Peripheral vascular disease	26.7	26.1	0.01	27.1	27.6	-0.01	27.6	26.3	0.03
Pulmonary embolism	1.7	1.4	0.02	1.6	1.4	0.01	2.0	1.4	0.04
Venous thrombosis	2.3	2.8	-0.03	2.3	2.4	0.00	2.5	2.8	-0.01
Medical history: Neoplasms									
Hematologic neoplasm	1.2	2.0	-0.06	1.1	1.3	-0.02	1.5	1.9	-0.03
Malignant lymphoma	0.7	0.9	-0.02	0.6	0.7	-0.01	0.5	0.8	-0.04
Malignant neoplasm of anorectum	0.2	0.4	-0.03	0.2	0.2	-0.01	0.2	0.4	-0.03
Malignant neoplastic disease	10.9	15.1	-0.12	11.1	11.1	0.00	15.1	14.6	0.01
Malignant tumor of breast	1.8	2.1	-0.02	1.9	2.0	-0.01	1.8	2.1	-0.03
Malignant tumor of colon	0.7	0.9	-0.02	0.8	0.6	0.02	1.1	0.9	0.02
Malignant tumor of lung	0.3	0.9	-0.08	0.3	0.4	0.00	1.7	0.9	0.08
Malignant tumor of urinary bladder	0.5	0.9	-0.06	0.5	0.5	0.00	0.9	0.9	0.00
Primary malignant neoplasm of prostate	1.8	3.1	-0.09	2.0	1.6	0.03	4.3	3.0	0.07
Medication use									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Agents acting on the renin-angiotensin system	72.7	75.8	-0.07	74.2	73.6	0.01	78.6	75.5	0.07
Antibacterials for systemic use	64.7	62.4	0.05	63.4	63.5	0.00	63.2	62.6	0.01
Antidepressants	43.0	30.3	0.26	40.0	41.8	-0.04	32.4	31.7	0.01
Antiepileptics	29.3	21.9	0.17	27.5	28.7	-0.03	23.7	22.8	0.02
Antiinflammatory and antirheumatic products	39.8	30.4	0.20	37.7	38.9	-0.03	28.2	31.4	-0.07
Antineoplastic agents	7.4	6.6	0.03	7.0	6.6	0.02	5.8	6.6	-0.03
Antipsoriatics	0.9	0.7	0.03	0.8	0.9	-0.01	0.6	0.7	-0.01
Antithrombotic agents	27.4	32.2	-0.10	28.0	28.4	-0.01	34.3	31.8	0.05
Beta blocking agents	47.4	54.6	-0.14	48.7	48.1	0.01	55.6	53.9	0.04
Calcium channel blockers	30.1	34.2	-0.09	31.1	30.8	0.01	35.3	33.8	0.03
Diuretics	51.4	50.8	0.01	50.7	51.3	-0.01	54.4	50.8	0.07
Drugs for acid related disorders	37.0	35.0	0.04	35.8	36.7	-0.02	40.7	35.2	0.11
Drugs for obstructive airway diseases	50.7	41.5	0.18	48.2	49.8	-0.03	46.0	42.5	0.07
Immunosuppressants	4.1	2.8	0.07	3.6	3.4	0.01	3.6	2.9	0.04
Lipid modifying agents	79.9	81.1	-0.03	80.8	81.1	-0.01	81.6	81.1	0.01
Opioids	36.3	33.5	0.06	34.9	36.0	-0.02	31.9	33.9	-0.04
Psycholeptics	34.1	28.8	0.11	32.3	33.2	-0.02	27.1	29.3	-0.05
Psychostimulants	3.8	1.4	0.15	3.0	3.0	0.00	1.9	1.6	0.02

Supplementary Table 35: Baseline patient characteristics for GLP1-RAs (T) and SUs (C) new-users in the MDCR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
50 - 54	<0.4	0.1	0.04	<0.5	0.2	0.02	<0.1	0.1	0.01
55 - 59	1.1	0.5	0.07	1.1	0.7	0.04	0.3	0.5	-0.03
60 - 64	2.5	1.3	0.09	2.6	1.8	0.06	2.2	1.4	0.06
65 - 69	34.6	19.8	0.34	33.3	35.4	-0.04	19.9	20.9	-0.03
70 - 74	36.8	28.4	0.18	37.0	36.3	0.02	34.3	28.7	0.12
75 - 79	16.2	23.3	-0.18	16.6	15.9	0.02	19.6	22.6	-0.07
80 - 84	6.1	16.4	-0.33	6.4	5.8	0.02	17.3	15.8	0.04
85 - 89	2.0	7.6	-0.27	2.1	2.6	-0.03	6.1	7.5	-0.05
90 - 94	0.6	2.2	-0.14	0.7	1.2	-0.05	<0.1	2.2	-0.20
Gender: female	49.2	42.6	0.13	48.7	48.2	0.01	45.2	42.6	0.05
Medical history: General									
Acute respiratory disease	25.8	24.4	0.03	25.8	25.2	0.01	33.9	25.0	0.20
Attention deficit hyperactivity disorder	<0.4	0.1	0.02	<0.5	0.5	-0.07	<0.1	0.1	-0.04
Chronic liver disease	2.1	2.3	-0.02	2.2	2.0	0.01	1.1	2.4	-0.10
Chronic obstructive lung disease	15.7	15.2	0.01	15.8	15.4	0.01	25.2	15.6	0.24
Crohn's disease	0.5	0.3	0.04	0.6	0.4	0.03	0.5	0.3	0.03
Dementia	2.1	4.5	-0.13	2.2	2.6	-0.02	4.0	4.5	-0.03
Depressive disorder	13.8	8.2	0.18	12.7	14.9	-0.06	17.5	9.2	0.24
Gastroesophageal reflux disease	17.2	11.8	0.15	16.5	16.9	-0.01	7.9	13.0	-0.16
Gastrointestinal hemorrhage	2.9	4.6	-0.09	2.8	3.1	-0.02	3.1	4.4	-0.07
Human immunodeficiency virus infection	<0.4	0.1	0.01	<0.5	0.1	0.01	<0.1	0.1	-0.02
Hyperlipidemia	69.0	52.6	0.34	67.2	71.1	-0.08	64.7	57.4	0.15
Hypertensive disorder	81.4	71.3	0.24	80.5	82.1	-0.04	79.2	74.4	0.12
Lesion of liver	0.9	1.3	-0.04	1.0	1.5	-0.05	0.3	1.4	-0.12
Obesity	29.5	8.2	0.56	25.8	28.8	-0.07	8.8	10.0	-0.04
Osteoarthritis	39.4	30.1	0.20	38.5	37.5	0.02	36.9	31.7	0.11
Pneumonia	4.8	8.3	-0.14	5.0	5.8	-0.03	12.7	8.1	0.15
Psoriasis	2.9	1.4	0.11	2.9	2.1	0.05	2.0	1.5	0.04
Renal impairment	14.5	16.4	-0.05	13.9	15.4	-0.04	26.2	17.7	0.20
Rheumatoid arthritis	1.9	1.8	0.00	1.7	2.2	-0.03	0.6	1.9	-0.12
Schizophrenia	<0.4	0.2	0.02	<0.5	0.1	0.05	<0.1	0.1	0.00
Ulcerative colitis	<0.4	0.4	-0.01	<0.5	0.4	0.00	0.2	0.4	-0.05
Urinary tract infectious disease	11.5	12.3	-0.02	11.2	10.1	0.04	9.8	12.5	-0.09
Viral hepatitis C	<0.4	0.3	-0.04	<0.5	0.5	-0.08	<0.1	0.3	-0.06
Visual system disorder	51.6	50.1	0.03	51.3	52.4	-0.02	57.5	50.8	0.13
Medical history: Cardiovascular disease									
Atrial fibrillation	12.1	16.4	-0.12	12.3	12.5	0.00	23.3	16.6	0.17
Cerebrovascular disease	17.9	22.0	-0.10	17.9	18.0	0.00	17.1	21.3	-0.10
Coronary arteriosclerosis	43.1	44.3	-0.03	42.5	42.8	-0.01	40.8	43.6	-0.06
Heart disease	62.3	66.9	-0.10	62.0	63.4	-0.03	70.5	66.1	0.10
Heart failure	11.3	16.6	-0.15	11.3	11.8	-0.02	24.1	15.9	0.20
Ischemic heart disease	17.9	21.8	-0.10	18.6	17.5	0.03	18.4	20.7	-0.06
Peripheral vascular disease	22.5	20.0	0.06	22.5	23.8	-0.03	17.6	20.3	-0.07
Pulmonary embolism	1.3	1.3	0.00	1.2	1.7	-0.04	2.7	1.3	0.10
Venous thrombosis	2.1	3.0	-0.06	2.2	2.5	-0.02	1.9	3.1	-0.08
Medical history: Neoplasms									
Hematologic neoplasm	2.1	2.1	0.00	2.0	1.9	0.01	1.3	2.2	-0.07
Malignant lymphoma	1.2	1.0	0.02	1.1	1.3	-0.02	0.6	1.0	-0.05
Malignant neoplastic disease	20.5	20.4	0.00	21.0	21.2	0.00	16.1	20.7	-0.12
Malignant tumor of breast	3.8	2.6	0.07	3.8	4.0	-0.01	1.9	2.6	-0.05
Malignant tumor of colon	0.5	1.1	-0.06	0.6	0.7	-0.01	<0.1	1.0	-0.12
Malignant tumor of lung	0.8	1.1	-0.03	0.9	0.9	-0.01	1.2	1.1	0.01
Malignant tumor of urinary bladder	1.8	1.4	0.03	1.8	1.3	0.04	1.6	1.5	0.01
Primary malignant neoplasm of prostate	4.6	5.3	-0.03	5.1	5.3	-0.01	5.1	5.3	-0.01
Medication use									
Agents acting on the renin-angiotensin system	78.2	74.3	0.09	78.5	77.7	0.02	80.1	75.9	0.10
Antibacterials for systemic use	66.7	65.0	0.04	66.2	64.7	0.03	63.2	65.7	-0.05
Antidepressants	36.6	27.3	0.20	34.8	36.1	-0.03	28.4	28.1	0.01
Antiepileptics	21.2	17.3	0.10	20.4	21.5	-0.03	23.1	18.3	0.12
Antiinflammatory and antirheumatic products	34.6	27.6	0.15	33.7	33.0	0.01	26.2	27.9	-0.04
Antineoplastic agents	10.1	9.6	0.01	10.3	9.1	0.04	7.6	9.1	-0.06

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antipsoriaties	1.2	0.8	0.04	1.2	1.0	0.02	0.7	0.8	-0.02
Antithrombotic agents	35.1	38.5	-0.07	35.9	34.1	0.04	45.3	38.6	0.14
Beta blocking agents	55.9	61.0	-0.10	56.2	54.6	0.03	70.0	61.4	0.18
Calcium channel blockers	33.7	37.1	-0.07	33.9	32.7	0.03	28.5	37.4	-0.19
Diuretics	56.4	56.7	0.00	56.4	54.3	0.04	57.5	56.4	0.02
Drugs for acid related disorders	39.9	36.7	0.06	39.4	37.9	0.03	35.9	36.8	-0.02
Drugs for obstructive airway diseases	53.1	41.9	0.23	51.8	52.2	-0.01	51.2	43.6	0.15
Immunosuppressants	4.1	2.9	0.07	4.0	4.0	0.00	11.8	3.1	0.33
Lipid modifying agents	86.7	80.2	0.18	86.7	86.9	0.00	78.0	82.4	-0.11
Opioids	32.1	32.4	-0.01	32.4	32.9	-0.01	39.4	32.9	0.13
Psycholeptics	31.2	29.0	0.05	31.0	31.5	-0.01	37.2	29.5	0.16
Psychostimulants	2.1	1.3	0.07	2.2	2.0	0.02	1.3	1.4	-0.01

Supplementary Table 36: Baseline patient characteristics for GLP1-RAs (T) and SUs (C) new-users in the Open Claims data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.2	0.1	0.02	0.2	0.1	0.01	0.2	0.1	0.01
25 - 29	0.3	0.2	0.03	0.3	0.2	0.01	0.2	0.2	0.01
30 - 34	0.8	0.4	0.05	0.7	0.7	-0.01	0.5	0.5	0.01
35 - 39	1.7	0.9	0.07	1.6	1.5	0.00	1.1	1.0	0.01
40 - 44	3.8	2.0	0.11	3.5	3.3	0.01	2.5	2.2	0.02
45 - 49	7.1	4.0	0.14	6.5	6.5	0.00	4.5	4.4	0.01
50 - 54	11.9	7.4	0.15	10.9	11.0	0.00	7.9	8.0	0.00
55 - 59	16.5	11.3	0.15	15.7	15.8	0.00	12.0	12.1	0.00
60 - 64	18.3	14.2	0.11	18.0	18.2	0.00	14.8	14.9	0.00
65 - 69	16.7	17.3	-0.02	17.5	17.8	-0.01	17.3	17.4	0.00
70 - 74	12.2	16.4	-0.12	13.3	13.0	0.01	16.3	16.0	0.01
75 - 79	6.8	18.1	-0.35	7.7	7.6	0.00	15.2	16.4	-0.03
80 - 84	3.3	7.4	-0.18	3.9	3.8	0.00	7.3	6.8	0.02
85 - 89	0.3	0.2	0.01	0.3	0.4	-0.01	0.2	0.2	-0.01
Gender: female	54.4	45.0	0.19	51.8	51.5	0.01	46.2	46.0	0.00
Medical history: General									
Acute respiratory disease	17.1	17.0	0.00	16.2	17.4	-0.03	17.5	17.1	0.01
Attention deficit hyperactivity disorder	0.9	0.3	0.08	0.7	0.6	0.00	0.4	0.3	0.01
Chronic liver disease	1.1	1.9	-0.06	1.2	1.2	0.00	1.8	1.7	0.01
Chronic obstructive lung disease	8.8	11.2	-0.08	8.8	9.8	-0.03	11.0	10.9	0.00
Crohn's disease	0.2	0.2	0.00	0.2	0.2	-0.01	0.1	0.2	-0.02
Dementia	0.7	2.0	-0.10	0.8	0.9	-0.01	1.8	1.8	0.00
Depressive disorder	12.0	8.8	0.10	10.9	11.2	-0.01	9.9	9.3	0.02
Gastroesophageal reflux disease	12.7	10.5	0.07	11.5	12.1	-0.02	10.9	10.9	0.00
Gastrointestinal hemorrhage	1.8	2.3	-0.04	1.7	1.9	-0.01	2.2	2.3	-0.01
Human immunodeficiency virus infection	0.4	0.3	0.02	0.3	0.3	0.01	0.3	0.3	0.00
Hyperlipidemia	50.1	50.0	0.00	49.0	49.9	-0.02	50.7	50.2	0.01
Hypertensive disorder	59.4	61.3	-0.04	58.5	59.4	-0.02	61.5	61.1	0.01
Lesion of liver	0.9	1.1	-0.03	0.9	0.9	0.00	0.9	1.1	-0.02
Obesity	23.1	11.2	0.32	19.3	19.7	-0.01	13.7	12.6	0.03
Osteoarthritis	23.6	20.5	0.07	22.1	22.8	-0.02	21.7	20.9	0.02
Pneumonia	3.4	4.6	-0.06	3.4	3.6	-0.01	4.2	4.4	-0.01
Psoriasis	1.5	0.9	0.05	1.3	1.4	0.00	1.1	1.0	0.01
Renal impairment	8.2	13.3	-0.16	8.5	8.8	-0.01	12.5	12.6	0.00
Rheumatoid arthritis	1.8	1.4	0.03	1.6	1.6	0.00	1.5	1.5	0.00
Schizophrenia	0.3	0.5	-0.02	0.3	0.3	0.00	0.3	0.3	0.00
Ulcerative colitis	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	0.00
Urinary tract infectious disease	6.5	7.7	-0.05	6.3	6.5	-0.01	8.1	7.6	0.01
Viral hepatitis C	0.3	0.6	-0.04	0.3	0.4	-0.01	0.5	0.5	-0.01
Visual system disorder	21.3	23.4	-0.05	21.0	21.5	-0.01	22.6	23.1	-0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	6.1	8.8	-0.11	6.2	6.5	-0.01	8.4	8.5	0.00
Cerebrovascular disease	6.4	9.6	-0.12	6.4	6.5	0.00	8.8	9.2	-0.01
Coronary arteriosclerosis	20.2	25.4	-0.12	20.4	21.1	-0.02	24.6	24.7	0.00
Heart disease	35.4	42.3	-0.14	35.2	36.3	-0.02	41.2	41.4	0.00
Heart failure	6.8	10.1	-0.12	6.9	7.4	-0.02	9.6	9.7	-0.01
Ischemic heart disease	9.7	12.6	-0.09	9.7	10.2	-0.02	11.8	12.2	-0.01
Peripheral vascular disease	13.3	14.0	-0.02	13.2	13.4	0.00	13.9	14.0	0.00
Pulmonary embolism	1.1	1.0	0.01	1.0	1.0	0.00	1.1	1.0	0.01
Venous thrombosis	1.2	1.6	-0.03	1.2	1.2	0.00	1.7	1.6	0.01
Medical history: Neoplasms									
Hematologic neoplasm	0.8	1.2	-0.04	0.8	0.8	0.00	1.2	1.1	0.01
Malignant lymphoma	0.4	0.6	-0.03	0.5	0.5	0.00	0.6	0.6	0.00
Malignant neoplasm of anorectum	0.1	0.2	-0.03	0.1	0.1	0.00	0.2	0.2	0.00
Malignant neoplastic disease	6.9	9.4	-0.09	7.0	7.2	-0.01	9.2	9.0	0.01
Malignant tumor of breast	1.3	1.4	0.00	1.3	1.4	-0.01	1.3	1.4	-0.01
Malignant tumor of colon	0.3	0.5	-0.04	0.3	0.3	0.00	0.5	0.5	0.01
Malignant tumor of lung	0.3	0.6	-0.05	0.6	0.5	0.01	0.6	0.5	0.01
Malignant tumor of urinary bladder	0.3	0.5	-0.03	0.3	0.4	-0.01	0.7	0.5	0.02
Primary malignant neoplasm of prostate	1.2	1.9	-0.06	1.3	1.3	0.00	2.0	1.9	0.01
Medication use									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Agents acting on the renin-angiotensin system	68.7	73.2	-0.10	69.5	70.1	-0.01	72.6	72.7	0.00
Antibacterials for systemic use	63.4	60.7	0.06	62.0	62.8	-0.01	61.7	61.2	0.01
Antidepressants	42.9	32.5	0.22	39.9	40.7	-0.02	35.7	34.1	0.04
Antiepileptics	30.0	25.3	0.10	28.3	29.4	-0.03	27.3	26.0	0.03
Antiinflammatory and antirheumatic products	43.4	37.7	0.12	41.8	42.4	-0.01	39.1	38.6	0.01
Antineoplastic agents	7.2	5.3	0.07	6.4	6.7	-0.01	6.1	5.7	0.02
Antipsoriatics	1.1	0.7	0.04	1.0	1.0	0.00	0.7	0.8	-0.01
Antithrombotic agents	29.8	36.4	-0.14	30.5	31.1	-0.01	35.9	35.6	0.01
Beta blocking agents	47.1	54.4	-0.15	47.8	48.3	-0.01	53.7	53.5	0.00
Calcium channel blockers	30.4	33.6	-0.07	30.8	31.2	-0.01	32.5	33.1	-0.01
Diuretics	49.1	48.6	0.01	48.2	48.4	0.00	48.9	48.5	0.01
Drugs for acid related disorders	43.3	41.1	0.04	41.8	42.7	-0.02	42.0	41.6	0.01
Drugs for obstructive airway diseases	48.7	40.9	0.16	46.4	47.7	-0.03	42.3	42.2	0.00
Immunosuppressants	4.4	2.9	0.08	4.0	3.9	0.00	3.3	3.1	0.01
Lipid modifying agents	76.1	77.7	-0.04	76.5	77.2	-0.02	77.9	77.7	0.00
Opioids	31.9	31.5	0.01	30.8	32.1	-0.03	32.6	31.4	0.03
Psycholeptics	31.8	27.9	0.08	29.8	31.0	-0.03	29.9	28.5	0.03
Psychostimulants	4.7	2.2	0.14	3.8	3.9	-0.01	2.7	2.5	0.02

Supplementary Table 37: Baseline patient characteristics for GLP1-RAs (T) and SUs (C) new-users in the OptumEHR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.1	0.1	0.02	<0.1	0.1	-0.01	<0.1	0.1	-0.01
25 - 29	0.4	0.1	0.06	0.4	0.3	0.02	0.4	0.1	0.06
30 - 34	0.6	0.3	0.05	0.7	0.5	0.02	0.9	0.3	0.07
35 - 39	2.0	0.9	0.09	1.9	1.7	0.01	1.4	1.0	0.03
40 - 44	4.8	2.0	0.16	4.2	4.3	0.00	2.3	2.3	0.00
45 - 49	8.3	4.6	0.15	8.0	7.6	0.01	4.4	5.0	-0.03
50 - 54	14.3	8.2	0.19	13.3	13.8	-0.01	9.8	8.8	0.04
55 - 59	17.6	12.6	0.14	17.5	17.3	0.00	12.8	13.1	-0.01
60 - 64	19.8	15.6	0.11	19.7	19.6	0.00	15.0	16.0	-0.03
65 - 69	15.2	16.3	-0.03	15.8	16.9	-0.03	15.5	16.3	-0.02
70 - 74	9.7	15.4	-0.17	10.5	10.3	0.01	15.7	14.8	0.02
75 - 79	5.0	13.2	-0.29	5.5	5.1	0.02	11.7	12.4	-0.02
80 - 84	1.6	8.7	-0.33	1.8	1.7	0.00	8.6	8.0	0.02
85 - 89	0.4	2.0	-0.14	0.5	0.7	-0.03	1.4	1.9	-0.04
Gender: female	50.2	39.3	0.22	47.6	48.4	-0.01	39.0	40.2	-0.02
Race									
Asian	1.1	1.7	-0.05	1.2	1.4	-0.02	0.9	1.7	-0.06
Black or African American	10.1	8.0	0.07	9.8	9.4	0.01	9.4	8.2	0.04
White	83.6	84.5	-0.02	83.9	83.7	0.01	85.1	84.4	0.02
Ethnicity									
Hispanic or Latino	4.0	4.9	-0.04	3.9	4.4	-0.02	5.0	4.8	0.01
Not Hispanic or Latino	88.3	88.4	-0.01	88.5	88.2	0.01	89.0	88.4	0.02
Medical history: General									
Acute respiratory disease	21.3	18.1	0.08	20.1	20.6	-0.01	16.7	18.3	-0.04
Attention deficit hyperactivity disorder	1.0	0.4	0.07	0.8	0.8	0.00	0.4	0.4	0.00
Chronic liver disease	2.7	3.1	-0.02	2.6	2.6	0.00	3.2	3.1	0.01
Chronic obstructive lung disease	10.2	12.1	-0.06	10.6	10.5	0.00	13.0	12.0	0.03
Crohn's disease	0.4	0.2	0.02	0.4	0.3	0.01	0.2	0.3	-0.02
Dementia	0.9	2.2	-0.11	0.9	0.9	0.00	0.8	2.1	-0.11
Depressive disorder	21.4	15.1	0.16	19.6	20.4	-0.02	17.1	15.7	0.04
Gastroesophageal reflux disease	24.8	19.8	0.12	22.9	24.0	-0.03	21.6	20.3	0.03
Gastrointestinal hemorrhage	2.0	2.2	-0.01	2.1	1.7	0.03	3.8	2.2	0.10
Human immunodeficiency virus infection	0.2	0.2	0.01	0.2	0.3	-0.01	0.1	0.2	-0.03
Hyperlipidemia	74.6	73.9	0.02	73.3	74.1	-0.02	77.5	73.9	0.08
Hypertensive disorder	77.5	76.8	0.02	76.5	77.5	-0.03	80.3	76.8	0.09
Lesion of liver	1.1	1.2	-0.01	0.9	1.4	-0.04	0.5	1.2	-0.08
Obesity	47.5	23.7	0.51	41.9	44.8	-0.06	28.8	25.8	0.07
Osteoarthritis	25.3	22.2	0.07	24.0	24.5	-0.01	22.0	22.4	-0.01
Pneumonia	3.0	3.8	-0.05	2.6	3.7	-0.06	2.6	3.7	-0.06
Psoriasis	2.3	1.5	0.06	2.1	1.8	0.02	1.3	1.5	-0.01
Renal impairment	9.1	13.9	-0.15	9.3	9.3	0.00	11.6	13.4	-0.06
Rheumatoid arthritis	1.8	1.5	0.02	1.7	1.8	-0.01	2.8	1.5	0.09
Schizophrenia	0.3	0.3	0.00	0.3	0.4	0.00	0.3	0.3	-0.01
Ulcerative colitis	0.4	0.3	0.01	0.4	0.3	0.01	0.1	0.3	-0.03
Urinary tract infectious disease	5.2	6.7	-0.06	5.0	5.4	-0.02	5.2	6.6	-0.06
Viral hepatitis C	0.8	0.7	0.01	0.8	0.6	0.03	0.5	0.7	-0.03
Visual system disorder	15.0	18.0	-0.08	14.5	14.5	0.00	13.9	17.6	-0.10
Medical history: Cardiovascular disease									
Atrial fibrillation	7.5	10.7	-0.11	7.7	7.5	0.01	11.5	10.4	0.04
Cerebrovascular disease	8.6	11.5	-0.10	8.5	8.8	-0.01	9.9	11.2	-0.04
Coronary arteriosclerosis	34.5	42.8	-0.17	35.0	34.6	0.01	42.7	42.0	0.01
Heart disease	52.6	59.1	-0.13	52.7	51.9	0.02	58.7	58.3	0.01
Heart failure	7.8	10.3	-0.09	8.1	8.0	0.00	11.6	10.1	0.05
Ischemic heart disease	17.8	19.6	-0.05	17.9	17.2	0.02	19.0	19.4	-0.01
Peripheral vascular disease	20.9	17.9	0.07	20.1	20.8	-0.02	16.3	18.2	-0.05
Pulmonary embolism	1.1	1.1	0.00	1.1	1.1	0.00	1.7	1.1	0.05
Venous thrombosis	1.8	1.9	-0.01	1.7	1.5	0.02	1.5	1.9	-0.03
Medical history: Neoplasms									
Hematologic neoplasm	0.6	1.2	-0.06	0.6	0.9	-0.03	2.2	1.1	0.08
Malignant lymphoma	0.5	0.7	-0.02	0.5	0.5	0.01	0.3	0.7	-0.05
Malignant neoplasm of anorectum	0.2	0.2	0.00	0.2	0.1	0.02	0.2	0.1	0.02

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant neoplastic disease	7.2	9.9	-0.09	7.0	6.9	0.00	11.1	9.6	0.05
Malignant tumor of breast	1.4	1.3	0.01	1.4	1.2	0.01	0.9	1.3	-0.04
Malignant tumor of colon	0.2	0.6	-0.06	0.2	0.3	-0.02	0.1	0.5	-0.07
Malignant tumor of lung	0.1	0.5	-0.06	0.2	0.3	-0.03	0.1	0.4	-0.08
Malignant tumor of urinary bladder	0.3	0.6	-0.04	0.3	0.3	-0.01	0.4	0.6	-0.02
Primary malignant neoplasm of prostate	1.0	2.2	-0.10	1.1	1.2	0.00	3.8	2.1	0.10
Medication use									
Agents acting on the renin-angiotensin system	71.3	73.0	-0.04	72.0	71.5	0.01	73.7	72.8	0.02
Antibacterials for systemic use	50.3	46.2	0.08	48.4	49.1	-0.01	48.0	46.5	0.03
Antidepressants	42.5	32.0	0.22	40.1	41.4	-0.03	34.8	32.9	0.04
Antiepileptics	26.5	22.2	0.10	25.1	25.9	-0.02	25.1	22.6	0.06
Antiinflammatory and antirheumatic products	70.5	69.5	0.02	70.1	70.3	0.00	69.8	69.6	0.00
Antineoplastic agents	6.1	4.8	0.06	5.6	5.7	0.00	5.8	4.8	0.04
Antipsoriatics	0.8	0.6	0.03	0.7	0.6	0.01	1.1	0.6	0.06
Antithrombotic agents	61.2	68.9	-0.16	62.0	61.6	0.01	62.0	61.6	0.01
Beta blocking agents	51.7	59.5	-0.16	52.4	51.9	0.01	59.7	58.7	0.02
Calcium channel blockers	29.3	30.4	-0.02	28.6	29.6	-0.02	33.5	30.3	0.07
Diuretics	50.4	48.4	0.04	48.9	49.3	-0.01	51.8	48.5	0.07
Drugs for acid related disorders	49.0	47.8	0.02	47.8	48.4	-0.01	50.3	47.8	0.05
Drugs for obstructive airway diseases	54.1	46.1	0.16	51.6	52.9	-0.03	46.0	46.8	-0.01
Immunosuppressants	4.4	2.8	0.09	4.3	4.0	0.01	4.4	2.9	0.08
Lipid modifying agents	81.5	82.4	-0.02	81.7	81.3	0.01	84.0	82.3	0.05
Opioids	36.6	36.2	0.01	35.6	35.7	0.00	41.0	36.2	0.10
Psycholeptics	39.4	34.4	0.10	37.6	38.6	-0.02	35.7	34.8	0.02
Psychostimulants	5.1	2.3	0.15	4.5	4.3	0.01	3.0	2.5	0.03

Supplementary Table 38: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the CCAE data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	-0.01	0.1	0.1	0.00	0.1	0.1	-0.01
30 - 34	0.5	0.4	0.01	0.5	0.4	0.02	0.5	0.4	0.01
35 - 39	1.5	1.6	0.00	1.6	1.6	0.00	1.6	1.6	0.00
40 - 44	4.3	4.2	0.00	4.2	4.1	0.01	4.3	4.2	0.01
45 - 49	9.3	9.2	0.00	9.4	9.2	0.01	9.4	9.2	0.01
50 - 54	18.1	17.7	0.01	18.0	17.7	0.01	17.8	17.7	0.00
55 - 59	27.6	27.3	0.01	27.6	27.5	0.00	27.4	27.2	0.00
60 - 64	35.0	35.6	-0.01	35.0	35.6	-0.01	35.1	35.7	-0.01
65 - 69	3.6	3.8	-0.01	3.6	3.8	-0.01	3.6	3.8	-0.01
Gender: female	42.2	39.2	0.06	40.9	41.5	-0.01	40.1	40.4	0.00
Medical history: General									
Acute respiratory disease	30.6	28.4	0.05	29.7	30.0	-0.01	29.7	29.7	0.00
Attention deficit hyperactivity disorder	0.7	0.5	0.02	0.6	0.6	0.00	0.6	0.6	0.00
Chronic liver disease	4.1	3.9	0.01	4.0	4.0	0.00	4.1	4.0	0.00
Chronic obstructive lung disease	6.2	7.0	-0.03	6.4	6.2	0.01	6.8	6.7	0.00
Crohn's disease	0.4	0.3	0.00	0.3	0.3	0.00	0.3	0.3	0.00
Dementia	0.3	0.4	0.00	0.4	0.3	0.00	0.4	0.3	0.00
Gastroesophageal reflux disease	14.7	12.8	0.06	14.1	14.5	-0.01	14.0	14.3	-0.01
Gastrointestinal hemorrhage	2.7	2.7	0.00	2.7	2.6	0.00	2.6	2.7	0.00
Human immunodeficiency virus infection	0.3	0.3	0.01	0.3	0.3	0.00	0.3	0.3	0.00
Hyperlipidemia	75.0	68.9	0.14	73.8	74.1	-0.01	72.8	72.9	0.00
Hypertensive disorder	76.5	73.1	0.08	76.0	76.2	0.00	75.9	75.7	0.00
Lesion of liver	0.9	1.2	-0.02	0.9	1.0	-0.01	1.0	1.1	-0.01
Obesity	19.6	17.5	0.06	19.3	19.5	0.00	19.2	19.5	-0.01
Osteoarthritis	23.7	21.8	0.05	23.2	23.5	-0.01	23.3	23.2	0.00
Pneumonia	3.2	4.0	-0.04	3.3	3.3	0.00	3.6	3.6	0.00
Psoriasis	1.7	1.5	0.01	1.7	1.7	0.00	1.6	1.6	0.00
Renal impairment	5.8	6.3	-0.02	6.0	6.0	0.00	6.6	6.4	0.00
Rheumatoid arthritis	1.6	1.4	0.01	1.5	1.5	-0.01	1.5	1.5	0.00
Schizophrenia	0.2	0.1	0.00	0.2	0.1	0.02	0.2	0.1	0.01
Ulcerative colitis	0.4	0.4	0.00	0.4	0.4	-0.01	0.4	0.4	-0.01
Urinary tract infectious disease	8.9	8.5	0.01	8.4	8.6	-0.01	8.8	8.6	0.00
Viral hepatitis C	0.5	0.6	-0.02	0.5	0.5	-0.01	0.5	0.6	-0.01
Visual system disorder	28.3	25.6	0.06	27.1	27.5	-0.01	26.5	26.9	-0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	4.8	5.0	-0.01	4.8	4.9	0.00	5.0	5.0	0.00
Cerebrovascular disease	10.4	11.0	-0.02	10.2	10.3	0.00	10.7	10.6	0.00
Coronary arteriosclerosis	32.1	33.8	-0.04	32.6	32.1	0.01	32.9	32.6	0.01
Heart disease	49.4	51.1	-0.03	49.3	49.0	0.01	49.9	49.6	0.01
Heart failure	5.8	7.0	-0.05	6.6	6.4	0.00	6.6	6.4	0.00
Ischemic heart disease	16.8	19.6	-0.07	17.1	17.0	0.00	17.9	17.8	0.00
Peripheral vascular disease	13.7	12.5	0.03	13.3	13.4	0.00	13.3	13.2	0.00
Pulmonary embolism	0.8	0.9	-0.01	0.9	0.9	0.00	0.9	0.9	0.00
Venous thrombosis	1.9	1.8	0.01	1.9	1.8	0.01	2.0	1.9	0.01
Medical history: Neoplasms									
Malignant lymphoma	0.6	0.6	0.00	0.5	0.6	0.00	0.5	0.6	-0.01
Malignant neoplasm of anorectum	0.2	0.2	-0.01	0.2	0.2	0.00	0.2	0.2	0.01
Malignant neoplastic disease	8.4	8.1	0.01	8.2	8.1	0.00	8.3	8.2	0.00
Malignant tumor of breast	1.5	1.4	0.01	1.5	1.5	0.00	1.5	1.5	0.00
Malignant tumor of colon	0.4	0.5	-0.01	0.5	0.4	0.00	0.5	0.5	0.01
Malignant tumor of lung	0.3	0.4	-0.01	0.3	0.3	0.01	0.4	0.3	0.01
Malignant tumor of urinary bladder	0.4	0.4	0.00	0.4	0.3	0.01	0.4	0.4	0.00
Primary malignant neoplasm of prostate	1.2	1.1	0.00	1.2	1.2	0.00	1.2	1.2	0.00
Medication use									
Agents acting on the renin-angiotensin system	73.8	73.2	0.01	73.7	73.4	0.00	74.2	73.9	0.01
Antibacterials for systemic use	64.3	62.8	0.03	63.3	63.8	-0.01	63.6	63.5	0.00
Antidepressants	29.3	30.2	-0.02	29.2	28.9	0.01	29.9	29.7	0.00
Antiepileptics	16.1	16.5	-0.01	16.3	15.9	0.01	16.9	16.5	0.01
Antiinflammatory and antirheumatic products	35.2	34.5	0.01	34.8	34.9	0.00	35.1	35.1	0.00
Antipsoriatics	0.7	0.7	0.01	0.7	0.7	0.00	0.7	0.7	0.00
Antithrombotic agents	26.1	27.7	-0.04	26.8	26.3	0.01	27.7	27.2	0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Beta blocking agents	46.6	49.1	-0.05	47.3	46.7	0.01	48.4	48.0	0.01
Calcium channel blockers	27.0	27.1	0.00	26.9	26.9	0.00	27.2	27.2	0.00
Diuretics	43.7	44.9	-0.03	43.7	43.4	0.01	44.7	44.1	0.01
Drugs for acid related disorders	32.2	31.3	0.02	31.5	31.4	0.00	31.4	31.5	0.00
Drugs for obstructive airway diseases	41.3	38.3	0.06	40.3	40.5	0.00	40.0	40.2	0.00
Immunosuppressants	3.0	2.5	0.03	2.9	2.8	0.01	2.9	2.8	0.01
Lipid modifying agents	78.3	76.7	0.04	78.0	77.8	0.00	77.8	77.8	0.00
Opioids	32.5	33.9	-0.03	32.7	32.5	0.00	33.9	33.6	0.01
Psychostimulants	3.2	2.8	0.02	3.1	3.0	0.01	3.1	3.0	0.01

Supplementary Table 39: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the GermanyDA data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
30 - 34	0.1	<0.2	-0.01	<0.3	0.2	-0.01	0.1	<0.1	0.00
35 - 39	0.3	0.4	-0.01	0.3	0.5	-0.03	0.3	0.5	-0.02
40 - 44	0.9	1.1	-0.02	0.8	1.2	-0.04	0.9	0.8	0.02
45 - 49	2.6	2.2	0.02	2.7	2.2	0.03	2.6	2.2	0.03
50 - 54	5.8	4.5	0.06	5.6	4.7	0.04	5.6	4.5	0.05
55 - 59	10.4	8.1	0.08	8.8	8.4	0.01	10.0	8.7	0.04
60 - 64	13.2	13.6	-0.01	13.1	12.6	0.01	13.2	13.1	0.00
65 - 69	14.6	16.9	-0.06	14.8	14.3	0.02	14.8	16.0	-0.03
70 - 74	15.7	19.2	-0.09	18.9	18.1	0.02	16.5	15.8	0.02
75 - 79	16.6	18.4	-0.05	16.9	19.1	-0.06	16.7	17.6	-0.02
80 - 84	12.4	10.5	0.06	11.7	12.0	-0.01	12.2	12.9	-0.02
85 - 89	5.7	3.9	0.08	5.0	5.4	-0.02	5.5	6.1	-0.03
90 - 94	1.5	0.9	0.05	1.2	1.4	-0.02	1.4	1.8	-0.03
Gender: female	40.5	43.5	-0.06	40.4	43.3	-0.06	41.2	41.7	-0.01
Medical history: General									
Acute respiratory disease	18.2	17.7	0.01	19.7	18.1	0.04	18.4	17.0	0.04
Attention deficit hyperactivity disorder	0.2	0.7	-0.07	<0.3	0.8	-0.09	0.2	0.4	-0.04
Chronic liver disease	0.5	0.3	0.04	0.3	0.2	0.02	0.5	<0.1	0.07
Chronic obstructive lung disease	8.7	8.7	0.00	8.4	8.7	-0.01	8.7	8.4	0.01
Crohn's disease	0.2	0.2	0.00	<0.3	0.2	0.00	0.2	0.3	-0.02
Dementia	3.2	3.9	-0.04	2.8	3.9	-0.06	3.2	3.2	0.00
Depressive disorder	10.4	11.6	-0.04	11.9	12.2	-0.01	10.9	11.6	-0.02
Gastroesophageal reflux disease	3.0	2.5	0.04	3.2	2.4	0.05	3.1	2.9	0.01
Gastrointestinal hemorrhage	1.0	1.3	-0.03	0.8	1.0	-0.03	0.9	0.7	0.03
Hyperlipidemia	30.4	34.4	-0.09	33.5	33.6	0.00	31.1	32.2	-0.02
Hypertensive disorder	54.7	64.4	-0.20	61.7	60.9	0.01	56.4	56.0	0.01
Lesion of liver	0.8	0.8	0.00	0.8	0.7	0.01	0.8	0.7	0.02
Obesity	8.2	8.4	-0.01	7.6	7.6	0.00	8.2	7.0	0.04
Osteoarthritis	14.1	16.9	-0.08	16.1	15.6	0.01	14.6	14.8	-0.01
Pneumonia	3.1	2.6	0.03	3.0	2.7	0.02	3.1	2.6	0.03
Psoriasis	1.4	1.6	-0.02	1.1	1.7	-0.05	1.4	1.7	-0.02
Renal impairment	9.5	7.1	0.09	7.5	8.2	-0.02	9.1	9.0	0.00
Rheumatoid arthritis	1.5	1.7	-0.02	1.3	1.6	-0.03	1.4	1.5	-0.01
Schizophrenia	0.2	0.2	-0.01	0.4	0.3	0.01	0.2	0.3	-0.01
Ulcerative colitis	0.3	0.2	0.03	0.3	<0.2	0.04	0.3	0.4	-0.01
Urinary tract infectious disease	6.1	6.1	0.00	6.0	6.2	-0.01	6.2	5.8	0.02
Visual system disorder	10.9	11.7	-0.03	12.3	11.4	0.03	11.2	12.2	-0.03
Medical history: Cardiovascular disease									
Atrial fibrillation	5.0	3.4	0.08	4.2	3.9	0.01	4.8	4.7	0.01
Cerebrovascular disease	9.6	10.7	-0.04	10.0	9.6	0.02	9.8	10.4	-0.02
Coronary arteriosclerosis	10.1	7.7	0.09	8.6	8.8	-0.01	9.6	10.6	-0.03
Heart disease	45.4	49.3	-0.08	46.9	45.0	0.04	45.7	45.3	0.01
Heart failure	11.4	13.2	-0.06	11.6	11.2	0.01	11.4	10.9	0.01
Ischemic heart disease	25.4	32.4	-0.16	28.5	26.9	0.04	26.1	25.5	0.01
Peripheral vascular disease	12.5	12.4	0.00	12.3	12.8	-0.02	12.4	12.2	0.00
Pulmonary embolism	0.9	0.5	0.05	0.9	0.6	0.03	0.9	1.3	-0.04
Venous thrombosis	2.0	1.6	0.03	1.3	1.6	-0.02	1.9	2.2	-0.02
Medical history: Neoplasms									
Hematologic neoplasm	0.5	0.3	0.03	0.6	0.4	0.03	0.6	0.3	0.04
Malignant lymphoma	0.4	0.3	0.01	0.5	0.3	0.03	0.4	<0.1	0.05
Malignant neoplasm of anorectum	0.2	0.2	0.01	<0.3	<0.2	0.03	0.3	<0.1	0.05
Malignant neoplastic disease	6.8	7.4	-0.02	6.3	7.3	-0.04	6.8	6.2	0.03
Malignant tumor of breast	0.6	1.3	-0.06	0.7	1.2	-0.05	0.7	0.9	-0.03
Malignant tumor of colon	0.5	0.4	0.01	0.4	0.3	0.00	0.5	0.2	0.06
Malignant tumor of lung	0.2	0.2	0.00	<0.3	0.3	-0.06	0.2	0.3	-0.01
Malignant tumor of urinary bladder	0.3	0.3	0.00	0.3	0.3	-0.01	0.3	0.2	0.02
Primary malignant neoplasm of prostate	1.1	1.4	-0.04	0.9	1.4	-0.05	1.1	1.5	-0.04
Medication use									
Agents acting on the renin-angiotensin system	77.3	73.7	0.08	76.0	74.6	0.03	77.0	77.4	-0.01
Antibacterials for systemic use	28.9	31.2	-0.05	30.4	30.9	-0.01	29.4	29.6	0.00
Antidepressants	12.5	11.4	0.03	11.5	11.6	0.00	12.3	11.5	0.02

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antiepileptics	6.6	4.4	0.10	4.0	4.9	-0.05	6.2	5.6	0.02
Antiinflammatory and antirheumatic products	54.9	59.0	-0.08	57.2	56.1	0.02	55.5	54.6	0.02
Antineoplastic agents	1.3	1.4	-0.01	1.1	1.4	-0.03	1.2	1.6	-0.03
Antipsoriatics	0.6	0.3	0.03	<0.3	0.2	-0.01	0.5	0.2	0.06
Antithrombotic agents	53.4	50.9	0.05	49.4	49.4	0.00	52.6	52.9	0.00
Beta blocking agents	61.9	59.0	0.06	62.9	60.6	0.05	61.8	61.0	0.02
Calcium channel blockers	38.6	36.9	0.04	37.7	37.8	0.00	38.5	39.1	-0.01
Diuretics	59.1	60.7	-0.03	62.7	60.2	0.05	59.8	59.7	0.00
Drugs for acid related disorders	43.9	38.8	0.10	42.0	41.1	0.02	43.3	44.9	-0.03
Drugs for obstructive airway diseases	20.5	19.2	0.03	18.8	19.0	0.00	20.1	19.1	0.03
Immunosuppressants	0.8	0.8	0.00	0.8	0.7	0.01	0.8	0.7	0.01
Lipid modifying agents	61.5	52.1	0.19	55.7	55.5	0.00	60.2	61.8	-0.03
Opioids	14.9	15.8	-0.02	14.1	15.5	-0.04	15.0	15.7	-0.02
Psycholeptics	11.8	13.4	-0.05	12.3	12.2	0.00	12.1	12.4	-0.01
Psychostimulants	0.3	0.7	-0.06	0.5	0.2	0.04	0.3	0.2	0.04

Supplementary Table 40: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the OptumDOD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	0.00	0.1	0.1	0.00	0.1	0.1	0.00
30 - 34	0.3	0.2	0.01	0.3	0.2	0.01	0.3	0.2	0.01
35 - 39	0.6	0.6	0.01	0.7	0.5	0.02	0.7	0.5	0.02
40 - 44	1.6	1.3	0.02	1.6	1.4	0.01	1.5	1.4	0.01
45 - 49	3.6	3.0	0.04	3.6	3.5	0.00	3.2	3.2	0.00
50 - 54	6.6	5.6	0.04	6.4	6.5	0.00	5.9	5.9	0.00
55 - 59	10.1	8.9	0.04	9.9	10.0	-0.01	9.2	9.2	0.00
60 - 64	12.7	11.7	0.03	12.5	12.5	0.00	12.0	12.0	0.00
65 - 69	16.6	17.8	-0.03	16.8	16.7	0.00	17.6	17.4	0.00
70 - 74	18.9	20.9	-0.05	19.1	19.9	-0.02	19.5	20.5	-0.03
75 - 79	14.2	15.6	-0.04	14.4	14.2	0.00	15.2	15.1	0.00
80 - 84	9.1	9.5	-0.01	9.2	9.0	0.01	9.6	9.3	0.01
85 - 89	5.1	4.6	0.02	4.8	4.7	0.00	4.8	4.7	0.00
90 - 94	0.4	0.3	0.02	0.4	0.3	0.02	0.5	0.3	0.02
Gender: female	47.3	44.2	0.06	46.7	47.2	-0.01	45.1	45.3	0.00
Medical history: General									
Acute respiratory disease	29.2	28.1	0.03	28.9	28.8	0.00	28.7	28.4	0.01
Attention deficit hyperactivity disorder	0.6	0.4	0.02	0.5	0.5	0.00	0.5	0.4	0.00
Chronic liver disease	4.0	3.7	0.02	3.8	3.8	0.00	3.8	3.8	0.00
Chronic obstructive lung disease	15.5	17.2	-0.04	15.8	15.6	0.00	16.9	16.7	0.01
Crohn's disease	0.4	0.3	0.02	0.4	0.3	0.02	0.4	0.3	0.02
Dementia	4.7	4.4	0.01	4.7	4.6	0.00	4.6	4.5	0.01
Depressive disorder	17.4	17.1	0.01	17.2	17.4	0.00	17.1	17.3	0.00
Gastroesophageal reflux disease	23.6	22.2	0.03	23.2	23.5	-0.01	22.8	22.7	0.00
Gastrointestinal hemorrhage	3.8	4.0	-0.01	3.8	3.9	-0.01	3.8	3.9	-0.01
Human immunodeficiency virus infection	0.3	0.2	0.02	0.3	0.3	0.01	0.3	0.2	0.01
Hypertensive disorder	88.1	87.4	0.02	87.9	87.7	0.00	87.9	87.6	0.01
Lesion of liver	1.5	1.9	-0.03	1.5	1.6	-0.01	1.7	1.8	-0.01
Obesity	23.3	23.4	0.00	23.5	23.6	0.00	23.7	23.5	0.00
Osteoarthritis	35.9	34.4	0.03	35.5	35.6	0.00	35.1	34.9	0.00
Pneumonia	6.3	7.2	-0.03	6.4	6.3	0.00	7.0	6.9	0.00
Psoriasis	1.8	1.6	0.01	1.7	1.7	0.00	1.7	1.6	0.01
Renal impairment	23.7	24.9	-0.03	24.0	23.6	0.01	25.1	24.5	0.01
Rheumatoid arthritis	2.5	2.5	0.00	2.5	2.6	-0.01	2.5	2.5	0.00
Schizophrenia	0.5	0.5	0.00	0.5	0.5	0.01	0.6	0.5	0.01
Ulcerative colitis	0.5	0.4	0.01	0.4	0.4	0.01	0.5	0.4	0.01
Urinary tract infectious disease	15.6	14.7	0.02	15.3	15.5	0.00	15.1	15.0	0.00
Viral hepatitis C	0.7	0.8	-0.01	0.7	0.8	-0.01	0.8	0.8	0.00
Visual system disorder	47.7	47.2	0.01	47.5	47.6	0.00	47.1	47.4	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	13.0	13.1	0.00	13.1	12.9	0.01	13.2	13.1	0.00
Coronary arteriosclerosis	38.4	40.0	-0.03	38.6	37.9	0.01	39.9	39.3	0.01
Heart disease	59.4	60.6	-0.02	59.4	58.7	0.01	60.7	60.0	0.01
Heart failure	14.7	16.0	-0.04	14.8	14.5	0.01	15.9	15.5	0.01
Ischemic heart disease	20.5	22.2	-0.04	20.8	20.5	0.01	21.9	21.7	0.01
Peripheral vascular disease	26.2	26.1	0.00	26.3	26.4	0.00	26.4	26.3	0.00
Pulmonary embolism	1.3	1.4	-0.01	1.4	1.4	0.00	1.4	1.4	0.00
Venous thrombosis	2.5	2.8	-0.02	2.6	2.6	0.00	2.7	2.8	-0.01
Medical history: Neoplasms									
Hematologic neoplasm	1.6	2.0	-0.03	1.6	1.7	-0.01	1.8	1.9	-0.01
Malignant neoplasm of anorectum	0.3	0.4	-0.01	0.3	0.3	0.00	0.4	0.4	0.00
Malignant neoplastic disease	14.3	15.1	-0.02	14.4	14.4	0.00	15.0	14.9	0.00
Malignant tumor of breast	2.2	2.1	0.00	2.2	2.3	0.00	2.2	2.2	0.00
Malignant tumor of colon	0.8	0.9	-0.01	0.9	0.9	0.00	0.9	0.9	0.00
Malignant tumor of lung	0.7	0.9	-0.03	0.7	0.7	0.00	0.9	0.9	0.00
Malignant tumor of urinary bladder	0.7	0.9	-0.02	0.8	0.8	0.00	0.9	0.9	0.00
Primary malignant neoplasm of prostate	3.2	3.1	0.00	3.2	3.1	0.01	3.2	3.1	0.01
Medication use									
Agents acting on the renin-angiotensin system	75.8	75.8	0.00	75.7	75.8	0.00	75.9	75.8	0.00
Antidepressants	31.6	30.3	0.03	31.4	31.5	0.00	30.9	30.8	0.00
Antiepileptics	22.2	21.9	0.01	22.1	22.3	-0.01	22.4	22.1	0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antiinflammatory and antirheumatic products	32.3	30.4	0.04	31.7	32.0	-0.01	30.7	31.0	-0.01
Antineoplastic agents	7.2	6.6	0.02	6.9	7.1	-0.01	6.8	6.8	0.00
Antipsoriatics	0.7	0.7	0.01	0.7	0.8	-0.01	0.6	0.7	-0.01
Antithrombotic agents	31.5	32.2	-0.01	32.2	32.1	0.00	32.2	32.1	0.00
Beta blocking agents	52.3	54.6	-0.05	52.5	52.0	0.01	54.1	53.7	0.01
Calcium channel blockers	33.6	34.2	-0.01	33.6	33.8	0.00	34.1	34.1	0.00
Diuretics	49.6	50.8	-0.02	49.6	49.3	0.01	50.8	50.4	0.01
Drugs for acid related disorders	36.2	35.0	0.03	35.7	36.1	-0.01	35.7	35.5	0.00
Drugs for obstructive airway diseases	43.9	41.5	0.05	43.2	43.8	-0.01	42.2	42.4	0.00
Immunosuppressants	3.3	2.8	0.03	3.1	3.1	0.00	3.1	2.9	0.01
Lipid modifying agents	82.6	81.1	0.04	82.4	82.5	0.00	81.3	81.6	-0.01
Opioids	33.2	33.5	-0.01	33.1	32.8	0.01	33.9	33.4	0.01
Psycholeptics	29.7	28.8	0.02	29.5	29.5	0.00	29.4	29.1	0.01
Psychostimulants	2.0	1.4	0.04	1.8	1.8	0.00	1.7	1.6	0.01

Supplementary Table 41: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the MDCR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
50 - 54	0.1	0.1	0.01	0.1	0.1	0.01	0.1	0.1	0.01
55 - 59	0.4	0.5	-0.01	0.4	0.5	-0.01	0.4	0.5	-0.01
60 - 64	1.5	1.3	0.02	1.5	1.4	0.01	1.5	1.4	0.01
65 - 69	22.1	19.8	0.06	21.8	22.0	-0.01	21.0	21.1	0.00
70 - 74	28.8	28.4	0.01	28.6	28.8	0.00	28.2	28.5	-0.01
75 - 79	22.1	23.3	-0.03	22.2	22.4	0.00	22.3	22.6	-0.01
80 - 84	15.0	16.4	-0.04	15.2	15.1	0.00	15.7	15.8	0.00
85 - 89	7.3	7.6	-0.01	7.4	7.4	0.00	7.6	7.6	0.00
90 - 94	2.3	2.2	0.00	2.3	1.9	0.03	2.5	2.1	0.03
95 - 99	0.4	0.3	0.02	0.4	0.3	0.02	0.5	0.3	0.03
Gender: female	44.1	42.6	0.03	43.4	43.6	0.00	42.5	42.7	0.00
Medical history: General									
Acute respiratory disease	25.4	24.4	0.03	24.9	24.6	0.01	25.7	25.1	0.01
Attention deficit hyperactivity disorder	0.1	0.1	0.01	0.1	0.2	-0.01	0.1	0.1	0.00
Chronic liver disease	2.7	2.3	0.03	2.7	2.6	0.01	2.6	2.5	0.00
Chronic obstructive lung disease	14.2	15.2	-0.03	14.4	14.2	0.01	15.7	15.2	0.01
Crohn's disease	0.3	0.3	0.01	0.3	0.3	0.01	0.3	0.3	0.01
Dementia	4.1	4.5	-0.02	4.3	4.3	0.00	4.6	4.6	0.00
Depressive disorder	8.6	8.2	0.02	8.7	9.0	-0.01	9.1	9.2	0.00
Gastroesophageal reflux disease	14.6	11.8	0.08	14.0	14.5	-0.02	13.3	13.9	-0.02
Gastrointestinal hemorrhage	4.2	4.6	-0.02	4.3	4.2	0.01	4.5	4.3	0.01
Hyperlipidemia	65.7	52.6	0.27	64.4	65.7	-0.03	60.6	62.0	-0.03
Hypertensive disorder	78.4	71.3	0.16	77.7	78.4	-0.02	76.2	76.7	-0.01
Lesion of liver	0.9	1.3	-0.03	1.0	1.2	-0.03	1.0	1.3	-0.03
Obesity	11.0	8.2	0.10	10.6	11.2	-0.02	9.9	10.5	-0.02
Osteoarthritis	34.6	30.1	0.10	34.0	34.0	0.00	32.7	33.0	-0.01
Pneumonia	6.6	8.3	-0.06	6.8	6.3	0.02	7.9	7.5	0.01
Psoriasis	1.6	1.4	0.02	1.5	1.8	-0.02	1.5	1.6	-0.01
Renal impairment	17.8	16.4	0.04	17.9	17.7	0.00	18.7	18.3	0.01
Rheumatoid arthritis	2.0	1.8	0.01	2.0	2.1	-0.01	2.0	2.1	-0.01
Schizophrenia	0.2	0.2	0.00	0.2	0.1	0.00	0.2	0.2	0.00
Ulcerative colitis	0.6	0.4	0.03	0.6	0.4	0.03	0.6	0.5	0.03
Urinary tract infectious disease	12.3	12.3	0.00	12.2	12.3	0.00	12.5	12.6	0.00
Viral hepatitis C	0.3	0.3	0.00	0.2	0.3	-0.01	0.2	0.3	-0.01
Visual system disorder	54.7	50.1	0.09	53.8	54.5	-0.01	52.0	52.5	-0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	16.7	16.4	0.01	16.8	16.3	0.01	17.6	16.8	0.02
Cerebrovascular disease	21.7	22.0	-0.01	21.8	21.3	0.01	21.8	21.3	0.01
Coronary arteriosclerosis	43.7	44.3	-0.01	43.4	44.2	-0.01	44.0	43.8	0.00
Heart disease	66.6	66.9	-0.01	66.0	66.4	-0.01	66.7	66.4	0.01
Heart failure	14.5	16.6	-0.06	14.7	14.1	0.01	16.4	15.3	0.03
Ischemic heart disease	19.4	21.8	-0.06	19.4	19.5	0.00	20.3	20.2	0.00
Peripheral vascular disease	22.2	20.0	0.06	21.8	22.1	-0.01	21.0	21.3	-0.01
Pulmonary embolism	1.2	1.3	0.00	1.2	1.3	-0.01	1.3	1.3	0.00
Venous thrombosis	2.7	3.0	-0.02	2.7	3.0	-0.02	2.9	3.2	-0.01
Medical history: Neoplasms									
Hematologic neoplasm	2.1	2.1	0.00	2.1	2.2	0.00	2.2	2.3	-0.01
Malignant lymphoma	1.1	1.0	0.01	1.1	1.1	0.00	1.2	1.1	0.01
Malignant neoplasm of anorectum	0.3	0.5	-0.02	0.3	0.3	0.00	0.4	0.4	0.00
Malignant neoplastic disease	21.1	20.4	0.02	21.0	20.9	0.00	20.8	21.0	0.00
Malignant tumor of breast	2.8	2.6	0.01	2.8	2.8	0.00	2.6	2.7	-0.01
Malignant tumor of colon	1.0	1.1	0.00	1.1	0.8	0.03	1.2	0.9	0.02
Malignant tumor of lung	0.8	1.1	-0.03	0.9	0.9	0.00	1.0	1.0	0.00
Malignant tumor of urinary bladder	1.5	1.4	0.01	1.6	1.4	0.01	1.6	1.4	0.01
Primary malignant neoplasm of prostate	5.0	5.3	-0.01	5.0	5.2	-0.01	5.0	5.3	-0.01
Medication use									
Agents acting on the renin-angiotensin system	77.1	74.3	0.06	77.0	76.6	0.01	76.9	76.3	0.01
Antibacterials for systemic use	66.1	65.0	0.02	65.4	65.3	0.00	65.7	65.7	0.00
Antidepressants	26.6	27.3	-0.02	26.8	26.5	0.01	27.4	27.4	0.00
Antiepileptics	17.7	17.3	0.01	17.7	18.1	-0.01	18.3	18.4	0.00
Antiinflammatory and antirheumatic products	29.5	27.6	0.04	28.9	29.0	0.00	27.9	28.2	-0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antineoplastic agents	9.3	9.6	-0.01	9.3	9.1	0.01	9.2	9.0	0.01
Antipsoriatics	0.9	0.8	0.01	0.8	1.0	-0.02	0.8	0.9	-0.01
Antithrombotic agents	37.2	38.5	-0.03	37.5	37.1	0.01	38.9	38.2	0.02
Beta blocking agents	60.9	61.0	0.00	61.0	60.7	0.01	61.9	61.6	0.00
Calcium channel blockers	38.4	37.1	0.03	38.4	37.9	0.01	38.1	37.7	0.01
Diuretics	54.1	56.7	-0.05	54.4	53.5	0.02	55.9	55.1	0.02
Drugs for acid related disorders	37.7	36.7	0.02	36.8	36.9	0.00	36.9	36.9	0.00
Drugs for obstructive airway diseases	44.4	41.9	0.05	44.1	44.0	0.00	44.0	44.0	0.00
Immunosuppressants	3.5	2.9	0.04	3.5	3.4	0.00	3.5	3.3	0.01
Lipid modifying agents	84.6	80.2	0.12	84.1	84.2	0.00	83.0	83.3	-0.01
Opioids	32.1	32.4	-0.01	32.0	31.7	0.01	33.0	32.5	0.01
Psycholeptics	29.3	29.0	0.01	29.2	28.9	0.01	29.5	29.3	0.00
Psychostimulants	1.5	1.3	0.02	1.4	1.4	0.01	1.5	1.4	0.01

Supplementary Table 42: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the MDCD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.2	0.3	-0.03	0.1	0.2	-0.02	0.1	0.3	-0.03
25 - 29	0.5	0.7	-0.02	0.5	0.6	-0.01	0.7	0.7	0.00
30 - 34	1.6	1.9	-0.02	1.6	1.8	-0.02	1.7	1.8	-0.01
35 - 39	4.2	4.1	0.00	4.3	3.9	0.02	4.3	4.0	0.01
40 - 44	7.0	6.8	0.01	7.1	6.8	0.01	6.9	6.8	0.00
45 - 49	12.1	11.9	0.01	12.1	11.6	0.01	12.2	11.8	0.01
50 - 54	16.3	17.0	-0.02	16.3	17.0	-0.02	16.6	17.1	-0.01
55 - 59	21.2	21.4	0.00	21.2	21.1	0.00	21.5	21.4	0.00
60 - 64	19.4	20.2	-0.02	19.5	19.7	0.00	19.6	19.9	-0.01
70 - 74	4.2	3.9	0.02	4.2	4.4	-0.01	3.8	4.1	-0.01
75 - 79	3.2	2.4	0.05	3.1	2.5	0.04	2.9	2.4	0.03
80 - 84	2.2	1.6	0.04	2.2	1.9	0.02	2.1	1.7	0.03
85 - 89	1.1	0.9	0.01	1.1	1.0	0.01	1.0	1.0	0.00
90 - 94	<0.1	0.1	0.00	<0.1	0.1	0.01	<0.1	0.1	0.00
Gender: female	61.2	58.4	0.06	60.7	60.5	0.00	59.0	59.2	0.00
Race									
Black or African American	21.9	25.5	-0.08	22.3	22.1	0.01	24.3	24.4	0.00
White	62.5	58.0	0.09	62.0	63.0	-0.02	58.8	59.7	-0.02
Ethnicity									
Hispanic or Latino	2.0	2.1	-0.01	2.0	2.2	-0.01	1.9	2.1	-0.01
Medical history: General									
Acute respiratory disease	39.8	40.7	-0.02	39.5	40.1	-0.01	40.0	40.6	-0.01
Attention deficit hyperactivity disorder	1.2	1.2	0.00	1.1	1.5	-0.03	1.1	1.3	-0.02
Chronic liver disease	5.8	7.0	-0.05	5.8	6.1	-0.02	6.4	6.8	-0.01
Chronic obstructive lung disease	32.3	31.2	0.02	32.0	31.8	0.00	31.9	31.5	0.01
Crohn's disease	0.3	0.4	-0.01	0.3	0.3	0.00	0.3	0.4	-0.01
Dementia	3.9	3.2	0.04	3.7	3.5	0.01	3.7	3.3	0.02
Depressive disorder	36.9	36.0	0.02	36.5	37.7	-0.02	35.5	36.6	-0.02
Gastroesophageal reflux disease	32.2	30.7	0.03	31.7	32.8	-0.02	30.3	31.5	-0.03
Gastrointestinal hemorrhage	4.9	5.2	-0.01	4.8	4.7	0.00	4.8	5.1	-0.01
Human immunodeficiency virus infection	0.7	0.6	0.01	0.6	0.4	0.03	0.7	0.5	0.03
Hyperlipidemia	75.6	72.4	0.07	74.9	75.4	-0.01	74.9	75.4	-0.01
Hypertensive disorder	87.1	86.4	0.02	87.0	86.4	0.02	87.1	86.4	0.02
Lesion of liver	1.8	2.5	-0.04	1.8	2.1	-0.02	2.2	2.4	-0.01
Obesity	36.3	35.4	0.02	36.1	36.4	-0.01	35.7	35.9	0.00
Osteoarthritis	44.9	42.7	0.04	44.3	45.2	-0.02	43.6	43.7	0.00
Pneumonia	10.0	10.4	-0.01	9.9	9.4	0.02	10.7	10.1	0.02
Psoriasis	1.6	1.3	0.02	1.5	1.6	0.00	1.6	1.4	0.02
Renal impairment	15.2	15.7	-0.01	15.3	15.4	0.00	15.3	15.5	-0.01
Rheumatoid arthritis	2.7	2.5	0.01	2.6	2.3	0.02	2.6	2.5	0.01
Schizophrenia	5.0	5.3	-0.01	5.0	4.9	0.00	5.4	5.1	0.01
Ulcerative colitis	0.2	0.3	-0.01	0.3	0.3	0.00	0.2	0.3	-0.01
Urinary tract infectious disease	14.5	15.4	-0.03	14.2	15.0	-0.02	14.7	15.3	-0.02
Viral hepatitis C	2.6	3.5	-0.05	2.7	2.9	-0.02	3.1	3.3	-0.01
Visual system disorder	46.6	43.6	0.06	46.1	47.8	-0.03	43.0	45.1	-0.04
Medical history: Cardiovascular disease									
Atrial fibrillation	7.5	7.6	-0.01	7.5	7.3	0.01	7.6	7.5	0.00
Cerebrovascular disease	13.5	14.6	-0.03	13.5	13.8	-0.01	14.0	14.4	-0.01
Coronary arteriosclerosis	34.0	33.1	0.02	33.9	33.6	0.01	33.4	33.2	0.00
Heart disease	56.9	57.8	-0.02	56.9	57.1	0.00	57.3	57.5	0.00
Heart failure	17.7	19.3	-0.04	17.8	18.2	-0.01	18.8	19.0	0.00
Ischemic heart disease	23.2	23.8	-0.01	23.1	23.2	0.00	23.8	23.6	0.00
Peripheral vascular disease	22.7	21.4	0.03	22.1	21.8	0.01	22.1	21.8	0.01
Pulmonary embolism	1.9	2.0	0.00	1.9	1.9	0.00	1.9	1.9	0.00
Venous thrombosis	3.0	3.2	-0.01	2.9	3.1	-0.01	3.1	3.2	0.00
Medical history: Neoplasms									
Hematologic neoplasm	1.3	1.4	-0.01	1.2	1.3	-0.01	1.2	1.3	-0.01
Malignant lymphoma	0.7	0.5	0.02	0.7	0.4	0.03	0.7	0.5	0.03
Malignant neoplasm of anorectum	0.2	0.4	-0.02	0.3	0.3	-0.01	0.2	0.3	-0.02
Malignant neoplastic disease	8.4	8.4	0.00	8.5	8.4	0.00	8.1	8.4	-0.01
Malignant tumor of breast	2.0	1.7	0.02	2.1	1.9	0.01	2.1	1.9	0.01

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant tumor of colon	0.6	0.6	0.00	0.6	0.6	0.00	0.6	0.6	-0.01
Malignant tumor of lung	0.7	0.7	0.00	0.7	0.6	0.01	0.8	0.7	0.01
Malignant tumor of urinary bladder	0.2	0.3	-0.02	0.2	0.3	-0.02	0.3	0.3	-0.01
Primary malignant neoplasm of prostate	0.8	0.7	0.01	0.8	0.7	0.01	0.9	0.7	0.02
Medication use									
Agents acting on the renin-angiotensin system	71.2	71.0	0.00	71.2	70.8	0.01	71.2	71.0	0.01
Antibacterials for systemic use	71.2	70.6	0.01	70.7	71.2	-0.01	70.4	70.9	-0.01
Antidepressants	58.0	55.0	0.06	57.2	58.3	-0.02	55.4	56.2	-0.02
Antiepileptics	48.8	45.8	0.06	48.0	48.6	-0.01	47.0	46.8	0.00
Antiinflammatory and antirheumatic products	59.9	58.8	0.02	59.7	60.2	-0.01	59.6	59.3	0.00
Antineoplastic agents	5.5	4.9	0.03	5.5	5.3	0.01	5.3	5.0	0.01
Antipsoriatics	0.7	0.6	0.01	0.6	0.8	-0.02	0.6	0.7	-0.01
Antithrombotic agents	44.8	43.2	0.03	45.0	44.9	0.00	44.1	43.7	0.01
Beta blocking agents	51.4	52.6	-0.03	51.6	51.8	0.00	51.5	52.4	-0.02
Calcium channel blockers	32.5	33.7	-0.02	32.4	32.8	-0.01	32.4	32.8	-0.01
Diuretics	54.6	56.8	-0.04	54.9	54.1	0.01	56.4	55.9	0.01
Drugs for acid related disorders	58.2	54.8	0.07	57.4	58.4	-0.02	54.9	56.2	-0.03
Drugs for obstructive airway diseases	63.5	60.9	0.05	62.8	63.8	-0.02	61.6	62.0	-0.01
Immunosuppressants	3.2	2.6	0.04	3.1	2.8	0.02	3.0	2.7	0.02
Lipid modifying agents	78.5	74.9	0.09	77.9	78.9	-0.02	75.8	76.4	-0.01
Opioids	53.5	54.6	-0.02	53.4	52.7	0.01	54.0	54.1	0.00
Psycholeptics	54.1	53.0	0.02	53.7	54.2	-0.01	53.2	53.5	-0.01
Psychostimulants	5.1	4.0	0.05	5.0	4.5	0.03	4.9	4.2	0.03

Supplementary Table 43: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the IMRD data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
40 - 44	0.9	1.2	-0.02	<1.2	1.0	-0.03	0.8	2.7	-0.14
45 - 49	2.6	2.0	0.04	3.0	1.6	0.09	2.7	0.9	0.13
50 - 54	5.7	5.8	0.00	6.4	7.2	-0.03	6.1	5.0	0.05
55 - 59	9.9	9.7	0.01	11.1	9.6	0.05	10.2	10.0	0.01
60 - 64	14.0	14.0	0.00	13.5	13.3	0.01	13.7	14.8	-0.03
65 - 69	16.9	19.4	-0.07	20.2	16.5	0.10	17.8	22.6	-0.12
70 - 74	17.1	19.6	-0.06	18.0	19.3	-0.03	17.1	20.6	-0.09
75 - 79	15.4	14.2	0.03	12.3	15.7	-0.10	14.6	10.2	0.13
80 - 84	10.5	9.3	0.04	8.9	9.6	-0.03	10.6	6.8	0.14
85 - 89	4.9	3.5	0.07	3.9	4.3	-0.02	4.3	5.8	-0.07
90 - 94	1.7	1.2	0.04	1.5	1.9	-0.03	1.6	0.6	0.10
Gender: female	31.5	34.8	-0.07	36.7	35.7	0.02	32.2	34.7	-0.05
Race									
White	28.6	32.7	-0.09	38.4	36.2	0.05	31.5	34.1	-0.06
Asian Indian	0.4	0.8	-0.05	<1.2	0.5	0.03	0.4	<0.2	0.04
Chinese	<0.1	<0.3	-0.01	<1.2	<0.3	0.06	<0.1	<0.2	0.02
Pakistani	0.2	<0.3	0.01	0.2	0.9	-0.09	0.2	0.9	-0.09
Black	0.2	<0.3	-0.01	0.2	0.9	-0.10	0.2	0.9	-0.10
European	0.1	<0.3	0.00	<0.1	<0.2	0.02	<0.1	<0.2	0.02
Middle Eastern or North African	<0.1	<0.3	-0.01	<0.1	0.9	-0.12	<0.1	0.9	-0.12
Medical history: General									
Acute respiratory disease	6.3	7.6	-0.05	10.1	6.8	0.12	6.9	4.0	0.13
Chronic obstructive lung disease	3.4	2.2	0.07	3.7	2.2	0.09	3.4	1.6	0.12
Dementia	0.6	<0.3	0.06	<1.2	<0.3	0.03	0.6	<0.2	0.08
Depressive disorder	1.5	2.7	-0.08	1.3	0.7	0.06	1.3	0.7	0.06
Gastroesophageal reflux disease	0.3	0.4	-0.01	<1.2	<0.3	0.03	0.5	<0.2	0.08
Gastrointestinal hemorrhage	0.7	1.3	-0.06	<1.2	1.3	-0.06	0.6	0.8	-0.02
Hyperlipidemia	0.6	2.1	-0.13	<1.2	<0.3	0.10	0.6	<0.2	0.07
Hypertensive disorder	1.8	4.0	-0.13	2.5	2.6	-0.01	1.9	5.0	-0.17
Obesity	0.4	1.3	-0.10	2.0	0.4	0.15	0.8	<0.2	0.08
Osteoarthritis	2.5	3.9	-0.08	3.0	2.6	0.02	2.5	1.3	0.09
Pneumonia	0.6	0.4	0.03	<1.2	<0.3	0.03	0.7	<0.2	0.09
Psoriasis	0.6	0.4	0.03	<1.2	0.4	0.01	0.7	<0.2	0.09
Renal impairment	5.6	6.0	-0.02	5.2	6.6	-0.06	5.3	4.3	0.05
Ulcerative colitis	<0.1	<0.3	-0.05	<0.1	2.3	-0.21	<0.1	2.3	-0.21
Urinary tract infectious disease	2.5	2.4	0.01	3.0	2.6	0.02	2.7	1.2	0.11
Visual system disorder	12.0	12.4	-0.01	13.3	13.0	0.01	11.9	20.5	-0.24
Medical history: Cardiovascular disease									
Atrial fibrillation	2.2	2.6	-0.02	1.2	2.4	-0.09	1.9	1.4	0.04
Cerebrovascular disease	3.3	3.7	-0.02	4.2	3.2	0.05	3.2	1.6	0.10
Coronary arteriosclerosis	0.8	1.0	-0.02	<1.2	1.1	-0.06	0.7	2.5	-0.15
Heart disease	9.8	15.1	-0.16	7.4	9.3	-0.07	9.3	8.7	0.02
Heart failure	1.9	2.9	-0.07	<1.2	1.2	-0.05	1.6	0.8	0.08
Ischemic heart disease	5.4	10.4	-0.19	4.4	5.8	-0.06	5.2	6.0	-0.04
Peripheral vascular disease	0.7	1.5	-0.07	<1.2	0.6	0.02	0.7	0.5	0.02
Pulmonary embolism	<0.1	<0.3	0.01	<0.1	<0.2	0.03	<0.1	<0.2	0.03
Venous thrombosis	0.4	0.6	-0.03	0.3	<0.2	0.02	0.3	<0.2	0.02
Medical history: Neoplasms									
Malignant lymphoma	<0.1	<0.3	-0.01	<0.1	<0.2	0.01	<0.1	<0.2	0.01
Malignant neoplastic disease	1.8	2.1	-0.02	1.5	1.8	-0.03	1.8	1.2	0.05
Malignant tumor of breast	<0.1	<0.3	-0.01	<1.2	<0.3	0.06	<0.1	<0.2	0.03
Malignant tumor of colon	<0.1	<0.3	-0.01	<0.1	<0.2	0.01	<0.1	<0.2	0.01
Malignant tumor of lung	0.1	<0.3	0.01	0.1	0.3	-0.04	0.1	0.3	-0.04
Malignant tumor of urinary bladder	0.1	<0.3	0.00	<1.2	<0.3	0.07	<0.1	<0.2	0.03
Medication use									
Agents acting on the renin-angiotensin system	77.2	68.5	0.20	75.6	77.2	-0.04	76.5	75.1	0.03
Antibacterials for systemic use	53.2	50.8	0.05	53.4	51.7	0.04	53.3	51.9	0.03
Antidepressants	27.7	21.9	0.13	29.1	27.2	0.04	27.0	24.4	0.06
Antiepileptics	10.7	6.7	0.14	8.6	8.3	0.01	9.9	6.9	0.11
Antiinflammatory and antirheumatic products	25.1	27.6	-0.06	23.4	25.4	-0.05	24.7	20.3	0.10
Antineoplastic agents	1.5	1.0	0.05	<1.2	0.8	0.01	1.4	0.4	0.10

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antipsoriaties	1.6	1.8	-0.01	2.5	2.5	0.00	1.8	2.0	-0.01
Antithrombotic agents	90.3	88.1	0.07	89.2	89.2	0.00	89.9	89.4	0.02
Beta blocking agents	58.1	51.5	0.13	54.4	56.5	-0.04	58.2	54.5	0.07
Calcium channel blockers	40.6	40.9	0.00	42.9	39.4	0.07	41.1	37.4	0.07
Diuretics	41.8	47.6	-0.12	47.5	45.8	0.04	42.7	35.8	0.14
Drugs for acid related disorders	56.1	44.5	0.23	54.7	53.7	0.02	55.7	55.9	0.00
Drugs for obstructive airway diseases	25.2	21.5	0.09	26.8	24.2	0.06	24.9	26.6	-0.04
Immunosuppressants	1.6	1.2	0.04	1.7	1.6	0.01	1.5	3.1	-0.11
Lipid modifying agents	93.4	84.2	0.29	94.8	94.5	0.01	93.7	93.9	0.00
Opioids	18.9	24.2	-0.13	20.4	21.6	-0.03	19.1	21.0	-0.05
Psycholeptics	16.5	17.8	-0.04	17.0	16.3	0.02	16.6	20.9	-0.11

Supplementary Table 44: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the Open Claims data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
20 - 24	0.1	0.1	0.00	0.1	0.1	0.00	0.1	0.1	0.00
25 - 29	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	0.00
30 - 34	0.4	0.4	0.00	0.4	0.4	0.00	0.4	0.4	0.00
35 - 39	0.9	0.9	0.00	0.9	0.9	0.01	0.9	0.9	0.01
40 - 44	2.0	2.0	0.00	2.0	1.9	0.01	2.0	2.0	0.00
45 - 49	4.2	4.1	0.01	4.2	4.2	0.00	4.1	4.1	0.00
50 - 54	7.7	7.3	0.01	7.7	7.7	0.00	7.4	7.5	-0.01
55 - 59	11.8	11.3	0.02	11.8	11.9	0.00	11.5	11.4	0.00
60 - 64	14.9	14.2	0.02	14.4	14.3	0.00	14.4	14.3	0.00
65 - 69	16.6	17.3	-0.02	16.6	16.7	0.00	17.0	17.1	0.00
70 - 74	15.5	16.4	-0.02	15.6	15.3	0.01	16.3	16.1	0.01
75 - 79	17.4	18.1	-0.02	17.4	17.6	0.00	17.7	17.9	0.00
80 - 84	8.0	7.5	0.02	7.9	8.0	0.00	7.6	7.7	0.00
85 - 89	0.2	0.2	0.00	0.2	0.1	0.01	0.3	0.2	0.01
Gender: female	48.6	44.9	0.07	48.1	48.4	0.00	48.1	48.4	0.00
Medical history: General									
Acute respiratory disease	17.7	16.8	0.02	17.5	17.6	0.00	17.3	17.2	0.00
Attention deficit hyperactivity disorder	0.3	0.3	0.00	0.3	0.3	0.00	0.3	0.3	0.00
Chronic liver disease	1.9	1.8	0.01	1.9	1.9	0.00	1.9	1.9	0.00
Chronic obstructive lung disease	10.2	11.1	-0.03	10.2	10.3	0.00	10.8	10.8	0.00
Crohn's disease	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	-0.01
Dementia	2.2	2.0	0.02	2.2	2.2	0.00	2.1	2.1	0.00
Depressive disorder	8.8	8.8	0.00	9.0	8.8	0.00	9.0	8.8	0.00
Gastroesophageal reflux disease	11.4	10.4	0.03	11.2	11.4	0.00	10.9	10.8	0.00
Gastrointestinal hemorrhage	2.4	2.3	0.01	2.4	2.4	-0.01	2.4	2.4	0.00
Human immunodeficiency virus infection	0.3	0.2	0.01	0.3	0.3	0.01	0.3	0.3	0.01
Hyperlipidemia	54.4	50.1	0.09	53.9	54.2	-0.01	51.4	51.6	0.00
Hypertensive disorder	63.9	61.3	0.05	63.5	63.8	-0.01	62.2	62.3	0.00
Lesion of liver	1.0	1.1	-0.01	1.0	1.0	0.00	1.0	1.1	0.00
Obesity	11.4	11.2	0.01	11.3	11.4	0.00	11.3	11.4	0.00
Osteoarthritis	22.0	20.4	0.04	21.5	21.7	0.00	21.1	21.1	0.00
Pneumonia	4.2	4.6	-0.02	4.2	4.3	0.00	4.5	4.5	0.00
Psoriasis	1.0	0.9	0.01	1.0	1.0	0.00	1.0	1.0	0.00
Renal impairment	12.9	13.3	-0.01	12.9	13.1	-0.01	13.3	13.3	0.00
Rheumatoid arthritis	1.6	1.4	0.02	1.6	1.6	0.00	1.5	1.5	0.00
Schizophrenia	0.5	0.5	0.00	0.5	0.5	0.00	0.5	0.5	0.00
Ulcerative colitis	0.3	0.2	0.01	0.3	0.2	0.01	0.3	0.2	0.01
Urinary tract infectious disease	8.7	7.9	0.03	8.4	8.4	0.00	8.2	8.1	0.01
Viral hepatitis C	0.5	0.5	0.00	0.5	0.5	0.00	0.5	0.5	0.00
Visual system disorder	24.9	23.4	0.04	24.1	23.9	0.00	24.1	23.9	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	8.8	8.9	0.00	8.8	8.9	0.00	9.0	8.8	0.00
Cerebrovascular disease	10.1	9.5	0.02	10.1	10.1	0.00	9.9	9.9	0.00
Coronary arteriosclerosis	25.3	25.4	0.00	25.3	25.4	0.00	25.3	25.4	0.00
Heart disease	42.6	42.3	0.00	42.4	42.5	0.00	42.6	42.4	0.00
Heart failure	9.6	10.2	-0.02	9.6	9.6	0.00	10.1	9.9	0.01
Ischemic heart disease	12.1	12.5	-0.01	12.1	12.2	0.00	12.5	12.4	0.00
Peripheral vascular disease	13.9	14.1	0.00	13.9	13.6	0.01	14.1	14.0	0.00
Pulmonary embolism	0.9	0.9	0.00	0.9	1.0	0.00	0.9	1.0	0.00
Venous thrombosis	1.6	1.6	0.00	1.6	1.6	0.00	1.6	1.6	0.00
Medical history: Neoplasms									
Hematologic neoplasm	1.1	1.2	-0.01	1.1	1.1	0.00	1.2	1.1	0.00
Malignant lymphoma	0.6	0.6	-0.01	0.6	0.6	0.00	0.6	0.6	0.00
Malignant neoplasm of anorectum	0.2	0.2	0.00	0.2	0.2	0.00	0.2	0.2	0.00
Malignant neoplastic disease	9.3	9.4	0.00	9.4	9.3	0.00	9.6	9.5	0.00
Malignant tumor of breast	1.5	1.4	0.01	1.6	1.5	0.00	1.5	1.4	0.00
Malignant tumor of colon	0.5	0.5	0.00	0.5	0.5	0.00	0.5	0.5	0.00
Malignant tumor of lung	0.5	0.6	-0.01	0.5	0.5	-0.01	0.5	0.5	-0.01
Primary malignant neoplasm of prostate	1.9	1.9	0.00	1.9	1.9	0.00	1.9	1.9	0.00
Medication use									
Agents acting on the renin-angiotensin system	73.7	73.2	0.01	73.6	73.4	0.00	73.5	73.4	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antibacterials for systemic use	62.5	60.6	0.04	62.2	62.4	0.00	61.4	61.2	0.00
Antidepressants	32.9	32.5	0.01	32.6	33.1	-0.01	32.6	33.1	-0.01
Antiepileptics	25.3	25.2	0.00	25.1	25.0	0.00	25.1	25.0	0.00
Antiinflammatory and antirheumatic products	40.2	37.8	0.05	39.7	39.6	0.00	38.9	38.5	0.01
Antineoplastic agents	6.3	5.4	0.04	6.1	6.0	0.00	5.9	5.6	0.01
Antipsoriatics	0.9	0.8	0.02	0.9	0.9	0.00	0.8	0.8	0.00
Antithrombotic agents	37.2	36.5	0.01	37.0	36.9	0.00	37.2	36.6	0.01
Beta blocking agents	53.2	54.3	-0.02	53.2	53.0	0.00	54.5	53.8	0.01
Calcium channel blockers	34.0	33.6	0.01	33.9	33.7	0.00	34.1	33.5	0.01
Diuretics	47.8	48.5	-0.01	47.8	47.5	0.01	48.7	48.2	0.01
Drugs for acid related disorders	43.8	40.9	0.06	43.2	43.4	0.00	42.3	42.0	0.01
Drugs for obstructive airway diseases	43.9	40.7	0.06	43.3	43.7	-0.01	42.0	42.1	0.00
Immunosuppressants	3.7	2.9	0.05	3.5	3.5	0.00	3.3	3.1	0.01
Lipid modifying agents	79.9	77.8	0.05	78.5	78.4	0.00	78.5	78.4	0.00
Opioids	31.6	31.4	0.00	31.4	31.3	0.00	31.8	31.5	0.01
Psycholeptics	28.6	27.9	0.02	28.3	28.6	-0.01	28.3	28.2	0.00
Psychostimulants	2.5	2.2	0.02	2.4	2.5	-0.01	2.2	2.3	-0.01

Supplementary Table 45: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the OptumEHR data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
25 - 29	0.1	0.1	0.00	0.1	0.1	-0.01	0.1	0.1	-0.01
30 - 34	0.3	0.3	-0.01	0.3	0.3	-0.01	0.3	0.3	-0.01
35 - 39	1.0	0.9	0.01	1.0	1.0	0.00	1.1	0.9	0.01
40 - 44	2.2	2.0	0.01	2.3	2.1	0.01	2.2	2.0	0.01
45 - 49	5.1	4.6	0.02	5.1	5.0	0.01	4.8	4.7	0.00
50 - 54	8.9	8.2	0.02	8.8	8.8	0.00	8.4	8.4	0.00
55 - 59	13.5	12.6	0.03	13.6	13.5	0.00	12.9	12.9	0.00
60 - 64	16.4	15.6	0.02	16.3	16.5	-0.01	15.8	15.8	0.00
65 - 69	16.7	16.3	0.01	16.5	17.0	-0.01	16.2	16.5	-0.01
70 - 74	14.3	15.4	-0.03	14.4	14.4	0.00	14.4	14.4	0.00
75 - 79	11.6	13.2	-0.05	11.7	11.5	0.01	12.6	12.7	0.00
80 - 84	7.6	8.7	-0.04	7.7	7.6	0.00	7.7	7.6	0.00
85 - 89	2.3	2.0	0.02	2.3	2.2	0.01	2.2	2.0	0.01
Gender: female	43.2	39.3	0.08	42.6	43.2	-0.01	40.4	40.6	-0.01
Race									
Asian	1.9	1.7	0.02	1.9	1.9	0.00	1.7	1.8	0.00
Black or African American	9.5	8.0	0.05	9.4	9.5	-0.01	8.4	8.5	0.00
White	82.3	84.5	-0.06	82.6	82.5	0.00	84.0	83.8	0.01
Ethnicity									
Hispanic or Latino	4.8	4.9	0.00	4.8	4.9	-0.01	4.6	4.9	-0.01
Not Hispanic or Latino	87.8	88.4	-0.02	88.1	88.1	0.00	88.6	88.3	0.01
Medical history: General									
Acute respiratory disease	20.0	18.1	0.05	19.5	19.8	-0.01	18.8	18.7	0.00
Attention deficit hyperactivity disorder	0.4	0.4	0.00	0.4	0.4	-0.01	0.4	0.4	-0.01
Chronic liver disease	3.1	3.1	0.00	3.0	3.0	0.00	3.1	3.1	0.00
Chronic obstructive lung disease	11.5	12.1	-0.02	11.4	11.3	0.00	12.0	11.9	0.00
Crohn's disease	0.3	0.2	0.00	0.3	0.2	0.00	0.3	0.2	0.00
Dementia	2.1	2.2	-0.01	2.1	2.0	0.01	2.4	2.1	0.02
Depressive disorder	15.0	15.1	0.00	15.0	15.1	0.00	15.0	15.2	-0.01
Gastroesophageal reflux disease	21.8	19.8	0.05	21.0	21.3	-0.01	20.7	20.4	0.01
Gastrointestinal hemorrhage	2.2	2.2	0.00	2.2	2.1	0.00	2.1	2.2	-0.01
Human immunodeficiency virus infection	0.2	0.2	0.01	0.2	0.2	0.00	0.2	0.2	0.00
Hyperlipidemia	77.3	73.9	0.08	76.5	77.1	-0.02	74.6	75.0	-0.01
Hypertensive disorder	79.2	76.8	0.06	78.7	79.1	-0.01	77.4	77.6	0.00
Lesion of liver	1.0	1.2	-0.01	1.0	1.1	0.00	1.1	1.2	0.00
Obesity	25.8	23.7	0.05	25.5	25.6	0.00	24.5	24.4	0.00
Osteoarthritis	22.6	22.2	0.01	22.3	22.4	0.00	22.4	22.4	0.00
Pneumonia	3.1	3.8	-0.04	3.2	3.3	0.00	3.7	3.7	0.00
Psoriasis	1.5	1.5	0.00	1.5	1.5	0.00	1.4	1.5	-0.01
Rheumatoid arthritis	1.5	1.5	0.00	1.4	1.5	0.00	1.4	1.5	-0.01
Schizophrenia	0.3	0.3	0.00	0.3	0.3	0.00	0.4	0.3	0.01
Ulcerative colitis	0.3	0.3	0.00	0.3	0.3	-0.01	0.3	0.3	0.00
Urinary tract infectious disease	6.9	6.7	0.00	6.8	6.8	0.00	6.9	6.8	0.01
Viral hepatitis C	0.6	0.7	-0.01	0.6	0.6	0.00	0.6	0.7	-0.01
Visual system disorder	15.2	18.0	-0.07	15.4	15.1	0.01	17.2	17.1	0.00
Medical history: Cardiovascular disease									
Atrial fibrillation	10.7	10.7	0.00	10.7	10.5	0.01	10.9	10.7	0.01
Cerebrovascular disease	11.4	11.5	0.00	11.2	11.4	-0.01	11.4	11.5	0.00
Coronary arteriosclerosis	42.6	42.8	0.00	42.4	42.6	0.00	42.4	42.8	-0.01
Heart disease	59.5	59.1	0.01	59.2	59.2	0.00	59.2	59.1	0.00
Heart failure	9.2	10.3	-0.04	9.1	9.3	-0.01	10.2	10.0	0.00
Ischemic heart disease	19.2	19.6	-0.01	19.1	19.1	0.00	19.5	19.5	0.00
Peripheral vascular disease	17.7	17.9	0.00	17.5	17.5	0.00	17.9	17.8	0.00
Pulmonary embolism	0.9	1.1	-0.02	0.9	1.0	-0.01	0.9	1.1	-0.01
Venous thrombosis	1.9	1.9	0.00	1.9	1.7	0.02	2.1	1.9	0.02
Medical history: Neoplasms									
Hematologic neoplasm	1.2	1.2	0.00	1.1	1.2	0.00	1.2	1.2	0.00
Malignant lymphoma	0.7	0.7	0.00	0.7	0.7	0.00	0.7	0.7	0.00
Malignant neoplasm of anorectum	0.1	0.2	-0.01	0.2	0.2	0.00	0.2	0.2	0.00
Malignant neoplastic disease	9.5	9.9	-0.01	9.4	9.5	0.00	9.6	9.8	-0.01
Malignant tumor of breast	1.5	1.3	0.02	1.5	1.5	0.00	1.4	1.4	0.00

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Malignant tumor of colon	0.4	0.6	-0.02	0.4	0.5	-0.01	0.5	0.5	-0.01
Malignant tumor of lung	0.5	0.5	0.00	0.4	0.5	0.00	0.4	0.5	0.00
Malignant tumor of urinary bladder	0.5	0.6	-0.01	0.5	0.5	0.01	0.6	0.6	0.01
Primary malignant neoplasm of prostate	2.0	2.2	-0.02	2.0	2.1	-0.01	2.1	2.2	-0.01
Medication use									
Agents acting on the renin-angiotensin system	73.7	73.0	0.02	73.5	73.4	0.00	73.5	73.2	0.01
Antibacterials for systemic use	47.0	46.2	0.02	46.4	46.8	-0.01	46.6	46.5	0.00
Antidepressants	32.8	32.0	0.02	32.4	32.3	0.00	32.4	32.3	0.00
Antiepileptics	22.1	22.2	0.00	22.0	22.1	0.00	22.4	22.2	0.00
Antiinflammatory and antirheumatic products	69.1	69.5	-0.01	68.9	68.8	0.00	69.4	69.3	0.00
Antineoplastic agents	5.2	4.8	0.02	5.1	5.1	0.00	5.0	4.9	0.00
Antipsoriatics	0.8	0.6	0.02	0.8	0.6	0.02	0.8	0.6	0.02
Antithrombotic agents	67.1	68.9	-0.04	67.1	66.5	0.01	68.8	68.1	0.01
Beta blocking agents	57.5	59.5	-0.04	57.5	57.1	0.01	59.3	58.7	0.01
Calcium channel blockers	31.7	30.4	0.03	31.2	31.7	-0.01	30.9	30.9	0.00
Diuretics	47.8	48.4	-0.01	47.6	47.4	0.00	48.6	48.2	0.01
Drugs for acid related disorders	48.1	47.8	0.01	47.6	47.9	-0.01	47.6	47.9	-0.01
Drugs for obstructive airway diseases	47.3	46.1	0.02	46.5	46.9	-0.01	46.7	46.5	0.00
Immunosuppressants	2.9	2.8	0.00	2.8	2.9	0.00	2.8	2.9	0.00
Lipid modifying agents	83.6	82.4	0.03	82.6	82.7	0.00	82.6	82.7	0.00
Opioids	34.8	36.2	-0.03	34.8	34.7	0.00	36.2	35.9	0.01
Psycholeptics	35.6	34.4	0.03	35.1	35.3	0.00	35.0	34.8	0.00
Psychostimulants	2.5	2.3	0.01	2.5	2.5	0.00	2.3	2.4	-0.01

Supplementary Table 46: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the SIDIAP data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
30 - 34	<0.1	<0.2	0.00	<0.3	<0.2	0.02	<0.1	<0.1	0.01
35 - 39	0.1	0.2	-0.02	<0.3	0.3	-0.03	0.1	0.2	0.00
40 - 44	0.4	1.1	-0.07	0.8	1.1	-0.03	0.5	0.9	-0.04
45 - 49	1.9	2.5	-0.04	3.6	2.8	0.04	2.2	2.6	-0.02
50 - 54	4.0	6.2	-0.10	5.7	6.1	-0.01	4.5	4.3	0.01
55 - 59	7.8	10.9	-0.11	10.5	11.2	-0.02	8.7	8.7	0.00
60 - 64	12.9	15.2	-0.07	15.4	14.5	0.02	13.4	13.6	-0.01
65 - 69	14.9	16.3	-0.04	16.2	16.3	0.00	15.4	16.9	-0.04
70 - 74	16.4	16.2	0.00	15.2	16.1	-0.02	16.3	18.4	-0.06
75 - 79	15.7	13.9	0.05	14.5	13.6	0.03	15.1	13.2	0.06
80 - 84	13.2	10.5	0.08	11.2	11.0	0.00	12.5	11.5	0.03
85 - 89	9.0	5.6	0.13	5.0	5.4	-0.02	8.1	8.3	-0.01
90 - 94	3.1	1.0	0.14	1.6	1.3	0.02	2.7	1.4	0.10
95 - 99	0.5	0.2	0.04	<0.3	0.2	-0.03	0.4	<0.1	0.06
Gender: female	28.4	28.8	-0.01	27.4	28.3	-0.02	28.5	29.2	-0.02
Medical history: General									
Acute respiratory disease	13.9	11.5	0.07	12.0	12.6	-0.02	13.5	13.8	-0.01
Chronic liver disease	0.3	0.6	-0.04	0.6	0.6	0.00	0.4	0.3	0.02
Chronic obstructive lung disease	2.4	2.9	-0.03	2.5	2.9	-0.02	2.3	1.9	0.03
Crohn's disease	<0.1	<0.2	-0.02	<0.1	<0.1	-0.01	<0.1	<0.1	-0.01
Dementia	1.0	1.3	-0.03	1.2	1.3	-0.01	1.0	1.0	0.00
Depressive disorder	2.6	3.7	-0.07	3.6	3.9	-0.02	2.8	3.5	-0.04
Gastroesophageal reflux disease	1.3	0.8	0.05	0.6	1.0	-0.05	1.2	2.0	-0.06
Gastrointestinal hemorrhage	2.1	1.4	0.06	1.9	1.5	0.04	2.0	1.1	0.07
Hyperlipidemia	2.7	4.0	-0.08	4.3	3.7	0.04	3.1	2.4	0.04
Hypertensive disorder	3.7	6.0	-0.10	5.6	5.3	0.01	4.2	5.5	-0.06
Lesion of liver	0.4	0.6	-0.03	0.4	0.7	-0.04	0.4	0.5	-0.02
Obesity	6.7	7.9	-0.05	7.6	8.1	-0.02	7.0	7.6	-0.03
Osteoarthritis	5.3	5.4	-0.01	6.8	5.5	0.05	5.5	4.6	0.04
Pneumonia	2.3	2.2	0.01	2.2	2.2	0.00	2.4	3.0	-0.04
Psoriasis	0.3	0.7	-0.06	0.4	0.7	-0.04	0.3	0.8	-0.06
Renal impairment	6.8	3.2	0.17	3.3	3.6	-0.02	5.9	5.1	0.04
Rheumatoid arthritis	0.1	<0.2	-0.01	<0.3	<0.2	-0.01	0.1	<0.1	0.00
Schizophrenia	<0.1	<0.2	-0.02	<0.3	<0.2	-0.02	<0.1	<0.1	0.00
Ulcerative colitis	<0.1	<0.2	-0.04	<0.1	<0.1	-0.03	<0.1	<0.1	-0.03
Urinary tract infectious disease	7.5	3.9	0.16	4.7	4.7	0.00	6.8	6.2	0.02
Viral hepatitis C	0.1	<0.2	0.00	<0.3	0.2	-0.01	0.2	<0.1	0.03
Visual system disorder	17.8	17.0	0.02	17.6	19.0	-0.04	17.6	19.0	-0.04
Medical history: Cardiovascular disease									
Atrial fibrillation	2.9	3.1	-0.01	2.2	2.9	-0.04	2.7	2.4	0.02
Cerebrovascular disease	6.4	8.3	-0.07	8.2	8.3	0.00	6.8	6.4	0.02
Coronary arteriosclerosis	<0.1	<0.2	-0.03	<0.1	<0.1	-0.01	<0.1	<0.1	-0.01
Heart disease	24.0	27.7	-0.09	29.4	27.2	0.05	24.8	25.1	-0.01
Heart failure	4.3	3.9	0.02	4.2	4.3	0.00	4.1	3.5	0.03
Ischemic heart disease	14.7	19.3	-0.12	21.3	18.5	0.07	15.8	14.3	0.04
Peripheral vascular disease	5.2	6.5	-0.06	5.4	6.1	-0.03	5.4	5.2	0.01
Pulmonary embolism	0.2	0.2	-0.01	<0.3	0.2	-0.04	0.2	0.2	0.00
Venous thrombosis	1.1	1.1	0.00	1.2	1.2	0.00	1.2	1.2	0.00
Medical history: Neoplasms									
Hematologic neoplasm	0.2	<0.2	0.02	<0.3	<0.2	0.01	0.1	<0.1	0.04
Malignant lymphoma	0.1	<0.2	-0.01	0.1	<0.1	0.00	0.1	<0.1	0.00
Malignant neoplasm of anorectum	0.1	<0.2	0.03	0.1	<0.1	0.03	0.1	<0.1	0.03
Malignant neoplastic disease	3.9	2.8	0.06	3.9	3.0	0.05	3.9	5.4	-0.07
Malignant tumor of breast	0.1	0.2	-0.01	<0.3	0.3	-0.02	0.2	<0.1	0.00
Malignant tumor of colon	0.5	0.4	0.01	0.5	0.4	0.01	0.5	0.3	0.04
Malignant tumor of lung	0.1	<0.2	0.01	<0.1	<0.1	0.01	<0.1	<0.1	0.01
Malignant tumor of urinary bladder	0.5	0.5	0.01	0.4	0.3	0.02	0.6	1.9	-0.12
Primary malignant neoplasm of prostate	0.4	0.3	0.01	0.7	0.3	0.05	0.4	1.1	-0.08
Medication use									
Agents acting on the renin-angiotensin system	75.2	69.1	0.14	72.7	72.3	0.01	74.0	74.4	-0.01
Antibacterials for systemic use	43.5	35.3	0.17	38.7	38.8	0.00	42.1	44.8	-0.06

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Antidepressants	23.1	20.9	0.06	20.6	21.7	-0.03	22.6	24.0	-0.03
Antiepileptics	11.8	9.2	0.09	9.6	10.2	-0.02	11.1	11.3	0.00
Antiinflammatory and antirheumatic products	74.9	72.3	0.06	75.1	74.8	0.01	74.9	75.1	0.00
Antineoplastic agents	2.2	1.6	0.04	1.7	1.7	0.00	2.1	1.4	0.06
Antipsoriatics	2.0	1.4	0.05	1.4	1.4	0.00	1.9	1.1	0.06
Antithrombotic agents	85.5	78.3	0.19	81.2	81.1	0.00	84.2	82.8	0.04
Beta blocking agents	57.3	50.6	0.13	53.5	54.2	-0.01	56.0	58.8	-0.06
Calcium channel blockers	36.6	32.1	0.09	35.8	33.5	0.05	35.8	33.5	0.05
Diuretics	56.9	50.0	0.14	51.8	52.4	-0.01	55.2	56.5	-0.03
Drugs for acid related disorders	75.2	68.5	0.15	71.3	71.4	0.00	74.0	75.5	-0.04
Drugs for obstructive airway diseases	32.3	27.3	0.11	27.2	29.0	-0.04	30.9	30.2	0.01
Immunosuppressants	1.6	1.2	0.04	0.8	1.3	-0.05	1.4	1.2	0.01
Lipid modifying agents	84.5	79.0	0.14	82.1	82.8	-0.02	83.9	82.7	0.03
Opioids	20.5	16.5	0.10	18.1	17.9	0.00	19.6	21.7	-0.05
Psycholeptics	35.9	33.4	0.05	34.7	34.6	0.00	35.5	38.6	-0.06

Supplementary Table 47: Baseline patient characteristics for DPP4is (T) and SUs (C) new-users in the VA data source. We report proportion of initiators satisfying selected base-line characteristics and the standardized difference of population proportions (StdDiff) before and after propensity score adjustment. Less extreme StdDiffs through matching and stratification suggest improved balance between patient cohorts through adjustment.

Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Age group									
30 - 34	0.1	0.1	0.01	<0.1	0.1	0.00	<0.1	0.1	0.00
35 - 39	0.3	0.3	0.00	0.3	0.4	-0.01	0.1	0.3	-0.04
40 - 44	0.8	0.9	-0.01	0.8	0.8	0.01	1.0	0.9	0.01
45 - 49	2.0	2.5	-0.03	2.1	2.1	0.00	1.9	2.4	-0.04
50 - 54	4.8	5.9	-0.05	4.8	4.9	0.00	2.5	5.4	-0.15
55 - 59	8.1	11.7	-0.12	8.0	7.8	0.00	8.9	9.9	-0.04
60 - 64	12.2	19.2	-0.19	12.4	12.1	0.01	17.5	19.7	-0.06
65 - 69	20.9	21.4	-0.01	21.2	20.8	0.01	22.7	23.4	-0.01
70 - 74	27.2	17.1	0.24	26.9	27.7	-0.02	19.4	18.3	0.03
75 - 79	11.7	10.9	0.03	11.7	11.8	0.00	12.3	9.7	0.08
80 - 84	6.5	6.9	-0.01	6.5	6.4	0.00	7.1	6.0	0.05
85 - 89	3.8	2.7	0.06	3.6	3.8	-0.01	4.5	3.0	0.08
90 - 94	1.3	0.6	0.07	1.3	1.2	0.01	1.8	0.8	0.09
95 - 99	0.3	0.1	0.05	0.3	0.2	0.02	0.1	0.1	0.01
Gender: female	5.2	2.9	0.12	5.1	5.0	0.00	4.1	3.5	0.03
Race									
Asian	1.1	0.5	0.06	1.1	1.0	0.01	0.6	0.6	0.00
Black or African American	13.6	10.8	0.09	13.2	13.3	0.00	9.8	12.1	-0.07
White	78.1	78.0	0.00	78.3	78.0	0.01	82.5	79.2	0.08
Unknown	5.6	9.3	-0.14	5.7	5.8	-0.01	5.2	6.5	-0.06
Native Hawaiian or Other Pacific Islander	1.0	0.8	0.02	1.0	0.9	0.00	1.3	0.8	0.04
American Indian or Alaska Native	0.7	0.6	0.01	0.7	0.9	-0.02	0.6	0.7	-0.02
Ethnicity									
Hispanic or Latino	4.4	4.6	-0.01	4.5	4.5	0.00	3.9	5.0	-0.05
Not Hispanic or Latino	93.4	89.8	0.13	93.4	93.2	0.01	92.9	92.1	0.03
Medical history: General									
Acute respiratory disease	9.9	10.3	-0.02	9.8	9.7	0.00	7.9	10.7	-0.10
Attention deficit hyperactivity disorder	0.5	0.3	0.03	0.5	0.5	0.00	0.3	0.3	0.00
Chronic liver disease	2.2	2.4	-0.01	2.2	2.3	0.00	3.1	2.8	0.02
Chronic obstructive lung disease	17.2	16.3	0.03	17.0	17.2	0.00	20.5	17.0	0.09
Crohn's disease	0.2	0.2	-0.01	0.2	0.2	-0.01	0.1	0.2	-0.03
Dementia	2.8	1.6	0.09	2.8	2.9	-0.01	2.0	1.8	0.01
Depressive disorder	22.3	21.5	0.02	22.0	22.2	0.00	27.6	23.2	0.10
Gastroesophageal reflux disease	22.6	22.4	0.01	22.6	22.7	0.00	23.9	23.5	0.01
Gastrointestinal hemorrhage	1.3	1.7	-0.04	1.3	1.3	0.00	0.8	1.7	-0.07
Human immunodeficiency virus infection	0.4	0.3	0.03	0.4	0.5	-0.01	0.4	0.3	0.01
Hyperlipidemia	75.6	78.1	-0.06	75.5	75.2	0.01	78.4	78.9	-0.01
Hypertensive disorder	79.5	82.6	-0.08	79.4	78.9	0.01	82.3	82.5	0.00
Lesion of liver	1.5	1.2	0.03	1.5	1.7	-0.01	0.9	1.4	-0.04
Obesity	26.6	28.0	-0.03	26.4	26.3	0.00	29.7	29.3	0.01
Osteoarthritis	23.0	24.2	-0.03	24.6	24.7	0.00	24.6	24.7	0.00
Pneumonia	1.9	2.0	-0.01	1.9	2.1	-0.01	1.7	2.2	-0.04
Psoriasis	1.9	1.6	0.02	1.9	1.7	0.01	1.9	1.7	0.01
Renal impairment	11.6	7.8	0.13	11.5	11.7	-0.01	12.3	9.5	0.09
Rheumatoid arthritis	0.8	1.0	-0.01	0.9	0.9	-0.01	0.8	1.0	-0.02
Schizophrenia	0.9	1.0	-0.02	0.9	0.8	0.00	0.6	1.0	-0.04
Ulcerative colitis	0.4	0.3	0.02	0.5	0.4	0.01	0.2	0.4	-0.03
Urinary tract infectious disease	3.0	2.9	0.00	2.9	2.8	0.00	2.4	3.1	-0.04
Viral hepatitis C	1.1	1.8	-0.06	1.2	1.3	-0.01	1.8	2.0	-0.01
Visual system disorder	48.9	47.5	0.03	48.8	48.3	0.01	49.4	48.9	0.01
Medical history: Cardiovascular disease									
Atrial fibrillation	12.2	9.2	0.10	12.0	12.4	-0.01	13.0	9.8	0.10
Cerebrovascular disease	7.5	10.5	-0.10	7.6	7.6	0.00	11.3	9.8	0.05
Coronary arteriosclerosis	36.6	37.4	-0.02	36.9	37.2	-0.01	37.6	34.9	0.06
Heart disease	55.1	62.2	-0.14	55.2	55.4	0.00	65.0	59.2	0.12
Heart failure	8.2	9.3	-0.04	8.2	8.5	-0.01	11.9	9.0	0.10
Ischemic heart disease	16.1	29.6	-0.33	16.4	15.8	0.02	31.0	27.1	0.09
Peripheral vascular disease	10.9	11.9	-0.03	10.8	11.1	-0.01	10.3	11.3	-0.03
Pulmonary embolism	0.9	0.7	0.01	0.9	1.0	-0.01	0.9	0.9	0.00
Venous thrombosis	1.7	1.4	0.02	1.7	1.8	0.00	1.4	1.7	-0.03
Medical history: Neoplasms									

(Continued) Characteristic	Before adjustment			After matching			After stratification		
	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff	T (%)	C (%)	StdDiff
Hematologic neoplasm	1.3	1.0	0.03	1.3	1.4	-0.01	1.8	1.1	0.06
Malignant lymphoma	0.8	0.5	0.04	0.8	1.0	-0.01	0.4	0.6	-0.04
Malignant neoplasm of anorectum	0.1	0.2	-0.02	<0.1	0.1	0.00	0.1	0.1	-0.03
Malignant neoplastic disease	11.5	11.4	0.00	11.3	11.5	-0.01	14.7	11.7	0.09
Malignant tumor of breast	0.1	0.1	0.00	0.1	0.1	0.00	0.1	0.1	0.00
Malignant tumor of colon	0.6	0.8	-0.02	0.6	0.6	0.00	0.7	0.7	0.00
Malignant tumor of lung	0.5	0.3	0.04	0.5	0.5	0.00	0.2	0.4	-0.02
Malignant tumor of urinary bladder	0.8	0.9	-0.01	0.8	0.8	0.00	0.6	0.9	-0.04
Primary malignant neoplasm of prostate	4.2	4.6	-0.02	4.1	4.2	-0.01	6.2	4.6	0.07
Medication use									
Agents acting on the renin-angiotensin system	66.9	75.9	-0.20	67.2	66.8	0.01	70.3	73.7	-0.08
Antibacterials for systemic use	31.0	33.8	-0.06	30.7	30.6	0.00	30.7	34.2	-0.07
Antidepressants	37.0	36.4	0.01	36.8	37.0	0.00	42.5	37.8	0.10
Antiepileptics	30.2	23.3	0.16	29.9	30.4	-0.01	29.3	27.1	0.05
Antiinflammatory and antirheumatic products	50.9	50.5	0.01	50.6	50.8	0.00	47.5	50.8	-0.07
Antineoplastic agents	4.9	3.3	0.08	4.8	4.7	0.00	5.4	3.6	0.09
Antipsoriatics	1.0	0.8	0.03	1.1	1.0	0.00	1.4	0.9	0.05
Antithrombotic agents	50.3	49.9	0.01	49.8	50.3	-0.01	50.4	49.4	0.02
Beta blocking agents	54.3	61.9	-0.16	54.8	54.7	0.00	58.6	60.6	-0.04
Calcium channel blockers	31.4	31.2	0.00	31.2	31.1	0.00	34.7	31.2	0.07
Diuretics	41.0	49.2	-0.17	41.2	40.9	0.01	47.4	48.0	-0.01
Drugs for acid related disorders	49.1	50.1	-0.02	49.1	49.0	0.00	58.5	51.1	0.15
Drugs for obstructive airway diseases	44.7	39.1	0.11	44.2	44.4	0.00	41.9	41.5	0.01
Immunosuppressants	2.6	1.7	0.06	2.6	2.7	-0.01	3.6	2.1	0.09
Lipid modifying agents	84.7	86.0	-0.04	84.7	84.7	0.00	85.1	86.7	-0.04
Opioids	19.2	23.8	-0.11	19.2	18.7	0.01	24.6	24.2	0.01
Psycholeptics	25.3	24.1	0.03	24.8	24.6	0.01	27.5	25.5	0.05
Psychostimulants	1.6	1.4	0.01	1.5	1.5	0.00	1.1	1.5	-0.03

Supplementary Table 48: Meta-analytic calibrated hazard ratio estimates and their 95% confidence intervals comparing the relative risk of cardiovascular effectiveness outcomes between target and comparator among new users of SGLT2is, GLP1-RAs, DPP4is, and SUs.

Target	Comparator	3-pt MACE	4-pt MACE	Acute MI	HF Hospitalization	Stroke	SCD
SGLT2is	GLP1-RAs	1.06 (0.96 - 1.17)	1.05 (0.97 - 1.13)	1.19 (1.05 - 1.35)	1.02 (0.93 - 1.12)	0.93 (0.82 - 1.05)	1.11 (0.84 - 1.45)
SGLT2is	DPP4is	0.89 (0.79 - 1.00)	0.84 (0.75 - 0.95)	0.95 (0.83 - 1.08)	0.80 (0.68 - 0.95)	0.89 (0.74 - 1.07)	0.62 (0.51 - 0.75)
SGLT2is	SUs	0.76 (0.65 - 0.89)	0.71 (0.61 - 0.83)	0.81 (0.69 - 0.95)	0.68 (0.58 - 0.80)	0.77 (0.65 - 0.92)	0.60 (0.48 - 0.73)
GLP1-RAs	DPP4is	0.83 (0.70 - 0.98)	0.81 (0.73 - 0.91)	0.85 (0.73 - 0.99)	0.76 (0.67 - 0.86)	0.89 (0.77 - 1.03)	0.65 (0.44 - 0.96)
GLP1-RAs	SUs	0.72 (0.58 - 0.88)	0.67 (0.55 - 0.82)	0.70 (0.56 - 0.87)	0.64 (0.52 - 0.78)	0.79 (0.63 - 0.98)	0.57 (0.42 - 0.78)
DPP4is	SUs	0.87 (0.79 - 0.95)	0.87 (0.79 - 0.95)	0.86 (0.77 - 0.95)	0.90 (0.82 - 0.99)	0.90 (0.81 - 0.99)	0.96 (0.81 - 1.13)

Supplementary Table 49: Exposures, outcomes and risk estimates for 3-point MACE in SGLT2is (T) vs GLP1-RAs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	8,744	4,024	6.7	2.7	86	24	0.76 (0.43 - 1.36)	0.74 (0.42 - 1.30)
OCEDM	10,015	4,550	6.1	2.4	157	48	1.24 (0.79 - 1.98)	1.28 (0.81 - 2.03)
MDCR	1,768	663	1.3	0.4	33	9	1.00 (0.38 - 2.93)	1.27 (0.46 - 3.51)
USOC	161,590	76,637	122.0	49.3	1,630	585	0.98 (0.86 - 1.12)	1.04 (0.90 - 1.19)
OEHR	8,053	3,448	2.5	0.9	41	16	1.16 (0.52 - 2.85)	1.30 (0.56 - 3.06)
Meta-analysis	188,402	88,659	137.3	55.4	1,914	673	0.99 (0.87 - 1.12)	1.04 (0.91 - 1.18)
PS-stratification / on-treatment TAR								
CCAЕ	8,747	4,800	6.7	3.1	86	29	1.10 (0.71 - 1.75)	1.11 (0.71 - 1.74)
OCEDM	10,018	5,304	6.1	2.8	157	54	1.22 (0.88 - 1.72)	1.24 (0.88 - 1.73)
MDCR	1,775	692	1.3	0.4	33	9	1.05 (0.50 - 2.43)	1.16 (0.52 - 2.56)
USOC	161,615	89,631	122.1	56.0	1,630	653	1.00 (0.91 - 1.10)	1.05 (0.95 - 1.16)
OEHR	8,063	3,993	2.5	1.1	41	16	1.08 (0.59 - 2.05)	1.15 (0.61 - 2.18)
Meta-analysis	188,443	103,728	137.4	62.9	1,914	752	1.02 (0.93 - 1.12)	1.06 (0.96 - 1.17)

Supplementary Table 50: Exposures, outcomes and risk estimates for 3-point MACE in SGLT2is (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	7,060	11,442	5.8	9.0	76	132	0.81 (0.53 - 1.22)	0.76 (0.49 - 1.17)
GDA	3,365	8,557	2.8	9.0	0	0		
OCEDM	7,471	15,256	5.0	11.6	131	404	1.00 (0.76 - 1.31)	0.98 (0.75 - 1.29)
MDCR	1,440	4,901	1.1	4.2	28	169	0.69 (0.38 - 1.21)	0.74 (0.41 - 1.32)
MDCD	964	2,878	0.5	2.2	18	80	1.05 (0.51 - 2.05)	0.98 (0.49 - 1.95)
USOC	119,943	251,237	99.4	225.9	1,320	4,493	0.79 (0.73 - 0.87)	0.81 (0.67 - 0.98)
OEHR	6,514	14,283	2.1	7.8	34	159	0.93 (0.55 - 1.50)	0.83 (0.50 - 1.36)
SIDIAP	1,241	5,180	1.7	10.6	7	100	0.47 (0.16 - 1.14)	0.46 (0.16 - 1.37)
VA	3,435	8,776	2.5	8.3	22	63	1.00 (0.51 - 1.92)	0.96 (0.49 - 1.87)
Meta-analysis	148,068	313,953	118.1	279.6	1,636	5,600	0.81 (0.75 - 0.88)	0.81 (0.74 - 0.89)
PS-stratification / on-treatment TAR								
CCAЕ	8,747	11,484	6.7	9.1	86	134	0.84 (0.63 - 1.13)	0.85 (0.64 - 1.15)
GDA	4,434	8,797	3.5	9.3	0	0		
OCEDM	10,018	15,616	6.1	11.9	157	427	0.86 (0.70 - 1.06)	0.87 (0.70 - 1.07)
MDCR	1,775	4,983	1.3	4.3	33	174	0.77 (0.49 - 1.18)	0.79 (0.51 - 1.22)
MDCD	1,030	2,889	0.6	2.2	20	80	1.11 (0.63 - 1.87)	0.99 (0.57 - 1.70)
USOC	161,615	251,760	122.1	226.3	1,630	4,525	0.87 (0.82 - 0.93)	0.91 (0.79 - 1.06)
OEHR	8,063	14,463	2.5	7.9	41	166	1.07 (0.73 - 1.55)	0.98 (0.67 - 1.43)
SIDIAP	1,726	5,570	2.2	11.7	10	108	0.55 (0.24 - 1.12)	0.54 (0.24 - 1.21)
VA	6,127	9,248	3.9	9.0	42	72	1.01 (0.60 - 1.67)	1.02 (0.61 - 1.70)
Meta-analysis	188,443	293,323	137.4	255.1	1,914	5,252	0.87 (0.82 - 0.93)	0.89 (0.79 - 1.00)

Supplementary Table 51: Exposures, outcomes and risk estimates for 3-point MACE in SGLT2is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	7,203	15,151	5.7	11.6	76	216	0.74 (0.50 - 1.07)	0.71 (0.49 - 1.05)
GDA	4,184	723	3.4	0.7	0	0		
OCEDM	8,841	32,054	5.6	28.2	139	1,153	0.87 (0.69 - 1.09)	0.90 (0.72 - 1.14)
MDCR	1,474	7,015	1.1	5.9	31	243	0.65 (0.36 - 1.11)	0.72 (0.41 - 1.27)
MDCD	1,018	5,034	0.6	3.4	20	144	0.84 (0.45 - 1.48)	0.83 (0.46 - 1.50)
USOC	144,004	460,852	112.1	472.7	1,509	11,428	0.74 (0.69 - 0.80)	0.77 (0.62 - 0.95)
OEHR	7,022	29,857	2.2	18.1	36	523	0.74 (0.47 - 1.11)	0.68 (0.44 - 1.04)
SIDIAP	1,347	289	1.9	0.5	7	0		
VA	4,298	23,732	3.1	20.3	30	220	0.95 (0.56 - 1.55)	0.97 (0.58 - 1.62)
Meta-analysis	169,562	549,963	127.2	540.0	1,811	13,707	0.75 (0.70 - 0.80)	0.76 (0.65 - 0.89)
PS-stratification / on-treatment TAR								
CCAЕ	8,747	15,421	6.7	11.8	86	221	0.76 (0.58 - 1.00)	0.75 (0.57 - 0.98)
GDA	4,337	1,235	3.5	1.3	0	0		
OCEDM	10,018	32,592	6.1	28.6	157	1,190	0.83 (0.69 - 1.00)	0.83 (0.69 - 1.00)
MDCR	1,775	7,469	1.3	6.3	33	264	0.82 (0.53 - 1.22)	0.79 (0.52 - 1.20)
MDCD	1,031	5,327	0.6	3.7	20	152	1.04 (0.61 - 1.67)	1.01 (0.61 - 1.67)
USOC	161,615	467,651	122.1	479.0	1,630	11,794	0.75 (0.71 - 0.79)	0.78 (0.65 - 0.93)
OEHR	8,063	31,364	2.5	19.3	41	573	0.68 (0.48 - 0.96)	0.64 (0.45 - 0.93)
SIDIAP	1,714	566	2.2	1.2	10	8	1.16 (0.27 - 4.49)	1.22 (0.30 - 5.01)
VA	6,127	34,583	3.9	32.5	42	424	1.02 (0.67 - 1.54)	1.05 (0.69 - 1.59)
Meta-analysis	188,443	547,028	137.4	538.7	1,914	13,778	0.75 (0.71 - 0.79)	0.76 (0.66 - 0.88)

Supplementary Table 52: Exposures, outcomes and risk estimates for 3-point MACE in GLP1-RAs (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAIE	4,967	20,049	3.3	16.5	32	228	0.91 (0.57 - 1.42)	0.93 (0.59 - 1.48)
OCEDM	4,476	20,558	2.5	16.4	54	522	0.76 (0.52 - 1.08)	0.75 (0.52 - 1.09)
MDCR	863	8,495	0.5	8.1	12	299	0.77 (0.36 - 1.50)	0.67 (0.33 - 1.38)
USOC	63,780	251,578	44.8	226.7	554	4,439	0.90 (0.80 - 1.02)	0.88 (0.76 - 1.01)
OEHR	3,337	16,582	1.0	8.9	17	187	0.90 (0.45 - 1.65)	0.76 (0.40 - 1.46)
Meta-analysis	76,560	308,767	51.6	268.5	657	5,376	0.89 (0.80 - 0.99)	0.87 (0.76 - 0.99)
PS-stratification / on-treatment TAR								
CCAIE	6,289	20,129	3.9	16.5	37	230	0.83 (0.55 - 1.20)	0.83 (0.56 - 1.23)
OCEDM	5,917	21,000	3.1	16.8	61	551	0.66 (0.48 - 0.89)	0.64 (0.47 - 0.88)
MDCR	940	9,093	0.5	8.7	12	330	0.67 (0.34 - 1.18)	0.59 (0.32 - 1.10)
USOC	89,766	253,586	56.1	228.5	654	4,557	0.89 (0.81 - 0.98)	0.88 (0.75 - 1.03)
OEHR	4,156	16,689	1.2	8.9	17	197	1.06 (0.60 - 1.76)	0.88 (0.51 - 1.51)
Meta-analysis	106,128	311,404	64.2	270.7	769	5,535	0.85 (0.73 - 0.98)	0.83 (0.69 - 0.99)

Supplementary Table 53: Exposures, outcomes and risk estimates for 3-point MACE in GLP1-RAs (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,270	29,862	3.4	23.2	36	399	0.78 (0.49 - 1.18)	0.73 (0.47 - 1.14)
OCEDM	4,967	39,869	2.7	35.6	54	1,294	0.62 (0.44 - 0.87)	0.63 (0.45 - 0.89)
MDCR	931	13,596	0.6	13.0	13	515	0.64 (0.32 - 1.18)	0.52 (0.27 - 1.02)
USOC	75,427	451,969	49.5	465.1	596	10,863	0.76 (0.68 - 0.84)	0.74 (0.61 - 0.89)
OEHR	3,547	34,330	1.0	20.6	17	559	0.74 (0.40 - 1.26)	0.68 (0.38 - 1.20)
Meta-analysis	90,142	569,626	57.2	557.5	716	13,630	0.74 (0.68 - 0.82)	0.71 (0.59 - 0.86)
PS-stratification / on-treatment TAR								
CCAЕ	6,624	30,474	4.1	23.6	38	412	0.69 (0.47 - 0.99)	0.68 (0.46 - 0.98)
OCEDM	5,917	45,550	3.1	41.6	61	1,715	0.71 (0.53 - 0.93)	0.71 (0.53 - 0.94)
MDCR	1,007	17,499	0.6	16.5	13	737	0.59 (0.32 - 1.01)	0.49 (0.27 - 0.87)
USOC	89,766	473,027	56.1	486.9	654	11,988	0.74 (0.67 - 0.80)	0.72 (0.58 - 0.89)
OEHR	4,157	38,799	1.2	23.6	17	699	0.69 (0.40 - 1.12)	0.57 (0.34 - 0.96)
Meta-analysis	96,390	503,501	60.1	510.5	692	12,400	0.73 (0.67 - 0.80)	0.72 (0.58 - 0.88)

Supplementary Table 54: Exposures, outcomes and risk estimates for 3-point MACE in DPP4is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	17,378	28,723	14.2	22.1	209	383	0.93 (0.73 - 1.19)	0.95 (0.74 - 1.22)
GDA	10,408	1,974	11.3	2.0	0	0		
OCEDM	19,834	45,526	15.8	41.6	520	1,712	0.91 (0.79 - 1.04)	0.96 (0.84 - 1.11)
MDCR	8,489	15,979	8.1	14.9	307	663	0.86 (0.71 - 1.04)	0.82 (0.67 - 1.00)
MDCD	3,453	7,647	2.6	5.4	86	232	0.83 (0.58 - 1.18)	0.87 (0.61 - 1.24)
IMRD	3,388	407	5.7	0.6	0	0		
USOC	246,318	473,034	220.3	487.0	4,410	11,989	0.87 (0.83 - 0.91)	0.87 (0.77 - 0.97)
OEHR	15,736	38,767	8.3	23.6	189	699	0.92 (0.74 - 1.14)	0.90 (0.72 - 1.11)
SIDIAP	7,174	1,676	19.0	4.2	153	25	1.50 (0.85 - 2.82)	1.46 (0.80 - 2.68)
VA	9,289	58,157	9.5	61.0	79	748	0.83 (0.60 - 1.14)	0.85 (0.62 - 1.17)
Meta-analysis	327,671	669,509	297.7	659.7	5,953	16,451	0.88 (0.84 - 0.92)	0.88 (0.79 - 0.97)
PS-stratification / on-treatment TAR								
CCAЕ	20,129	28,846	16.5	22.2	230	386	0.89 (0.75 - 1.06)	0.90 (0.75 - 1.07)
GDA	10,428	2,365	11.3	2.5	0	0		
OCEDM	21,003	45,554	16.8	41.6	551	1,715	0.90 (0.81 - 0.99)	0.91 (0.82 - 1.01)
MDCR	9,093	16,082	8.7	15.0	330	669	0.92 (0.80 - 1.06)	0.92 (0.80 - 1.06)
MDCD	3,622	7,678	2.8	5.4	94	232	0.88 (0.68 - 1.14)	0.90 (0.70 - 1.17)
IMRD	4,024	846	6.5	1.5	0	0		
USOC	253,598	473,060	228.5	487.0	4,557	11,991	0.86 (0.83 - 0.89)	0.85 (0.75 - 0.97)
OEHR	16,689	38,798	8.9	23.6	197	699	0.85 (0.72 - 1.00)	0.88 (0.75 - 1.04)
SIDIAP	7,322	2,193	19.1	5.8	154	33	1.21 (0.79 - 1.91)	1.15 (0.74 - 1.78)
VA	9,928	88,164	9.9	97.7	81	1,239	0.77 (0.59 - 0.98)	0.80 (0.62 - 1.03)
Meta-analysis	324,134	610,018	282.2	594.7	5,959	15,692	0.87 (0.84 - 0.89)	0.87 (0.79 - 0.95)

Supplementary Table 55: Exposures, outcomes and risk estimates for 4-point MACE in SGLT2is (T) vs GLP1-RAs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	8,362	3,841	6.4	2.5	132	42	1.13 (0.71 - 1.83)	1.09 (0.68 - 1.76)
OCEDM	9,034	4,169	5.6	2.2	239	88	1.09 (0.78 - 1.53)	1.13 (0.81 - 1.57)
MDCR	1,604	601	1.2	0.4	47	13	1.05 (0.48 - 2.50)	1.34 (0.58 - 3.06)
USOC	147,379	71,400	112.6	46.1	2,402	884	0.99 (0.89 - 1.10)	1.05 (0.93 - 1.18)
OEHR	7,602	3,277	2.3	0.9	76	23	1.70 (0.94 - 3.25)	1.91 (1.02 - 3.55)
Meta-analysis	172,377	82,687	127.0	51.7	2,849	1,037	1.03 (0.91 - 1.16)	1.08 (0.95 - 1.23)
PS-stratification / on-treatment TAR								
CCAЕ	8,365	4,571	6.4	2.9	132	47	1.16 (0.82 - 1.68)	1.17 (0.82 - 1.67)
OCEDM	9,043	4,874	5.6	2.6	239	99	0.99 (0.77 - 1.28)	1.00 (0.77 - 1.29)
MDCR	1,610	631	1.2	0.4	47	13	1.01 (0.54 - 2.02)	1.11 (0.58 - 2.15)
USOC	147,404	83,802	112.7	52.3	2,404	994	0.99 (0.92 - 1.08)	1.05 (0.96 - 1.14)
OEHR	7,615	3,800	2.3	1.1	76	26	1.35 (0.85 - 2.22)	1.45 (0.88 - 2.39)
Meta-analysis	172,427	97,047	127.0	58.9	2,851	1,166	1.01 (0.94 - 1.08)	1.05 (0.97 - 1.13)

Supplementary Table 56: Exposures, outcomes and risk estimates for 4-point MACE in SGLT2is (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	6,786	10,911	5.5	8.6	110	193	0.78 (0.55 - 1.08)	0.73 (0.51 - 1.04)
GDA	3,365	8,557	2.8	9.0	0	0		
OCEDM	6,863	13,775	4.6	10.4	183	615	0.79 (0.63 - 1.00)	0.78 (0.62 - 0.99)
MDCR	1,323	4,392	1.0	3.7	40	252	0.58 (0.33 - 0.95)	0.62 (0.37 - 1.04)
MDCD	836	2,430	0.5	1.8	27	117	1.38 (0.78 - 2.38)	1.28 (0.73 - 2.24)
USOC	112,057	231,516	93.2	207.3	1,902	7,197	0.73 (0.68 - 0.78)	0.75 (0.63 - 0.90)
OEHR	6,202	13,496	2.0	7.2	61	291	0.94 (0.66 - 1.34)	0.84 (0.59 - 1.21)
SIDIAP	1,228	5,121	1.7	10.5	10	126	0.55 (0.23 - 1.12)	0.54 (0.22 - 1.33)
VA	3,203	8,277	2.4	7.7	39	150	0.81 (0.49 - 1.31)	0.78 (0.48 - 1.27)
Meta-analysis	138,498	289,918	110.8	257.2	2,372	8,941	0.77 (0.69 - 0.86)	0.77 (0.68 - 0.87)
PS-stratification / on-treatment TAR								
CCAЕ	8,365	10,985	6.4	8.7	132	196	0.90 (0.71 - 1.14)	0.91 (0.71 - 1.16)
GDA	4,434	8,797	3.5	9.3	0	0		
OCEDM	9,043	14,029	5.6	10.6	239	642	0.84 (0.70 - 0.99)	0.84 (0.71 - 1.00)
MDCR	1,610	4,436	1.2	3.8	47	254	0.70 (0.48 - 0.98)	0.71 (0.50 - 1.01)
MDCD	882	2,440	0.5	1.8	29	118	1.23 (0.78 - 1.89)	1.09 (0.70 - 1.70)
USOC	147,404	231,761	112.7	207.5	2,404	7,224	0.81 (0.76 - 0.85)	0.84 (0.73 - 0.98)
OEHR	7,615	13,660	2.3	7.3	76	305	1.02 (0.76 - 1.34)	0.93 (0.70 - 1.24)
SIDIAP	1,693	5,507	2.1	11.6	12	140	0.55 (0.27 - 1.05)	0.55 (0.27 - 1.12)
VA	5,379	8,732	3.5	8.4	70	161	0.68 (0.47 - 0.97)	0.69 (0.47 - 0.99)
Meta-analysis	172,427	270,435	127.0	234.0	2,851	8,367	0.82 (0.77 - 0.88)	0.84 (0.75 - 0.94)

Supplementary Table 57: Exposures, outcomes and risk estimates for 4-point MACE in SGLT2is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	6,910	14,382	5.4	11.0	114	310	0.69 (0.50 - 0.94)	0.67 (0.49 - 0.91)
GDA	4,184	723	3.4	0.7	0	0		
OCEDM	8,093	28,804	5.1	24.9	205	1,810	0.70 (0.58 - 0.85)	0.73 (0.60 - 0.89)
MDCR	1,340	6,162	1.0	5.2	43	360	0.54 (0.33 - 0.86)	0.60 (0.37 - 0.98)
MDCD	873	4,253	0.5	2.9	29	209	0.94 (0.58 - 1.48)	0.93 (0.58 - 1.48)
USOC	133,349	422,207	104.5	430.5	2,218	18,027	0.68 (0.64 - 0.73)	0.71 (0.58 - 0.87)
OEHR	6,668	28,113	2.1	16.7	68	898	0.79 (0.58 - 1.07)	0.73 (0.53 - 1.00)
SIDIAP	1,331	287	1.9	0.5	10	<5	1.31 (0.23 - 9.93)	1.40 (0.21 - 9.14)
VA	3,947	22,020	2.9	18.7	53	481	0.68 (0.47 - 0.97)	0.70 (0.48 - 1.01)
Meta-analysis	157,233	503,921	118.6	491.1	2,677	21,614	0.69 (0.65 - 0.73)	0.70 (0.59 - 0.81)
PS-stratification / on-treatment TAR								
CCAЕ	8,365	14,619	6.4	11.1	132	318	0.78 (0.62 - 0.97)	0.76 (0.61 - 0.96)
GDA	4,337	1,235	3.5	1.3	0	0		
OCEDM	9,043	29,169	5.6	25.3	239	1,853	0.74 (0.63 - 0.86)	0.74 (0.63 - 0.86)
MDCR	1,610	6,535	1.2	5.5	47	398	0.69 (0.48 - 0.98)	0.67 (0.47 - 0.96)
MDCD	883	4,455	0.5	3.0	29	220	0.96 (0.63 - 1.43)	0.94 (0.62 - 1.42)
USOC	147,404	427,514	112.7	435.4	2,404	18,602	0.70 (0.66 - 0.73)	0.72 (0.60 - 0.87)
OEHR	7,615	29,444	2.3	17.6	76	986	0.77 (0.60 - 0.99)	0.73 (0.55 - 0.97)
SIDIAP	1,681	564	2.1	1.2	12	10	1.17 (0.34 - 3.83)	1.23 (0.36 - 4.16)
VA	5,379	32,188	3.5	29.9	70	851	0.78 (0.57 - 1.05)	0.79 (0.58 - 1.08)
Meta-analysis	172,427	500,746	127.0	489.5	2,851	21,759	0.70 (0.67 - 0.73)	0.71 (0.61 - 0.82)

Supplementary Table 58: Exposures, outcomes and risk estimates for 4-point MACE in GLP1-RAs (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	4,722	19,211	3.1	15.8	50	340	0.84 (0.57 - 1.21)	0.85 (0.58 - 1.25)
OCEDM	4,125	18,746	2.3	14.9	95	805	0.87 (0.65 - 1.15)	0.86 (0.65 - 1.14)
MDCR	798	7,678	0.5	7.4	20	455	0.83 (0.46 - 1.38)	0.73 (0.42 - 1.25)
USOC	59,432	232,281	41.8	208.4	846	7,161	0.86 (0.78 - 0.95)	0.83 (0.74 - 0.95)
OEHR	3,175	15,734	0.9	8.2	25	348	1.01 (0.59 - 1.63)	0.85 (0.51 - 1.41)
Meta-analysis	71,454	285,972	48.1	247.2	1,016	8,654	0.86 (0.79 - 0.94)	0.84 (0.75 - 0.95)
PS-stratification / on-treatment TAR								
CCAЕ	5,986	19,270	3.7	15.8	59	344	0.78 (0.57 - 1.06)	0.79 (0.58 - 1.08)
OCEDM	5,463	19,085	2.9	15.2	108	837	0.80 (0.63 - 1.00)	0.78 (0.62 - 0.99)
MDCR	861	8,112	0.5	7.8	21	503	0.76 (0.46 - 1.18)	0.67 (0.42 - 1.08)
USOC	83,933	233,481	52.4	209.5	996	7,287	0.84 (0.78 - 0.90)	0.83 (0.71 - 0.96)
OEHR	3,963	15,807	1.1	8.2	28	358	0.89 (0.57 - 1.33)	0.73 (0.48 - 1.12)
Meta-analysis	99,345	287,643	60.1	248.7	1,191	8,826	0.83 (0.78 - 0.89)	0.81 (0.72 - 0.92)

Supplementary Table 59: Exposures, outcomes and risk estimates for 4-point MACE in GLP1-RAs (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,023	28,402	3.2	21.9	54	601	0.62 (0.42 - 0.89)	0.59 (0.40 - 0.85)
OCEDM	4,576	36,498	2.5	32.1	97	2,122	0.74 (0.58 - 0.94)	0.75 (0.59 - 0.96)
MDCR	856	11,819	0.5	11.1	22	751	0.73 (0.42 - 1.20)	0.60 (0.35 - 1.02)
USOC	70,228	415,477	46.2	424.7	900	17,219	0.69 (0.64 - 0.76)	0.68 (0.57 - 0.81)
OEHR	3,381	32,483	1.0	19.0	25	985	0.62 (0.39 - 0.95)	0.57 (0.36 - 0.90)
Meta-analysis	84,064	524,679	53.4	508.8	1,098	21,678	0.69 (0.64 - 0.75)	0.67 (0.56 - 0.80)
PS-stratification / on-treatment TAR								
CCAЕ	6,307	28,864	3.9	22.2	61	617	0.64 (0.47 - 0.85)	0.62 (0.46 - 0.84)
OCEDM	5,463	40,955	2.9	36.8	108	2,679	0.72 (0.58 - 0.89)	0.71 (0.58 - 0.89)
MDCR	924	15,279	0.6	14.2	23	1,142	0.66 (0.42 - 1.01)	0.55 (0.35 - 0.85)
USOC	83,933	432,544	52.4	442.7	996	18,923	0.69 (0.64 - 0.73)	0.67 (0.55 - 0.82)
OEHR	3,964	36,554	1.1	21.6	28	1,239	0.63 (0.42 - 0.93)	0.52 (0.35 - 0.78)
Meta-analysis	90,240	461,408	56.3	465.0	1,057	19,540	0.68 (0.64 - 0.73)	0.67 (0.55 - 0.82)

Supplementary Table 60: Exposures, outcomes and risk estimates for 4-point MACE in DPP4is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	16,582	27,224	13.6	20.8	317	573	0.92 (0.75 - 1.12)	0.94 (0.77 - 1.14)
GDA	10,408	1,974	11.3	2.0	0	0		
OCEDM	17,930	40,945	14.2	36.8	793	2,677	0.82 (0.73 - 0.91)	0.86 (0.77 - 0.97)
MDCR	7,545	13,935	7.2	12.9	466	1,026	0.92 (0.79 - 1.07)	0.88 (0.75 - 1.03)
MDCD	2,925	6,391	2.2	4.4	148	346	0.78 (0.59 - 1.02)	0.81 (0.62 - 1.07)
IMRD	3,388	407	5.7	0.6	0	0		
USOC	226,514	432,555	201.7	442.8	7,046	18,926	0.86 (0.83 - 0.90)	0.86 (0.77 - 0.97)
OEHR	14,880	36,524	7.6	21.6	341	1,239	0.91 (0.78 - 1.07)	0.89 (0.76 - 1.04)
SIDIAP	7,106	1,668	18.8	4.2	200	32	1.55 (0.93 - 2.73)	1.51 (0.88 - 2.61)
VA	8,765	54,613	8.9	56.7	170	1,485	0.84 (0.67 - 1.04)	0.86 (0.69 - 1.07)
Meta-analysis	302,247	613,855	274.1	600.2	9,481	26,304	0.87 (0.83 - 0.91)	0.87 (0.78 - 0.96)
PS-stratification / on-treatment TAR								
CCAЕ	19,270	27,338	15.8	20.9	344	577	0.90 (0.78 - 1.03)	0.90 (0.78 - 1.04)
GDA	10,428	2,365	11.3	2.5	0	0		
OCEDM	19,088	40,959	15.2	36.8	837	2,679	0.85 (0.78 - 0.92)	0.86 (0.79 - 0.94)
MDCR	8,112	14,038	7.8	13.0	503	1,041	0.91 (0.81 - 1.02)	0.91 (0.81 - 1.02)
MDCD	3,076	6,408	2.3	4.4	156	346	0.93 (0.76 - 1.13)	0.95 (0.77 - 1.16)
IMRD	4,024	846	6.5	1.5	0	0		
USOC	233,492	432,576	209.5	442.8	7,287	18,928	0.87 (0.84 - 0.89)	0.86 (0.76 - 0.98)
OEHR	15,807	36,553	8.2	21.6	358	1,239	0.87 (0.77 - 0.99)	0.91 (0.80 - 1.03)
SIDIAP	7,248	2,181	18.9	5.8	201	41	1.18 (0.81 - 1.76)	1.11 (0.75 - 1.65)
VA	9,378	82,904	9.3	90.9	176	2,479	0.79 (0.66 - 0.94)	0.82 (0.69 - 0.98)
Meta-analysis	298,845	557,872	258.8	539.5	9,485	24,810	0.87 (0.85 - 0.89)	0.87 (0.79 - 0.95)

Supplementary Table 61: Exposures, outcomes and risk estimates for Acute myocardial infarction in SGLT2is (T) vs GLP1-RAs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAIE	9,190	4,234	7.0	2.8	54	16	0.62 (0.31 - 1.27)	0.60 (0.29 - 1.22)
OCEDM	10,597	4,787	6.5	2.6	87	24	1.42 (0.75 - 2.83)	1.46 (0.75 - 2.84)
MDCR	1,852	708	1.3	0.4	17	5	1.76 (0.43 - 12.0)	2.24 (0.42 - 11.9)
USOC	173,455	82,094	130.5	52.8	926	287	1.03 (0.86 - 1.24)	1.09 (0.91 - 1.32)
OEHR	8,303	3,561	2.6	1.0	23	8	1.02 (0.38 - 3.00)	1.14 (0.41 - 3.19)
Meta-analysis	201,545	94,676	146.6	59.1	1,090	335	1.02 (0.87 - 1.21)	1.07 (0.90 - 1.28)
PS-stratification / on-treatment TAR								
CCAIE	9,193	5,072	7.0	3.2	54	18	1.02 (0.59 - 1.84)	1.03 (0.58 - 1.81)
OCEDM	10,601	5,571	6.5	2.9	87	25	1.49 (0.94 - 2.45)	1.51 (0.93 - 2.44)
MDCR	1,859	741	1.3	0.4	17	5	1.30 (0.49 - 4.13)	1.44 (0.49 - 4.18)
USOC	173,486	95,798	130.5	59.8	927	318	1.13 (0.99 - 1.30)	1.19 (1.03 - 1.36)
OEHR	8,313	4,129	2.6	1.2	23	8	1.02 (0.45 - 2.55)	1.09 (0.45 - 2.64)
Meta-analysis	201,593	110,570	146.6	67.1	1,091	369	1.14 (1.01 - 1.30)	1.19 (1.05 - 1.35)

Supplementary Table 62: Exposures, outcomes and risk estimates for Acute myocardial infarction in SGLT2is (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	7,445	12,129	6.1	9.5	47	79	1.08 (0.63 - 1.86)	1.02 (0.59 - 1.77)
GDA	3,365	8,557	2.8	9.0	0	0		
OCEDM	7,925	16,520	5.3	12.7	70	177	1.12 (0.76 - 1.64)	1.10 (0.75 - 1.62)
MDCR	1,507	5,342	1.2	4.6	13	85	0.74 (0.31 - 1.58)	0.79 (0.35 - 1.79)
MDCD	1,081	3,213	0.6	2.4	12	39	1.07 (0.44 - 2.44)	0.99 (0.42 - 2.34)
USOC	128,879	272,160	106.4	244.7	755	2,242	0.83 (0.73 - 0.93)	0.85 (0.69 - 1.04)
OEHR	6,727	14,808	2.1	8.1	16	87	0.79 (0.39 - 1.53)	0.71 (0.36 - 1.40)
SIDIAP	1,284	5,346	1.8	11.0	5	48	0.35 (0.08 - 1.06)	0.34 (0.09 - 1.34)
VA	3,561	9,128	2.6	8.6	17	37	1.33 (0.58 - 2.96)	1.27 (0.56 - 2.89)
Meta-analysis	158,409	338,646	126.1	301.6	935	2,794	0.86 (0.77 - 0.96)	0.86 (0.76 - 0.97)
PS-stratification / on-treatment TAR								
CCAЕ	9,193	12,152	7.0	9.5	54	79	0.86 (0.59 - 1.25)	0.88 (0.60 - 1.27)
GDA	4,434	8,797	3.5	9.3	0	0		
OCEDM	10,601	16,845	6.5	12.9	87	184	1.04 (0.77 - 1.39)	1.04 (0.77 - 1.41)
MDCR	1,859	5,406	1.3	4.7	17	88	0.72 (0.38 - 1.32)	0.74 (0.40 - 1.39)
MDCD	1,153	3,228	0.6	2.4	12	39	1.24 (0.59 - 2.46)	1.10 (0.54 - 2.26)
USOC	173,486	272,871	130.5	245.3	927	2,256	0.93 (0.85 - 1.01)	0.97 (0.83 - 1.14)
OEHR	8,313	14,995	2.6	8.2	23	90	0.89 (0.52 - 1.45)	0.81 (0.49 - 1.35)
SIDIAP	1,790	5,752	2.2	12.1	6	49	0.69 (0.24 - 1.68)	0.68 (0.25 - 1.85)
VA	6,402	9,633	4.0	9.3	30	41	1.24 (0.65 - 2.36)	1.25 (0.65 - 2.40)
Meta-analysis	201,593	316,863	146.6	275.9	1,091	2,609	0.93 (0.86 - 1.01)	0.95 (0.84 - 1.08)

Supplementary Table 63: Exposures, outcomes and risk estimates for Acute myocardial infarction in SGLT2is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	7,603	16,222	6.0	12.4	48	125	0.87 (0.54 - 1.38)	0.84 (0.53 - 1.35)
GDA	4,184	723	3.4	0.7	0	0		
OCEDM	9,353	34,610	6.0	30.7	76	614	0.75 (0.54 - 1.02)	0.78 (0.56 - 1.08)
MDCR	1,544	7,647	1.2	6.5	16	120	1.05 (0.49 - 2.11)	1.17 (0.56 - 2.43)
MDCD	1,135	5,804	0.6	4.0	12	81	0.77 (0.30 - 1.72)	0.76 (0.32 - 1.82)
USOC	154,829	501,492	119.9	514.6	854	5,861	0.77 (0.70 - 0.85)	0.80 (0.64 - 0.99)
OEHR	7,261	31,099	2.2	19.0	18	303	0.54 (0.29 - 0.93)	0.49 (0.27 - 0.88)
SIDIAP	1,392	302	1.9	0.5	<5	<5	0.17 (0.01 - 8.21)	0.18 (0.00 - 6.42)
VA	4,465	24,654	3.2	21.1	21	143	1.23 (0.65 - 2.23)	1.26 (0.68 - 2.33)
Meta-analysis	181,725	596,874	135.9	587.3	1,024	7,104	0.77 (0.70 - 0.84)	0.77 (0.65 - 0.92)
PS-stratification / on-treatment TAR								
CCAЕ	9,193	16,529	7.0	12.6	54	129	0.78 (0.55 - 1.10)	0.76 (0.54 - 1.08)
GDA	4,337	1,235	3.5	1.3	0	0		
OCEDM	10,601	35,263	6.5	31.2	87	632	0.80 (0.62 - 1.02)	0.80 (0.62 - 1.03)
MDCR	1,859	8,152	1.3	6.9	17	133	0.82 (0.44 - 1.46)	0.80 (0.44 - 1.46)
MDCD	1,154	6,044	0.6	4.2	12	87	1.08 (0.54 - 2.00)	1.05 (0.54 - 2.04)
USOC	173,486	509,521	130.5	522.2	927	6,070	0.81 (0.75 - 0.87)	0.84 (0.69 - 1.01)
OEHR	8,313	32,721	2.6	20.2	23	332	0.58 (0.36 - 0.89)	0.54 (0.34 - 0.88)
SIDIAP	1,776	583	2.2	1.3	6	5	0.56 (0.07 - 3.59)	0.59 (0.08 - 4.17)
VA	6,402	36,055	4.0	33.9	30	273	1.23 (0.73 - 2.01)	1.25 (0.75 - 2.08)
Meta-analysis	201,593	594,034	146.6	586.3	1,091	7,163	0.80 (0.74 - 0.86)	0.81 (0.69 - 0.94)

Supplementary Table 64: Exposures, outcomes and risk estimates for Acute myocardial infarction in GLP1-RAs (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAIE	5,211	21,004	3.4	17.2	19	135	0.98 (0.51 - 1.80)	1.00 (0.54 - 1.89)
OCEDM	4,694	21,852	2.6	17.5	24	231	0.84 (0.47 - 1.44)	0.83 (0.47 - 1.46)
MDCR	918	9,149	0.6	8.8	7	138	0.59 (0.17 - 1.61)	0.52 (0.17 - 1.61)
USOC	68,496	272,508	48.0	245.5	265	2,216	0.87 (0.73 - 1.03)	0.85 (0.70 - 1.02)
OEHR	3,452	17,135	1.0	9.2	7	98	0.78 (0.26 - 1.93)	0.66 (0.24 - 1.81)
Meta-analysis	81,853	332,499	55.1	289.5	315	2,680	0.88 (0.75 - 1.02)	0.85 (0.72 - 1.02)
PS-stratification / on-treatment TAR								
CCAIE	6,605	21,112	4.1	17.3	22	137	0.89 (0.52 - 1.45)	0.89 (0.54 - 1.49)
OCEDM	6,199	22,466	3.3	18.1	29	249	0.81 (0.51 - 1.24)	0.79 (0.51 - 1.23)
MDCR	1,000	9,810	0.6	9.4	7	155	0.67 (0.27 - 1.45)	0.60 (0.26 - 1.39)
USOC	95,937	274,790	59.9	247.5	319	2,272	0.87 (0.76 - 1.00)	0.86 (0.71 - 1.03)
OEHR	4,293	17,251	1.2	9.3	8	101	0.78 (0.32 - 1.64)	0.64 (0.28 - 1.45)
Meta-analysis	113,034	335,619	68.4	292.1	378	2,759	0.87 (0.77 - 0.98)	0.85 (0.72 - 0.99)

Supplementary Table 65: Exposures, outcomes and risk estimates for Acute myocardial infarction in GLP1-RAs (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,530	31,661	3.6	24.7	21	232	0.78 (0.43 - 1.36)	0.74 (0.41 - 1.32)
OCEDM	5,221	42,347	2.9	38.2	25	661	0.58 (0.34 - 0.92)	0.58 (0.35 - 0.96)
MDCR	990	14,802	0.6	14.3	8	253	0.63 (0.21 - 1.51)	0.51 (0.19 - 1.38)
USOC	80,833	490,831	52.9	505.5	292	5,566	0.74 (0.64 - 0.85)	0.72 (0.58 - 0.89)
OEHR	3,665	35,550	1.1	21.4	7	330	0.40 (0.15 - 0.87)	0.37 (0.15 - 0.88)
Meta-analysis	96,239	615,191	61.0	604.0	353	7,042	0.71 (0.62 - 0.82)	0.69 (0.56 - 0.85)
PS-stratification / on-treatment TAR								
CCAЕ	6,948	32,445	4.3	25.2	22	236	0.70 (0.42 - 1.12)	0.69 (0.42 - 1.13)
OCEDM	6,199	48,951	3.3	45.1	29	875	0.64 (0.42 - 0.94)	0.63 (0.42 - 0.95)
MDCR	1,069	19,142	0.6	18.2	8	354	0.74 (0.32 - 1.47)	0.61 (0.28 - 1.30)
USOC	95,937	515,263	59.9	530.7	319	6,171	0.71 (0.63 - 0.80)	0.70 (0.55 - 0.88)
OEHR	4,294	40,322	1.2	24.7	8	407	0.46 (0.20 - 0.92)	0.39 (0.18 - 0.82)
Meta-analysis	102,885	547,708	64.1	555.9	341	6,407	0.71 (0.63 - 0.80)	0.70 (0.56 - 0.87)

Supplementary Table 66: Exposures, outcomes and risk estimates for Acute myocardial infarction in DPP4is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	18,304	30,604	14.9	23.6	127	216	0.95 (0.68 - 1.30)	0.96 (0.70 - 1.33)
GDA	10,408	1,974	11.3	2.0	0	0		
OCEDM	21,253	48,925	17.0	45.1	232	873	0.81 (0.66 - 0.99)	0.86 (0.70 - 1.06)
MDCR	9,146	17,469	8.8	16.4	143	320	0.83 (0.63 - 1.10)	0.79 (0.60 - 1.05)
MDCD	3,852	8,599	2.9	6.1	43	125	0.73 (0.45 - 1.14)	0.76 (0.48 - 1.22)
IMRD	3,388	407	5.7	0.6	0	0		
USOC	267,334	515,266	239.1	530.8	2,212	6,170	0.89 (0.83 - 0.95)	0.89 (0.78 - 1.00)
OEHR	16,282	40,290	8.6	24.7	99	407	0.79 (0.59 - 1.06)	0.77 (0.58 - 1.04)
SIDIAP	7,365	1,710	19.5	4.3	72	14	1.10 (0.54 - 2.39)	1.07 (0.51 - 2.27)
VA	9,639	60,093	9.8	62.9	44	461	0.72 (0.47 - 1.07)	0.73 (0.49 - 1.11)
Meta-analysis	353,175	722,956	320.5	713.9	2,972	8,586	0.87 (0.82 - 0.92)	0.87 (0.78 - 0.97)
PS-stratification / on-treatment TAR								
CCAЕ	21,112	30,744	17.3	23.7	137	218	0.95 (0.76 - 1.19)	0.96 (0.76 - 1.20)
GDA	10,428	2,365	11.3	2.5	0	0		
OCEDM	22,470	48,955	18.1	45.1	249	875	0.82 (0.70 - 0.94)	0.83 (0.71 - 0.97)
MDCR	9,810	17,584	9.4	16.5	155	322	0.93 (0.76 - 1.14)	0.93 (0.76 - 1.14)
MDCD	4,022	8,634	3.1	6.1	47	125	0.85 (0.59 - 1.21)	0.87 (0.61 - 1.25)
IMRD	4,024	846	6.5	1.5	0	0		
USOC	274,802	515,297	247.6	530.8	2,272	6,172	0.86 (0.82 - 0.90)	0.85 (0.74 - 0.98)
OEHR	17,251	40,321	9.3	24.7	101	407	0.74 (0.58 - 0.92)	0.77 (0.61 - 0.97)
SIDIAP	7,523	2,232	19.6	5.9	74	19	1.14 (0.64 - 2.12)	1.08 (0.59 - 1.96)
VA	10,323	91,068	10.3	101.0	46	773	0.68 (0.48 - 0.95)	0.71 (0.51 - 1.00)
Meta-analysis	349,467	661,535	304.7	646.9	2,961	8,119	0.86 (0.82 - 0.89)	0.86 (0.78 - 0.94)

Supplementary Table 67: Exposures, outcomes and risk estimates for Stroke in SGLT2is (T) vs GLP1-RAs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	9,658	4,386	7.4	2.9	38	11	0.51 (0.21 - 1.30)	0.50 (0.20 - 1.26)
OCEDM	10,964	4,837	6.6	2.6	84	29	0.74 (0.42 - 1.33)	0.77 (0.43 - 1.36)
MDCR	1,911	700	1.4	0.4	14	<5	0.28 (0.04 - 1.53)	0.36 (0.06 - 2.28)
USOC	183,553	84,139	138.6	54.1	831	338	0.89 (0.75 - 1.06)	0.94 (0.78 - 1.12)
OEHR	8,720	3,666	2.7	1.0	19	6	1.73 (0.51 - 7.95)	1.95 (0.49 - 7.72)
Meta-analysis	212,895	97,028	155.4	60.6	972	384	0.87 (0.74 - 1.02)	0.91 (0.77 - 1.08)
PS-stratification / on-treatment TAR								
CCAЕ	9,662	5,177	7.4	3.3	38	15	1.07 (0.58 - 2.09)	1.08 (0.57 - 2.05)
OCEDM	10,969	5,621	6.6	2.9	85	32	0.95 (0.62 - 1.50)	0.96 (0.62 - 1.50)
MDCR	1,919	729	1.4	0.4	14	<5	0.76 (0.25 - 2.88)	0.83 (0.24 - 2.85)
USOC	183,570	97,627	138.6	61.0	831	376	0.87 (0.77 - 1.00)	0.92 (0.80 - 1.05)
OEHR	8,732	4,211	2.7	1.2	19	6	1.36 (0.54 - 3.93)	1.45 (0.53 - 3.97)
Meta-analysis	212,933	112,636	155.4	68.4	973	429	0.89 (0.79 - 1.01)	0.93 (0.82 - 1.05)

Supplementary Table 68: Exposures, outcomes and risk estimates for Stroke in SGLT2is (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated	
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)	
PS-matching / on-treatment TAR									
CCAЕ	7,664	12,416	6.2	9.9	34	64	0.58 (0.30 - 1.05)	0.54 (0.29 - 1.02)	
GDA	3,365	8,557	2.8	9.0	0	0			
OCEDM	7,973	16,284	5.3	12.4	72	239	0.96 (0.67 - 1.35)	0.94 (0.66 - 1.34)	
MDCR	1,534	5,251	1.2	4.5	12	93	0.40 (0.13 - 0.98)	0.43 (0.16 - 1.16)	
MDCD	1,096	3,186	0.6	2.4	10	52	1.45 (0.60 - 3.28)	1.34 (0.57 - 3.15)	
USOC	131,975	274,309	110.1	247.7	679	2,558	0.79 (0.70 - 0.89)	0.81 (0.66 - 0.99)	
OEHR	6,954	15,073	2.2	8.3	18	72	1.43 (0.66 - 2.98)	1.28 (0.60 - 2.72)	
SIDIAP	1,448	5,702	2.1	11.8	<5	64	0.58 (0.13 - 1.72)	0.57 (0.15 - 2.20)	
VA	3,766	9,330	2.8	8.8	<10	29	1.09 (0.28 - 3.62)	1.05 (0.29 - 3.76)	
Meta-analysis	162,410	341,551	130.5	305.8	<840	3,171	0.83 (0.69 - 1.01)	0.83 (0.68 - 1.01)	
PS-stratification / on-treatment TAR									
CCAЕ	9,662	12,459	7.4	9.9	38	64	0.92 (0.59 - 1.40)	0.93 (0.60 - 1.44)	
GDA	4,434	8,797	3.5	9.3	0	0			
OCEDM	10,969	16,681	6.6	12.8	85	254	0.87 (0.65 - 1.15)	0.87 (0.66 - 1.16)	
MDCR	1,919	5,346	1.4	4.6	14	95	0.65 (0.34 - 1.18)	0.67 (0.36 - 1.25)	
MDCD	1,171	3,201	0.7	2.4	10	52	0.95 (0.44 - 1.90)	0.85 (0.41 - 1.77)	
USOC	183,570	274,921	138.6	248.2	831	2,578	0.82 (0.75 - 0.89)	0.86 (0.73 - 1.01)	
OEHR	8,732	15,259	2.7	8.4	19	75	1.44 (0.81 - 2.47)	1.32 (0.75 - 2.31)	
SIDIAP	2,219	6,058	2.8	12.8	5	72	0.45 (0.14 - 1.18)	0.45 (0.15 - 1.32)	
VA	6,992	9,823	4.4	9.5	16	36	0.97 (0.43 - 2.13)	0.98 (0.44 - 2.19)	
Meta-analysis	212,933	319,320	155.4	279.2	973	2,971	0.87 (0.75 - 1.01)	0.89 (0.74 - 1.06)	

Supplementary Table 69: Exposures, outcomes and risk estimates for Stroke in SGLT2is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	7,885	16,681	6.2	12.9	35	100	0.82 (0.47 - 1.41)	0.80 (0.46 - 1.39)
GDA	4,184	723	3.4	0.7	0	0		
OCEDM	9,556	34,467	6.0	30.5	72	586	0.98 (0.72 - 1.33)	1.03 (0.75 - 1.40)
MDCR	1,585	7,548	1.2	6.5	13	145	0.39 (0.14 - 0.88)	0.43 (0.17 - 1.06)
MDCD	1,145	5,692	0.6	3.9	10	79	0.89 (0.37 - 1.92)	0.88 (0.38 - 2.01)
USOC	161,306	508,864	126.0	524.4	772	6,174	0.77 (0.70 - 0.85)	0.80 (0.64 - 0.99)
OEHR	7,554	31,707	2.4	19.5	19	226	1.04 (0.54 - 1.87)	0.95 (0.51 - 1.78)
SIDIAP	1,601	308	2.3	0.6	<5	0		
VA	4,778	25,940	3.5	22.2	12	106	0.91 (0.44 - 1.75)	0.93 (0.46 - 1.85)
Meta-analysis	189,031	604,959	142.4	597.7	921	7,310	0.80 (0.71 - 0.91)	0.81 (0.67 - 0.98)
PS-stratification / on-treatment TAR								
CCAЕ	9,662	16,907	7.4	13.0	38	100	0.83 (0.55 - 1.24)	0.82 (0.54 - 1.23)
GDA	4,337	1,235	3.5	1.3	0	0		
OCEDM	10,969	35,168	6.6	31.1	85	612	0.91 (0.70 - 1.17)	0.91 (0.70 - 1.18)
MDCR	1,919	8,109	1.4	6.9	14	160	0.68 (0.36 - 1.22)	0.66 (0.36 - 1.22)
MDCD	1,172	5,980	0.7	4.1	10	86	1.01 (0.48 - 1.93)	0.99 (0.49 - 1.99)
USOC	183,570	516,987	138.6	532.0	831	6,403	0.73 (0.67 - 0.79)	0.76 (0.63 - 0.92)
OEHR	8,732	33,298	2.7	20.7	19	247	0.90 (0.53 - 1.46)	0.85 (0.50 - 1.43)
SIDIAP	2,206	600	2.8	1.3	5	<5	1.98 (0.26 - 12.4)	2.08 (0.30 - 14.5)
VA	6,992	37,498	4.4	35.3	16	197	0.68 (0.34 - 1.28)	0.69 (0.36 - 1.34)
Meta-analysis	212,933	602,360	155.4	596.8	973	7,362	0.76 (0.69 - 0.84)	0.77 (0.65 - 0.92)

Supplementary Table 70: Exposures, outcomes and risk estimates for Stroke in GLP1-RAs (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,374	21,649	3.5	18.0	15	107	0.76 (0.37 - 1.44)	0.77 (0.39 - 1.52)
OCEDM	4,722	21,900	2.6	17.6	34	303	0.81 (0.51 - 1.26)	0.80 (0.51 - 1.27)
MDCR	908	9,007	0.6	8.6	6	177	0.53 (0.18 - 1.28)	0.46 (0.17 - 1.25)
USOC	69,620	274,462	48.9	248.3	325	2,515	0.97 (0.83 - 1.13)	0.94 (0.79 - 1.12)
OEHR	3,513	17,436	1.0	9.4	7	85	1.15 (0.37 - 2.89)	0.97 (0.35 - 2.71)
Meta-analysis	83,229	335,447	56.1	293.3	381	3,010	0.94 (0.82 - 1.09)	0.92 (0.78 - 1.09)
PS-stratification / on-treatment TAR								
CCAЕ	6,757	21,772	4.1	18.1	18	107	0.86 (0.47 - 1.48)	0.87 (0.49 - 1.53)
OCEDM	6,253	22,330	3.3	17.9	36	317	0.73 (0.48 - 1.07)	0.71 (0.48 - 1.06)
MDCR	987	9,741	0.6	9.3	6	195	0.61 (0.23 - 1.31)	0.54 (0.23 - 1.29)
USOC	97,769	276,869	61.1	250.5	376	2,595	0.92 (0.81 - 1.04)	0.91 (0.76 - 1.09)
OEHR	4,377	17,560	1.3	9.5	7	92	1.31 (0.54 - 2.73)	1.08 (0.48 - 2.45)
Meta-analysis	115,156	338,531	69.8	296.0	437	3,111	0.91 (0.81 - 1.02)	0.89 (0.77 - 1.03)

Supplementary Table 71: Exposures, outcomes and risk estimates for Stroke in GLP1-RAs (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,699	32,641	3.7	25.7	20	173	0.76 (0.39 - 1.38)	0.72 (0.38 - 1.35)
OCEDM	5,259	42,410	2.8	38.1	33	679	0.94 (0.60 - 1.43)	0.95 (0.62 - 1.47)
MDCR	978	14,526	0.6	14.0	6	301	0.53 (0.18 - 1.24)	0.43 (0.16 - 1.14)
USOC	82,560	497,956	54.1	514.8	347	5,843	0.81 (0.70 - 0.93)	0.79 (0.64 - 0.97)
OEHR	3,746	36,039	1.1	21.8	7	233	0.89 (0.33 - 1.98)	0.82 (0.33 - 2.00)
Meta-analysis	98,242	623,572	62.3	614.3	413	7,229	0.81 (0.72 - 0.92)	0.78 (0.64 - 0.96)
PS-stratification / on-treatment TAR								
CCAЕ	7,119	33,346	4.4	26.1	20	185	0.82 (0.47 - 1.37)	0.81 (0.48 - 1.38)
OCEDM	6,253	48,963	3.3	45.0	36	909	0.90 (0.61 - 1.29)	0.90 (0.62 - 1.30)
MDCR	1,058	19,052	0.6	18.1	6	456	0.54 (0.21 - 1.16)	0.45 (0.19 - 1.05)
USOC	97,769	522,751	61.1	540.5	376	6,508	0.80 (0.72 - 0.90)	0.79 (0.63 - 0.99)
OEHR	4,378	40,993	1.3	25.2	7	300	0.78 (0.32 - 1.60)	0.65 (0.29 - 1.44)
Meta-analysis	104,888	556,097	65.5	566.6	396	6,693	0.81 (0.72 - 0.90)	0.79 (0.63 - 0.98)

Supplementary Table 72: Exposures, outcomes and risk estimates for Stroke in DPP4is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	18,883	31,456	15.7	24.4	94	176	0.90 (0.62 - 1.30)	0.92 (0.63 - 1.33)
GDA	10,408	1,974	11.3	2.0	0	0		
OCEDM	21,131	48,934	16.9	45.0	304	906	1.02 (0.86 - 1.22)	1.08 (0.90 - 1.30)
MDCR	9,136	17,372	8.7	16.3	186	404	0.83 (0.65 - 1.07)	0.79 (0.62 - 1.02)
MDCD	3,826	8,480	2.9	6.0	53	132	0.88 (0.55 - 1.37)	0.92 (0.59 - 1.45)
IMRD	3,388	407	5.7	0.6	0	0		
USOC	269,428	522,756	242.0	540.5	2,517	6,509	0.90 (0.85 - 0.96)	0.90 (0.80 - 1.02)
OEHR	16,561	40,955	8.8	25.2	86	300	0.94 (0.68 - 1.29)	0.92 (0.67 - 1.26)
SIDIAP	7,715	1,757	20.4	4.5	97	16	1.56 (0.71 - 3.91)	1.52 (0.65 - 3.56)
VA	9,845	62,310	10.0	65.4	40	339	0.81 (0.50 - 1.27)	0.83 (0.52 - 1.32)
Meta-analysis	356,525	734,020	325.4	727.4	3,377	8,782	0.91 (0.86 - 0.97)	0.91 (0.82 - 1.02)
PS-stratification / on-treatment TAR								
CCAЕ	21,772	31,598	18.1	24.5	107	177	0.90 (0.70 - 1.16)	0.91 (0.70 - 1.17)
GDA	10,428	2,365	11.3	2.5	0	0		
OCEDM	22,333	48,967	17.9	45.1	317	909	0.97 (0.85 - 1.11)	0.99 (0.86 - 1.14)
MDCR	9,741	17,495	9.3	16.4	195	407	0.89 (0.74 - 1.06)	0.89 (0.74 - 1.06)
MDCD	3,996	8,512	3.1	6.0	56	132	0.94 (0.67 - 1.30)	0.96 (0.69 - 1.34)
IMRD	4,024	846	6.5	1.5	0	0		
USOC	276,882	522,785	250.5	540.5	2,595	6,509	0.89 (0.85 - 0.93)	0.88 (0.77 - 1.01)
OEHR	17,560	40,992	9.5	25.2	92	300	0.93 (0.73 - 1.19)	0.97 (0.76 - 1.24)
SIDIAP	7,892	2,289	20.6	6.1	97	20	1.17 (0.68 - 2.10)	1.11 (0.63 - 1.94)
VA	10,531	94,263	10.5	104.7	42	555	0.87 (0.60 - 1.24)	0.91 (0.63 - 1.31)
Meta-analysis	352,284	670,349	308.4	657.8	3,362	8,434	0.90 (0.86 - 0.94)	0.90 (0.81 - 0.99)

Supplementary Table 73: Exposures, outcomes and risk estimates for Sudden cardiac death in SGLT2is (T) vs GLP1-RAs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	10,084	4,579	7.7	3.0	6	5	1.29 (0.24 - 9.60)	1.25 (0.20 - 7.91)
OCEDM	11,546	5,065	7.1	2.7	17	7	0.74 (0.23 - 2.60)	0.77 (0.23 - 2.58)
MDCR	1,997	739	1.4	0.4	9	<5		
USOC	195,288	89,502	146.8	57.5	214	67	1.03 (0.72 - 1.51)	1.09 (0.75 - 1.59)
OEHR	8,953	3,776	2.8	1.0	<5	<5	0.64 (0.07 - 5.56)	0.72 (0.08 - 6.26)
Meta-analysis	206,834	94,567	153.8	60.3	231	74	1.00 (0.70 - 1.44)	1.05 (0.73 - 1.51)
PS-stratification / on-treatment TAR								
CCAЕ	10,088	5,427	7.7	3.5	6	5	0.64 (0.18 - 2.35)	0.65 (0.18 - 2.32)
OCEDM	11,552	5,880	7.1	3.1	17	7	0.93 (0.38 - 2.51)	0.94 (0.36 - 2.42)
MDCR	2,005	771	1.4	0.4	9	<5	2.18 (0.39 - 40.7)	2.40 (0.24 - 24.5)
USOC	195,307	103,692	146.8	64.7	215	75	1.08 (0.82 - 1.43)	1.13 (0.85 - 1.50)
OEHR	8,965	4,349	2.8	1.2	<5	<5	0.63 (0.13 - 3.32)	0.67 (0.13 - 3.39)
Meta-analysis	206,859	109,572	153.8	67.8	232	82	1.06 (0.81 - 1.39)	1.11 (0.84 - 1.45)

Supplementary Table 74: Exposures, outcomes and risk estimates for Sudden cardiac death in SGLT2is (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated	
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)	
PS-matching / on-treatment TAR									
CCAIE	8,032	13,091	6.5	10.4	5	13	0.47 (0.07 - 2.14)	0.44 (0.08 - 2.50)	
GDA	3,365	8,557	2.8	9.0	0	0			
OCEDM	8,440	17,580	5.7	13.5	12	90	0.48 (0.20 - 1.02)	0.47 (0.21 - 1.06)	
MDCR	1,607	5,722	1.3	4.9	8	23	1.76 (0.36 - 6.63)	1.88 (0.44 - 8.01)	
MDCD	1,216	3,541	0.7	2.7	<5	18	1.31 (0.26 - 5.38)	1.21 (0.26 - 5.57)	
USOC	140,950	295,487	116.9	266.6	148	720	0.58 (0.45 - 0.75)	0.59 (0.44 - 0.81)	
OEHR	7,150	15,593	2.3	8.6	<5	21	0.26 (0.01 - 1.49)	0.23 (0.02 - 2.41)	
SIDIAP	1,497	5,892	2.1	12.2	0	<5			
VA	3,908	9,710	2.9	9.1	<10	<10	0.88 (0.04 - 9.66)	0.84 (0.05 - 13.2)	
Meta-analysis	171,303	360,724	136.3	315.7	<193	<895	0.59 (0.47 - 0.75)	0.59 (0.47 - 0.75)	
PS-stratification / on-treatment TAR									
CCAIE	10,088	13,116	7.7	10.4	6	14	0.55 (0.18 - 1.50)	0.56 (0.19 - 1.60)	
GDA	4,434	8,797	3.5	9.3	0	0			
OCEDM	11,552	17,937	7.1	13.8	17	92	0.39 (0.21 - 0.67)	0.39 (0.22 - 0.69)	
MDCR	2,005	5,793	1.4	5.0	9	23	1.81 (0.70 - 4.35)	1.85 (0.74 - 4.61)	
MDCD	1,302	3,561	0.7	2.7	<5	18	0.85 (0.19 - 2.77)	0.76 (0.20 - 2.91)	
USOC	195,307	296,299	146.8	267.2	215	728	0.63 (0.53 - 0.75)	0.66 (0.53 - 0.82)	
OEHR	8,965	15,785	2.8	8.7	<5	23	0.72 (0.19 - 2.14)	0.66 (0.20 - 2.20)	
SIDIAP	2,288	6,265	2.9	13.3	0	<5			
VA	7,274	10,232	4.5	9.9	<10	<10	0.92 (0.21 - 4.05)	0.93 (0.21 - 4.12)	
Meta-analysis	225,912	343,137	164.3	300.1	<243	857	0.61 (0.51 - 0.71)	0.62 (0.51 - 0.75)	

Supplementary Table 75: Exposures, outcomes and risk estimates for Sudden cardiac death in SGLT2is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	8,285	17,761	6.5	13.7	6	40	0.29 (0.07 - 0.91)	0.28 (0.08 - 1.04)
GDA	4,184	723	3.4	0.7	0	0		
OCEDM	10,076	37,084	6.4	33.0	15	204	0.55 (0.26 - 1.06)	0.58 (0.28 - 1.17)
MDCR	1,660	8,237	1.3	7.1	9	31	2.31 (0.67 - 7.39)	2.57 (0.78 - 8.51)
MDCD	1,274	6,483	0.7	4.5	<5	25	0.80 (0.12 - 3.40)	0.78 (0.14 - 4.27)
USOC	172,056	549,964	133.6	566.3	186	1,751	0.56 (0.46 - 0.68)	0.58 (0.44 - 0.77)
OEHR	7,784	32,954	2.4	20.4	<5	77	0.45 (0.10 - 1.42)	0.42 (0.11 - 1.55)
SIDIAP	1,648	320	2.4	0.6	0	0		
VA	4,946	26,895	3.6	23.0	<10	12	1.48 (0.28 - 6.58)	1.51 (0.31 - 7.35)
Meta-analysis	201,135	652,483	150.9	645.0	<226	2,128	0.60 (0.42 - 0.87)	0.61 (0.41 - 0.90)
PS-stratification / on-treatment TAR								
CCAЕ	10,088	18,021	7.7	13.9	6	40	0.29 (0.11 - 0.68)	0.29 (0.11 - 0.72)
GDA	4,337	1,235	3.5	1.3	0	0		
OCEDM	11,552	37,919	7.1	33.7	17	217	0.61 (0.34 - 1.01)	0.61 (0.35 - 1.05)
MDCR	2,005	8,843	1.4	7.5	9	33	1.93 (0.75 - 4.62)	1.87 (0.75 - 4.65)
MDCD	1,304	6,690	0.7	4.6	<5	29	0.63 (0.15 - 1.91)	0.62 (0.17 - 2.24)
USOC	195,307	559,493	146.8	575.4	215	1,822	0.60 (0.51 - 0.70)	0.62 (0.49 - 0.79)
OEHR	8,965	34,672	2.8	21.6	<5	87	0.56 (0.16 - 1.51)	0.53 (0.17 - 1.64)
SIDIAP	2,273	619	2.9	1.4	0	0		
VA	7,274	39,031	4.5	36.7	<10	25	1.62 (0.37 - 6.22)	1.65 (0.40 - 6.72)
Meta-analysis	225,912	650,105	164.3	644.7	<243	2,166	0.59 (0.51 - 0.68)	0.60 (0.49 - 0.73)

Supplementary Table 76: Exposures, outcomes and risk estimates for Sudden cardiac death in GLP1-RAs (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,610	22,583	3.7	18.7	7	22	1.87 (0.51 - 6.43)	1.90 (0.54 - 6.75)
OCEDM	4,933	23,099	2.8	18.6	7	102	0.46 (0.17 - 1.06)	0.45 (0.18 - 1.14)
MDCR	959	9,661	0.6	9.3	<5	41	0.55 (0.03 - 3.19)	0.48 (0.05 - 5.12)
USOC	74,338	295,582	52.1	267.2	65	706	0.81 (0.57 - 1.14)	0.79 (0.56 - 1.12)
OEHR	3,634	17,979	1.1	9.7	<5	27	0.63 (0.09 - 2.78)	0.53 (0.10 - 2.97)
Meta-analysis	88,515	359,243	59.7	314.2	<84	857	0.79 (0.55 - 1.13)	0.77 (0.53 - 1.12)
PS-stratification / on-treatment TAR								
CCAЕ	7,047	22,729	4.3	18.8	7	23	1.34 (0.49 - 3.33)	1.34 (0.51 - 3.52)
OCEDM	6,525	23,819	3.5	19.2	8	110	0.39 (0.16 - 0.81)	0.38 (0.17 - 0.85)
MDCR	1,040	10,492	0.6	10.1	<5	42	0.70 (0.04 - 3.41)	0.63 (0.07 - 5.85)
USOC	103,838	298,333	64.8	269.6	75	730	0.64 (0.48 - 0.83)	0.63 (0.47 - 0.85)
OEHR	4,516	18,109	1.3	9.8	<5	29	0.88 (0.19 - 2.85)	0.72 (0.19 - 2.78)
Meta-analysis	121,926	362,990	73.9	317.4	<95	892	0.66 (0.45 - 0.97)	0.65 (0.43 - 0.96)

Supplementary Table 77: Exposures, outcomes and risk estimates for Sudden cardiac death in GLP1-RAs (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,953	34,454	3.8	27.1	6	71	1.49 (0.46 - 4.11)	1.41 (0.47 - 4.23)
OCEDM	5,502	44,858	3.0	40.7	8	187	0.92 (0.38 - 1.96)	0.94 (0.41 - 2.12)
MDCR	1,031	15,659	0.6	15.3	<5	57	0.37 (0.02 - 2.25)	0.30 (0.03 - 3.30)
USOC	87,882	537,539	57.6	555.7	66	1,617	0.60 (0.44 - 0.80)	0.59 (0.42 - 0.82)
OEHR	3,870	37,279	1.1	22.7	<5	76	1.39 (0.29 - 4.73)	1.27 (0.31 - 5.15)
Meta-analysis	103,207	654,130	65.5	646.1	<85	1,951	0.79 (0.52 - 1.22)	0.76 (0.48 - 1.21)
PS-stratification / on-treatment TAR								
CCAЕ	7,417	35,329	4.6	27.7	7	73	0.74 (0.28 - 1.67)	0.72 (0.30 - 1.76)
OCEDM	6,525	52,453	3.5	48.6	8	287	0.73 (0.31 - 1.49)	0.73 (0.34 - 1.59)
MDCR	1,113	20,776	0.7	19.9	<5	91	0.41 (0.02 - 2.01)	0.34 (0.04 - 3.17)
USOC	103,838	565,620	64.8	584.5	75	1,845	0.58 (0.44 - 0.73)	0.56 (0.41 - 0.77)
OEHR	4,517	42,529	1.3	26.3	<5	106	0.99 (0.23 - 2.91)	0.82 (0.23 - 2.93)
Meta-analysis	111,255	600,949	69.4	612.2	82	1,918	0.59 (0.46 - 0.75)	0.57 (0.42 - 0.78)

Supplementary Table 78: Exposures, outcomes and risk estimates for Sudden cardiac death in DPP4is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	19,792	33,348	16.4	25.9	21	71	0.66 (0.33 - 1.27)	0.68 (0.35 - 1.32)
GDA	10,408	1,974	11.3	2.0	0	0		
OCEDM	22,570	52,421	18.1	48.6	104	287	1.06 (0.78 - 1.43)	1.12 (0.82 - 1.52)
MDCR	9,814	18,945	9.4	17.9	41	83	0.85 (0.49 - 1.42)	0.81 (0.47 - 1.37)
MDCD	4,249	9,440	3.2	6.7	22	41	0.83 (0.33 - 1.92)	0.87 (0.36 - 2.10)
IMRD	3,388	407	5.7	0.6	0	0		
USOC	290,676	565,621	260.8	584.6	713	1,845	0.89 (0.79 - 1.00)	0.89 (0.76 - 1.04)
OEHR	17,092	42,491	9.1	26.3	28	106	0.99 (0.56 - 1.70)	0.97 (0.55 - 1.69)
SIDIAP	7,933	1,797	21.0	4.6	<5	0		
VA	10,219	64,285	10.4	67.3	<10	50	1.48 (0.38 - 4.62)	1.51 (0.44 - 5.23)
Meta-analysis	374,412	786,551	327.4	777.3	<939	2,483	0.91 (0.81 - 1.01)	0.90 (0.78 - 1.04)
PS-stratification / on-treatment TAR								
CCAЕ	22,729	33,507	18.8	26.0	23	71	0.55 (0.33 - 0.88)	0.55 (0.33 - 0.90)
GDA	10,428	2,365	11.3	2.5	0	0		
OCEDM	23,823	52,457	19.2	48.6	110	287	1.12 (0.88 - 1.40)	1.14 (0.90 - 1.44)
MDCR	10,492	19,080	10.1	18.1	42	85	1.01 (0.68 - 1.48)	1.01 (0.69 - 1.49)
MDCD	4,421	9,467	3.4	6.7	22	41	1.12 (0.64 - 1.91)	1.14 (0.66 - 1.98)
IMRD	4,024	846	6.5	1.5	0	0		
USOC	298,346	565,656	269.6	584.6	730	1,846	0.94 (0.86 - 1.03)	0.94 (0.80 - 1.09)
OEHR	18,109	42,528	9.8	26.3	29	106	0.93 (0.60 - 1.41)	0.97 (0.63 - 1.49)
SIDIAP	8,121	2,335	21.2	6.3	<5	0		
VA	10,950	97,207	10.9	108.0	<10	82	0.92 (0.32 - 2.33)	0.96 (0.35 - 2.60)
Meta-analysis	377,920	722,695	330.9	710.3	956	2,436	0.96 (0.84 - 1.10)	0.96 (0.81 - 1.13)

Supplementary Table 79: Exposures, outcomes and risk estimates for Hospitalization with heart failure in SGLT2is (T) vs GLP1-RAs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	9,482	4,327	7.3	2.9	80	27	1.34 (0.74 - 2.51)	1.30 (0.70 - 2.39)
OCEDM	10,071	4,554	6.3	2.4	175	65	1.08 (0.74 - 1.60)	1.11 (0.76 - 1.65)
MDCR	1,760	654	1.3	0.4	35	11	2.50 (0.79 - 11.1)	3.18 (0.85 - 11.9)
USOC	173,187	82,053	132.5	52.9	1,647	581	1.05 (0.92 - 1.19)	1.10 (0.96 - 1.27)
OEHR	8,356	3,557	2.6	1.0	54	16	1.45 (0.75 - 3.01)	1.63 (0.81 - 3.28)
Meta-analysis	201,096	94,491	148.6	59.1	1,956	689	1.07 (0.95 - 1.20)	1.12 (0.98 - 1.27)
PS-stratification / on-treatment TAR								
CCAЕ	9,485	5,119	7.3	3.3	80	29	1.29 (0.83 - 2.06)	1.30 (0.82 - 2.05)
OCEDM	10,084	5,301	6.3	2.8	175	71	0.93 (0.69 - 1.26)	0.94 (0.70 - 1.27)
MDCR	1,767	690	1.3	0.4	35	11	1.11 (0.55 - 2.40)	1.22 (0.58 - 2.55)
USOC	173,214	95,533	132.5	59.7	1,649	657	0.96 (0.88 - 1.06)	1.01 (0.92 - 1.12)
OEHR	8,371	4,092	2.6	1.1	55	20	1.25 (0.73 - 2.21)	1.34 (0.76 - 2.37)
Meta-analysis	201,154	110,045	148.6	66.9	1,959	777	0.98 (0.90 - 1.07)	1.02 (0.93 - 1.12)

Supplementary Table 80: Exposures, outcomes and risk estimates for Hospitalization with heart failure in SGLT2is (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	7,609	12,295	6.2	9.8	63	113	0.79 (0.50 - 1.22)	0.74 (0.47 - 1.17)
GDA	3,365	8,557	2.8	9.0	0	0		
OCEDM	7,558	15,376	5.1	11.6	126	489	0.74 (0.56 - 0.98)	0.73 (0.55 - 0.97)
MDCR	1,442	4,929	1.1	4.3	29	183	0.83 (0.45 - 1.45)	0.88 (0.49 - 1.59)
MDCD	1,013	2,892	0.6	2.1	19	92	1.02 (0.50 - 1.97)	0.94 (0.48 - 1.87)
USOC	129,185	266,519	108.1	239.2	1,242	5,411	0.67 (0.61 - 0.73)	0.69 (0.57 - 0.83)
OEHR	6,729	14,588	2.1	7.8	42	225	0.99 (0.63 - 1.53)	0.88 (0.57 - 1.38)
SIDIAP	1,484	5,821	2.1	12.1	<5	36	0.52 (0.12 - 1.69)	0.51 (0.12 - 2.10)
VA	3,557	8,994	2.6	8.4	32	129	0.65 (0.38 - 1.08)	0.62 (0.37 - 1.06)
Meta-analysis	158,577	331,414	128.0	295.3	<1,558	6,678	0.69 (0.64 - 0.75)	0.69 (0.63 - 0.76)
PS-stratification / on-treatment TAR								
CCAЕ	9,485	12,359	7.3	9.8	80	114	0.93 (0.68 - 1.26)	0.94 (0.69 - 1.28)
GDA	4,434	8,797	3.5	9.3	0	0		
OCEDM	10,084	15,580	6.3	11.8	175	503	0.78 (0.64 - 0.95)	0.78 (0.64 - 0.96)
MDCR	1,767	4,968	1.3	4.3	35	185	0.76 (0.50 - 1.14)	0.78 (0.52 - 1.18)
MDCD	1,068	2,906	0.6	2.1	20	93	1.03 (0.60 - 1.70)	0.92 (0.54 - 1.55)
USOC	173,214	266,932	132.5	239.6	1,649	5,455	0.72 (0.68 - 0.77)	0.76 (0.65 - 0.88)
OEHR	8,371	14,761	2.6	7.9	55	238	0.97 (0.69 - 1.33)	0.88 (0.64 - 1.23)
SIDIAP	2,252	6,192	2.9	13.1	<5	41	0.32 (0.06 - 1.10)	0.32 (0.07 - 1.33)
VA	6,102	9,499	3.9	9.1	63	133	0.62 (0.42 - 0.91)	0.62 (0.42 - 0.92)
Meta-analysis	201,154	309,632	148.6	269.1	1,959	6,310	0.79 (0.69 - 0.90)	0.80 (0.68 - 0.95)

Supplementary Table 81: Exposures, outcomes and risk estimates for Hospitalization with heart failure in SGLT2is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.

	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAIE	7,827	16,603	6.1	12.8	66	188	0.63 (0.41 - 0.95)	0.61 (0.40 - 0.93)
GDA	4,184	723	3.4	0.7	0	0		
OCEDM	8,986	32,296	5.8	28.2	145	1,384	0.66 (0.53 - 0.83)	0.69 (0.55 - 0.87)
MDCR	1,476	6,933	1.1	5.9	31	269	0.57 (0.31 - 0.99)	0.64 (0.36 - 1.14)
MDCD	1,054	5,163	0.6	3.5	20	164	0.90 (0.50 - 1.54)	0.89 (0.51 - 1.56)
USOC	155,896	492,655	122.4	503.9	1,469	13,293	0.63 (0.59 - 0.68)	0.65 (0.53 - 0.80)
OEHR	7,307	30,706	2.3	18.5	49	654	0.82 (0.56 - 1.16)	0.75 (0.52 - 1.08)
SIDIAP	1,634	317	2.4	0.6	<5	<5	0.33 (0.01 - 3.72)	0.36 (0.02 - 5.66)
VA	4,420	24,348	3.2	20.6	41	408	0.72 (0.47 - 1.07)	0.74 (0.49 - 1.11)
Meta-analysis	182,546	584,356	138.3	572.8	1,780	15,952	0.64 (0.60 - 0.68)	0.65 (0.55 - 0.76)
PS-stratification / on-treatment TAR								
CCAIE	9,485	16,807	7.3	12.9	80	195	0.77 (0.57 - 1.02)	0.75 (0.56 - 1.01)
GDA	4,337	1,235	3.5	1.3	0	0		
OCEDM	10,084	32,769	6.3	28.6	175	1,433	0.69 (0.58 - 0.82)	0.69 (0.58 - 0.83)
MDCR	1,767	7,419	1.3	6.3	35	302	0.75 (0.49 - 1.12)	0.73 (0.49 - 1.10)
MDCD	1,069	5,365	0.6	3.6	20	170	0.86 (0.51 - 1.36)	0.84 (0.51 - 1.37)
USOC	173,214	499,973	132.5	511.0	1,649	13,876	0.65 (0.62 - 0.69)	0.68 (0.57 - 0.82)
OEHR	8,371	32,179	2.6	19.5	55	732	0.82 (0.60 - 1.10)	0.78 (0.56 - 1.08)
SIDIAP	2,237	616	2.9	1.4	<5	<5	1.70 (0.11 - 24.3)	1.79 (0.12 - 26.0)
VA	6,102	35,626	3.9	33.1	63	705	0.76 (0.54 - 1.04)	0.77 (0.55 - 1.07)
Meta-analysis	201,154	581,728	148.6	572.0	1,959	16,236	0.67 (0.63 - 0.73)	0.68 (0.58 - 0.80)

Supplementary Table 82: Exposures, outcomes and risk estimates for Hospitalization with heart failure in GLP1-RAs (T) vs DPP4is (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.


	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,272	21,388	3.5	17.7	28	187	0.59 (0.35 - 0.97)	0.60 (0.36 - 1.01)
OCEDM	4,470	20,568	2.5	16.4	68	594	0.94 (0.66 - 1.32)	0.94 (0.66 - 1.32)
MDCR	871	8,539	0.5	8.2	16	310	0.87 (0.44 - 1.60)	0.77 (0.40 - 1.47)
USOC	68,153	267,295	47.9	240.4	552	5,383	0.78 (0.69 - 0.88)	0.76 (0.66 - 0.87)
OEHR	3,418	16,895	1.0	8.9	17	267	0.96 (0.51 - 1.69)	0.81 (0.45 - 1.47)
Meta-analysis	81,313	326,146	54.8	283.4	665	6,431	0.79 (0.71 - 0.88)	0.77 (0.68 - 0.88)
PS-stratification / on-treatment TAR								
CCAЕ	6,644	21,496	4.1	17.8	34	193	0.67 (0.44 - 1.00)	0.68 (0.45 - 1.02)
OCEDM	5,916	21,034	3.1	16.8	76	630	0.87 (0.65 - 1.14)	0.85 (0.64 - 1.12)
MDCR	938	9,068	0.6	8.7	17	365	0.88 (0.50 - 1.45)	0.78 (0.46 - 1.33)
USOC	95,674	268,831	59.8	241.8	658	5,510	0.77 (0.70 - 0.84)	0.76 (0.65 - 0.89)
OEHR	4,259	16,984	1.2	8.9	21	273	0.87 (0.52 - 1.38)	0.72 (0.44 - 1.17)
Meta-analysis	112,493	328,345	68.2	285.3	789	6,606	0.78 (0.71 - 0.85)	0.76 (0.67 - 0.86)

Supplementary Table 83: Exposures, outcomes and risk estimates for Hospitalization with heart failure in GLP1-RAs (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.


	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	5,606	32,248	3.6	25.3	29	373	0.57 (0.34 - 0.91)	0.54 (0.33 - 0.88)
OCEDM	4,978	40,094	2.7	35.7	72	1,588	0.80 (0.59 - 1.06)	0.81 (0.61 - 1.09)
MDCR	934	13,239	0.6	12.6	18	550	0.78 (0.40 - 1.38)	0.64 (0.34 - 1.19)
USOC	80,521	483,889	52.9	496.1	604	12,582	0.65 (0.59 - 0.72)	0.63 (0.52 - 0.76)
OEHR	3,645	35,006	1.1	20.7	18	705	0.73 (0.42 - 1.19)	0.67 (0.40 - 1.13)
Meta-analysis	95,684	604,476	60.8	590.4	741	15,798	0.66 (0.61 - 0.73)	0.64 (0.53 - 0.77)
PS-stratification / on-treatment TAR								
CCAЕ	6,996	33,018	4.3	25.8	35	388	0.56 (0.37 - 0.81)	0.55 (0.37 - 0.81)
OCEDM	5,916	45,669	3.1	41.5	76	2,045	0.69 (0.53 - 0.89)	0.69 (0.53 - 0.89)
MDCR	1,006	17,464	0.6	16.5	19	893	0.79 (0.47 - 1.26)	0.65 (0.40 - 1.07)
USOC	95,674	505,613	59.8	519.2	658	14,102	0.65 (0.60 - 0.71)	0.64 (0.52 - 0.79)
OEHR	4,260	39,634	1.2	23.7	21	929	0.70 (0.43 - 1.08)	0.58 (0.36 - 0.92)
Meta-analysis	102,670	538,631	64.1	545.0	693	14,490	0.65 (0.60 - 0.70)	0.64 (0.52 - 0.78)

Supplementary Table 84: Exposures, outcomes and risk estimates for Hospitalization with heart failure in DPP4is (T) vs SUs (C) new-user cohorts under two different propensity score (PS) adjustment / time-at-risk (TAR) designs across data sources. We report total patient exposure time in 1,000 patient-year (KYr) units, uncalibrated and calibrated hazard ratios (HRs) and their 95% confidence intervals (CIs). Greyed out entries did not pass study diagnostics and are included only for completeness.


	Patients		Exposure (KYr)		Outcomes		Uncalibrated	Calibrated
	T	C	T	C	T	C	HR (95% CI)	HR (95% CI)
PS-matching / on-treatment TAR								
CCAЕ	18,650	31,183	15.4	24.2	181	361	1.00 (0.77 - 1.28)	1.02 (0.79 - 1.31)
GDA	10,408	1,974	11.3	2.0	0	0		
OCEDM	19,817	45,657	15.7	41.5	600	2,043	0.84 (0.74 - 0.95)	0.88 (0.78 - 1.01)
MDCR	8,439	15,905	8.1	14.8	340	806	0.83 (0.70 - 1.00)	0.79 (0.66 - 0.95)
MDCD	3,460	7,581	2.6	5.2	121	268	0.81 (0.60 - 1.10)	0.85 (0.63 - 1.16)
IMRD	3,388	407	5.7	0.6	0	0		
USOC	261,555	505,623	233.6	519.3	5,340	14,104	0.89 (0.85 - 0.93)	0.89 (0.79 - 0.99)
OEHR	16,001	39,601	8.3	23.7	259	929	0.93 (0.78 - 1.11)	0.91 (0.76 - 1.08)
SIDIAP	7,853	1,788	20.8	4.6	56	8	0.86 (0.31 - 2.79)	0.84 (0.28 - 2.51)
VA	9,482	59,199	9.6	61.4	136	1,182	0.81 (0.63 - 1.03)	0.83 (0.64 - 1.06)
Meta-analysis	345,257	706,537	314.1	694.6	7,033	19,701	0.88 (0.85 - 0.92)	0.88 (0.79 - 0.97)
PS-stratification / on-treatment TAR								
CCAЕ	21,496	31,324	17.8	24.3	193	363	0.87 (0.72 - 1.04)	0.87 (0.72 - 1.05)
GDA	10,428	2,365	11.3	2.5	0	0		
OCEDM	21,038	45,673	16.8	41.5	630	2,045	0.85 (0.78 - 0.94)	0.87 (0.79 - 0.96)
MDCR	9,068	16,035	8.7	15.0	365	819	0.90 (0.79 - 1.03)	0.90 (0.79 - 1.03)
MDCD	3,626	7,602	2.7	5.2	127	269	0.93 (0.74 - 1.17)	0.95 (0.76 - 1.20)
IMRD	4,024	846	6.5	1.5	0	0		
USOC	268,843	505,648	241.8	519.3	5,510	14,106	0.90 (0.87 - 0.93)	0.90 (0.79 - 1.02)
OEHR	16,984	39,633	8.9	23.7	273	929	0.91 (0.79 - 1.05)	0.95 (0.82 - 1.10)
SIDIAP	8,035	2,321	21.0	6.2	56	9	1.04 (0.49 - 2.44)	0.98 (0.44 - 2.19)
VA	10,169	90,050	10.1	98.8	143	2,004	0.78 (0.64 - 0.95)	0.81 (0.67 - 0.99)
Meta-analysis	341,055	645,915	296.8	629.0	7,098	18,531	0.90 (0.87 - 0.92)	0.90 (0.82 - 0.98)




Supplementary Figure 1: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in CCAE. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 2: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in GDA. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 3: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumDOD. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 4: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCR. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 5: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCD. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 6: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in IMRD. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 7: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in US Open Claims. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 8: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumEHR. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 9: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in SIDIAP. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 10: Preference score distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in VA. The preference score is a transformation of the propensity score that adjusts for prevalence differences between populations. For each class pair, we fit a large-scale propensity score model using >40,000 baseline patient characteristics. A higher overlap between score distributions indicates that patients in the target (left, red) and comparator (bottom, blue) populations are more similar in terms of their predicted probability of receiving one treatment over the other. We define clinical empirical equipoise when a majority of patients in both populations carry preference scores between 0.3 and 0.7.




Supplementary Figure 11: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in CCAE before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 12: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in CCAE before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.




Supplementary Figure 13: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in GDA before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 14: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in GDA before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.




Supplementary Figure 15: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumDOD before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 16: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumDOD before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.




Supplementary Figure 17: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCR before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 18: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCR before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.




Supplementary Figure 19: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCD before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 20: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCD before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.




Supplementary Figure 21: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in IMRD before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 22: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in IMRD before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.




Supplementary Figure 23: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in US Open Claims before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 24: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in US Open Claims before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.




Supplementary Figure 25: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumEHR before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 26: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumEHR before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.




Supplementary Figure 27: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in SIDIAP before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.



Supplementary Figure 28: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in SIDIAP before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.



Supplementary Figure 29: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in VA before/after PS stratification. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS stratification.




Supplementary Figure 30: Covariate balance comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in VA before/after PS matching. Covariate balance is measured by standardized mean differences (SMDs) between covariates in target and comparator cohorts. We show SMDs on >40,000 baseline patient characteristics before and after PS matching.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i


SU

Supplementary Figure 31: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in CCAE using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i




SU

Supplementary Figure 32: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in CCAE using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i




SU

Supplementary Figure 33: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in GDA using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i


SU

Supplementary Figure 34: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in GDA using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i


SU

Supplementary Figure 35: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumDOD using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i


SU

Supplementary Figure 36: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumDOD using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i


SU

Supplementary Figure 37: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCR using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i




SU

Supplementary Figure 38: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCR using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i




SU

Supplementary Figure 39: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCD using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.

SGLT2i

GLP1-RA

DPP4i




GLP1-RA


DPP4i

SU

Supplementary Figure 40: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in MDCD using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.



Supplementary Figure 41: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in IMRD using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.




Supplementary Figure 42: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in IMRD using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i


SU

Supplementary Figure 43: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in US Open Claims using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i


SU

Supplementary Figure 44: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in US Open Claims using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.

SGLT2i

GLP1-RA

DPP4i





GLP1-RA

DPP4i



SU

Supplementary Figure 45: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumEHR using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.


SGLT2i



GLP1-RA



DPP4i



GLP1-RA

DPP4i




SU

Supplementary Figure 46: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in OptumEHR using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i




SU

Supplementary Figure 47: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in SIDIAP using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i




SU

Supplementary Figure 48: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in SIDIAP using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.

SGLT2i

GLP1-RA

DPP4i



GLP1-RA

DPP4i




SU

Supplementary Figure 49: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in VA using PS stratification. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS stratification.

SGLT2i

GLP1-RA

DPP4i







GLP1-RA





DPP4i

SU


Supplementary Figure 50: Systematic error distributions comparing SGLT2is, GLP1-RAs, DPP4is, and SUs new-users with established CVD in VA using PS matching. Systematic error distributions are measured by effect estimates and 95% confidence intervals for negative control outcomes, presented before (bottom) and after (top) empirical calibration. Results are shown using PS matching.




Supplementary Figure 51: Leave-one-out meta-analysis of calibrated hazard ratio estimates of cardiovascular outcomes for SGLT2i vs GLP1-RA comparison across databases.




Supplementary Figure 52: Leave-one-out meta-analysis of calibrated hazard ratio estimates of cardiovascular outcomes for SGLT2i vs DPP4i comparison across databases.




Supplementary Figure 53: Leave-one-out meta-analysis of calibrated hazard ratio estimates of cardiovascular outcomes for SGLT2i vs SU comparison across databases.



Supplementary Figure 54: Leave-one-out meta-analysis of calibrated hazard ratio estimates of cardiovascular outcomes for GLP1-RA vs DPP4i comparison across databases.



Supplementary Figure 55: Leave-one-out meta-analysis of calibrated hazard ratio estimates of cardiovascular outcomes for GLP1-RA vs SU comparison across databases.



Supplementary Figure 56: Leave-one-out meta-analysis of calibrated hazard ratio estimates of cardiovascular outcomes for DPP4i vs SU comparison across databases.